two arm study
  5
  C0557651|Room of building - Study|0
  C0205448|Two (qualifier value)|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0947630|Scientific Study|0
prostate
  2
  C0033572|Prostate|0
  C1278980|Entire prostate|0
pelvic lymphadenectomy
  1
  C0193883|Pelvic lymphadenectomy (procedure)|0
acceptable toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
advances
  2
  C0205179|Advanced phase|0
  C0725066|Advance|0
not contiguous parametrial tissue
  2
  C0205283|Contiguous (qualifier value)|0
  C0040300|Tissues|0
only eligible patients
  1
  C0030705|Patients|0
spleen
  2
  C0037993|Spleen|0
  C1278932|Entire spleen|0
hematologic effects
  2
  C1280500|Effect (qualifier value)|0
  C0205488|Hematologic (qualifier value)|0
gog performance scale
  5
  C0349674|Intellectual scale|0
  C0175659|Weight measurement scales|0
  C0597198|Performance|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
staging
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
grade proctitis
  3
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
  C0033246|Proctitis|0
body
  1
  C0242821|Human Body|0
prolonged neurologic toxicity
  4
  C0040539|Toxicity aspects|0
  C0205494|Neurologic (qualifier value)|0
  C0600688|Toxic effect|0
  C0439590|Prolonged (qualifier value)|0
c patients
  2
  C0007886|Cesium|0
  C0030705|Patients|0
major surgery
  1
  C0679637|major surgery|0
same dose
  1
  C0445247|Same (qualifier value)|0
first
  1
  C0205435|First (qualifier value)|0
two sample wilcoxon test
  5
  C0870078|Sampling|0
  C0205448|Two (qualifier value)|0
  C0039593|Testing|0
  C0441621|Sampling - Surgical action|0
  C0392366|Tests (qualifier value)|0
consistent observations
  3
  C0302523|Observation in research|0
  C0332290|Consistent with (qualifier value)|0
  C0700325|Patient observation|0
tissue
  1
  C0040300|Tissues|0
poor prognosis
  1
  C0278252|Prognosis bad (finding)|0
other factors
  1
  C0205394|Other|0
clinical congestive heart failure
  5
  C0205210|Clinical (qualifier value)|0
  C0680095|Personal failure|0
  C0742742|CONGESTIVE|0
  C0231174|Failure (biologic function)|0
  C0018787|Heart|0
white blood cell count
  2
  C0023508|White Blood Cell Count procedure|0
  C0427512|White blood cell count laboratory result|0
significantly higher response rates
  2
  C0871208|Rating|0
  C0871261|Responses|0
previous malignancy
  3
  C0205156|Previous (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
radiosensitivity
  1
  C0034537|Radiation Tolerance|0
m observed group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
different stages
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
ssd
  1
  C0723179|SSD|0
dukes cl
  2
  C0201952|Chloride measurement|0
  C0010575|Cycloleucine|0
transient diarrhea
  4
  C0205374|Transitory|0
  C0687129|Encounter due to vagabond status|0
  C0040704|Transient Population Group|0
  C0011991|Diarrhea|0
indeed poor prognostic features
  3
  C0542537|Poor - grade value|0
  C0220901|prognostic|0
  C0699761|Financially poor|0
high toxicity rate
  5
  C0205250|High|0
  C0040539|Toxicity aspects|0
  C0871208|Rating|0
  C0235146|Euphoric mood|0
  C0600688|Toxic effect|0
function
  4
  C0031843|physiological aspects|0
  C0700205|Function Axis|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
pulmonary disease
  1
  C0024115|Lung diseases|0
complete blood counts
  1
  C0009555|Blood Count, Complete|0
maximum therapeutic effect
  4
  C0039796|The science and art of healing|0
  C1280500|Effect (qualifier value)|0
  C0302350|Therapeutic|0
  C0806909|Maximum|0
gastrointestinal anastomosis
  4
  C0521362|Gastrointestinal|0
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
more organs
  2
  C0178784|Organ|0
  C0205172|More (qualifier value)|0
compelling reason to
  1
  C0684328|Reasoning|0
10th percentile
  1
  C1264641|Percentile (property) (qualifier value)|0
simultaneous therapy group
  5
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0521115|Simultaneous (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
pulmonary toxicity
  1
  C0919924|Pulmonary toxicity|0
mayo clinic study
  5
  C0557651|Room of building - Study|0
  C0442592|Clinic (environment)|0
  C0454788|Mayo County, Republic of Ireland|0
  C1077578|Bikinia le-testui|0
  C0947630|Scientific Study|0
residual pelvic tumor
  3
  C0030797|Pelvis|0
  C0205347|Residual (qualifier value)|0
  C0027651|Neoplasms|0
clinical decisions
  2
  C0205210|Clinical (qualifier value)|0
  C0679006|decision|0
second generation
  3
  C0205436|Second (qualifier value)|0
  C0079411|Generations|0
  C0457385|seconds|0
intestinal perforation
  1
  C0021845|Intestinal Perforation|0
three way interactions
  3
  C0205449|Three (qualifier value)|0
  C0037420|Social Interaction|0
  C0687133|Drug Interactions|0
pilot data
  1
  C0473169|Pilot - aircraft (occupation)|0
l2
  1
  C1179699|L2 innervation|0
continuing adverse effects
  2
  C1280500|Effect (qualifier value)|0
  C0750536|CONTINUED|0
kaplan–meier estimates
  1
  C0750572|ESTIMATED|0
similar patterns
  1
  C0449774|Patterns (qualifier value)|0
treatment group
  5
  C0039798|therapeutic aspects|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
enhanced tumor cell kill
  4
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0027651|Neoplasms|0
  C0162388|Killing|0
previous findings
  2
  C0205156|Previous (qualifier value)|0
  C0243095|findings|0
preoperative tumor size
  3
  C0445204|Preoperative (qualifier value)|0
  C0027651|Neoplasms|0
  C0702146|Size (attribute)|0
ischemia
  1
  C0022116|Ischemia|0
two treatment
  3
  C0039798|therapeutic aspects|0
  C0205448|Two (qualifier value)|0
  C0087111|Therapeutic procedure|0
latter group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
significant survival advantage
  4
  C0038952|Continuance of life|0
  C0308269|ADVANTAGE|0
  C0750502|Significant (qualifier value)|0
  C0220921|survival aspects|0
partially hyperfractionated radiation fractionation schedule
  5
  C0086960|Schedules|0
  C0524811|Dose Fractionation|0
  C0205539|Scheduled (qualifier value)|0
  C0016640|Fractionation|0
  C0851346|Radiation|0
fever
  1
  C0015967|Fever|0
liver
  3
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0023884|Liver|0
dox arm
  2
  C0003792|Arm|0
  C0446516|Upper arm|0
underlies
  1
  C0444455|Underlay (qualifier value)|0
more nodes
  2
  C0746922|NODE|0
  C0205172|More (qualifier value)|0
clinical research efforts
  3
  C0205210|Clinical (qualifier value)|0
  C0035168|Research|0
  C0015264|Exertion|0
namely cmf
  1
  C0950521|CMF|0
possible neurotoxicity
  2
  C0332149|Possible|0
  C0235032|Neurotoxicity Syndromes|0
third stands out
  5
  C0205437|Third (qualifier value)|0
  C0439787|Out (qualifier value)|0
  C0596013|Does stand (finding)|0
  C0695581|Standing instruction|0
  C0231472|Orthostatic body position|0
primary radiotherapy
  4
  C0034619|radiotherapeutic|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0034618|Radiation therapy|0
serum bilirubin
  3
  C1318178|Serum bilirubin NOS|0
  C0863144|Serum bilirubin|0
  C0428442|Serum bilirubin NOS (procedure)|0
assay
  1
  C0243073|assay|0
two layer interrupted anastomosis
  5
  C0677554|Anastomosis - action|0
  C0205448|Two (qualifier value)|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
  C0443239|Interrupted (qualifier value)|0
initial ps
  1
  C0205265|Initial (qualifier value)|0
one postoperative ureterovaginal fistula
  3
  C0205447|One (qualifier value)|0
  C0032790|Postoperative Period|0
  C0016169|Fistula|0
radiation therapy oncology group
  5
  C0278627|oncology|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
  C0851346|Radiation|0
5-fu arm
  4
  C0003792|Arm|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
  C0446516|Upper arm|0
ib
  2
  C0022104|Irritable Bowel Syndrome|0
  C0444976|Ib (qualifier value)|0
treatment-related toxicities
  5
  C0040539|Toxicity aspects|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0600688|Toxic effect|0
  C0445223|Related (finding)|0
gog 92 multicenter prospective randomized study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
sgot
  1
  C0201899|Aspartate aminotransferase assay|0
50% reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
primary tumor related poor prognostic factors
  5
  C0220901|prognostic|0
  C0163712|Relate|0
  C0027651|Neoplasms|0
  C0205225|Primary|0
  C0445223|Related (finding)|0
reasonable balance
  4
  C0205415|Balanced - adjective|0
  C0014653|Equilibrium|0
  C0542274|Does balance|0
  C0179199|Balance, device|0
followed one
  2
  C0205447|One (qualifier value)|0
  C0332282|Following (attribute)|0
gynecologic oncology group performance status
  5
  C0449438|Status (attribute)|0
  C0278627|oncology|0
  C0205480|Gynecologic (qualifier value)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
fields
  2
  C0440042|Field's stain|0
  C0331809|Fielding|0
relative dose intensity
  2
  C0080103|Relative (related person)|0
  C0205345|Relative|0
creatinine clearance
  1
  C0812399|Creatinine clearance|0
clinical chf
  2
  C0205210|Clinical (qualifier value)|0
  C0018802|Heart Failure, Congestive|0
further cancer treatment
  5
  C0039798|therapeutic aspects|0
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0087111|Therapeutic procedure|0
90th percentiles
  1
  C1264641|Percentile (property) (qualifier value)|0
started one
  3
  C1272689|Started (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0452588|Start (substance)|0
further years
  1
  C0439234|year (qualifier value)|0
model selection
  3
  C0026336|Models|0
  C0036576|Selection (Genetics)|0
  C0870071|Modeling|0
ast 2.5 x n
  2
  C0004002|Aspartate Transaminase|0
  C0439225|ns (qualifier value)|0
dose reduction scheme
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
wilcoxon test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
21.0 weeks
  1
  C0439230|week (qualifier value)|0
reduced overall mortality
  4
  C0392756|Reduced (qualifier value)|0
  C0026565|Mortality Vital Statistics|0
  C0282416|Overall [Publication Type]|0
  C0026566|Aspects of mortality statistics|0
first recurrence
  2
  C0034897|Recurrence|0
  C0205435|First (qualifier value)|0
perioperative adjuvant chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
eight radiotherapy patients
  4
  C0034619|radiotherapeutic|0
  C0205454|Eight (qualifier value)|0
  C0030705|Patients|0
  C0034618|Radiation therapy|0
safe use
  1
  C0042153|utilization|0
lactate dehydrogenase
  2
  C0022917|Lactate Dehydrogenase|0
  C1260230|Lactate Dehydrogenases|0
poorer results
  1
  C1274040|Result (navigational concept)|0
calcium folinate
  1
  C0731033|Leucovorin Calcium|0
evaluable patients
  1
  C0030705|Patients|0
initial therapy
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205265|Initial (qualifier value)|0
rectum
  2
  C0034896|Rectum|0
  C1278926|Entire rectum|0
methotrexate
  1
  C0025677|Methotrexate|0
platelet count x l
  3
  C0005821|Blood Platelets|0
  C0750480|COUNT|0
  C0439157|counts (qualifier value)|0
original design
  1
  C0205313|Original (qualifier value)|0
attenuator
  2
  C0599946|attenuation|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
pelvic examination
  1
  C0200045|Manual pelvic examination (procedure)|0
radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
corpus
  1
  C0227813|Body of uterus|0
five studies
  3
  C0557651|Room of building - Study|0
  C0205451|Five (qualifier value)|0
  C0947630|Scientific Study|0
ii disease
  2
  C0012634|Disease|0
  C0439069|Roman numeral II|0
elastic sleeve
  2
  C0681018|elastic|0
  C0183336|Sleeves|0
deep stromal invasion
  1
  C0205125|Depth (qualifier value)|0
urogenital toxicity
  3
  C0040539|Toxicity aspects|0
  C0447566|Urogenital structure|0
  C0600688|Toxic effect|0
rt regimen
  1
  C0677937|regimen|0
used endomyocardial biopsy
  3
  C0220797|biopsy characteristics|0
  C0042153|utilization|0
  C0005558|Biopsy|0
ct scan
  1
  C0040405|X-Ray Computed Tomography|0
czech republic
  1
  C0206578|Czech Republic|0
main important pharmacologic factor affecting tumor response
  5
  C1314940|Affecting (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0027651|Neoplasms|0
  C0001721|Affect|0
  C0205225|Primary|0
renal function
  2
  C0042031|Urinary Tract Physiology|0
  C0232804|Renal function, NOS|0
same problem
  2
  C0033213|Problem (finding)|0
  C0445247|Same (qualifier value)|0
closure
  1
  C0185003|Reparative closure (procedure)|0
similar trial
  1
  C0442729|Strains similar (qualifier value)|0
recent reports
  3
  C0332185|Recent episode (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
iatrogenic mortality
  3
  C0439669|Iatrogenic (qualifier value)|0
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
antitumor effect
  1
  C1280500|Effect (qualifier value)|0
planned reoperation
  3
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0035110|Reoperation|0
register
  1
  C0600375|Registers (PT)|0
reasonable possibility
  5
  C0679200|syllogistic reasoning|0
  C0870397|Deductive Reasoning|0
  C0742713|COLOSTOMY REASON|0
  C0684328|Reasoning|0
  C0582553|Difficulty reasoning (finding)|0
curative potential
  1
  C0237399|Potential|0
median durations
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0449238|Duration|0
electrocardiogram
  2
  C0013798|Electrocardiogram|0
  C1258009|Electrocardiogram|0
absolute neutrophil count 2.0 l
  4
  C0027950|Neutrophils|0
  C0750480|COUNT|0
  C0205344|Absolute (qualifier value)|0
  C0439157|counts (qualifier value)|0
next day to
  1
  C0439228|day (qualifier value)|0
patients then
  1
  C0030705|Patients|0
fewer positive nodes
  2
  C0746922|NODE|0
  C0205159|Positive (qualifier value)|0
correct position
  4
  C0733755|Positioning Attribute|0
  C0150305|Positioning - therapy|0
  C0205202|Remediated (finding)|0
  C0719517|Correct|0
small surgical adjuvant study
  5
  C0557651|Room of building - Study|0
  C0038895|Surgical aspects|0
  C0700321|Small|0
  C0001551|Adjuvants, Immunologic|0
  C0947630|Scientific Study|0
same trend
  2
  C0445247|Same (qualifier value)|0
  C0040833|trends|0
local recurrences only
  2
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
minor deviations
  3
  C0012727|Spatial Displacement|0
  C0026193|Minor|0
  C0205165|Minor (value)|0
effective adjuvant combination chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0205195|Combined (qualifier value)|0
  C0013216|Pharmacotherapy|0
charcoal
  1
  C0007955|Charcoal|0
equal therapeutic effects
  5
  C0039796|The science and art of healing|0
  C1280500|Effect (qualifier value)|0
  C0439089|Equals|0
  C0302350|Therapeutic|0
  C0205163|Equal (qualifier value)|0
early analysis
  3
  C0205085|Early (qualifier value)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
mlr stepping option
  2
  C0859325|Stepping|0
  C1261552|Step (qualifier value)|0
fifteen patients
  1
  C0030705|Patients|0
latter approach
  1
  C0449445|Approach (attribute)|0
reactions
  1
  C0443286|Reaction (qualifier value)|0
perioperative portal chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
  C0205054|Hepatic|0
trend
  1
  C0040833|trends|0
stepwise logistic regression
  1
  C0206031|Logistic Regression|0
two treatment-related deaths
  5
  C0011065|Cessation of life|0
  C0205448|Two (qualifier value)|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
95% confidence limit
  1
  C0237530|Confidence Limits|0
negative psychologic reactions
  3
  C0443286|Reaction (qualifier value)|0
  C0205486|Psychologic|0
  C0205160|Negative (qualifier value)|0
selection criteria
  1
  C0242801|Selection Criteria|0
secondary analyses
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0027627|Neoplasm Metastasis|0
study period
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
hazard ratios
  2
  C0456603|Ratio (property) (qualifier value)|0
  C0598697|hazard|0
limited adverse effects
  2
  C1280500|Effect (qualifier value)|0
  C0439801|Limited (qualifier value)|0
examinations
  1
  C0579007|Examination - action (qualifier value)|0
serum bilirubin level
  2
  C0428441|Serum bilirubin measurement (procedure)|0
  C1287366|Finding of serum bilirubin level (finding)|0
technical aspects
  5
  C0871490|Technical Personnel|0
  C0237126|Technical procedure|0
  C0871491|Technical Schools|0
  C0681521|technical requirement|0
  C0080214|Technical Expertise|0
less time
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
5-year survival rates
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
sgpt
  1
  C0001899|Alanine Transaminase|0
late effects
  1
  C0543419|Sequela (disorder)|0
meccnu dose reductions
  3
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0036637|Semustine|0
post-operative chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0687676|After values (qualifier value)|0
  C0013216|Pharmacotherapy|0
survival rate
  1
  C0038954|Survival Rate|0
preferred treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
randomized trials
  5
  C0680732|jury trial|0
  C0680733|bench trial|0
  C0008976|Clinical Trials|0
  C0680734|trial procedure|0
  C0206012|Multicenter Trials|0
discontinuation
  1
  C0457454|Discontinuation (procedure)|0
one dose
  1
  C0205447|One (qualifier value)|0
patient entry criteria
  2
  C0243161|criteria|0
  C0030705|Patients|0
factor is
  1
  C0441913|is (tumor staging)|0
synergistic activity
  3
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
moderate patients
  2
  C0030705|Patients|0
  C0205081|Moderate (severity modifier) (qualifier value)|0
control arms
  4
  C0702113|Controlled (qualifier value)|0
  C0003792|Arm|0
  C0243148|control|0
  C0446516|Upper arm|0
one fatal pulmonary embolism
  4
  C1302234|Fatal (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0013922|Embolism|0
  C0024109|Lung|0
tumor-specific biologic action
  5
  C0005522|Biological Products|0
  C0205460|Biologic (qualifier value)|0
  C1263442|SPECIFIC|0
  C0027651|Neoplasms|0
  C0441472|Action (qualifier value)|0
spine
  3
  C0037949|Vertebral column|0
  C1267072|Entire vertebral column|0
  C1280065|Entire spine|0
primary diameter cm
  4
  C0475210|cm (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
  C0205225|Primary|0
multicenter study
  1
  C0282439|Multicenter Studies|0
new york memorial study
  3
  C0557651|Room of building - Study|0
  C0205314|New (qualifier value)|0
  C0947630|Scientific Study|0
radiation therapy now
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
postoperative radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0032790|Postoperative Period|0
  C0034618|Radiation therapy|0
cox multiple regression analysis
  5
  C0002778|Analysis of substances|0
  C0684321|Regression - mental defense mechanism|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
  C0684320|Disease regression|0
dose schedule
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
age 30–70 years
  4
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
  C0439234|year (qualifier value)|0
cls
  2
  C0201952|Chloride measurement|0
  C0010575|Cycloleucine|0
similar differences
  1
  C0442729|Strains similar (qualifier value)|0
main complication
  3
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0205225|Primary|0
internal mammary lymph nodes
  1
  C0229755|Parasternal lymph node (body structure)|0
assessable patients
  1
  C0030705|Patients|0
secondary leukemias
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0036525|Metastatic to|0
  C0027627|Neoplasm Metastasis|0
  C0023418|Leukemia|0
im iv
  1
  C0231377|At risk for impaired home maintenance management (finding)|0
80.8 gy
  1
  C0556636|Gy (qualifier value)|0
central review
  2
  C0205099|Central|0
  C0282443|Review [Publication Type]|0
men
  3
  C0025266|Male population group|0
  C0086418|Homo sapiens|0
  C0024554|Male gender|0
curative local therapy
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205276|Local (qualifier value)|0
reassuring
  1
  C0557055|Reassuring (procedure)|0
leukocytopenia
  1
  C0023530|Leukopenia|0
information
  1
  C0870705|Information|0
consistency
  1
  C0332529|Consistency finding (finding)|0
squamous cell carcinoma
  1
  C0007137|Carcinoma, Squamous Cell|0
hemoglobin g
  1
  C1319312|Hemoglobin G (substance)|0
two sided significance level
  4
  C0441889|Levels (qualifier value)|0
  C0205448|Two (qualifier value)|0
  C0456079|Disease classification level|0
  C0441987|Side (qualifier value)|0
poor quality
  3
  C0542537|Poor - grade value|0
  C0699761|Financially poor|0
  C0332306|With quality (attribute)|0
five year rates
  3
  C0871208|Rating|0
  C0205451|Five (qualifier value)|0
  C0439234|year (qualifier value)|0
local failure
  3
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
  C0205276|Local (qualifier value)|0
patients to
  1
  C0030705|Patients|0
patients characteristics
  1
  C0815172|patient characteristics|0
five postoperative radiation only
  3
  C0032790|Postoperative Period|0
  C0205451|Five (qualifier value)|0
  C0851346|Radiation|0
pelvic radiotherapy
  3
  C0030797|Pelvis|0
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
use
  1
  C0042153|utilization|0
two scheduled interim analyses
  5
  C0086960|Schedules|0
  C0205448|Two (qualifier value)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0205539|Scheduled (qualifier value)|0
sequence dependent synergy
  1
  C0851827|Dependent (qualifier value)|0
figo stage advance
  5
  C0332305|With staging (attribute)|0
  C0205179|Advanced phase|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0725066|Advance|0
  C1306673|Stages (qualifier value)|0
disturbing finding
  1
  C0243095|findings|0
bowel obstruction
  1
  C0021843|Intestinal Obstruction|0
excess number
  2
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
four cycles
  1
  C0205450|Four (qualifier value)|0
6.7 weeks
  1
  C0439230|week (qualifier value)|0
myoblastoma
  1
  C0027043|Myoblastoma|0
powerful prognostic predictor
  1
  C0220901|prognostic|0
two multidrug combinations
  3
  C0453882|Combinations (physical object)|0
  C0205448|Two (qualifier value)|0
  C0205195|Combined (qualifier value)|0
astler coller modification
  5
  C0850398|Home modification|0
  C0598331|drug modification|0
  C0679628|blood modification|0
  C0579005|Modification - action|0
  C0086153|Dietary Modification|0
relative shortterm adjuvant systemic treatment
  5
  C0039798|therapeutic aspects|0
  C0080103|Relative (related person)|0
  C0205345|Relative|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
curative surgery
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
eighty one
  1
  C0205447|One (qualifier value)|0
images
  1
  C0011923|Diagnostic Imaging|0
synergistic effect
  1
  C1280500|Effect (qualifier value)|0
2-day difference
  1
  C0439228|day (qualifier value)|0
frequent vomiting
  4
  C0332183|Frequent (qualifier value)|0
  C0042965|Vomitus|0
  C0401156|Vomiting NOS (disorder)|0
  C0042963|Vomiting|0
serum levels
  3
  C0441889|Levels (qualifier value)|0
  C0229671|Serum|0
  C0456079|Disease classification level|0
lower midline incision
  4
  C0184898|Surgical incisions|0
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
  C0549183|Median (qualifier value)|0
responding patients
  1
  C0030705|Patients|0
abnormal renal function
  1
  C0151746|Abnormal renal function (finding)|0
only minimal effect
  2
  C1280500|Effect (qualifier value)|0
  C0547039|Minimal (qualifier value)|0
select patient population
  2
  C0030705|Patients|0
  C0032659|Population|0
single layer technique
  5
  C0037179|Unmarried person|0
  C0934502|Layer|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0449851|Techniques|0
sleep disturbance
  2
  C0700201|Dyssomnias|0
  C0037317|Sleep disturbances|0
m fluorouracil
  1
  C0016360|Fluorouracil|0
36.0 gy
  1
  C0556636|Gy (qualifier value)|0
6.5 years
  1
  C0439234|year (qualifier value)|0
important finding to
  1
  C0243095|findings|0
basis
  1
  C0178499|Base|0
pulmonary embolism
  1
  C0034065|Pulmonary Embolism|0
survival advantage
  3
  C0038952|Continuance of life|0
  C0308269|ADVANTAGE|0
  C0220921|survival aspects|0
neutron therapy
  1
  C0278623|high-LET neutron therapy|0
costal margins
  1
  C0582240|Border of rib (body structure)|0
localised radiation therapy to
  4
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
  C0392752|Localized (qualifier value)|0
cell division
  1
  C0007590|Cell Division|0
technique to
  2
  C0025664|Methodology|0
  C0449851|Techniques|0
negative
  1
  C0205160|Negative (qualifier value)|0
statistically significant benefit
  2
  C0814225|benefits|0
  C0750502|Significant (qualifier value)|0
urea nitrogen
  1
  C0521881|Urea nitrogen (substance)|0
ctx
  1
  C0010583|Cyclophosphamide|0
high proportion
  2
  C0205250|High|0
  C0235146|Euphoric mood|0
insufficient to significantly impact
  3
  C0726639|Impact|0
  C0231180|Insufficient|0
  C0333125|Impacted (qualifier value)|0
investigators
  1
  C0035173|Research Personnel|0
5-fu patients
  3
  C0016360|Fluorouracil|0
  C0030705|Patients|0
  C0268696|Feline urological syndrome (disorder)|0
eortc qlqc30 questionnaire
  1
  C0034394|Questionnaires|0
females
  2
  C0015780|Female|0
  C0086287|Females|0
cox model multivariate analysis
  5
  C0026336|Models|0
  C0002778|Analysis of substances|0
  C0870071|Modeling|0
  C0442996|Cox microbiology subtype|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
platelet count nadir
  3
  C0005821|Blood Platelets|0
  C0750480|COUNT|0
  C0439157|counts (qualifier value)|0
one patient receiving epi
  2
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
central neurotoxicity
  2
  C0235032|Neurotoxicity Syndromes|0
  C0205099|Central|0
x-ray
  5
  C0043299|Diagnostic radiologic examination|0
  C0043309|Roentgen Rays|0
  C0034571|roentgenographic|0
  C1306645|Plain film (procedure)|0
  C0885876|X-rays, Homeopathic Preparations|0
sublethal damage
  1
  C0010957|Damage (morphologic abnormality)|0
five year survival rate
  5
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0205451|Five (qualifier value)|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
laboratory evidence
  1
  C0022877|Laboratories|0
disagreement
  1
  C0680238|Discord|0
one hundred four patients
  3
  C0205450|Four (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
prior therapy
  3
  C0039798|therapeutic aspects|0
  C0750516|PRIOR|0
  C0087111|Therapeutic procedure|0
definitive results
  2
  C1274040|Result (navigational concept)|0
  C0443196|Definitive (qualifier value)|0
stabilisation
  1
  C1293130|Stabilization (procedure)|0
apparent success
  2
  C0597535|success|0
  C0750489|APPARENT|0
treated patients
  2
  C0030705|Patients|0
  C1292734|Treats (attribute)|0
phase ii study
  1
  C0278782|phase II study|0
mm3
  1
  C1300558|mm3 (qualifier value)|0
total white cell count
  2
  C1318024|Total white cell count NOS|0
  C0427547|Total white cell count NOS (procedure)|0
stages ib
  2
  C0456597|Stage 1 upper case bee|0
  C0457152|Stage 1 lower case bee|0
high response rates
  4
  C0205250|High|0
  C0871208|Rating|0
  C0235146|Euphoric mood|0
  C0871261|Responses|0
significant survival benefit
  4
  C0038952|Continuance of life|0
  C0814225|benefits|0
  C0750502|Significant (qualifier value)|0
  C0220921|survival aspects|0
significantly more hysterectomy specimens
  3
  C0370003|Specimen (specimen)|0
  C0205172|More (qualifier value)|0
  C0020699|Hysterectomy|0
81.0 gy
  1
  C0556636|Gy (qualifier value)|0
exponential model
  2
  C0026336|Models|0
  C0870071|Modeling|0
surviving patients
  2
  C0030705|Patients|0
  C0310255|SURVIVE (product)|0
hormonal manipulations
  4
  C0947647|Manipulation procedure|0
  C0458083|Hormonal (qualifier value)|0
  C0185111|Surgical Manipulation|0
  C1306805|Manipulations NOS (regime/therapy)|0
fewer deaths
  1
  C0011065|Cessation of life|0
provision
  2
  C0359589|Provide (product)|0
  C1138603|PROVIDER|0
cervical stromal invasion
  1
  C0205064|Cervical (qualifier value)|0
more extreme result
  3
  C0205403|Extreme (qualifier value)|0
  C1274040|Result (navigational concept)|0
  C0205172|More (qualifier value)|0
remote control afterloading system to
  4
  C0702113|Controlled (qualifier value)|0
  C0449913|System (attribute)|0
  C0243148|control|0
  C0205157|Remote (qualifier value)|0
$4-cm tumor
  2
  C0475210|cm (qualifier value)|0
  C0027651|Neoplasms|0
abdominal hernia
  1
  C0178282|Hernia of abdominal cavity|0
definitive statement
  1
  C0443196|Definitive (qualifier value)|0
untreated patients
  1
  C0030705|Patients|0
adverse events
  1
  C0877248|Adverse event|0
ureters
  2
  C0041951|Ureter|0
  C1281572|Entire ureter|0
other trials
  1
  C0205394|Other|0
requiring hospitalization
  1
  C0019993|Hospitalization|0
anthracycline
  2
  C0282564|Anthracyclines|0
  C0003234|Anthracycline Antibiotics|0
intravaginal radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0442122|Intravaginal (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
concomitant treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
additional toxic problems
  2
  C0033213|Problem (finding)|0
  C0600688|Toxic effect|0
concurrent chemotherapy usually
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205420|Concurrent (qualifier value)|0
  C0013216|Pharmacotherapy|0
subclinical clonogenic cell repopulation
  3
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0205211|Subclinical (qualifier value)|0
radiological examination
  1
  C0579007|Examination - action (qualifier value)|0
adjuvant cmf
  2
  C0950521|CMF|0
  C0001551|Adjuvants, Immunologic|0
important prognostic factor
  1
  C0220901|prognostic|0
retrospective stratification
  1
  C0035363|Retrospective Studies|0
elevation
  2
  C0439775|Elevation (procedure)|0
  C0702240|Elevation - value (qualifier value)|0
secondary endpoints
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0036525|Metastatic to|0
  C0027627|Neoplasm Metastasis|0
  C0150100|ENDPOINT|0
cancer related mortality
  5
  C0163712|Relate|0
  C0026565|Mortality Vital Statistics|0
  C0006826|Malignant Neoplasms|0
  C0026566|Aspects of mortality statistics|0
  C0445223|Related (finding)|0
stage ib
  2
  C0456597|Stage 1 upper case bee|0
  C0457152|Stage 1 lower case bee|0
single colorectal cancer patient
  5
  C0555952|Colorectal (qualifier value)|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0006826|Malignant Neoplasms|0
  C0030705|Patients|0
four field box technique
  5
  C0179400|Boxes|0
  C0205450|Four (qualifier value)|0
  C0331809|Fielding|0
  C0006080|Boxing|0
  C0449851|Techniques|0
effects presumably
  1
  C1280500|Effect (qualifier value)|0
intracavitary radiotherapy
  3
  C0034619|radiotherapeutic|0
  C1298613|Intracavitary (qualifier value)|0
  C0034618|Radiation therapy|0
then oral folinic acid rescue
  2
  C0442027|Oral (qualifier value)|0
  C0001128|Acids|0
severe late gastrointestinal complications
  5
  C0521362|Gastrointestinal|0
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0009566|Complication|0
  C0205087|Late (qualifier value)|0
  C1171258|Complication Aspects|0
intended operation
  2
  C0038895|Surgical aspects|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
large cervical lesion
  3
  C0549177|Large|0
  C0221198|Lesion|0
  C0205064|Cervical (qualifier value)|0
bony structures
  2
  C0443157|Bony (qualifier value)|0
  C0678594|structure|0
dose intensity
  5
  C0237686|Stimulus Intensity|0
  C0428760|Intensity change (finding)|0
  C0871362|Signal Intensity|0
  C0518690|Symptom intensity|0
  C0596836|light intensity|0
prescribed regimen
  2
  C0677937|regimen|0
  C0278329|Prescribed|0
systemic recurrence
  2
  C0205373|Systemic (qualifier value)|0
  C0034897|Recurrence|0
surgical specimen
  2
  C0038895|Surgical aspects|0
  C0370003|Specimen (specimen)|0
tumor masses
  2
  C0027651|Neoplasms|0
  C0728811|Masse|0
similar treatment regimen
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0677937|regimen|0
sufficient patients to
  2
  C0205410|Sufficient (qualifier value)|0
  C0030705|Patients|0
severe toxicity
  3
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
hazard ratio
  2
  C0456603|Ratio (property) (qualifier value)|0
  C0598697|hazard|0
multivariate cox regression analysis to
  5
  C0002778|Analysis of substances|0
  C0684321|Regression - mental defense mechanism|0
  C0442996|Cox microbiology subtype|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0684320|Disease regression|0
preclinical studies
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
following systemic treatment
  4
  C0205373|Systemic (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0332282|Following (attribute)|0
  C0087111|Therapeutic procedure|0
95% confidence intervals
  1
  C0009667|Confidence Intervals|0
considerably lower dose
  2
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
bleomycin u
  1
  C0005740|Bleomycin|0
only treatment to
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
increasing serum creatinine
  1
  C0700225|Serum creatinine raised (finding)|0
x l
  5
  C0043297|X Inactivation|0
  C0630658|vespakinin-X|0
  C0050651|actinomycin X|0
  C0056015|coagulopoietin X|0
  C0023819|Lipoprotein-X|0
grade
  2
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
tumour characteristics
  1
  C0027651|Neoplasms|0
radiation scheme
  1
  C0851346|Radiation|0
default conditions
  2
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
cr
  1
  C0008574|Chromium|0
previous meta-analysis
  4
  C0002778|Analysis of substances|0
  C0205156|Previous (qualifier value)|0
  C0936012|Analysis|0
  C1042496|Meta|0
hysterectomy specimens
  2
  C0370003|Specimen (specimen)|0
  C0020699|Hysterectomy|0
liver scans
  1
  C0203758|Radioisotope study of liver (procedure)|0
study performance
  3
  C0557651|Room of building - Study|0
  C0597198|Performance|0
  C0947630|Scientific Study|0
senior authors
  1
  C0221192|Author (occupation)|0
localized disease
  1
  C0277565|Local disease (finding)|0
prolonged continuous infusion
  3
  C0574032|Infusion (procedure)|0
  C0549178|Continuous (qualifier value)|0
  C0439590|Prolonged (qualifier value)|0
radiation
  1
  C0851346|Radiation|0
exact timing
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0059927|Exact|0
computed tomographic scans
  1
  C0441633|Scanning|0
local treatment
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205276|Local (qualifier value)|0
relative frequency
  4
  C0080103|Relative (related person)|0
  C0376249|With frequency|0
  C0205345|Relative|0
  C0439603|Frequencies (time pattern)|0
eleven patients
  3
  C0445482|Serotype eleven|0
  C0030705|Patients|0
  C0205457|Number eleven|0
two fractions
  2
  C0205448|Two (qualifier value)|0
  C0457426|Fractions of (qualifier value)|0
protocol entry criteria
  2
  C0243161|criteria|0
  C0442711|Protocols documentation|0
dukes b
  3
  C0524498|Duke Method|0
  C0276638|Pseudoscarlatina (disorder)|0
  C1272820|Dukes stage (observable entity)|0
asia
  1
  C0003980|Asia|0
relevant prognostic factors
  1
  C0220901|prognostic|0
unknown v negative
  2
  C0439673|Unknown (qualifier value)|0
  C0205160|Negative (qualifier value)|0
total amount
  2
  C0439810|Total (qualifier value)|0
  C0205389|Quantity (attribute)|0
presence
  1
  C0392148|Providing presence (regime/therapy)|0
earlier gynecologic oncology group trial
  5
  C0278627|oncology|0
  C0205480|Gynecologic (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
whole pelvic postoperative radiation therapy
  5
  C0030797|Pelvis|0
  C0039798|therapeutic aspects|0
  C0032790|Postoperative Period|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
additional effect
  1
  C1280500|Effect (qualifier value)|0
central pathology review
  5
  C0030664|Pathology|0
  C0205099|Central|0
  C0677042|Pathology processes|0
  C0282443|Review [Publication Type]|0
  C0205469|Pathological aspects|0
therapeutic effect
  3
  C0039796|The science and art of healing|0
  C1280500|Effect (qualifier value)|0
  C0302350|Therapeutic|0
treatment methodology
  4
  C0025664|Methodology|0
  C0039798|therapeutic aspects|0
  C0969625|Methodology aspects|0
  C0087111|Therapeutic procedure|0
stage iia cancer
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C1306673|Stages (qualifier value)|0
other criteria
  2
  C0243161|criteria|0
  C0205394|Other|0
significant difference
  1
  C0750502|Significant (qualifier value)|0
patient follow-up
  4
  C0547043|Up (qualifier value)|0
  C0030705|Patients|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
five scales
  5
  C0349674|Intellectual scale|0
  C0175659|Weight measurement scales|0
  C0205451|Five (qualifier value)|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
21.6 gy
  1
  C0556636|Gy (qualifier value)|0
or delayed chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205421|Deferred (qualifier value)|0
  C0069590|ORALIT|0
  C0013216|Pharmacotherapy|0
tumor size $2 cm
  3
  C0475210|cm (qualifier value)|0
  C0027651|Neoplasms|0
  C0702146|Size (attribute)|0
complete blood cell count
  5
  C0007634|Cells|0
  C0750480|COUNT|0
  C0005767|Blood|0
  C0205197|Complete (qualifier value)|0
  C0439157|counts (qualifier value)|0
kaplan–meier analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
percent difference
  1
  C0439165|Percent (qualifier value)|0
recurrence outcomes
  1
  C0034897|Recurrence|0
activityin cervical cancer
  1
  C0007847|Malignant neoplasm of cervix uteri|0
additional benefit
  1
  C0814225|benefits|0
lower margin
  4
  C1269830|Tumor margin status|0
  C0205284|Marginal (qualifier value)|0
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
karnofsky scale
  1
  C0206065|Karnofsky Performance Status|0
gy
  1
  C0556636|Gy (qualifier value)|0
sex ratios
  1
  C0036893|Sex Ratio|0
cardiac disease
  1
  C0018799|Heart Diseases|0
only combined modality regimens
  4
  C0336789|Combine, device (physical object)|0
  C0677937|regimen|0
  C0205195|Combined (qualifier value)|0
  C0695347|MODALITY|0
equally likely explanation
  2
  C0750504|Likely|0
  C0681841|explanation|0
acute toxicities
  3
  C0040539|Toxicity aspects|0
  C0205178|Acuteness (qualifier value)|0
  C0600688|Toxic effect|0
nine
  1
  C0205455|Nine (qualifier value)|0
recommendations
  1
  C0034866|Recommendations|0
laparotomy scar
  3
  C0036287|Scarring|0
  C0008767|Scar|0
  C0023038|Laparotomy|0
cycles
  2
  C0439596|Cyclic (qualifier value)|0
  C0031084|Periodicity|0
frequency
  2
  C0376249|With frequency|0
  C0439603|Frequencies (time pattern)|0
platinum based regimens
  4
  C1171558|Platinum metallicum, platinum, Homeopathic preparation|0
  C0178499|Base|0
  C0032207|Platinum|0
  C0677937|regimen|0
sample size goal
  4
  C0870078|Sampling|0
  C0441621|Sampling - Surgical action|0
  C0702146|Size (attribute)|0
  C0018017|Goals|0
further treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
patients often
  2
  C0332183|Frequent (qualifier value)|0
  C0030705|Patients|0
other specific tests
  5
  C0039593|Testing|0
  C1263442|SPECIFIC|0
  C0205369|Specific (qualifier value)|0
  C0392366|Tests (qualifier value)|0
  C0205394|Other|0
hemoglobin
  1
  C0019046|Hemoglobin|0
affect performance status
  5
  C0449438|Status (attribute)|0
  C1314940|Affecting (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0597198|Performance|0
  C0001721|Affect|0
sufficient data
  1
  C0205410|Sufficient (qualifier value)|0
present prospective randomized study
  3
  C0557651|Room of building - Study|0
  C0150312|Present|0
  C0947630|Scientific Study|0
14% response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
more conservative approach
  2
  C0205172|More (qualifier value)|0
  C0449445|Approach (attribute)|0
financial scores
  2
  C0376243|financial|0
  C0449820|Scores (qualifier value)|0
important information
  1
  C0870705|Information|0
simon
  1
  C0443058|Simon (qualifier value)|0
common set
  3
  C0542559|contextual factors|0
  C0205214|Common (qualifier value)|0
  C0036849|Set (Psychology)|0
cox’s proportional hazard model
  1
  C0033489|Proportional Hazards Models|0
envelope system
  1
  C0449913|System (attribute)|0
treatment efficacy
  1
  C0087113|Treatment Effectiveness|0
enhanced efficacy
  5
  C0087113|Treatment Effectiveness|0
  C0600564|Self Efficacy|0
  C0598333|drug efficacy|0
  C0235828|EFFICACY, LACK OF|0
  C0683261|efficacy expectations|0
additional relapses
  3
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
close surgical margins
  5
  C0677512|Closed approach|0
  C0038895|Surgical aspects|0
  C1269830|Tumor margin status|0
  C0205284|Marginal (qualifier value)|0
  C0587267|Closed|0
best adjuvant treatment
  3
  C0039798|therapeutic aspects|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
similar proportions
  1
  C0442729|Strains similar (qualifier value)|0
total number
  3
  C0439810|Total (qualifier value)|0
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
most distressing side effects
  5
  C1280500|Effect (qualifier value)|0
  C0700361|Feeling upset (finding)|0
  C0231303|Distress (finding)|0
  C0205393|Most (qualifier value)|0
  C0441987|Side (qualifier value)|0
urine ph
  1
  C0042044|Urine pH test (procedure)|0
first 5-year analysis
  4
  C0002778|Analysis of substances|0
  C0205435|First (qualifier value)|0
  C0936012|Analysis|0
  C0439234|year (qualifier value)|0
relative likelihood
  2
  C0080103|Relative (related person)|0
  C0205345|Relative|0
chronic toxicities
  3
  C0040539|Toxicity aspects|0
  C0205191|Chronic (qualifier value)|0
  C0600688|Toxic effect|0
accelerated repopulation
  1
  C0521110|Accelerated (contextual qualifier) (qualifier value)|0
observed reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
purine concentrations
  3
  C0086045|Concentration|0
  C0034140|Purines|0
  C0220903|purine|0
postirradiation recurrent cancer
  4
  C0205335|Recurrent (qualifier value)|0
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
cervical diameter
  2
  C0205064|Cervical (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
methods
  2
  C0025664|Methodology|0
  C0025663|Methods|0
two pa dissemination
  2
  C0205448|Two (qualifier value)|0
  C0030125|p-Aminosalicylic Acid|0
hydroxyl group
  1
  C0700307|hydroxyl group|0
disease-free survival advantage
  4
  C0038952|Continuance of life|0
  C0308269|ADVANTAGE|0
  C0012634|Disease|0
  C0220921|survival aspects|0
originally pro1 posed
  1
  C0769010|PRO1 protein, Sordaria macrospora|0
adequate bone marrow
  5
  C0262950|Skeletal bone|0
  C0376152|Marrow|0
  C0205411|Adequate (qualifier value)|0
  C1266909|Entire bony skeleton|0
  C0086590|Vegetable marrow|0
small fraction
  2
  C0457426|Fractions of (qualifier value)|0
  C0700321|Small|0
required follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
fibrosarcoma
  1
  C0016057|Fibrosarcoma|0
high-risk cervical cancers
  5
  C0998265|Cancer Genus|0
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0006826|Malignant Neoplasms|0
  C0035647|Risk|0
underwent surgery
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
toxicity profile
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
multimodality approach
  1
  C0449445|Approach (attribute)|0
primary reason
  3
  C0439631|Primary operation (qualifier value)|0
  C0684328|Reasoning|0
  C0205225|Primary|0
presacral nodes
  1
  C0746922|NODE|0
much poorer rate
  1
  C0871208|Rating|0
treatment weeks
  3
  C0039798|therapeutic aspects|0
  C0439230|week (qualifier value)|0
  C0087111|Therapeutic procedure|0
significantly fewer recurrences
  1
  C0034897|Recurrence|0
clinical assessment
  2
  C0205210|Clinical (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
internal iliac vessels
  3
  C0020889|Bone structure of ilium|0
  C0005847|Blood Vessels|0
  C0205102|Intrinsic|0
adjuvant therapy
  1
  C0677850|adjuvant therapy|0
sudden onset
  2
  C1276802|Sudden onset (attribute)|0
  C1272517|Sudden onset (contextual qualifier) (qualifier value)|0
kruskal–wallis test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
preoperative four preoperative radiation
  3
  C0205450|Four (qualifier value)|0
  C0445204|Preoperative (qualifier value)|0
  C0851346|Radiation|0
clinical data
  1
  C0205210|Clinical (qualifier value)|0
55% decrease
  3
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
cardiotoxicity
  1
  C0876994|Cardiotoxicity|0
mid-axilla
  3
  C1279154|Entire axilla|0
  C0444598|Mid (qualifier value)|0
  C0004454|Axilla|0
many investigations
  2
  C0430007|Clinical investigation|0
  C0439064|Numerous (qualifier value)|0
feasible histologic examination
  2
  C0579007|Examination - action (qualifier value)|0
  C0205462|Histologic|0
blood chemistries
  1
  C0005774|Blood Chemical Analysis|0
cholinergic syndromes
  1
  C0274702|Poisoning by parasympathomimetic drug (disorder)|0
third patient
  2
  C0205437|Third (qualifier value)|0
  C0030705|Patients|0
survival decline
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
commonly
  1
  C0205214|Common (qualifier value)|0
phase trials
  2
  C0585064|Numerical phases (qualifier value)|0
  C0205390|Phase (qualifier value)|0
greater effects
  2
  C1280500|Effect (qualifier value)|0
  C0443228|Greater (qualifier value)|0
intervals
  1
  C1272706|Interval (qualifier value)|0
earlier extensive phase i
  3
  C0585064|Numerical phases (qualifier value)|0
  C0205231|Extensive (qualifier value)|0
  C0205390|Phase (qualifier value)|0
magnesium sulfate
  1
  C0024480|Magnesium Sulfate|0
39.0 mg
  2
  C0024467|Magnesium|0
  C0439210|milligram|0
neoadjuvant chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
similar survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
certain patients
  2
  C0205423|Certainty (attribute)|0
  C0030705|Patients|0
continuous 3.0 polypropylene
  2
  C0032582|Polypropylenes|0
  C0549178|Continuous (qualifier value)|0
central telephone randomization
  3
  C0205099|Central|0
  C0034656|Random Allocation|0
  C0039457|Telephone|0
planned number
  4
  C0449788|Count of entities (property) (qualifier value)|0
  C1301732|Planned (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
units heparin
  2
  C0439148|Unit|0
  C0019134|Heparin|0
standard dose prescription
  3
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
  C0033080|Prescriptions|0
vincristine combination
  3
  C0453882|Combinations (physical object)|0
  C0042679|Vincristine|0
  C0205195|Combined (qualifier value)|0
actuarial probability
  1
  C0033204|Probability|0
brazil
  1
  C0006137|Brazil|0
mammography
  1
  C0024671|Mammography|0
argument
  1
  C0680226|Disputes|0
sites
  1
  C0205145|Associated topography (attribute)|0
remarkable consistency
  1
  C0332529|Consistency finding (finding)|0
suggestion
  1
  C0038659|Suggestion|0
intracavitary placement
  3
  C0449268|PLACEMENT|0
  C1298613|Intracavitary (qualifier value)|0
  C0441587|Clinical act of insertion|0
entirely human antibodies
  4
  C0020114|Human|0
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
  C0086418|Homo sapiens|0
barium enema
  1
  C0203075|Barium enema (procedure)|0
condition
  2
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
65% 5-year survival rate
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
further four courses
  3
  C0205450|Four (qualifier value)|0
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
high antitumour efficacy
  2
  C0205250|High|0
  C0235146|Euphoric mood|0
treatment-related intestinal obstructions
  5
  C0021853|Intestines|0
  C0163712|Relate|0
  C0028778|Obstruction|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
significant coexistent disease
  2
  C0750502|Significant (qualifier value)|0
  C0012634|Disease|0
serum creatinine concentration
  3
  C0086045|Concentration|0
  C0229671|Serum|0
  C0010294|Creatinine|0
remaining patients
  1
  C0030705|Patients|0
stage ib cervical cancer
  1
  C0278582|Cervical carcinoma stage IB|0
median dose
  2
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
programmed local treatment
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205276|Local (qualifier value)|0
17-la target
  1
  C0599894|targeting|0
regimens
  1
  C0677937|regimen|0
al’s study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
extended serum half-lives
  4
  C0376558|Life|0
  C0229671|Serum|0
  C0231449|Extended (qualifier value)|0
  C0332258|Extending (qualifier value)|0
not eligible central nervous system metastasis
  5
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0027769|Nervousness|0
  C0449913|System (attribute)|0
  C0205099|Central|0
  C0027627|Neoplasm Metastasis|0
failure patterns
  3
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
  C0449774|Patterns (qualifier value)|0
arm
  2
  C0003792|Arm|0
  C0446516|Upper arm|0
national surgical adjuvant breast
  5
  C0038895|Surgical aspects|0
  C0006141|Breast|0
  C1268990|Entire breast|0
  C0001551|Adjuvants, Immunologic|0
  C0015737|Federal Government|0
bladder
  2
  C1281573|Entire bladder|0
  C0005682|Bladder|0
s1 junction
  2
  C1179704|S1 innervation|0
  C0205144|Junctional (qualifier value)|0
dosage schedule
  3
  C0086960|Schedules|0
  C0178602|Dosages (qualifier value)|0
  C0205539|Scheduled (qualifier value)|0
31% chance
  1
  C0237506|Chance|0
source
  1
  C0449416|Source (attribute)|0
mtx
  1
  C0025677|Methotrexate|0
partially fixed tumours
  2
  C0027651|Neoplasms|0
  C0443218|Fixed (qualifier value)|0
balance potential benefit to
  5
  C0205415|Balanced - adjective|0
  C0237399|Potential|0
  C0814225|benefits|0
  C0014653|Equilibrium|0
  C0542274|Does balance|0
randomized trial to
  5
  C0034660|Randomized Response Technique|0
  C0282440|Randomized Controlled Trials|0
  C0008976|Clinical Trials|0
  C0206012|Multicenter Trials|0
  C0206034|Clinical Trials, Randomized|0
older equipment
  2
  C0014672|Equipment|0
  C0220824|Equipment used|0
full drug doses
  4
  C0684270|Drugged|0
  C0719635|DOS|0
  C0443225|Full (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
histology
  3
  C0205462|Histologic|0
  C0344441|Histology Procedure|0
  C0019638|Histology|0
end
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
kinetics
  2
  C0220865|kinetic characteristics|0
  C0022702|Kinetics|0
secondary objective
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0036525|Metastatic to|0
  C0027627|Neoplasm Metastasis|0
  C0018017|Goals|0
skin reactions
  1
  C0221743|Skin reaction (observable entity)|0
leukocyte count nadir
  3
  C0023516|Leukocytes|0
  C0750480|COUNT|0
  C0439157|counts (qualifier value)|0
contrast computed tomography
  1
  C0040395|Tomography|0
only sampling
  2
  C0870078|Sampling|0
  C0441621|Sampling - Surgical action|0
improved overall response rate
  5
  C1272745|Improving (qualifier value)|0
  C0871208|Rating|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0282416|Overall [Publication Type]|0
  C0184511|Improved (qualifier value)|0
lower limit wasthe caudal pole
  5
  C0935623|Pole|0
  C0439801|Limited (qualifier value)|0
  C0441994|Lower (qualifier value)|0
  C0205097|Caudal (qualifier value)|0
  C0337815|Poles (ethnic group)|0
subsequent morbidity
  3
  C0026538|Morbidity - disease rate|0
  C0750530|SUBSEQUENT|0
  C0220880|morbidity aspects|0
cardiac failure
  1
  C0018801|Heart failure NOS (disorder)|0
meccnu patients
  2
  C0036637|Semustine|0
  C0030705|Patients|0
late complications
  3
  C0009566|Complication|0
  C0205087|Late (qualifier value)|0
  C1171258|Complication Aspects|0
list
  1
  C0745732|LIST|0
adjuvant x-ray
  3
  C0086894|Rajiformes|0
  C0001551|Adjuvants, Immunologic|0
  C0851346|Radiation|0
best supportive care
  2
  C0150499|Caring|0
  C0728734|Caring caregiver-patient relationship|0
increased morbidity
  5
  C0442808|Increasing (qualifier value)|0
  C0026538|Morbidity - disease rate|0
  C0205217|Increased (qualifier value)|0
  C0220880|morbidity aspects|0
  C0442805|Increase (qualifier value)|0
median follow-up
  5
  C0547043|Up (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C1282911|Upward (qualifier value)|0
  C0549183|Median (qualifier value)|0
  C0332282|Following (attribute)|0
european trial
  1
  C0239307|EUROPEAN|0
chemistry profile
  1
  C0545265|Chemistry profile|0
running absorbable suture
  5
  C0600140|Does run (finding)|0
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0502420|Suture Joint|0
  C0035953|Running|0
finding
  1
  C0243095|findings|0
informed consent form
  1
  C0009797|Consent Forms|0
gastrointestinal series
  2
  C0521362|Gastrointestinal|0
  C0205549|Series (qualifier value)|0
normal blood counts
  5
  C0392895|Bloods (ethnic group)|0
  C0005768|In Blood|0
  C0750480|COUNT|0
  C0005767|Blood|0
  C0439157|counts (qualifier value)|0
pathologic risk factors
  2
  C0205469|Pathological aspects|0
  C0035647|Risk|0
supervoltage radiation therapy
  1
  C0454064|Megavoltage radiation therapy (procedure)|0
others probably increased toxicity
  5
  C0750492|Probably|0
  C0442808|Increasing (qualifier value)|0
  C0332148|Probable diagnosis|0
  C0600688|Toxic effect|0
  C0442805|Increase (qualifier value)|0
depletion
  1
  C0333668|Depletion (morphologic abnormality)|0
uterine vessels
  2
  C0005847|Blood Vessels|0
  C0042149|Uterus|0
median interval
  3
  C0876920|Median Statistical Measurement|0
  C1272706|Interval (qualifier value)|0
  C0549183|Median (qualifier value)|0
major response rate
  3
  C0205164|Major (qualifier value)|0
  C0871208|Rating|0
  C0871261|Responses|0
radiotherapy group patients
  5
  C0034619|radiotherapeutic|0
  C0030705|Patients|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0034618|Radiation therapy|0
measurable lesion
  1
  C0221198|Lesion|0
therapeutic responses
  1
  C0521982|Therapeutic response, function (observable entity)|0
perioperative complications
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
very few patients
  3
  C0030705|Patients|0
  C0205388|Few (qualifier value)|0
  C0442824|Very (qualifier value)|0
combined postoperative chemotherapy
  5
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0032790|Postoperative Period|0
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0013216|Pharmacotherapy|0
prophylactic radiation
  3
  C0009653|Condoms, Male|0
  C0445202|Prophylactic (qualifier value)|0
  C0851346|Radiation|0
disease-free survival rates
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0012634|Disease|0
  C0220921|survival aspects|0
time days
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0439228|day (qualifier value)|0
  C0392761|Timed (qualifier value)|0
assistance
  1
  C0018896|Helping Behavior|0
local relapses
  4
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
serum creatinine 1.5 mg
  2
  C0229671|Serum|0
  C0010294|Creatinine|0
opinion
  1
  C0871010|Opinions|0
other advantages
  2
  C0308269|ADVANTAGE|0
  C0205394|Other|0
student t test
  1
  C0871453|Students T Test|0
time intervals
  1
  C0872291|time interval|0
high-pressure bladder
  5
  C0205250|High|0
  C0392677|Pressure|0
  C0005682|Bladder|0
  C0033095|Pressure- physical agent|0
  C0460139|Pressure - action|0
preferentially adriamycin containing regimen
  3
  C0085752|Adriamycin|0
  C0332256|Containing (qualifier value)|0
  C0677937|regimen|0
colonoscopy
  1
  C0009378|Colonoscopy|0
9.3 weeks
  1
  C0439230|week (qualifier value)|0
probably alkylating agent
  3
  C0750492|Probably|0
  C0332148|Probable diagnosis|0
  C0450442|Agent (attribute)|0
acute side effects
  3
  C1280500|Effect (qualifier value)|0
  C0205178|Acuteness (qualifier value)|0
  C0441987|Side (qualifier value)|0
large retrospective analyses
  4
  C0549177|Large|0
  C0002778|Analysis of substances|0
  C0035363|Retrospective Studies|0
  C0936012|Analysis|0
three clinical stages
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0205210|Clinical (qualifier value)|0
  C0205449|Three (qualifier value)|0
  C1306673|Stages (qualifier value)|0
cumulative epi doses
  1
  C0719635|DOS|0
repair
  4
  C0374711|Repair - action|0
  C0205340|Repaired (qualifier value)|0
  C0043240|Wound Healing|0
  C0184985|Surgical repair (procedure)|0
adjust
  4
  C0376209|Individual Adjustment|0
  C0001537|Clinical Adjustment|0
  C0683269|Psychological adjustment|0
  C0456081|Adjustment Action|0
two layer
  2
  C0934502|Layer|0
  C0205448|Two (qualifier value)|0
written informed consent
  1
  C0700287|Reporting|0
less cardiotoxic drug
  2
  C0684270|Drugged|0
  C0013227|Pharmaceutical Preparations|0
six patients
  2
  C0030705|Patients|0
  C0205452|Six (qualifier value)|0
two deaths
  2
  C0011065|Cessation of life|0
  C0205448|Two (qualifier value)|0
survival time
  5
  C0038952|Continuance of life|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0220921|survival aspects|0
  C0392761|Timed (qualifier value)|0
not cells
  2
  C0007634|Cells|0
  C1269647|Entire cell|0
twenty five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
lemberts method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
three risk factors
  2
  C0205449|Three (qualifier value)|0
  C0035647|Risk|0
insulin-dependent diabetic man
  5
  C0241863|Diabetic|0
  C0025266|Male population group|0
  C0086418|Homo sapiens|0
  C0024554|Male gender|0
  C0851827|Dependent (qualifier value)|0
similar pharmacokinetic behavior
  3
  C0004927|Behavior|0
  C0031328|Pharmacokinetic|0
  C0677505|Behaviors and observations relating to behavior|0
tion therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
treatment allocation
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
tumor response
  2
  C0027651|Neoplasms|0
  C0871261|Responses|0
acceptable radiation doses
  2
  C0719635|DOS|0
  C0851346|Radiation|0
improving survival
  5
  C1272745|Improving (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
serum creatinine
  2
  C0201976|SERUM CREATININE TESTS|0
  C0600061|Serum creatinine level|0
surgical treatment
  1
  C0543467|GENERAL OPERATIVE PROCEDURES|0
interaction
  2
  C0037420|Social Interaction|0
  C0687133|Drug Interactions|0
one death
  2
  C0011065|Cessation of life|0
  C0205447|One (qualifier value)|0
great proportion
  1
  C0549177|Large|0
bowel preparation
  1
  C0455052|Preparation of bowel for procedure (procedure)|0
qlq-c30 questionnaire
  1
  C0034394|Questionnaires|0
renewed interest
  1
  C0543488|Interested (finding)|0
associated mortality
  2
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
wrong primary tumor
  3
  C0027651|Neoplasms|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
subclinical cardiac injury
  4
  C0205041|Cardio-|0
  C0021501|injuries|0
  C0205211|Subclinical (qualifier value)|0
  C0175677|Injury inflicted to the body by an external force|0
cumulative dose to
  4
  C0035127|Cumulative Trauma Disorders|0
  C0683233|cumulative gene|0
  C0678785|cumulative drug effect|0
  C0010456|Cumulative Survival Rate|0
overall pelvic control
  4
  C0702113|Controlled (qualifier value)|0
  C0030797|Pelvis|0
  C0243148|control|0
  C0282416|Overall [Publication Type]|0
dukes c
  1
  C0007886|Cesium|0
three week schedule
  4
  C0086960|Schedules|0
  C0439230|week (qualifier value)|0
  C0205449|Three (qualifier value)|0
  C0205539|Scheduled (qualifier value)|0
systemic relapses
  4
  C0205373|Systemic (qualifier value)|0
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
reproducibility
  5
  C0748342|REPRODUCTIVE|0
  C0439659|Beginning|0
  C0314603|Genetic|0
  C0005615|Parturition|0
  C0079946|National origin|0
independent additive cytotoxic effect
  3
  C1280500|Effect (qualifier value)|0
  C0442796|Additive (qualifier value)|0
  C1299583|Independently able (qualifier value)|0
experienced recurrences
  2
  C0596545|experience|0
  C0034897|Recurrence|0
endomyocardial biopsy
  1
  C0189785|Endomyocardial biopsy (procedure)|0
concomitant therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
follow-up examinations
  1
  C0260832|[V]Follow-up examination (context-dependent category)|0
completeness
  1
  C0439812|Completeness (qualifier value)|0
median cumulative doses
  3
  C0876920|Median Statistical Measurement|0
  C0719635|DOS|0
  C0549183|Median (qualifier value)|0
only high-risk patients
  4
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0030705|Patients|0
  C0035647|Risk|0
low response rates
  4
  C0234886|Lowing, function (observable entity)|0
  C0871208|Rating|0
  C0871261|Responses|0
  C0205251|Low (qualifier value)|0
m treated group
  4
  C1292734|Treats (attribute)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
disease-free survival analyses
  5
  C0038952|Continuance of life|0
  C0002778|Analysis of substances|0
  C0012634|Disease|0
  C0936012|Analysis|0
  C0220921|survival aspects|0
iib tumors
  1
  C0027651|Neoplasms|0
evaluation
  2
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
excessive toxicity
  3
  C0040539|Toxicity aspects|0
  C0442802|Excessive (qualifier value)|0
  C0600688|Toxic effect|0
other eligibility criteria
  2
  C0243161|criteria|0
  C0205394|Other|0
subsequent mortality
  3
  C0026565|Mortality Vital Statistics|0
  C0750530|SUBSEQUENT|0
  C0026566|Aspects of mortality statistics|0
7.5 mg
  2
  C0024467|Magnesium|0
  C0439210|milligram|0
only .05 probability
  1
  C0033204|Probability|0
different methods
  2
  C0025664|Methodology|0
  C0025663|Methods|0
cervical neoplasms
  1
  C0007873|Cervix Neoplasms|0
17-ia antibody
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
major symptoms
  2
  C0205164|Major (qualifier value)|0
  C0683368|symptoms|0
median cumulative dose
  2
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
computed tomography scan
  2
  C0441633|Scanning|0
  C0040395|Tomography|0
wide resection
  3
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
  C0332464|Widened structure (morphologic abnormality)|0
injections
  2
  C0021485|Injections|0
  C1272883|Injection (product)|0
history
  5
  C0019665|history|0
  C1321503|History of (contextual qualifier) (qualifier value)|0
  C0019664|Recording of previous events|0
  C0262512|History of (present illness) (contextual qualifier) (qualifier value)|0
  C0262926|Medical History|0
patient’s informed consent
  1
  C0021430|Informed Consent|0
local metastases
  3
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0027627|Neoplasm Metastasis|0
  C0205276|Local (qualifier value)|0
therefore high incidence
  4
  C0021149|Incidence|0
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0220856|incidence of cases|0
epirubicin
  1
  C0014582|Epirubicin|0
initial radiation
  2
  C0851346|Radiation|0
  C0205265|Initial (qualifier value)|0
placebo
  1
  C0032042|Placebos|0
treatment protocol epi
  3
  C0039798|therapeutic aspects|0
  C0442711|Protocols documentation|0
  C0087111|Therapeutic procedure|0
anastomotic failure
  3
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
  C0332854|Anastomotic|0
m2 epirubicin x days
  2
  C0014582|Epirubicin|0
  C0439228|day (qualifier value)|0
one refusal
  1
  C0205447|One (qualifier value)|0
data forms
  3
  C0376315|Manufactured form|0
  C0205431|Formed (qualifier value)|0
  C0348078|Qualitative form|0
therapeutic results
  1
  C0808233|THERAPEUTIC RESULTS|0
vascular invasion
  1
  C0005847|Blood Vessels|0
six protocol violations
  2
  C0442711|Protocols documentation|0
  C0205452|Six (qualifier value)|0
cisplatin based regimens
  3
  C0008838|Cisplatin|0
  C0178499|Base|0
  C0677937|regimen|0
pt4 tumors however
  1
  C0027651|Neoplasms|0
full protocol doses
  3
  C0719635|DOS|0
  C0442711|Protocols documentation|0
  C0443225|Full (qualifier value)|0
thomas deviations
  1
  C0012727|Spatial Displacement|0
radiosensitizer
  1
  C0034541|Radiation-Sensitizing Agents|0
center
  2
  C0935444|Centering|0
  C0205099|Central|0
fu mg
  2
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
two sided
  2
  C0205448|Two (qualifier value)|0
  C0441987|Side (qualifier value)|0
haemoglobin g
  1
  C1319312|Hemoglobin G (substance)|0
calculations
  5
  C0870240|Calculators|0
  C0006675|Calcium|0
  C1135892|Limes|0
  C0444686|Calculated (qualifier value)|0
  C0064990|Calcium oxide|0
adverse effects
  2
  C0001688|adverse effects|0
  C0879626|adverse effect|0
patients’ medical records
  1
  C0025102|Medical Records|0
treatment cycle
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
weekly cisplatin
  2
  C0008838|Cisplatin|0
  C0332174|Weekly (qualifier value)|0
delivery
  3
  C0011209|Obstetric Delivery|0
  C0559563|Delivery finding (finding)|0
  C1135594|Delivery|0
eight weeks
  2
  C0205454|Eight (qualifier value)|0
  C0439230|week (qualifier value)|0
study end point
  4
  C1272693|Ended (qualifier value)|0
  C0557651|Room of building - Study|0
  C0444930|End (qualifier value)|0
  C0947630|Scientific Study|0
ii axillary lymph nodes
  4
  C0746922|NODE|0
  C0024202|Lymph|0
  C0004454|Axilla|0
  C0439069|Roman numeral II|0
lymphangiogram nodal findings
  3
  C0443268|Nodal (qualifier value)|0
  C0024219|Lymphangiography|0
  C0243095|findings|0
cervical cancer results
  5
  C1274040|Result (navigational concept)|0
  C0998265|Cancer Genus|0
  C0205064|Cervical (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
inadequate irradiation dosage
  5
  C0205412|Inadequate (qualifier value)|0
  C0178602|Dosages (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
interval
  1
  C1272706|Interval (qualifier value)|0
participating institutions
  1
  C1272753|Institution (social concept)|0
site
  1
  C0205145|Associated topography (attribute)|0
patient population
  2
  C0030705|Patients|0
  C0032659|Population|0
iqr 4.12 days
  1
  C0439228|day (qualifier value)|0
extrafascial hysterectomy
  1
  C0020699|Hysterectomy|0
1-year survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
estimated five year survival rates
  5
  C0038952|Continuance of life|0
  C0205451|Five (qualifier value)|0
  C0220921|survival aspects|0
  C0750572|ESTIMATED|0
  C0439234|year (qualifier value)|0
significantly longer hazard ratio
  2
  C0456603|Ratio (property) (qualifier value)|0
  C0598697|hazard|0
resection
  2
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
median size
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0702146|Size (attribute)|0
20% mortality
  2
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
disease relapsed interval
  5
  C0035020|Relapse|0
  C0012634|Disease|0
  C0205336|Relapsing course|0
  C1272706|Interval (qualifier value)|0
  C0580802|Relapse phase|0
abdominal carcinomatosis
  2
  C0456438|Abdominal (qualifier value)|0
  C0205699|Carcinomatosis|0
continuous infusion
  1
  C0444889|Continuous infusion (qualifier value)|0
single agent weekly cisplatin
  5
  C0037179|Unmarried person|0
  C0008838|Cisplatin|0
  C0205171|Singular|0
  C0332174|Weekly (qualifier value)|0
  C0087136|Unmarried|0
treatment effect
  3
  C1280500|Effect (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
e e m
  5
  C0022985|Laminin M|0
  C0009293|Colicin M|0
  C0039939|Thioredoxin M|0
  C0032538|Polymyxin M|0
  C0019030|Hemoglobin M|0
protocol specific eligibility checklists
  3
  C0442711|Protocols documentation|0
  C1263442|SPECIFIC|0
  C0205369|Specific (qualifier value)|0
bowel project
  1
  C0021853|Intestines|0
recurrent tumors
  1
  C0521158|Recurrent tumor (finding)|0
pelvic lymph nodes
  2
  C1280315|Entire pelvic lymph node|0
  C0729595|Pelvic lymph node group|0
ifosfamide 5.0 g
  2
  C0162832|APC Gene|0
  C0020823|Ifosfamide|0
min.
  5
  C0439232|Minute of time|0
  C0026162|Minerals|0
  C0026193|Minor|0
  C0205165|Minor (value)|0
  C0026158|Mineralization, NOS|0
irradiation
  3
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
condition requiring surgery
  5
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
day
  1
  C0439228|day (qualifier value)|0
radiation responsiveness
  1
  C0851346|Radiation|0
required treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
intravaginal therapy
  3
  C0039798|therapeutic aspects|0
  C0442122|Intravaginal (qualifier value)|0
  C0087111|Therapeutic procedure|0
30-month rate
  2
  C0871208|Rating|0
  C0439231|month (qualifier value)|0
previous adjuvant therapy
  4
  C0039798|therapeutic aspects|0
  C0205156|Previous (qualifier value)|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
magnesium
  1
  C0024467|Magnesium|0
preoperative treatment
  3
  C0039798|therapeutic aspects|0
  C0445204|Preoperative (qualifier value)|0
  C0087111|Therapeutic procedure|0
conflicting results
  2
  C1274040|Result (navigational concept)|0
  C0009671|Conflict (Psychology)|0
recurrence free intervals
  2
  C0034897|Recurrence|0
  C1272706|Interval (qualifier value)|0
platelets 100,000/cu mm
  1
  C0005821|Blood Platelets|0
local event
  2
  C0441471|Events (event)|0
  C0205276|Local (qualifier value)|0
x
  1
  C0078606|xanthosine|0
patients considerable amount
  2
  C0205389|Quantity (attribute)|0
  C0030705|Patients|0
significant similarity
  1
  C0750502|Significant (qualifier value)|0
retroperitoneal surgical exploration
  4
  C0038895|Surgical aspects|0
  C0035359|Retroperitoneal Space|0
  C0581690|Exploration - action (qualifier value)|0
  C1280903|Exploration procedure (procedure)|0
confirmation
  2
  C0750484|CONFIRMED|0
  C0750568|CONFIRMATORY|0
several approaches
  2
  C0443302|Several (qualifier value)|0
  C0449445|Approach (attribute)|0
only regimen
  1
  C0677937|regimen|0
stomatitis
  1
  C0038362|Stomatitis|0
angiography
  1
  C0002978|Angiography|0
repeat measurements
  2
  C0205341|Repeat (qualifier value)|0
  C0242485|Measurement|0
more high70 years
  2
  C0205172|More (qualifier value)|0
  C0439234|year (qualifier value)|0
prognostic importance
  1
  C0220901|prognostic|0
severity
  2
  C0449294|With severity (attribute)|0
  C0439793|Severities (qualifier value)|0
4 6 mo thereafter
  1
  C0026402|Molybdenum|0
two compounds
  2
  C0205448|Two (qualifier value)|0
  C0205198|Compound (qualifier value)|0
singularly discouraging
  5
  C0037179|Unmarried person|0
  C0260600|Single liveborn|0
  C0037177|Single Parent|0
  C0205171|Singular|0
  C0087136|Unmarried|0
survival benefit
  3
  C0038952|Continuance of life|0
  C0814225|benefits|0
  C0220921|survival aspects|0
chemotherapy group
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0013216|Pharmacotherapy|0
to follow-up evaluation
  5
  C0220825|Evaluation|0
  C0547043|Up (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
prior irradiation
  4
  C0750516|PRIOR|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
surface
  1
  C0205148|Surface (qualifier value)|0
colon cancer
  1
  C0007102|Malignant tumor of colon|0
occasional confusion
  1
  C0009676|Confusion|0
cell culture
  1
  C0007585|Cell Culture|0
systemic chemotherapy
  4
  C0205373|Systemic (qualifier value)|0
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
leukemogenic effect
  1
  C1280500|Effect (qualifier value)|0
persisting bone pain
  5
  C0030193|Pain|0
  C0262950|Skeletal bone|0
  C0391978|Bone Tissue|0
  C1266909|Entire bony skeleton|0
  C1266908|Entire bone (organ)|0
cisplatin therapy
  3
  C0039798|therapeutic aspects|0
  C0008838|Cisplatin|0
  C0087111|Therapeutic procedure|0
patient accrual
  1
  C0030705|Patients|0
nine additional deaths
  2
  C0011065|Cessation of life|0
  C0205455|Nine (qualifier value)|0
young unpublished data
  1
  C0332239|Young (qualifier value)|0
improved results
  4
  C1274040|Result (navigational concept)|0
  C1272745|Improving (qualifier value)|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
32% objective response rate
  3
  C0871208|Rating|0
  C0871261|Responses|0
  C0018017|Goals|0
40% cause specific survival rate
  5
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0015127|Causality|0
10.5 months
  1
  C0439231|month (qualifier value)|0
multiple regression analysis
  5
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0684321|Regression - mental defense mechanism|0
  C0439064|Numerous (qualifier value)|0
  C0684320|Disease regression|0
mesna
  2
  C0000294|Mesna|0
  C0917779|Mesnum|0
median total dose
  3
  C0439810|Total (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
dose effect relationships
  1
  C0683160|dose-effect relationship|0
surveillance committees
  3
  C0220920|surveillance aspects|0
  C0684245|legal surveillance|0
  C0733511|Medical Surveillance|0
only group significantly
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
homogeneity
  1
  C0181200|Homogenizers|0
opaque
  2
  C0029053|Decreased translucency|0
  C1261286|Opaque (qualifier value)|0
lateral surface
  2
  C0205093|Lateral (qualifier value)|0
  C0205148|Surface (qualifier value)|0
tumor size $5 cm
  3
  C0475210|cm (qualifier value)|0
  C0027651|Neoplasms|0
  C0702146|Size (attribute)|0
nationwide use
  1
  C0042153|utilization|0
accurate method—a direct measurement
  4
  C0439851|Direct type of relationship|0
  C0242485|Measurement|0
  C0700157|Direct type of resin cement|0
  C0443131|Accurate (qualifier value)|0
other topoisomerase i inhibitor
  2
  C0243077|inhibitors|0
  C0205394|Other|0
visceral involvement
  3
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0442045|Visceral (qualifier value)|0
vomiting
  3
  C0042965|Vomitus|0
  C0401156|Vomiting NOS (disorder)|0
  C0042963|Vomiting|0
favoring patients
  2
  C0030705|Patients|0
  C0309049|FAVOR (product)|0
other eight studies
  4
  C0557651|Room of building - Study|0
  C0205454|Eight (qualifier value)|0
  C0205394|Other|0
  C0947630|Scientific Study|0
wbc
  1
  C0023516|Leukocytes|0
group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
drug
  2
  C0684270|Drugged|0
  C0013227|Pharmaceutical Preparations|0
activity
  3
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
metaanalyses
  1
  C0920317|Meta-Analysis|0
university
  1
  C0041740|Universities|0
vincristine
  1
  C0042679|Vincristine|0
treatment control group
  5
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
common iliac lymph nodes
  1
  C0229807|Structure of iliac lymph node (body structure)|0
dyspnoea
  1
  C0013404|Dyspnea|0
median followirinotecan group
  5
  C0876920|Median Statistical Measurement|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0549183|Median (qualifier value)|0
  C0441833|Groups (qualifier value)|0
10/533 patients
  1
  C0030705|Patients|0
acceptable to virtually patients
  1
  C0030705|Patients|0
calcium folinate only
  1
  C0006675|Calcium|0
radical surgery
  5
  C0038895|Surgical aspects|0
  C0439807|Radical (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0302912|Radicals (chemistry)|0
received prior chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0750516|PRIOR|0
  C0013216|Pharmacotherapy|0
benefits
  1
  C0814225|benefits|0
significant improvement
  1
  C0750502|Significant (qualifier value)|0
fisher exact test
  4
  C0039593|Testing|0
  C0325045|Martes pennanti (organism)|0
  C0392366|Tests (qualifier value)|0
  C0059927|Exact|0
closer analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
dox cardiomyopathy
  1
  C0027049|Cardiomyopathy|0
corticosteroids
  1
  C0001617|Adrenal Cortex Hormones|0
route
  1
  C0449444|Route (attribute)|0
concurrent malignant disease
  4
  C0012634|Disease|0
  C0006826|Malignant Neoplasms|0
  C0205420|Concurrent (qualifier value)|0
  C0205282|Malignant - descriptor|0
empiric dose limitation
  1
  C0449295|Limitation (attribute)|0
combination therapy treatment plan
  5
  C0453882|Combinations (physical object)|0
  C0039798|therapeutic aspects|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0087111|Therapeutic procedure|0
  C0205195|Combined (qualifier value)|0
daily fractions
  2
  C0457426|Fractions of (qualifier value)|0
  C0332173|Daily (qualifier value)|0
other drugs to
  3
  C0684270|Drugged|0
  C0205394|Other|0
  C0013227|Pharmaceutical Preparations|0
two other randomized trials
  2
  C0205448|Two (qualifier value)|0
  C0205394|Other|0
stage iib bulky
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
colleagues pated toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
possible chemotherapy infusion
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0332149|Possible|0
  C0574032|Infusion (procedure)|0
  C0013216|Pharmacotherapy|0
primary stage ib squamous adenosquamous carcinoma
  5
  C0022104|Irritable Bowel Syndrome|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0007097|Carcinoma|0
  C0205225|Primary|0
sensitivity
  3
  C0312418|Personality Sensitivity|0
  C0036667|Statistical sensitivity|0
  C0427965|Antimicrobial susceptibility|0
regional recurrence
  2
  C0034897|Recurrence|0
  C0205147|Regional (qualifier value)|0
written consent
  2
  C0681288|written language|0
  C0237440|Written Communication|0
meccnu treatment arm
  5
  C0039798|therapeutic aspects|0
  C0003792|Arm|0
  C0036637|Semustine|0
  C0446516|Upper arm|0
  C0087111|Therapeutic procedure|0
fractionation scheme
  2
  C0524811|Dose Fractionation|0
  C0016640|Fractionation|0
concomitant chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
following end points
  3
  C1272693|Ended (qualifier value)|0
  C0332282|Following (attribute)|0
  C0444930|End (qualifier value)|0
access
  1
  C0444454|Access (attribute)|0
comparative frequency
  2
  C0376249|With frequency|0
  C0439603|Frequencies (time pattern)|0
partially hyperfractionated rt
  5
  C1098273|RT-3003|0
  C0319120|RT parvovirus (organism)|0
  C0722979|RT Capsin|0
  C0310073|RT-MUNE (product)|0
  C0062769|histocompatibility antigens RT|0
randomized study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
lung toxicity
  4
  C0040539|Toxicity aspects|0
  C1278908|Entire lung|0
  C0024109|Lung|0
  C0600688|Toxic effect|0
linear logistic model
  3
  C0205132|Linear|0
  C0026336|Models|0
  C0870071|Modeling|0
scan
  1
  C0441633|Scanning|0
m stage
  1
  C0456533|M category (observable entity)|0
chicago
  1
  C0008044|Chicago|0
postoperative pelvic radiotherapy
  4
  C0030797|Pelvis|0
  C0034619|radiotherapeutic|0
  C0032790|Postoperative Period|0
  C0034618|Radiation therapy|0
sequential delivery
  3
  C0011209|Obstetric Delivery|0
  C0559563|Delivery finding (finding)|0
  C1135594|Delivery|0
recurrent tumor
  1
  C0521158|Recurrent tumor (finding)|0
low dose rate intracavitary irradiation to
  5
  C0234886|Lowing, function (observable entity)|0
  C0871208|Rating|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C0205251|Low (qualifier value)|0
life style
  1
  C0023676|Life Style|0
age 18 75 years
  4
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
  C0439234|year (qualifier value)|0
test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
financial impact scores
  4
  C0726639|Impact|0
  C0376243|financial|0
  C0449820|Scores (qualifier value)|0
  C0333125|Impacted (qualifier value)|0
surgery group patients
  5
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0030705|Patients|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0441833|Groups (qualifier value)|0
hypoxic cell radiation sensitizers
  4
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0242184|Oxygen Deficiency|0
  C0851346|Radiation|0
radiographic techniques
  3
  C0025664|Methodology|0
  C0444708|Radiographic (qualifier value)|0
  C0449851|Techniques|0
patients
  1
  C0030705|Patients|0
significance level
  1
  C0814896|significance level|0
less time to
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
significant prolongation
  1
  C0750502|Significant (qualifier value)|0
gynecology
  1
  C0018417|Gynecology|0
statistical evaluation
  3
  C0220825|Evaluation|0
  C0220917|statistical|0
  C1261322|Assessment procedure (procedure)|0
lack
  1
  C0332268|Lacking (qualifier value)|0
cisplatin based regimen
  3
  C0008838|Cisplatin|0
  C0178499|Base|0
  C0677937|regimen|0
c m regimen
  2
  C0007886|Cesium|0
  C0677937|regimen|0
antineoplastic effects
  2
  C1280500|Effect (qualifier value)|0
  C0003392|Antineoplastic Agents|0
unfavorable prognostic factor
  1
  C0220901|prognostic|0
country variable
  2
  C0454664|Countries (geographic location)|0
  C0439828|Variable (qualifier value)|0
end to side
  3
  C1272693|Ended (qualifier value)|0
  C0441987|Side (qualifier value)|0
  C0444930|End (qualifier value)|0
timing
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
long-term analysis
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
radiotherapy group
  5
  C0034619|radiotherapeutic|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0034618|Radiation therapy|0
patients previously
  1
  C0030705|Patients|0
white blood cells
  1
  C0023516|Leukocytes|0
local response
  2
  C0871261|Responses|0
  C0205276|Local (qualifier value)|0
only five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
chemotherapy concurrently
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
log rank tests
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0699794|Rank|0
randomized radiotherapy trial
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
high-dose brachytherapy
  1
  C1273556|High dose brachytherapy (regime/therapy)|0
observation
  2
  C0302523|Observation in research|0
  C0700325|Patient observation|0
above-mentioned statement
  1
  C1282910|Supra- (qualifier value)|0
medical contraindications
  1
  C1301624|Medical contraindication (finding)|0
threeyear survival rates
  1
  C0038954|Survival Rate|0
future cooperative group trials
  5
  C0679729|cooperative|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0016884|Future|0
pooling
  1
  C0337051|Pool (environment)|0
single models
  5
  C0037179|Unmarried person|0
  C0026336|Models|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0870071|Modeling|0
cox model
  1
  C0010234|Cox Models|0
useful predictor
  2
  C0683956|predictive factor|0
  C0035648|Risk Factors|0
cardiac toxicity
  1
  C0280951|cardiac toxicity|0
radiographic evidence
  1
  C0444708|Radiographic (qualifier value)|0
reduced potential
  2
  C0392756|Reduced (qualifier value)|0
  C0237399|Potential|0
ability
  1
  C0085732|Ability|0
toxic manifestations
  1
  C0600688|Toxic effect|0
cooperative german group
  5
  C0679729|cooperative|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0337805|German population|0
  C0441833|Groups (qualifier value)|0
regional recurrences
  2
  C0034897|Recurrence|0
  C0205147|Regional (qualifier value)|0
local recurrences
  2
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
dl
  1
  C0439241|dL (qualifier value)|0
colleagues study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
similar findings
  1
  C0243095|findings|0
analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
adjustment
  4
  C0376209|Individual Adjustment|0
  C0001537|Clinical Adjustment|0
  C0683269|Psychological adjustment|0
  C0456081|Adjustment Action|0
adult patients
  2
  C0030705|Patients|0
  C0001675|Adult|0
to accrue patients
  1
  C0030705|Patients|0
capillary lymphatic space
  4
  C1280521|Entire capillary blood vessel (organ)|0
  C0006901|Blood capillaries|0
  C0229889|Lymphatic vessel|0
  C0935624|Capillary, Unspecified|0
optimal duration
  1
  C0449238|Duration|0
overall major response rate
  4
  C0205164|Major (qualifier value)|0
  C0871208|Rating|0
  C0871261|Responses|0
  C0282416|Overall [Publication Type]|0
renal sonogram
  2
  C0022646|Kidney|0
  C0041618|Ultrasonography|0
patients evenly
  1
  C0030705|Patients|0
theoretical risk
  1
  C0035647|Risk|0
life-threatening episodes
  3
  C0376558|Life|0
  C0332189|Episode of|0
  C0678231|Episodes (qualifier value)|0
alone group
  4
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0679994|alone|0
  C0441833|Groups (qualifier value)|0
combination
  2
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
retrospective analysis
  3
  C0002778|Analysis of substances|0
  C0035363|Retrospective Studies|0
  C0936012|Analysis|0
appropriate guidelines
  3
  C0282423|Guideline [Publication Type]|0
  C0162791|Guidelines|0
  C0220845|guiding characteristics|0
principal effect
  3
  C1280500|Effect (qualifier value)|0
  C0401925|Teaching principal|0
  C0205225|Primary|0
permuted block
  3
  C0233660|Mental blocking|0
  C0332206|Blocking|0
  C0028778|Obstruction|0
slow rise
  3
  C0995005|Rose extract|0
  C0035853|Rosa|0
  C0439834|Slow (qualifier value)|0
axillary node dissection
  5
  C0746922|NODE|0
  C0012737|Dissection|0
  C1293093|Dissection procedure (procedure)|0
  C0004454|Axilla|0
  C1306808|Dissection - action (qualifier value)|0
intestinal obstruction
  1
  C0021843|Intestinal Obstruction|0
four groups
  4
  C0205450|Four (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
total
  1
  C0439810|Total (qualifier value)|0
interim tests
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
prospective randomized study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
primary treatment failure
  5
  C0680095|Personal failure|0
  C0439631|Primary operation (qualifier value)|0
  C0231174|Failure (biologic function)|0
  C0087111|Therapeutic procedure|0
  C0205225|Primary|0
medical treatments
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205476|Medical (qualifier value)|0
p120 nucleolar antigen
  2
  C0003320|Antigens|0
  C0521448|Nucleolar|0
bilirubin
  1
  C0005437|Bilirubin|0
randomly assigned treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
acceptable treatment deviations
  3
  C0039798|therapeutic aspects|0
  C0012727|Spatial Displacement|0
  C0087111|Therapeutic procedure|0
vast majorities
  2
  C0680220|majority|0
  C0814230|Veterans Alcoholism Screening Test|0
fluorodeoxyuridine monophosphate
  1
  C0016343|Floxuridine|0
considerable research effort
  2
  C0035168|Research|0
  C0015264|Exertion|0
middle third stromal invasion
  2
  C0205437|Third (qualifier value)|0
  C0549183|Median (qualifier value)|0
estimating tumor diameter
  3
  C0027651|Neoplasms|0
  C0332517|Diameter (qualifier value)|0
  C0750572|ESTIMATED|0
node dissection
  4
  C0746922|NODE|0
  C0012737|Dissection|0
  C1293093|Dissection procedure (procedure)|0
  C1306808|Dissection - action (qualifier value)|0
eight patients randomly
  2
  C0205454|Eight (qualifier value)|0
  C0030705|Patients|0
reference values
  1
  C0034926|Reference Values|0
total dose to
  1
  C0439810|Total (qualifier value)|0
iib disease
  1
  C0012634|Disease|0
equivalent
  1
  C0439185|Eq (qualifier value)|0
agent
  1
  C0450442|Agent (attribute)|0
survival probability
  3
  C0038952|Continuance of life|0
  C0033204|Probability|0
  C0220921|survival aspects|0
significant hypoxic cell populations
  5
  C0007634|Cells|0
  C0750502|Significant (qualifier value)|0
  C1269647|Entire cell|0
  C0242184|Oxygen Deficiency|0
  C0032659|Population|0
pelvic radiation
  2
  C0030797|Pelvis|0
  C0851346|Radiation|0
os
  1
  C0262950|Skeletal bone|0
neoadjuvant bomp ct
  2
  C0040405|X-Ray Computed Tomography|0
  C0053926|BOMP protocol|0
hypothesis tests
  1
  C0681918|hypothesis testing|0
percent confidence interval
  3
  C0237529|Self-confidence (observable entity)|0
  C0439165|Percent (qualifier value)|0
  C1272706|Interval (qualifier value)|0
dose reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
greater decrease
  4
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
  C0443228|Greater (qualifier value)|0
longest delay
  1
  C0205421|Deferred (qualifier value)|0
univariate analyses to
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
most unfavourable pathological prognostic factors
  3
  C0220901|prognostic|0
  C0205393|Most (qualifier value)|0
  C0205469|Pathological aspects|0
malignant fibrous histiocytoma
  1
  C0334463|[M]Fibroxanthosarcoma (morphologic abnormality)|0
detection
  3
  C0180392|detector|0
  C0335385|Detective (occupation)|0
  C0442726|Detected (qualifier value)|0
one other patient
  3
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
  C0205394|Other|0
mediastinum
  2
  C1278909|Entire mediastinum|0
  C0025066|Mediastinum|0
controversy
  1
  C0680243|controversy|0
large number
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0549177|Large|0
  C0237753|Numbers (qualifier value)|0
descending
  1
  C0205386|Descending (qualifier value)|0
follow-up studies pretreatment evaluation
  5
  C0220825|Evaluation|0
  C0547043|Up (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
  C0332282|Following (attribute)|0
  C0947630|Scientific Study|0
nominal level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
actuarial disease-free survival
  3
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
less local progression
  2
  C0449258|Progression (attribute)|0
  C0205276|Local (qualifier value)|0
other patients
  2
  C0030705|Patients|0
  C0205394|Other|0
mean time
  5
  C0040223|Time|0
  C0876919|Meaning|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0444504|Mean (qualifier value)|0
5.8 years
  1
  C0439234|year (qualifier value)|0
further studies
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
pilot study used mitolactol
  5
  C0557651|Room of building - Study|0
  C0473169|Pilot - aircraft (occupation)|0
  C0026252|Mitolactol|0
  C0042153|utilization|0
  C0947630|Scientific Study|0
blood loss
  2
  C0553700|Actual blood loss|0
  C0019080|Hemorrhage|0
m control group
  5
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
risk
  1
  C0035647|Risk|0
persistent leukopenia
  2
  C0023530|Leukopenia|0
  C0205322|Persistent (qualifier value)|0
remaining tumors
  1
  C0027651|Neoplasms|0
statistics
  1
  C0038215|Science of Statistics|0
effects
  1
  C1280500|Effect (qualifier value)|0
ulceration
  1
  C0041582|Ulcer|0
death
  1
  C0011065|Cessation of life|0
larger total cumulative dose
  2
  C0439810|Total (qualifier value)|0
  C0443228|Greater (qualifier value)|0
figo stage
  1
  C0450454|FIGO Stage (attribute)|0
leukemogenic potential
  1
  C0237399|Potential|0
low toxicity
  4
  C0234886|Lowing, function (observable entity)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
  C0205251|Low (qualifier value)|0
postirradiation fibrosis
  1
  C0016059|Fibrosis|0
diarrhea
  1
  C0011991|Diarrhea|0
potential selection factors
  2
  C0237399|Potential|0
  C0036576|Selection (Genetics)|0
one package
  2
  C0030176|Packaging|0
  C0205447|One (qualifier value)|0
abdominal ct scanning
  3
  C0456438|Abdominal (qualifier value)|0
  C0040405|X-Ray Computed Tomography|0
  C0441633|Scanning|0
total doxorubicin doses
  3
  C0439810|Total (qualifier value)|0
  C0013089|Doxorubicin|0
  C0719635|DOS|0
toxic death
  2
  C0011065|Cessation of life|0
  C0600688|Toxic effect|0
cmf cycles
  1
  C0950521|CMF|0
tests
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
laterally fields
  2
  C0440042|Field's stain|0
  C0331809|Fielding|0
cross-resistance
  4
  C0205203|Crossed (qualifier value)|0
  C0917925|Cancer resistance to treatment|0
  C0237834|Resistance (Psychotherapeutic)|0
  C0683598|social resistance|0
control arm
  4
  C0702113|Controlled (qualifier value)|0
  C0003792|Arm|0
  C0243148|control|0
  C0446516|Upper arm|0
median overall dfs
  3
  C0876920|Median Statistical Measurement|0
  C0282416|Overall [Publication Type]|0
  C0549183|Median (qualifier value)|0
demonstrated transient tumor regression
  5
  C0205374|Transitory|0
  C0040704|Transient Population Group|0
  C0684321|Regression - mental defense mechanism|0
  C0027651|Neoplasms|0
  C0684320|Disease regression|0
advanced colorectal carcinoma
  4
  C0205179|Advanced phase|0
  C0555952|Colorectal (qualifier value)|0
  C0725066|Advance|0
  C0007097|Carcinoma|0
meaningful advantage
  1
  C0308269|ADVANTAGE|0
small cell carcinoma
  1
  C0149925|Carcinoma, Small Cell|0
leucocyte nadir
  1
  C0023516|Leukocytes|0
grade histology
  5
  C0441800|Grade|0
  C0205462|Histologic|0
  C0796573|Cancer cells grading system|0
  C0344441|Histology Procedure|0
  C0019638|Histology|0
randomized trial
  5
  C0680732|jury trial|0
  C0680733|bench trial|0
  C0008976|Clinical Trials|0
  C0680734|trial procedure|0
  C0206012|Multicenter Trials|0
texas
  1
  C0039711|Texas|0
administration
  2
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
alkaline phosphatase u
  1
  C0031678|Phosphoric Monoester Hydrolases|0
reported benefits
  3
  C0814225|benefits|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
75th percentiles
  1
  C1264641|Percentile (property) (qualifier value)|0
lowest level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
target sample size
  4
  C0870078|Sampling|0
  C0599894|targeting|0
  C0441621|Sampling - Surgical action|0
  C0702146|Size (attribute)|0
noirinotecan group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
intraabdominal abscesses
  2
  C0230168|Abdominal cavity structure|0
  C0000833|Abscess|0
disease progression
  1
  C0242656|Disease Progression|0
creatinine clearance 1.0 ml
  3
  C0449297|Clearance (attribute)|0
  C0439242|mL (qualifier value)|0
  C0010294|Creatinine|0
immune response
  1
  C0301872|Immune response|0
escalation
  1
  C0014829|Escalators|0
disease recurrence
  1
  C0679254|Disease recurrence|0
sufficient uniformity
  2
  C0205410|Sufficient (qualifier value)|0
  C0439827|Uniformities (qualifier value)|0
members
  1
  C0680022|Member of (attribute)|0
only 4.6 months
  1
  C0439231|month (qualifier value)|0
melphalan
  1
  C0025241|Melphalan|0
factorial analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
centers
  2
  C0935444|Centering|0
  C0205099|Central|0
17-la treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
nineteen patients
  1
  C0030705|Patients|0
exploratory laparotomy
  1
  C0085704|Exploratory laparotomy (procedure)|0
uncontrolled infections
  2
  C0205318|Uncontrolled (qualifier value)|0
  C0021311|Infection|0
neoadjuvant bomp chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0053926|BOMP protocol|0
  C0013216|Pharmacotherapy|0
complete blood count
  1
  C0009555|Blood Count, Complete|0
clinical prognostic factors
  2
  C0205210|Clinical (qualifier value)|0
  C0220901|prognostic|0
two treatments
  3
  C0039798|therapeutic aspects|0
  C0205448|Two (qualifier value)|0
  C0087111|Therapeutic procedure|0
also observed one additional response
  2
  C0205447|One (qualifier value)|0
  C0871261|Responses|0
cervical cancers
  1
  C0007847|Malignant neoplasm of cervix uteri|0
superior extent
  2
  C0205105|Superior (qualifier value)|0
  C0439792|Extents (qualifier value)|0
dose reduction schedule
  4
  C0086960|Schedules|0
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0205539|Scheduled (qualifier value)|0
primary objective
  3
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0018017|Goals|0
5-fu activity
  5
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0016360|Fluorouracil|0
  C0441655|Activities|0
  C0268696|Feline urological syndrome (disorder)|0
prognosis
  1
  C0033325|Forecast of outcome|0
gastrointestinal tumor study group
  5
  C0557651|Room of building - Study|0
  C0521362|Gastrointestinal|0
  C0027651|Neoplasms|0
  C0441833|Groups (qualifier value)|0
  C0947630|Scientific Study|0
portal catheter
  2
  C0085590|Catheter|0
  C0205054|Hepatic|0
advantages
  1
  C0308269|ADVANTAGE|0
tumour status
  1
  C0475752|Tumor status (attribute)|0
treatment duration
  1
  C0444921|Duration of treatment (qualifier value)|0
significantly fewer distant recurrences
  2
  C0443203|Distant (qualifier value)|0
  C0034897|Recurrence|0
specimen
  1
  C0370003|Specimen (specimen)|0
observed complication rate
  3
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0871208|Rating|0
thoracic spine
  2
  C1269870|Entire thoracic spine|0
  C0581269|Thoracic spine structure|0
total proteins
  2
  C1261360|Total protein|0
  C0555903|Total protein measurement (procedure)|0
upfront ct
  1
  C0040405|X-Ray Computed Tomography|0
overall operative mortality
  3
  C0026565|Mortality Vital Statistics|0
  C0282416|Overall [Publication Type]|0
  C0026566|Aspects of mortality statistics|0
intestinal anastomosis
  1
  C0192711|Anastomosis of intestine NOS (procedure)|0
studies
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
greater stromal invasion
  1
  C0443228|Greater (qualifier value)|0
false pelvis
  1
  C0230276|Major pelvis structure (body structure)|0
treatment assignments
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
pt3 tumors
  1
  C0027651|Neoplasms|0
major role
  2
  C0205164|Major (qualifier value)|0
  C0035820|Role|0
wide acceptance
  1
  C0332464|Widened structure (morphologic abnormality)|0
limiting toxic effect
  3
  C1280500|Effect (qualifier value)|0
  C0439801|Limited (qualifier value)|0
  C0600688|Toxic effect|0
performance status deterioration
  3
  C0449438|Status (attribute)|0
  C0597198|Performance|0
  C0868945|Deterioration|0
extraperitoneal surgical staging
  5
  C0038895|Surgical aspects|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C0442090|Extraperitoneal (qualifier value)|0
clearly defined perfusion defect
  2
  C0031001|Perfusion|0
  C0243067|defects|0
main finding
  2
  C0243095|findings|0
  C0205225|Primary|0
percent decrease
  4
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0439165|Percent (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
enhanced activity
  3
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
3.0 polypropylene suture
  1
  C0491217|Polypropylene suture (physical object)|0
normal serum bilirubin levels
  5
  C0441889|Levels (qualifier value)|0
  C0229671|Serum|0
  C0005437|Bilirubin|0
  C0205307|Normal (qualifier value)|0
  C0456079|Disease classification level|0
leukocyte depression
  5
  C0460137|Depression motion|0
  C0011581|Depressive disorder|0
  C0023516|Leukocytes|0
  C0349217|Depressive episode, unspecified|0
  C0011570|Mental Depression|0
sigmoid colon
  1
  C0227391|Sigmoid colon|0
completion
  3
  C0439812|Completeness (qualifier value)|0
  C0725685|Compleat|0
  C0205197|Complete (qualifier value)|0
minimal residual disease
  1
  C0242596|Neoplasm, Residual|0
most important prognostic factor
  2
  C0220901|prognostic|0
  C0205393|Most (qualifier value)|0
cell synchronization
  2
  C0007634|Cells|0
  C1269647|Entire cell|0
five randomized trials
  1
  C0205451|Five (qualifier value)|0
eight patients
  2
  C0205454|Eight (qualifier value)|0
  C0030705|Patients|0
bleomycin dose
  1
  C0005740|Bleomycin|0
external pelvic irradiation
  5
  C0030797|Pelvis|0
  C0205101|External (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
long delay
  3
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C0205421|Deferred (qualifier value)|0
significant interobserver variability
  1
  C0750502|Significant (qualifier value)|0
further follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
dose limits
  1
  C0935905|dose-limiting|0
intergroup rectal adjuvant protocol
  3
  C0205052|Rectal (qualifier value)|0
  C0442711|Protocols documentation|0
  C0001551|Adjuvants, Immunologic|0
range 4–81 months
  1
  C0439231|month (qualifier value)|0
dose attenuation percent
  2
  C0599946|attenuation|0
  C0439165|Percent (qualifier value)|0
radiotherapy related complications
  5
  C0034619|radiotherapeutic|0
  C0009566|Complication|0
  C0163712|Relate|0
  C0034618|Radiation therapy|0
  C0445223|Related (finding)|0
now matured study
  3
  C0557651|Room of building - Study|0
  C0205286|Mature (qualifier value)|0
  C0947630|Scientific Study|0
fm
  1
  C0015853|Fermium|0
brachytherapy
  1
  C0006098|Brachytherapy|0
point b
  5
  C0006487|Butirosin B|0
  C0002679|Amphotericin B|0
  C0004544|B Fibers|0
  C0053514|betacin, Bacillus subtilis|0
  C0001999|Aldolase B|0
ct
  1
  C0040405|X-Ray Computed Tomography|0
primary outcome measures
  4
  C0444706|Measured (qualifier value)|0
  C0079809|Measures|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
informed written consent
  1
  C0700287|Reporting|0
most common toxic effects
  4
  C1280500|Effect (qualifier value)|0
  C0205214|Common (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0600688|Toxic effect|0
further analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
major toxicity
  3
  C0205164|Major (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
epi less cardiotoxic anthracycline
  2
  C0282564|Anthracyclines|0
  C0003234|Anthracycline Antibiotics|0
unnecessary side effects
  2
  C1280500|Effect (qualifier value)|0
  C0441987|Side (qualifier value)|0
standard therapy
  1
  C0879531|standard therapy|0
dose reductions
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
treatment assignment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
low-dose brachytherapy
  3
  C0234886|Lowing, function (observable entity)|0
  C0006098|Brachytherapy|0
  C0205251|Low (qualifier value)|0
data analysis
  1
  C0010992|Data Analysis|0
estimated cumulative incidence function
  5
  C0031843|physiological aspects|0
  C0021149|Incidence|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
  C0220856|incidence of cases|0
active infection
  2
  C0021311|Infection|0
  C0205177|Active|0
opcs death certificate
  2
  C0011065|Cessation of life|0
  C0586303|Certificates (administrative concept)|0
nominal significance level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
additive effects
  2
  C1280500|Effect (qualifier value)|0
  C0442796|Additive (qualifier value)|0
subsequently
  1
  C0750530|SUBSEQUENT|0
respiratory death
  2
  C0521346|Respiratory|0
  C0011065|Cessation of life|0
interim analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
single layer anastomoses
  5
  C0934502|Layer|0
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0087136|Unmarried|0
  C0500470|Anatomical anastomosis|0
one rectovaginal fistula
  3
  C0205447|One (qualifier value)|0
  C0016169|Fistula|0
  C0450213|Rectovaginal (qualifier value)|0
histologic grade
  1
  C0919553|Histopathologic Grade|0
pathologic predictors
  1
  C0205469|Pathological aspects|0
myocardial infarctions
  1
  C0027051|Myocardial Infarction|0
14% incidence
  2
  C0021149|Incidence|0
  C0220856|incidence of cases|0
cause specific survival analysis
  5
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0015127|Causality|0
29% cr rate
  2
  C0871208|Rating|0
  C0008574|Chromium|0
more recurrences
  2
  C0034897|Recurrence|0
  C0205172|More (qualifier value)|0
11.9 months
  1
  C0439231|month (qualifier value)|0
90th percentile
  1
  C1264641|Percentile (property) (qualifier value)|0
megavoltage radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
cervix
  1
  C0007874|Uterine cervix-Anatomy|0
protocol methodology
  3
  C0025664|Methodology|0
  C0442711|Protocols documentation|0
  C0969625|Methodology aspects|0
local recurrence rate
  3
  C0871208|Rating|0
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
revised sample size goal
  4
  C0870078|Sampling|0
  C0441621|Sampling - Surgical action|0
  C0702146|Size (attribute)|0
  C0018017|Goals|0
direction
  2
  C0439755|Directions (qualifier value)|0
  C0449738|Direction|0
randomization
  1
  C0034656|Random Allocation|0
impact
  2
  C0726639|Impact|0
  C0333125|Impacted (qualifier value)|0
median disease-free survival
  5
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
subsequent treatment course
  5
  C0039798|therapeutic aspects|0
  C0449922|Course (attribute)|0
  C0750530|SUBSEQUENT|0
  C0087111|Therapeutic procedure|0
  C0750729|Courses (qualifier value)|0
twenty four percent
  2
  C0205450|Four (qualifier value)|0
  C0439165|Percent (qualifier value)|0
permanent interruption
  1
  C0205355|Permanent (qualifier value)|0
rt interruptions
  1
  C0234780|Phonatory interruption, function (observable entity)|0
substantial difference
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
most extreme case
  3
  C0205403|Extreme (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0868928|Case (qualifier value)|0
permanent indiana pouch urinary conduit
  4
  C0021206|Indiana|0
  C0042066|Urogenital System|0
  C0441247|Conduit implant|0
  C0205355|Permanent (qualifier value)|0
c m arm
  3
  C0003792|Arm|0
  C0007886|Cesium|0
  C0446516|Upper arm|0
4% experienced grade thrombocytopenia
  4
  C0441800|Grade|0
  C0596545|experience|0
  C0796573|Cancer cells grading system|0
  C0040034|Thrombocytopenia|0
months
  1
  C0439231|month (qualifier value)|0
volume
  1
  C0449468|Volume (property) (qualifier value)|0
average age
  3
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
drug levels
  2
  C0428212|Finding of drug level (finding)|0
  C1261153|Drug measurement (procedure)|0
kaplan meier method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
assessment
  1
  C1261322|Assessment procedure (procedure)|0
most significant prognostic factor
  3
  C0220901|prognostic|0
  C0205393|Most (qualifier value)|0
  C0750502|Significant (qualifier value)|0
less toxic compound
  2
  C0205198|Compound (qualifier value)|0
  C0600688|Toxic effect|0
other conditions
  3
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
  C0205394|Other|0
other symptomatic therapy
  4
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0231220|Symptomatic (qualifier value)|0
  C0205394|Other|0
four centers
  3
  C0205450|Four (qualifier value)|0
  C0935444|Centering|0
  C0205099|Central|0
unacceptable toxic effects
  2
  C1280500|Effect (qualifier value)|0
  C0600688|Toxic effect|0
equal number
  4
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0439089|Equals|0
  C0205163|Equal (qualifier value)|0
study design
  1
  C0035171|Research Design|0
transfusions
  1
  C0199960|Transfusion - action (qualifier value)|0
consistent improvement
  1
  C0332290|Consistent with (qualifier value)|0
promising improvement
  1
  C0307404|Promise Toothpaste|0
few reports
  3
  C0684224|Report (document)|0
  C0205388|Few (qualifier value)|0
  C0700287|Reporting|0
prospective randomized clinical trial
  1
  C0205210|Clinical (qualifier value)|0
more detailed description
  2
  C0205172|More (qualifier value)|0
  C0678257|description|0
imbalance clearly
  5
  C0947898|Sodium imbalance|0
  C0887935|Allelic Imbalance|0
  C0262561|MUSCULAR IMBALANCE|0
  C0947897|Potassium imbalance|0
  C0542042|Immune imbalance|0
poor performance status
  4
  C0449438|Status (attribute)|0
  C0542537|Poor - grade value|0
  C0699761|Financially poor|0
  C0597198|Performance|0
survival prognosis
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0033325|Forecast of outcome|0
ii trials
  1
  C0439069|Roman numeral II|0
levamisole
  1
  C0023556|Levamisole|0
significantly higher 5-year disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
subcutaneous soft tissue
  3
  C0443315|Subcutaneous (qualifier value)|0
  C0205358|Soft (qualifier value)|0
  C0040300|Tissues|0
major protocol viola patients
  4
  C0205164|Major (qualifier value)|0
  C0330463|Viola|0
  C0442711|Protocols documentation|0
  C0030705|Patients|0
im
  1
  C0231377|At risk for impaired home maintenance management (finding)|0
levamisole treated patients
  3
  C0023556|Levamisole|0
  C0030705|Patients|0
  C1292734|Treats (attribute)|0
haematology
  1
  C0200627|Hematology procedure|0
chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
recruitment
  1
  C0271510|Recruitment (finding)|0
50% increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
two layer anastomoses
  5
  C0934502|Layer|0
  C0205448|Two (qualifier value)|0
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
swiss group
  4
  C0241315|Swiss (ethnic group)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
cisplatin treatment day
  4
  C0039798|therapeutic aspects|0
  C0008838|Cisplatin|0
  C0439228|day (qualifier value)|0
  C0087111|Therapeutic procedure|0
likely
  1
  C0750504|Likely|0
indices
  2
  C0021200|Indexing|0
  C0918012|Indexes|0
stereoisomer
  1
  C0376211|Stereoisomers|0
shrinkage
  1
  C0332513|Shrinkage (finding)|0
produced impressive response rates
  2
  C0871208|Rating|0
  C0871261|Responses|0
width
  1
  C0487742|Width (qualifier value)|0
recurrent squamous cell carcinoma
  5
  C1182670|Squamous|0
  C0205335|Recurrent (qualifier value)|0
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0007097|Carcinoma|0
serum carcinoembryonic antigen measurement
  3
  C0229671|Serum|0
  C0003320|Antigens|0
  C0242485|Measurement|0
recent introduction
  2
  C0332185|Recent episode (qualifier value)|0
  C1293116|Introduction (procedure)|0
iproplatin
  1
  C0057856|iproplatin|0
different adjuvant treatments
  3
  C0039798|therapeutic aspects|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
pr
  1
  C0279766|progesterone receptor negative|0
provided data
  1
  C0359589|Provide (product)|0
scheduled treatment
  4
  C0086960|Schedules|0
  C0039798|therapeutic aspects|0
  C0205539|Scheduled (qualifier value)|0
  C0087111|Therapeutic procedure|0
one event
  2
  C0441471|Events (event)|0
  C0205447|One (qualifier value)|0
measurements
  1
  C0242485|Measurement|0
myocardial infarction
  1
  C0027051|Myocardial Infarction|0
m2 x days
  1
  C0439228|day (qualifier value)|0
normal tissues
  1
  C0332441|Normal tissue (finding)|0
more evidence
  1
  C0205172|More (qualifier value)|0
cox’s proportional hazards model
  1
  C0033489|Proportional Hazards Models|0
number
  2
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
ischiorectal abscess
  1
  C0149816|Ischiorectal abscess (disorder)|0
receiving three doses
  2
  C0719635|DOS|0
  C0205449|Three (qualifier value)|0
fifty one patients
  2
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
austria
  1
  C0004348|Austria|0
limited future
  2
  C0439801|Limited (qualifier value)|0
  C0016884|Future|0
bipedal lymphangiogram
  1
  C0024219|Lymphangiography|0
six months
  2
  C0439231|month (qualifier value)|0
  C0205452|Six (qualifier value)|0
calcium folinate weekly
  2
  C0006675|Calcium|0
  C0332174|Weekly (qualifier value)|0
significant number
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0750502|Significant (qualifier value)|0
f
  5
  C0489829|Mathematical formula|0
  C0015895|Fertility|0
  C0016702|French Population|0
  C0016330|Fluorine|0
  C0441722|Force|0
1.4 years
  1
  C0439234|year (qualifier value)|0
5-year data
  1
  C0439234|year (qualifier value)|0
pattern
  1
  C0449774|Patterns (qualifier value)|0
kaplan meier estimates
  1
  C0750572|ESTIMATED|0
irradiated patients
  1
  C0030705|Patients|0
steady progressive decline
  2
  C0205329|Progressive (qualifier value)|0
  C0205361|Steady (qualifier value)|0
logrank tests
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
association
  2
  C0004083|Mental association|0
  C0699792|Relationship by association|0
prearranged time
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
preoperative investigations
  2
  C0445204|Preoperative (qualifier value)|0
  C0430007|Clinical investigation|0
two series
  2
  C0205448|Two (qualifier value)|0
  C0205549|Series (qualifier value)|0
hematology
  2
  C0200627|Hematology procedure|0
  C0018943|Hematology|0
study protocol
  3
  C0557651|Room of building - Study|0
  C0442711|Protocols documentation|0
  C0947630|Scientific Study|0
peritoneal carcinomatosis
  2
  C0442034|Peritoneal (qualifier value)|0
  C0205699|Carcinomatosis|0
concurrent chemotherapy truly adds
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205420|Concurrent (qualifier value)|0
  C0013216|Pharmacotherapy|0
series
  1
  C0205549|Series (qualifier value)|0
40 patients
  1
  C0030705|Patients|0
provincial cancer institute
  4
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0021622|Institutes|0
immunohistochemical staining
  2
  C0038129|Staining|0
  C0038128|Stains|0
tumour progresses
  1
  C0027651|Neoplasms|0
endometrial carcinoma
  1
  C0476089|Endometrial Carcinoma|0
cytopenias
  1
  C0010828|Cytopenia (finding)|0
55.0 gy
  1
  C0556636|Gy (qualifier value)|0
areas
  1
  C0205146|Area (qualifier value)|0
median total duration
  4
  C0439810|Total (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0449238|Duration|0
mortality
  2
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
brain
  2
  C1269537|Entire brain|0
  C0006104|Brain|0
cardiac impairment
  3
  C0205041|Cardio-|0
  C0231171|Physical impairment|0
  C0684336|Impaired health|0
overall crude survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
flow
  1
  C0806140|FLOW|0
authors
  1
  C0221192|Author (occupation)|0
­ days
  1
  C0439228|day (qualifier value)|0
postoperative irradiation
  4
  C0032790|Postoperative Period|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
neck region
  1
  C0920882|Region of neck (body structure)|0
cisplatin combinations
  3
  C0453882|Combinations (physical object)|0
  C0008838|Cisplatin|0
  C0205195|Combined (qualifier value)|0
procedure
  2
  C0025664|Methodology|0
  C0184661|Procedures|0
gog performance score
  2
  C0449820|Scores (qualifier value)|0
  C0597198|Performance|0
weeks
  1
  C0439230|week (qualifier value)|0
present results
  2
  C1274040|Result (navigational concept)|0
  C0150312|Present|0
thirty nine
  1
  C0205455|Nine (qualifier value)|0
wash-out
  1
  C0392674|Exhaustion (finding)|0
short-term interval
  3
  C0453933|Shorts (physical object)|0
  C0205167|Short (qualifier value)|0
  C1272706|Interval (qualifier value)|0
significant morbidity
  3
  C0026538|Morbidity - disease rate|0
  C0750502|Significant (qualifier value)|0
  C0220880|morbidity aspects|0
added efficacy
  5
  C0087113|Treatment Effectiveness|0
  C0600564|Self Efficacy|0
  C0598333|drug efficacy|0
  C0235828|EFFICACY, LACK OF|0
  C0683261|efficacy expectations|0
direct internal mammary field
  5
  C0440042|Field's stain|0
  C0439851|Direct type of relationship|0
  C0331809|Fielding|0
  C0205102|Intrinsic|0
  C0700157|Direct type of resin cement|0
absolute benefit
  2
  C0814225|benefits|0
  C0205344|Absolute (qualifier value)|0
peritoneal seeding
  2
  C0036563|Seeds|0
  C0442034|Peritoneal (qualifier value)|0
slightly higher percentage
  1
  C0750482|SLIGHTLY|0
abdominoperineal excision
  3
  C0442411|Abdominoperineal approach (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
relative mortality rate
  5
  C0080103|Relative (related person)|0
  C0871208|Rating|0
  C0026565|Mortality Vital Statistics|0
  C0205345|Relative|0
  C0026566|Aspects of mortality statistics|0
seventh years
  2
  C0205441|Seventh (qualifier value)|0
  C0439234|year (qualifier value)|0
grade gastrointestinal toxicity
  5
  C0521362|Gastrointestinal|0
  C0441800|Grade|0
  C0040539|Toxicity aspects|0
  C0796573|Cancer cells grading system|0
  C0600688|Toxic effect|0
en bloc resection
  2
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
additional entry criteria
  1
  C0243161|criteria|0
complete data
  1
  C0205197|Complete (qualifier value)|0
treatment regimen
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0677937|regimen|0
enrollment goal
  1
  C0018017|Goals|0
relatively even distribution
  3
  C0520511|Distributing|0
  C0587117|Evening (qualifier value)|0
  C0037775|Spatial Distribution|0
elisa
  1
  C0014441|Enzyme-Linked Immunosorbent Assay|0
combining radiotherapy
  1
  C0436241|Combined radiotherapy NOS (procedure)|0
more courses
  3
  C0449922|Course (attribute)|0
  C0205172|More (qualifier value)|0
  C0750729|Courses (qualifier value)|0
natural history
  1
  C0175860|Natural History|0
premature discontinuation
  2
  C0457454|Discontinuation (procedure)|0
  C0205252|Immature (qualifier value)|0
baseline prognostic factors
  2
  C0220901|prognostic|0
  C0168634|BaseLine|0
cisplatin containing chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0008838|Cisplatin|0
  C0332256|Containing (qualifier value)|0
  C0013216|Pharmacotherapy|0
alkaline phosphatase
  2
  C1318717|Alkaline phosphatase stain|0
  C0002059|Alkaline Phosphatase|0
treatments
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
obstetrics
  2
  C0700061|Obstetric Patient|0
  C0028773|Discipline of obstetrics|0
disease status
  2
  C0449438|Status (attribute)|0
  C0012634|Disease|0
disease characteristics
  1
  C0599878|disease characteristic|0
visible disease
  2
  C0012634|Disease|0
  C0205379|Visible (qualifier value)|0
tumor cell type
  5
  C0007634|Cells|0
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0027651|Neoplasms|0
optimal time delay
  4
  C0205421|Deferred (qualifier value)|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
neck
  3
  C0027536|Necking (finding)|0
  C0027530|Neck|0
  C1281592|Entire neck|0
prior treatment
  3
  C0039798|therapeutic aspects|0
  C0750516|PRIOR|0
  C0087111|Therapeutic procedure|0
second tumors
  3
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
  C0027651|Neoplasms|0
d sc
  1
  C0112081|D-D mixture|0
deep third stromal invasion
  2
  C0205437|Third (qualifier value)|0
  C0205125|Depth (qualifier value)|0
cytologic documentation
  3
  C0175636|Act of Documentation|0
  C0205471|Cytologic (qualifier value)|0
  C0920316|Documentation|0
cumulative dose
  1
  C0683233|cumulative gene|0
escalating 5-fu treatment results
  5
  C1274040|Result (navigational concept)|0
  C0039798|therapeutic aspects|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
  C0087111|Therapeutic procedure|0
recurrence rate
  2
  C0871208|Rating|0
  C0034897|Recurrence|0
concurrent chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205420|Concurrent (qualifier value)|0
  C0013216|Pharmacotherapy|0
ifo 1.8 g
  1
  C0162832|APC Gene|0
lymph node involvement
  1
  C0806692|LYMPH NODE INVOLVEMENT|0
additional patient
  1
  C0030705|Patients|0
transvaginal parametrial needle biopsy
  5
  C0007431|Arterial catheterization|0
  C0220797|biopsy characteristics|0
  C0027551|Needles|0
  C0005558|Biopsy|0
  C0175672|Transvaginal approach|0
cardiopulmonary functions
  5
  C0700205|Function Axis|0
  C0542341|Function|0
  C0553534|Cardiopulmonary|0
  C0422812|Functions (observable entity)|0
  C1261339|Heart and lung|0
platelet count
  2
  C1287267|Finding of platelet count (finding)|0
  C0032181|Platelet Count|0
supportive care
  1
  C0344211|Supportive care|0
host
  1
  C1167395|host|0
most common complications
  4
  C0009566|Complication|0
  C0205214|Common (qualifier value)|0
  C1171258|Complication Aspects|0
  C0205393|Most (qualifier value)|0
moderately high response rate
  4
  C0205250|High|0
  C0871208|Rating|0
  C0235146|Euphoric mood|0
  C0871261|Responses|0
chance observation
  3
  C0302523|Observation in research|0
  C0700325|Patient observation|0
  C0237506|Chance|0
post-operative rt
  1
  C0687676|After values (qualifier value)|0
treatment delays
  3
  C0039798|therapeutic aspects|0
  C0205421|Deferred (qualifier value)|0
  C0087111|Therapeutic procedure|0
to follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
most active nonhormonal drug
  4
  C0684270|Drugged|0
  C0205393|Most (qualifier value)|0
  C0205177|Active|0
  C0013227|Pharmaceutical Preparations|0
difference
  1
  C0443199|Differential (qualifier value)|0
safety
  1
  C0036043|Safety|0
later curves
  1
  C0205134|Curved (qualifier value)|0
bilateral removal
  4
  C0728940|Surgical Removal - Action|0
  C0015252|Excision|0
  C0281267|bilateral breast cancer|0
  C0238767|Bilateral|0
median 64.7 years
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0439234|year (qualifier value)|0
disease recurrences
  1
  C0679254|Disease recurrence|0
irinotecan combination
  3
  C0453882|Combinations (physical object)|0
  C0123931|irinotecan|0
  C0205195|Combined (qualifier value)|0
too few patients
  2
  C0030705|Patients|0
  C0205388|Few (qualifier value)|0
stage iva
  2
  C0441773|Stage 4 lower case ay|0
  C0456600|Stage 4 upper case ay|0
exact test
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0059927|Exact|0
differ debate
  1
  C0870392|Debates|0
five field radiotherapy
  5
  C0034619|radiotherapeutic|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0205451|Five (qualifier value)|0
  C0034618|Radiation therapy|0
significant superiority
  2
  C0750502|Significant (qualifier value)|0
  C0680218|superiority|0
severe leukopenia
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0023530|Leukopenia|0
step
  2
  C0859325|Stepping|0
  C1261552|Step (qualifier value)|0
7-year analysis
  3
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0439234|year (qualifier value)|0
95% confidence limits
  1
  C0237530|Confidence Limits|0
continuous single layer suture
  5
  C0038969|Surgical sutures|0
  C0934502|Layer|0
  C0009068|Closure by suture|0
  C0502420|Suture Joint|0
  C0549178|Continuous (qualifier value)|0
low-risk group
  5
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0205251|Low (qualifier value)|0
  C0035647|Risk|0
greater reduction
  3
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0443228|Greater (qualifier value)|0
cut edge
  3
  C1306235|Cutting, NOS|0
  C0205154|Along edge (qualifier value)|0
  C0000925|Incised wound - morphology (morphologic abnormality)|0
suggested survival advantage
  3
  C0038952|Continuance of life|0
  C0308269|ADVANTAGE|0
  C0220921|survival aspects|0
cardiac monitoring
  2
  C0150496|Cardiac monitoring (regime/therapy)|0
  C0179608|Cardiac Monitors|0
slight excess
  1
  C0547040|Slight (qualifier value)|0
subsequent patients
  2
  C0750530|SUBSEQUENT|0
  C0030705|Patients|0
lung
  2
  C1278908|Entire lung|0
  C0024109|Lung|0
measurable parameters
  2
  C0549193|Parameter (attribute)|0
  C0449381|Observation parameter (observable entity)|0
adequacy
  1
  C0205411|Adequate (qualifier value)|0
3.0 silk lembert sutures
  1
  C0183745|Silk suture, device (physical object)|0
monoclonal antibody
  1
  C0003250|Antibodies, Monoclonal|0
substantial shift
  1
  C0333051|Shift (morphologic abnormality)|0
fixed limitation
  2
  C0449295|Limitation (attribute)|0
  C0443218|Fixed (qualifier value)|0
especially pain
  1
  C0030193|Pain|0
undergone specific type
  5
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
  C1263442|SPECIFIC|0
para-aortic radiation
  3
  C0003483|Aorta|0
  C0030563|PARITY|0
  C0851346|Radiation|0
m v dox
  5
  C1134452|doxorubicin-magnetic targeted carrier complex|0
  C0724160|V-Dec-M|0
  C0077956|V-9-M cholecystokinin nonapeptide|0
  C0052034|allergen Dol m V|0
  C1135139|cBR96-doxorubicin immunoconjugate|0
inclusion
  1
  C0332257|Including (qualifier value)|0
antineoplastic therapy
  3
  C0039798|therapeutic aspects|0
  C0003392|Antineoplastic Agents|0
  C0087111|Therapeutic procedure|0
synergy
  2
  C0920877|Synergist|0
  C0599739|synergism|0
alt
  2
  C1140170|Alternative Billing Concepts|0
  C0001899|Alanine Transaminase|0
clinical examination
  1
  C0031809|Clinical examination|0
follow-up visits
  1
  C0589121|Follow-up visit (procedure)|0
similar regimen
  1
  C0677937|regimen|0
cox proportional hazard
  4
  C0205351|Proportional (qualifier value)|0
  C0598697|hazard|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
minimum time
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
potential source
  2
  C0237399|Potential|0
  C0449416|Source (attribute)|0
main reason
  2
  C0684328|Reasoning|0
  C0205225|Primary|0
three prospective randomized comparison
  1
  C0205449|Three (qualifier value)|0
toxicity sometimes troublesome
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
preoperative carcinoembryonic antigen concentration
  3
  C0086045|Concentration|0
  C0003320|Antigens|0
  C0445204|Preoperative (qualifier value)|0
treatment effects
  3
  C1280500|Effect (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
pearson chi-square test
  3
  C0039593|Testing|0
  C0205120|Square (qualifier value)|0
  C0392366|Tests (qualifier value)|0
combined chemotherapy hormonal therapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0087111|Therapeutic procedure|0
  C0205195|Combined (qualifier value)|0
  C0013216|Pharmacotherapy|0
26% patients
  1
  C0030705|Patients|0
patient years old
  4
  C0580836|Old|0
  C0030705|Patients|0
  C0677546|Old episode|0
  C0439234|year (qualifier value)|0
abnormal liver function
  1
  C0232742|Abnormal liver function (finding)|0
creatinine 1.25 x n
  2
  C0439225|ns (qualifier value)|0
  C0010294|Creatinine|0
17-percentage-point improvement
  5
  C0683655|community improvement|0
  C0421829|Improvement grant NOS|0
  C0680092|sexual improvement|0
  C0683848|curriculum improvement|0
  C0554898|Improvement grant admin|0
phase iii clinical trial
  2
  C0282461|Clinical Trials, Phase III|0
  C1096780|Clinical Trial, Phase III [Publication Type]|0
first generation trials
  2
  C0079411|Generations|0
  C0205435|First (qualifier value)|0
superior border
  2
  C0205284|Marginal (qualifier value)|0
  C0205105|Superior (qualifier value)|0
alkaline phosphatase level two
  4
  C0441889|Levels (qualifier value)|0
  C0205448|Two (qualifier value)|0
  C0031678|Phosphoric Monoester Hydrolases|0
  C0456079|Disease classification level|0
upper third
  1
  C0442049|Upper third (qualifier value)|0
adjunctive radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
hematologic toxicity
  3
  C0040539|Toxicity aspects|0
  C0205488|Hematologic (qualifier value)|0
  C0600688|Toxic effect|0
hemoglobin level
  2
  C1314664|Dipstick assessment of hemoglobin concentration (procedure)|0
  C0019029|Hemoglobin Level|0
local regional s
  2
  C0205147|Regional (qualifier value)|0
  C0205276|Local (qualifier value)|0
mitomycin
  2
  C0026254|Mitomycins|0
  C0002475|Mitomycin|0
only external beam treatment
  3
  C0039798|therapeutic aspects|0
  C0205101|External (qualifier value)|0
  C0087111|Therapeutic procedure|0
radiological lymph node status
  3
  C0449438|Status (attribute)|0
  C0746922|NODE|0
  C0024202|Lymph|0
ii study
  3
  C0557651|Room of building - Study|0
  C0439069|Roman numeral II|0
  C0947630|Scientific Study|0
recent studies
  3
  C0557651|Room of building - Study|0
  C0332185|Recent episode (qualifier value)|0
  C0947630|Scientific Study|0
median observation time
  5
  C0876920|Median Statistical Measurement|0
  C0040223|Time|0
  C0302523|Observation in research|0
  C0700325|Patient observation|0
  C0549183|Median (qualifier value)|0
important role
  1
  C0035820|Role|0
six weeks
  2
  C0439230|week (qualifier value)|0
  C0205452|Six (qualifier value)|0
exploration
  2
  C0581690|Exploration - action (qualifier value)|0
  C1280903|Exploration procedure (procedure)|0
planned adjuvant
  3
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0001551|Adjuvants, Immunologic|0
various drugs
  3
  C0684270|Drugged|0
  C0440102|Various (substance)|0
  C0013227|Pharmaceutical Preparations|0
common toxicity criteria
  4
  C0243161|criteria|0
  C0205214|Common (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
grade 3.4 neutropenia
  3
  C0027947|Neutropenia|0
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
lymph node metastases
  1
  C0686619|Secondary malignant neoplasm of lymph node (disorder)|0
equal
  2
  C0439089|Equals|0
  C0205163|Equal (qualifier value)|0
various other reasons
  3
  C0440102|Various (substance)|0
  C0684328|Reasoning|0
  C0205394|Other|0
contour
  2
  C0302821|Contour Alloy|0
  C0876954|Contour form|0
primarily headache
  1
  C0018681|Headache|0
higher rates
  1
  C0871208|Rating|0
anterior border
  2
  C0205094|Anterior|0
  C0205284|Marginal (qualifier value)|0
6.2 1 8 months
  1
  C0439231|month (qualifier value)|0
probabilities
  1
  C0033204|Probability|0
para-aortic radiotherapy
  4
  C0034619|radiotherapeutic|0
  C0003483|Aorta|0
  C0030563|PARITY|0
  C0034618|Radiation therapy|0
regressions
  2
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
external iliac nodes
  2
  C1305261|Entire external iliac lymph node|0
  C0229815|External iliac lymph node group|0
vein
  3
  C1278960|Entire vein|0
  C0042449|Veins|0
  C0923878|Vein|0
intravenous 5-fu mg
  3
  C0348016|Intravenous|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
statistical methods comparison
  3
  C0025664|Methodology|0
  C0220917|statistical|0
  C0025663|Methods|0
cisplatinbased chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
present trial
  1
  C0150312|Present|0
calculated response rates
  3
  C0871208|Rating|0
  C0871261|Responses|0
  C0444686|Calculated (qualifier value)|0
interrupted radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0443239|Interrupted (qualifier value)|0
  C0034618|Radiation therapy|0
onset
  2
  C0332162|Onset of (contextual qualifier) (qualifier value)|0
  C1299997|Onsets (qualifier value)|0
intracavitary irradiation
  4
  C1298613|Intracavitary (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
possibly detrimental effect
  2
  C1280500|Effect (qualifier value)|0
  C0332149|Possible|0
superior definitive therapy
  4
  C0039798|therapeutic aspects|0
  C0443196|Definitive (qualifier value)|0
  C0205105|Superior (qualifier value)|0
  C0087111|Therapeutic procedure|0
estrogen receptor positive
  1
  C0279754|Estrogen receptor positive|0
thrombocytopenia
  1
  C0040034|Thrombocytopenia|0
myocardium
  1
  C0027061|Myocardium|0
46.8 months
  1
  C0439231|month (qualifier value)|0
seven patients
  2
  C0030705|Patients|0
  C0205453|Seven (qualifier value)|0
gonadal function
  5
  C0031843|physiological aspects|0
  C0700205|Function Axis|0
  C0542341|Function|0
  C0018067|Gonadal structure|0
  C0422812|Functions (observable entity)|0
two patients
  2
  C0205448|Two (qualifier value)|0
  C0030705|Patients|0
prospective randomised trial
  5
  C0033522|Prospective Studies|0
  C0033519|Prospective Payment System|0
  C0184820|Prospective audit (procedure)|0
  C0589154|Prospective memory, function (observable entity)|0
  C0086862|Prospective Pricing|0
previous radio
  3
  C0034546|Radio|0
  C0205156|Previous (qualifier value)|0
  C1304639|Radio (physical object)|0
portal
  1
  C0205054|Hepatic|0
locoregional recurrences
  1
  C0034897|Recurrence|0
chemotherapy records
  1
  C0552366|CHEMOTHERAPY RECORDS|0
less times
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
delayed diarrhoea
  2
  C0205421|Deferred (qualifier value)|0
  C0011991|Diarrhea|0
tumor control
  3
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0027651|Neoplasms|0
women
  2
  C0043210|Human adult females|0
  C0043209|Human Females|0
pilot study
  1
  C0031928|Pilot Projects|0
recent national institutes of health consensus conference
  5
  C0332185|Recent episode (qualifier value)|0
  C0086047|Conferences|0
  C0018684|Health|0
  C0015737|Federal Government|0
  C0021622|Institutes|0
concomitant use
  1
  C0042153|utilization|0
ab3 antibodies
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
lymphography
  1
  C0024290|Lymphography|0
primary cervical cancers
  5
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0439631|Primary operation (qualifier value)|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0205225|Primary|0
population
  1
  C0032659|Population|0
performed several prospective randomized studies
  4
  C0557651|Room of building - Study|0
  C0443302|Several (qualifier value)|0
  C0884358|Performed (qualifier value)|0
  C0947630|Scientific Study|0
second rnca study
  4
  C0205436|Second (qualifier value)|0
  C0557651|Room of building - Study|0
  C0457385|seconds|0
  C0947630|Scientific Study|0
multigated radionuclide cineangiocardiography
  2
  C0202855|Cineradiography of cardiovascular system (procedure)|0
  C0034595|Radioisotopes|0
recurrence free survival
  3
  C0038952|Continuance of life|0
  C0034897|Recurrence|0
  C0220921|survival aspects|0
randomized studies
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
alternative approach
  1
  C0449445|Approach (attribute)|0
cervical site
  2
  C0205064|Cervical (qualifier value)|0
  C0205145|Associated topography (attribute)|0
parametrial failure
  2
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
neurologic adverse effects
  2
  C1280500|Effect (qualifier value)|0
  C0205494|Neurologic (qualifier value)|0
histopathology
  2
  C0677043|Histopathology|0
  C0243140|Histopathological aspects|0
median randomization time
  5
  C0876920|Median Statistical Measurement|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0034656|Random Allocation|0
  C0549183|Median (qualifier value)|0
significant renal toxicity
  4
  C0022646|Kidney|0
  C0040539|Toxicity aspects|0
  C0750502|Significant (qualifier value)|0
  C0600688|Toxic effect|0
nerves
  3
  C0027769|Nervousness|0
  C1280541|Entire nerve|0
  C0027740|Nerve|0
preplanned limitation
  1
  C0449295|Limitation (attribute)|0
immediate surgery
  4
  C0038895|Surgical aspects|0
  C0205253|Immediate (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
histologically positive axillary nodes
  3
  C0746922|NODE|0
  C0205159|Positive (qualifier value)|0
  C0004454|Axilla|0
remainder clear cell
  3
  C0205305|Clear (qualifier value)|0
  C0007634|Cells|0
  C1269647|Entire cell|0
one more
  2
  C0205447|One (qualifier value)|0
  C0205172|More (qualifier value)|0
biopsy proved metastasis
  4
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0220797|biopsy characteristics|0
  C0005558|Biopsy|0
  C0027627|Neoplasm Metastasis|0
antagonistic interactions
  2
  C0037420|Social Interaction|0
  C0687133|Drug Interactions|0
kaplanmeier survival curves
  3
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
time gap to
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0061928|GTPase-Activating Proteins|0
95.5 mg
  2
  C0024467|Magnesium|0
  C0439210|milligram|0
cardiac complications
  1
  C0161816|Cardiac complication of care NOS (disorder)|0
hyperfractionated rt
  5
  C1098273|RT-3003|0
  C0319120|RT parvovirus (organism)|0
  C0722979|RT Capsin|0
  C0310073|RT-MUNE (product)|0
  C1136259|SNOMED Reference Terminology|0
sections
  2
  C0700320|Sectioning technique|0
  C1293097|Division (procedure)|0
additional external beam therapy
  3
  C0039798|therapeutic aspects|0
  C0205101|External (qualifier value)|0
  C0087111|Therapeutic procedure|0
serious late complication rate
  5
  C0205404|Serious (qualifier value)|0
  C0009566|Complication|0
  C0205087|Late (qualifier value)|0
  C1171258|Complication Aspects|0
  C0871208|Rating|0
radiation dose violations
  1
  C0851346|Radiation|0
posterior ports
  4
  C0205095|Dorsal|0
  C0935727|port-a-cath|0
  C0475311|Harbor|0
  C0452253|Port - alcoholic beverage|0
anastomosis related complications
  5
  C0009566|Complication|0
  C0163712|Relate|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
  C0445223|Related (finding)|0
minimum
  4
  C0439232|Minute of time|0
  C0547039|Minimal (qualifier value)|0
  C0240346|Miner (general) (occupation)|0
  C0026175|Mining|0
parametrial extension
  1
  C0231448|Extension (qualifier value)|0
chisquare test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
more weeks
  2
  C0439230|week (qualifier value)|0
  C0205172|More (qualifier value)|0
meager effectiveness
  2
  C1280519|Effectiveness (qualifier value)|0
  C0205414|Effective (qualifier value)|0
occasional severe diarrhea
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0011991|Diarrhea|0
1.5 cm
  1
  C0475210|cm (qualifier value)|0
one tail
  2
  C0205447|One (qualifier value)|0
  C0039259|Tail|0
groups
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
actuarial survival curves
  3
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
7.4,and 6.8 months
  1
  C0439231|month (qualifier value)|0
irinotecan group
  4
  C0123931|irinotecan|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
fig
  1
  C0349966|Figs - dietary|0
two layer anastomosis
  5
  C0934502|Layer|0
  C0205448|Two (qualifier value)|0
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
p value
  1
  C0879541|p-value|0
forty five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
statistically significant greater cumulative dose
  2
  C0750502|Significant (qualifier value)|0
  C0443228|Greater (qualifier value)|0
side-effects
  1
  C0001688|adverse effects|0
patients tolerance
  3
  C0231197|Physiologic tolerance|0
  C0030705|Patients|0
  C0220929|Mental tolerance|0
antiemetic treatment
  3
  C0039798|therapeutic aspects|0
  C0003297|Antiemetics|0
  C0087111|Therapeutic procedure|0
adjusted relative risk
  3
  C0080103|Relative (related person)|0
  C0205345|Relative|0
  C0035647|Risk|0
longterm remissions
  2
  C0687702|Cancer Remission|0
  C0544452|Disease remission|0
white blood cell counts
  2
  C0023508|White Blood Cell Count procedure|0
  C0427512|White blood cell count laboratory result|0
only long-term analysis
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
antigen expression
  2
  C0185117|Expression - action (qualifier value)|0
  C0003320|Antigens|0
sixty first events
  2
  C0441471|Events (event)|0
  C0205435|First (qualifier value)|0
hope frequently
  2
  C0392347|hope|0
  C0332183|Frequent (qualifier value)|0
grade iv
  1
  C0547054|Grade four rank|0
age yr
  4
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
  C0439234|year (qualifier value)|0
granulocyte count
  1
  C0857490|Granulocyte count (procedure)|0
continuous anastomosis
  4
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0549178|Continuous (qualifier value)|0
  C0500470|Anatomical anastomosis|0
date patient
  3
  C0011008|Dates|0
  C0030705|Patients|0
  C0237553|dating|0
local radiation
  2
  C0851346|Radiation|0
  C0205276|Local (qualifier value)|0
second countries
  3
  C0205436|Second (qualifier value)|0
  C0454664|Countries (geographic location)|0
  C0457385|seconds|0
5-year analysis
  3
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0439234|year (qualifier value)|0
negative cls
  3
  C0201952|Chloride measurement|0
  C0010575|Cycloleucine|0
  C0205160|Negative (qualifier value)|0
baseline
  1
  C0168634|BaseLine|0
higher numbers
  2
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
tumor grade
  3
  C0441800|Grade|0
  C0027651|Neoplasms|0
  C0796573|Cancer cells grading system|0
5-yr rfs
  2
  C0748398|RF|0
  C0439234|year (qualifier value)|0
overall 5-year survival rates
  5
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
  C0439234|year (qualifier value)|0
single doses
  4
  C0037179|Unmarried person|0
  C0719635|DOS|0
  C0205171|Singular|0
  C0087136|Unmarried|0
south africa
  1
  C0037712|South Africa|0
better estimate
  2
  C0332272|Better (qualifier value)|0
  C0750572|ESTIMATED|0
relatively favorable prognosis
  1
  C0033325|Forecast of outcome|0
day via continuous 24-hr infusion
  3
  C0574032|Infusion (procedure)|0
  C0439228|day (qualifier value)|0
  C0549178|Continuous (qualifier value)|0
superior results
  2
  C1274040|Result (navigational concept)|0
  C0205105|Superior (qualifier value)|0
then months
  1
  C0439231|month (qualifier value)|0
underwent preoperative radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0445204|Preoperative (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
biochemical profiles
  1
  C0205474|Biochemical (qualifier value)|0
pilot trial
  1
  C0473169|Pilot - aircraft (occupation)|0
gastric cancer
  1
  C0024623|Malignant neoplasm of stomach|0
therefore patients
  1
  C0030705|Patients|0
g
  1
  C0162832|APC Gene|0
cea
  1
  C0007082|Carcinoembryonic Antigen|0
enteric fistula
  2
  C0021852|Intestines, Small|0
  C0016169|Fistula|0
weakness
  3
  C0086525|Lassitude|0
  C0004093|Asthenia|0
  C0030552|Paresis|0
performance states
  2
  C1301808|State (environment)|0
  C0597198|Performance|0
event
  1
  C0441471|Events (event)|0
disappointing
  1
  C0870427|Disappointment|0
fisher
  1
  C0325045|Martes pennanti (organism)|0
improvement
  3
  C1272745|Improving (qualifier value)|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
treatment schedule
  4
  C0086960|Schedules|0
  C0039798|therapeutic aspects|0
  C0205539|Scheduled (qualifier value)|0
  C0087111|Therapeutic procedure|0
full thickness
  1
  C0439809|Full thickness (qualifier value)|0
significant effect
  2
  C1280500|Effect (qualifier value)|0
  C0750502|Significant (qualifier value)|0
power
  1
  C0032863|Power (Psychology)|0
m intravenously
  5
  C0022985|Laminin M|0
  C0009293|Colicin M|0
  C0039939|Thioredoxin M|0
  C0032538|Polymyxin M|0
  C0019030|Hemoglobin M|0
bones
  4
  C0262950|Skeletal bone|0
  C0391978|Bone Tissue|0
  C1266909|Entire bony skeleton|0
  C1266908|Entire bone (organ)|0
male
  2
  C0086582|Males|0
  C0024554|Male gender|0
minor response
  3
  C0026193|Minor|0
  C0205165|Minor (value)|0
  C0871261|Responses|0
six additional patients
  2
  C0030705|Patients|0
  C0205452|Six (qualifier value)|0
paraaortic radiation
  1
  C0851346|Radiation|0
percent confidence intervals
  3
  C0237529|Self-confidence (observable entity)|0
  C0439165|Percent (qualifier value)|0
  C1272706|Interval (qualifier value)|0
bone marrow function
  5
  C0262950|Skeletal bone|0
  C0376152|Marrow|0
  C0542341|Function|0
  C1266909|Entire bony skeleton|0
  C0086590|Vegetable marrow|0
again trend
  1
  C0040833|trends|0
unexpectedly high proportion
  2
  C0205250|High|0
  C0235146|Euphoric mood|0
rectum cancer patients
  5
  C0998265|Cancer Genus|0
  C0034896|Rectum|0
  C0006826|Malignant Neoplasms|0
  C0030705|Patients|0
  C1278926|Entire rectum|0
comparing patients
  1
  C0030705|Patients|0
treatment strategies
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0679199|strategy|0
potential candidates
  1
  C0237399|Potential|0
actuarial survival rates
  3
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
occult parametrial involvement
  3
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0205262|Occult (qualifier value)|0
safety profile
  1
  C0036043|Safety|0
categorical data
  5
  C0011000|Data Reporting|0
  C0010991|Data Aggregation|0
  C0010990|Data Adjustment|0
  C0010992|Data Analysis|0
  C0425928|Menstrual data NOS (context-dependent category)|0
alternative hypothesis
  2
  C0681918|hypothesis testing|0
  C0242256|Easterlin Hypothesis|0
second diagnosis
  4
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
  C0348026|Diagnostic|0
  C0011900|Diagnosis|0
m2 body surface area intravenously infusion
  4
  C0205146|Area (qualifier value)|0
  C0574032|Infusion (procedure)|0
  C0242821|Human Body|0
  C0205148|Surface (qualifier value)|0
two vulvar
  2
  C0205448|Two (qualifier value)|0
  C0042993|Vulva|0
therapeutic efficacy
  2
  C0039796|The science and art of healing|0
  C0302350|Therapeutic|0
normal liver
  4
  C1278929|Entire liver|0
  C0205307|Normal (qualifier value)|0
  C0023899|Liver Extract|0
  C0023884|Liver|0
adjuvant radiotherapy
  1
  C0242939|Radiotherapy, Adjuvant|0
cardiotoxic effects
  1
  C1280500|Effect (qualifier value)|0
reducing chemotherapeutic regimen
  2
  C0392756|Reduced (qualifier value)|0
  C0677937|regimen|0
one fraction
  2
  C0457426|Fractions of (qualifier value)|0
  C0205447|One (qualifier value)|0
daily infusions
  2
  C0574032|Infusion (procedure)|0
  C0332173|Daily (qualifier value)|0
prognostic variables
  2
  C0439828|Variable (qualifier value)|0
  C0220901|prognostic|0
time point
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
majority
  1
  C0680220|majority|0
toxic effects
  1
  C0600688|Toxic effect|0
distinct hama response
  1
  C0871261|Responses|0
pathology documents
  5
  C0030664|Pathology|0
  C0677042|Pathology processes|0
  C1301725|Documented (qualifier value)|0
  C0205469|Pathological aspects|0
  C1301746|Documents (qualifier value)|0
ny chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
univariate analyses
  1
  C0683962|univariate analysis|0
41% reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
paraaortic lymph nodes
  1
  C0229789|Aortic lymph node (body structure)|0
true differences
  1
  C0205238|True (qualifier value)|0
deep invasion
  1
  C0205125|Depth (qualifier value)|0
other sites
  2
  C0205145|Associated topography (attribute)|0
  C0205394|Other|0
positive result
  2
  C1274040|Result (navigational concept)|0
  C0205159|Positive (qualifier value)|0
selection bias
  1
  C0036577|Selection Bias|0
perineal pain
  1
  C0240717|Perineal pain (finding)|0
figs
  1
  C0349966|Figs - dietary|0
borderline values
  2
  C0205189|Borderline (qualifier value)|0
  C0042295|VALUING|0
difficulties
  1
  C1299586|Has difficulty doing (qualifier value)|0
failure to
  2
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
infusion treatment
  3
  C0039798|therapeutic aspects|0
  C0574032|Infusion (procedure)|0
  C0087111|Therapeutic procedure|0
rather mild toxicity
  3
  C0205080|Mild (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
pathological findings
  2
  C0205469|Pathological aspects|0
  C0243095|findings|0
mucosal toxicity
  3
  C0026724|Mucous Membrane|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
further five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
ii trial
  1
  C0439069|Roman numeral II|0
more risk factors
  2
  C0205172|More (qualifier value)|0
  C0035647|Risk|0
again significant treatment advantage
  4
  C0308269|ADVANTAGE|0
  C0039798|therapeutic aspects|0
  C0750502|Significant (qualifier value)|0
  C0087111|Therapeutic procedure|0
severe events
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0441471|Events (event)|0
fluorouracil
  1
  C0016360|Fluorouracil|0
negative pretreatment
  1
  C0205160|Negative (qualifier value)|0
neoplastic cells
  1
  C0597032|neoplastic cell|0
one-sided significance level
  4
  C0441889|Levels (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0456079|Disease classification level|0
  C0441987|Side (qualifier value)|0
clinical cardiac dysfunction
  4
  C0205041|Cardio-|0
  C0205210|Clinical (qualifier value)|0
  C0031847|physiopathological|0
  C0277785|Functional disorder|0
hours
  1
  C0439227|Hour|0
only single risk factor
  4
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0035647|Risk|0
radiation proctitis re
  2
  C0033246|Proctitis|0
  C0851346|Radiation|0
arm ii post-operative rt
  4
  C0003792|Arm|0
  C0687676|After values (qualifier value)|0
  C0446516|Upper arm|0
  C0439069|Roman numeral II|0
hence survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
leukocyte count
  1
  C0023508|White Blood Cell Count procedure|0
first stopping rule
  4
  C0723457|Stop|0
  C0870077|Rules|0
  C0205435|First (qualifier value)|0
  C0450446|Stops (attribute)|0
positive paraaortic lymph node biopsy
  5
  C0746922|NODE|0
  C0220797|biopsy characteristics|0
  C0205159|Positive (qualifier value)|0
  C0005558|Biopsy|0
  C0024202|Lymph|0
adverse effect
  2
  C0001688|adverse effects|0
  C0879626|adverse effect|0
significance levels
  1
  C0814896|significance level|0
positive impact
  3
  C0726639|Impact|0
  C0205159|Positive (qualifier value)|0
  C0333125|Impacted (qualifier value)|0
biochemistries
  1
  C0005477|Biochemistry|0
radical hysterectomy
  1
  C0677962|Total hysterectomy (procedure)|0
inherently superior prognosis
  2
  C0205105|Superior (qualifier value)|0
  C0033325|Forecast of outcome|0
highest combined frequency
  4
  C0376249|With frequency|0
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0439603|Frequencies (time pattern)|0
pain control
  1
  C1304888|Pain control (procedure)|0
increasing 5-fu incorporation
  5
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0243126|incorporation|0
  C0016360|Fluorouracil|0
  C0442805|Increase (qualifier value)|0
or death
  2
  C0011065|Cessation of life|0
  C0069590|ORALIT|0
overall survival curve
  4
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
prospective study
  1
  C0033522|Prospective Studies|0
irinotecan mg
  1
  C0123931|irinotecan|0
external beam
  1
  C0205101|External (qualifier value)|0
overall survival improvement
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
angiosarcoma
  1
  C0018923|Hemangiosarcoma|0
international federation
  1
  C0024552|Malaysia|0
further infection
  1
  C0021311|Infection|0
higher rate
  1
  C0871208|Rating|0
well recognized prognostic factors
  2
  C0220901|prognostic|0
  C0205170|Good (qualifier value)|0
screening
  4
  C0220909|Aspects of disease screening|0
  C0183185|Screens|0
  C1305399|Screening - procedure intent (qualifier value)|0
  C0220908|Screening procedure|0
several prospective randomised comparisons
  1
  C0443302|Several (qualifier value)|0
intravenous pyelography
  1
  C0203108|Intravenous pyelogram|0
paraaortic nodal disease
  2
  C0443268|Nodal (qualifier value)|0
  C0012634|Disease|0
leukopenia
  1
  C0023530|Leukopenia|0
pelvic disease volume
  3
  C0030797|Pelvis|0
  C0012634|Disease|0
  C0449468|Volume (property) (qualifier value)|0
complications
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
pelvic wall
  1
  C0230284|Pelvic wall structure (body structure)|0
factorial design
  1
  C0681865|factorial design|0
dextrose
  1
  C0017725|Glucose|0
made use
  1
  C0042153|utilization|0
lesion
  1
  C0221198|Lesion|0
questions
  1
  C0876928|Questioning|0
continued interest
  2
  C0543488|Interested (finding)|0
  C0750536|CONTINUED|0
agents
  1
  C0450442|Agent (attribute)|0
first generation
  2
  C0079411|Generations|0
  C0205435|First (qualifier value)|0
participating clinic
  1
  C0442592|Clinic (environment)|0
local tumor control
  4
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0027651|Neoplasms|0
  C0205276|Local (qualifier value)|0
response category
  2
  C0683312|categories|0
  C0871261|Responses|0
imprecise method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
chemotherapeutic regimens
  1
  C0677937|regimen|0
double needle suture
  5
  C0205173|Duplicate|0
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0027551|Needles|0
  C0502420|Suture Joint|0
reduced incidence
  3
  C0392756|Reduced (qualifier value)|0
  C0021149|Incidence|0
  C0220856|incidence of cases|0
same prognosis
  2
  C0445247|Same (qualifier value)|0
  C0033325|Forecast of outcome|0
regional lymph node metastases
  1
  C0332397|pN1 category (finding)|0
interim analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
other findings
  2
  C0243095|findings|0
  C0205394|Other|0
total doses
  2
  C0439810|Total (qualifier value)|0
  C0719635|DOS|0
81/4 months
  1
  C0439231|month (qualifier value)|0
advanced disease patients
  4
  C0205179|Advanced phase|0
  C0725066|Advance|0
  C0012634|Disease|0
  C0030705|Patients|0
significant sequence dependent differences
  2
  C0750502|Significant (qualifier value)|0
  C0851827|Dependent (qualifier value)|0
6.5 cm
  1
  C0475210|cm (qualifier value)|0
hepatic function
  1
  C0232741|Liver function (observable entity)|0
rare histologic subtype
  3
  C0449560|Subtype (attribute)|0
  C0205462|Histologic|0
  C0332184|Rare (qualifier value)|0
local sites
  2
  C0205145|Associated topography (attribute)|0
  C0205276|Local (qualifier value)|0
only first
  1
  C0205435|First (qualifier value)|0
negative impact
  3
  C0726639|Impact|0
  C0205160|Negative (qualifier value)|0
  C0333125|Impacted (qualifier value)|0
duration
  1
  C0449238|Duration|0
and mesna
  2
  C0000294|Mesna|0
  C0917779|Mesnum|0
response rates
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
iia cervical cancer
  4
  C0998265|Cancer Genus|0
  C0205064|Cervical (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
first intracavitary treatment
  4
  C0039798|therapeutic aspects|0
  C1298613|Intracavitary (qualifier value)|0
  C0205435|First (qualifier value)|0
  C0087111|Therapeutic procedure|0
safe regimen
  1
  C0677937|regimen|0
17-1a treatment again
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0450344|1A (qualifier value)|0
hemoglobin level g
  4
  C0441889|Levels (qualifier value)|0
  C0162832|APC Gene|0
  C0456079|Disease classification level|0
  C0019046|Hemoglobin|0
only small proportion
  1
  C0700321|Small|0
surgical procedure
  1
  C0543467|GENERAL OPERATIVE PROCEDURES|0
gynaecologist
  1
  C0237419|Gynecologist (occupation)|0
intent adjuvant
  3
  C0679197|Has intent (attribute)|0
  C0001551|Adjuvants, Immunologic|0
  C1285529|Intents (nature of procedure values) (qualifier value)|0
pathologic factors
  1
  C0205469|Pathological aspects|0
marked modulation
  1
  C0522501|Massive (qualifier value)|0
pelvic recurrence
  2
  C0030797|Pelvis|0
  C0034897|Recurrence|0
physiologic level
  3
  C0441889|Levels (qualifier value)|0
  C0205463|Physiologic (qualifier value)|0
  C0456079|Disease classification level|0
locoregional radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
urothelial cancer
  3
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
cmf
  1
  C0950521|CMF|0
end points
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
radiation oncology
  1
  C0243005|Radiation Oncology|0
late toxicities
  3
  C0205087|Late (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
nine other drugs
  4
  C0684270|Drugged|0
  C0205455|Nine (qualifier value)|0
  C0205394|Other|0
  C0013227|Pharmaceutical Preparations|0
ascending
  2
  C0205385|Ascending (qualifier value)|0
  C0308355|ASCEND (product)|0
physicians
  1
  C0031831|Physicians|0
preoperative findings
  2
  C0445204|Preoperative (qualifier value)|0
  C0243095|findings|0
continuous data
  1
  C0549178|Continuous (qualifier value)|0
fixation
  2
  C0185023|Fixation - action|0
  C0728733|Psychological fixation|0
isocentric technique
  2
  C0025664|Methodology|0
  C0449851|Techniques|0
two refills
  2
  C0205448|Two (qualifier value)|0
  C0807726|REFILLS|0
two courses
  3
  C0205448|Two (qualifier value)|0
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
3.5 percent
  1
  C0439165|Percent (qualifier value)|0
prior chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0750516|PRIOR|0
  C0013216|Pharmacotherapy|0
first results
  2
  C1274040|Result (navigational concept)|0
  C0205435|First (qualifier value)|0
postoperative radiation “prevented local recurrences
  4
  C0032790|Postoperative Period|0
  C0034897|Recurrence|0
  C0851346|Radiation|0
  C0205276|Local (qualifier value)|0
neutrophils l
  1
  C0027950|Neutrophils|0
powerful prognostic determinant
  1
  C0220901|prognostic|0
less protracted exposure
  3
  C0391838|Exposure condition|0
  C0728853|Accident due to exposure to weather conditions|0
  C0274281|EFFECTS OF EXPOSURE TO EXTERNAL CAUSES|0
localisation
  1
  C0475264|Localization - action (qualifier value)|0
confidence limits
  1
  C0237530|Confidence Limits|0
intention to
  1
  C0162425|Intention|0
s3 posteriorly
  1
  C1179706|S3|0
radiation oncologist
  1
  C0278603|radiation oncologist|0
compliance
  2
  C0030680|Patient Compliance|0
  C0009563|Biomechanical compliance|0
recurrences
  1
  C0034897|Recurrence|0
median 17.4 4 irinotecan group
  5
  C0123931|irinotecan|0
  C0876920|Median Statistical Measurement|0
  C0439745|Grouped (qualifier value)|0
  C0549183|Median (qualifier value)|0
  C0441833|Groups (qualifier value)|0
significance
  1
  C0750502|Significant (qualifier value)|0
flexible granulocyte colony-stimulating factor
  3
  C0443220|Flexible (qualifier value)|0
  C0439158|colonies (qualifier value)|0
  C0018183|Granulocytes|0
d
  5
  C0011011|Daughters|0
  C0439228|day (qualifier value)|0
  C0178602|Dosages (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
  C0449238|Duration|0
major site
  2
  C0205164|Major (qualifier value)|0
  C0205145|Associated topography (attribute)|0
gpt
  1
  C0001899|Alanine Transaminase|0
amputation
  1
  C0002688|Amputation|0
full treatment
  3
  C0039798|therapeutic aspects|0
  C0443225|Full (qualifier value)|0
  C0087111|Therapeutic procedure|0
histological evidence
  1
  C0205462|Histologic|0
10.30 patients
  1
  C0030705|Patients|0
only one cycle
  1
  C0205447|One (qualifier value)|0
pump
  1
  C0182537|Pump, device (physical object)|0
one report
  3
  C0205447|One (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
small bowel
  1
  C0021852|Intestines, Small|0
gastrointestinal bleeding
  1
  C0017181|Gastrointestinal Hemorrhage|0
distribution
  2
  C0520511|Distributing|0
  C0037775|Spatial Distribution|0
improvements
  3
  C1272745|Improving (qualifier value)|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
cumulative doses
  1
  C0719635|DOS|0
important prognostic variables
  2
  C0439828|Variable (qualifier value)|0
  C0220901|prognostic|0
success
  1
  C0597535|success|0
cancer progression
  1
  C0178874|Neoplasm progression|0
one global health status scale
  5
  C0175659|Weight measurement scales|0
  C0205447|One (qualifier value)|0
  C0205246|Generalized (qualifier value)|0
  C0222045|Integumentary scale|0
  C0018684|Health|0
pre-operative radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0740175|Before values (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
large tumor diameter
  3
  C0549177|Large|0
  C0027651|Neoplasms|0
  C0332517|Diameter (qualifier value)|0
adjuvant chemotherapy
  1
  C0085533|Chemotherapy, Adjuvant|0
platelets
  1
  C0005821|Blood Platelets|0
metoclopramide
  1
  C0025853|Metoclopramide|0
distal margin
  3
  C1269830|Tumor margin status|0
  C0205284|Marginal (qualifier value)|0
  C0205108|Distal (qualifier value)|0
reversible alopecia
  2
  C0002170|Alopecia|0
  C0205343|Reversible (qualifier value)|0
dox
  4
  C0048808|5'-deoxy-5-fluorouridine|0
  C0699957|Vibramycin|0
  C0013089|Doxorubicin|0
  C0013090|Doxycycline|0
breast irradiation
  5
  C0006141|Breast|0
  C1268990|Entire breast|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
then effect
  1
  C1280500|Effect (qualifier value)|0
consistent trend
  2
  C0332290|Consistent with (qualifier value)|0
  C0040833|trends|0
maintaining reasonable state
  3
  C1314677|Maintained (qualifier value)|0
  C1301808|State (environment)|0
  C0721534|Maintain|0
occult local satellites
  4
  C0036238|Satellite Viruses|0
  C0205262|Occult (qualifier value)|0
  C0205276|Local (qualifier value)|0
  C0332221|Satellite (qualifier value)|0
definitive deterioration
  2
  C0443196|Definitive (qualifier value)|0
  C0868945|Deterioration|0
cyclophosphamide
  1
  C0010583|Cyclophosphamide|0
primary end-point
  4
  C1272693|Ended (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0444930|End (qualifier value)|0
linear accelerator
  2
  C0023730|Linear Accelerators|0
  C1318457|Linear accelerator electrons (procedure)|0
second line cytotoxic chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0700221|Intravascular line|0
  C0205132|Linear|0
  C0013216|Pharmacotherapy|0
deep tumor invasion
  2
  C0205125|Depth (qualifier value)|0
  C0027651|Neoplasms|0
filgrastim
  1
  C0210630|Filgrastim|0
only small number
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0700321|Small|0
one progression
  2
  C0205447|One (qualifier value)|0
  C0449258|Progression (attribute)|0
institutional upper normal limit
  3
  C0439801|Limited (qualifier value)|0
  C0205307|Normal (qualifier value)|0
  C0547042|Upper (qualifier value)|0
modifications
  1
  C0205349|Altered (qualifier value)|0
bypass surgery
  4
  C0038895|Surgical aspects|0
  C0741847|Bypass|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
m2 patients
  1
  C0030705|Patients|0
skeleton
  3
  C1283922|Entire skeleton|0
  C0037253|Skeletal system|0
  C0816871|Skeleton|0
other grade toxicities
  5
  C0441800|Grade|0
  C0040539|Toxicity aspects|0
  C0796573|Cancer cells grading system|0
  C0600688|Toxic effect|0
  C0205394|Other|0
actuarial survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
stable patients
  2
  C0205360|Stable (qualifier value)|0
  C0030705|Patients|0
multivariate analyses
  1
  C0026777|Multivariate Analysis|0
dextran-coated charcoal assay
  5
  C0011806|Dextrans|0
  C0453946|Coat|0
  C0007955|Charcoal|0
  C0243073|assay|0
  C0086140|Dextran|0
appropriate therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
unfavorable effects
  1
  C1280500|Effect (qualifier value)|0
stage ivb patients
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0030705|Patients|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
exclusion criteria
  2
  C0680251|exclusion|0
  C0243161|criteria|0
preexisting malignancy
  2
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
indeterminate
  1
  C0205258|Indeterminate|0
a1
  1
  C0933653|Trunk of apical segmental artery|0
progressive metastatic disease
  3
  C0036525|Metastatic to|0
  C0205329|Progressive (qualifier value)|0
  C0012634|Disease|0
more effective treatment
  4
  C0039798|therapeutic aspects|0
  C0205414|Effective (qualifier value)|0
  C0205172|More (qualifier value)|0
  C0087111|Therapeutic procedure|0
renal failure afterone course
  5
  C0022646|Kidney|0
  C0449922|Course (attribute)|0
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
  C0750729|Courses (qualifier value)|0
fibrosis
  1
  C0016059|Fibrosis|0
dose response curve
  1
  C0683162|dose-response curve|0
gastric adenocarcinoma
  2
  C0001418|Adenocarcinoma|0
  C0038351|Stomach|0
equivalent degrees
  3
  C0449286|Degree or extent|0
  C0542560|Academic degree|0
  C0439185|Eq (qualifier value)|0
same staging criteria
  5
  C0243161|criteria|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0445247|Same (qualifier value)|0
  C1306673|Stages (qualifier value)|0
treatment-related toxicity
  5
  C0040539|Toxicity aspects|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0600688|Toxic effect|0
  C0445223|Related (finding)|0
erroneous staging
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
somewhat more frequent diarrhea
  3
  C0332183|Frequent (qualifier value)|0
  C0205172|More (qualifier value)|0
  C0011991|Diarrhea|0
median tumor size
  4
  C0876920|Median Statistical Measurement|0
  C0027651|Neoplasms|0
  C0549183|Median (qualifier value)|0
  C0702146|Size (attribute)|0
requiring medication
  1
  C0013227|Pharmaceutical Preparations|0
p values to
  1
  C0042295|VALUING|0
roche
  1
  C0331965|Roche|0
four arm study
  5
  C0557651|Room of building - Study|0
  C0205450|Four (qualifier value)|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0947630|Scientific Study|0
demolitive surgery now
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
three patients
  2
  C0030705|Patients|0
  C0205449|Three (qualifier value)|0
first course
  3
  C0449922|Course (attribute)|0
  C0205435|First (qualifier value)|0
  C0750729|Courses (qualifier value)|0
d orally
  2
  C0026635|Mouth Breathing|0
  C0112081|D-D mixture|0
ci
  1
  C0162854|Commonwealth of Independent States|0
linear source
  2
  C0205132|Linear|0
  C0449416|Source (attribute)|0
umbilicus
  3
  C1280744|Entire umbilicus|0
  C0041638|Umbilicus (Anatomy)|0
  C1040830|Umbilicus Genus|0
one caesium-137 ldr insertion
  4
  C0205447|One (qualifier value)|0
  C0007886|Cesium|0
  C0441587|Clinical act of insertion|0
  C0021107|Implantation procedure|0
because most responding patients
  2
  C0205393|Most (qualifier value)|0
  C0030705|Patients|0
previous trials
  1
  C0205156|Previous (qualifier value)|0
recovery
  1
  C0237820|recovery from disease|0
sound clinical reasons to
  5
  C0037709|Sound - physical agent|0
  C0205210|Clinical (qualifier value)|0
  C1293120|Sounding (procedure)|0
  C0684328|Reasoning|0
  C0175663|Sounds device|0
therapy forms
  5
  C0039798|therapeutic aspects|0
  C0376315|Manufactured form|0
  C0205431|Formed (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0348078|Qualitative form|0
only small subgroup
  1
  C0700321|Small|0
5-year follow-up evaluation
  5
  C0220825|Evaluation|0
  C0547043|Up (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
  C0332282|Following (attribute)|0
  C0439234|year (qualifier value)|0
haemorrhage
  1
  C0019080|Hemorrhage|0
crude estimate
  1
  C0750572|ESTIMATED|0
previous study
  3
  C0557651|Room of building - Study|0
  C0205156|Previous (qualifier value)|0
  C0947630|Scientific Study|0
overall toxicity
  3
  C0040539|Toxicity aspects|0
  C0282416|Overall [Publication Type]|0
  C0600688|Toxic effect|0
chest x-ray
  1
  C0202783|Radiographic procedure on chest (procedure)|0
radiodermatitis
  1
  C0034561|Radiodermatitis|0
possible patients
  2
  C0332149|Possible|0
  C0030705|Patients|0
concurrent administration
  3
  C1262471|Administration (procedure)|0
  C0205420|Concurrent (qualifier value)|0
  C0001554|Administration|0
bias
  1
  C0242568|Biases|0
bilateral hydronephrosis
  1
  C0521622|Bilateral hydronephrosis (disorder)|0
intensive radiation
  1
  C0851346|Radiation|0
confirming evidence
  1
  C0750484|CONFIRMED|0
planned program
  3
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0376691|Programs [Publication Type]|0
infection
  1
  C0021311|Infection|0
infusion
  1
  C0574032|Infusion (procedure)|0
prediction
  1
  C0681842|prediction|0
randomization procedures
  3
  C0025664|Methodology|0
  C0184661|Procedures|0
  C0034656|Random Allocation|0
cut
  2
  C1306235|Cutting, NOS|0
  C0000925|Incised wound - morphology (morphologic abnormality)|0
onthe cifx arm
  2
  C0003792|Arm|0
  C0446516|Upper arm|0
nadir sepsis days
  3
  C0243026|Systemic infection|0
  C1090821|Sepsis (Invertebrate)|0
  C0439228|day (qualifier value)|0
calibration
  1
  C0006751|Calibration|0
further month
  1
  C0439231|month (qualifier value)|0
chambers
  2
  C0935616|Chamber|0
  C0179874|Chambers|0
estimation
  1
  C0680844|estimation|0
c2 equivalent
  3
  C1305857|C2 innervation|0
  C0009505|Complement 2|0
  C0439185|Eq (qualifier value)|0
severe morbidity
  3
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
better pelvic control
  4
  C0702113|Controlled (qualifier value)|0
  C0030797|Pelvis|0
  C0332272|Better (qualifier value)|0
  C0243148|control|0
seven relapses
  4
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0205453|Seven (qualifier value)|0
  C0580802|Relapse phase|0
preliminary data
  1
  C0439611|Preliminary (qualifier value)|0
federal regulations
  2
  C0851285|Regulation|0
  C0220905|regulatory|0
leakage rate
  2
  C0871208|Rating|0
  C0015376|Extravasation (morphologic abnormality)|0
methods patient eligibility study
  5
  C0557651|Room of building - Study|0
  C0025664|Methodology|0
  C0025663|Methods|0
  C0030705|Patients|0
  C0947630|Scientific Study|0
multiple data sets
  3
  C0542559|contextual factors|0
  C0036849|Set (Psychology)|0
  C0439064|Numerous (qualifier value)|0
bleeding requiring transfusion
  2
  C0199960|Transfusion - action (qualifier value)|0
  C0019080|Hemorrhage|0
institution’s equipment
  2
  C0014672|Equipment|0
  C0220824|Equipment used|0
france
  1
  C0016674|France|0
apparent lack
  2
  C0332268|Lacking (qualifier value)|0
  C0750489|APPARENT|0
chest x ray
  1
  C0202783|Radiographic procedure on chest (procedure)|0
potassium chloride
  1
  C0032825|Potassium Chloride|0
highest proportion
  3
  C0429144|Facial proportion (observable entity)|0
  C0007725|Cephalopelvic Proportion|0
  C0491073|SUBSYSTEM, PROPORTIONING|0
significant reductions
  3
  C0301630|Reduction (chemical)|0
  C0750502|Significant (qualifier value)|0
  C0441610|Reduction - action|0
log rank statistic
  2
  C0038215|Science of Statistics|0
  C0699794|Rank|0
overall survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
m treatment group
  5
  C0039798|therapeutic aspects|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
suggested maximal doses
  2
  C0205289|Maximal (qualifier value)|0
  C0719635|DOS|0
bilateral pelvic lymphadenectomy
  4
  C0030797|Pelvis|0
  C0024203|Lymph node excision|0
  C0281267|bilateral breast cancer|0
  C0238767|Bilateral|0
10-fold increase
  5
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0332462|Folded structure (morphologic abnormality)|0
  C0185026|Plication|0
  C0442805|Increase (qualifier value)|0
slides
  2
  C0444330|Slide (specimen)|0
  C0332246|Sliding|0
mf
  4
  C0027075|Myofibrils|0
  C0752265|Microfibrils|0
  C0025979|Microfilaments|0
  C0026987|Myelofibrosis|0
nonhematologic toxicities
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
initial response rate
  3
  C0871208|Rating|0
  C0871261|Responses|0
  C0205265|Initial (qualifier value)|0
type i error
  1
  C0871555|Type I Errors|0
four additional patients
  2
  C0205450|Four (qualifier value)|0
  C0030705|Patients|0
urogenital tract
  2
  C1185740|Tract|0
  C0447566|Urogenital structure|0
leukemic potential
  1
  C0237399|Potential|0
intracavitary radiation
  2
  C1298613|Intracavitary (qualifier value)|0
  C0851346|Radiation|0
residual disease
  1
  C0543478|Residual Tumor|0
upper quarter
  1
  C0547042|Upper (qualifier value)|0
adjuvant portal chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
  C0205054|Hepatic|0
median duration
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0449238|Duration|0
yield tumor response rates
  3
  C0871208|Rating|0
  C0027651|Neoplasms|0
  C0871261|Responses|0
hazards ratio
  2
  C0456603|Ratio (property) (qualifier value)|0
  C0598697|hazard|0
risks
  1
  C0035647|Risk|0
median diameter
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
radiation techniques
  3
  C0025664|Methodology|0
  C0449851|Techniques|0
  C0851346|Radiation|0
statistical significance
  1
  C0237881|Statistical Significance|0
total treatment time
  5
  C0439810|Total (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0087111|Therapeutic procedure|0
partial response
  1
  C0677924|partial response|0
transient leucopenia
  4
  C0205374|Transitory|0
  C0687129|Encounter due to vagabond status|0
  C0023530|Leukopenia|0
  C0040704|Transient Population Group|0
paraortic region
  1
  C0205147|Regional (qualifier value)|0
three received surgery
  4
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0205449|Three (qualifier value)|0
80% power to
  1
  C0032863|Power (Psychology)|0
postoperative complications
  1
  C0032787|Postoperative Complications|0
remaining nine patients
  2
  C0030705|Patients|0
  C0205455|Nine (qualifier value)|0
curative resection
  2
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
inferior margin
  4
  C0678975|inferiority|0
  C1269830|Tumor margin status|0
  C0542339|Inferior|0
  C0205284|Marginal (qualifier value)|0
missing chart
  2
  C0007963|Charts|0
  C0684240|chart|0
one arm
  3
  C0003792|Arm|0
  C0205447|One (qualifier value)|0
  C0446516|Upper arm|0
primary objectives
  3
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0018017|Goals|0
significantly lower rate
  3
  C0871208|Rating|0
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
logrank test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
carcinoembryonic antigen
  1
  C0007082|Carcinoembryonic Antigen|0
institutional pathologists
  1
  C0334866|Medical pathologist (occupation)|0
concurrent use
  2
  C0042153|utilization|0
  C0205420|Concurrent (qualifier value)|0
minor responses
  3
  C0026193|Minor|0
  C0205165|Minor (value)|0
  C0871261|Responses|0
five surviving patients
  3
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
  C0310255|SURVIVE (product)|0
short course
  4
  C0449922|Course (attribute)|0
  C0453933|Shorts (physical object)|0
  C0205167|Short (qualifier value)|0
  C0750729|Courses (qualifier value)|0
lateral fields
  3
  C0205093|Lateral (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
second application
  3
  C0205436|Second (qualifier value)|0
  C0185125|Application (procedure)|0
  C0457385|seconds|0
italy
  1
  C0022277|Italy|0
peripheral blood
  1
  C0229664|Peripheral blood (substance)|0
participants
  1
  C0679646|participant|0
adriamycin containing regimen
  3
  C0085752|Adriamycin|0
  C0332256|Containing (qualifier value)|0
  C0677937|regimen|0
complete blood analysis
  5
  C0002778|Analysis of substances|0
  C0005768|In Blood|0
  C0936012|Analysis|0
  C0005767|Blood|0
  C0205197|Complete (qualifier value)|0
radiation trials
  1
  C0851346|Radiation|0
complete responses
  1
  C0677874|In complete remission (qualifier value)|0
stroke
  1
  C0038454|Cerebrovascular accident|0
other five cycles
  2
  C0205451|Five (qualifier value)|0
  C0205394|Other|0
lymph node biopsy to
  4
  C0746922|NODE|0
  C0220797|biopsy characteristics|0
  C0005558|Biopsy|0
  C0024202|Lymph|0
recognition
  1
  C0524637|Recognition (Psychology)|0
overt liver metastases
  5
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0023884|Liver|0
  C0027627|Neoplasm Metastasis|0
diarrhoea
  1
  C0011991|Diarrhea|0
pelvic radiography
  3
  C0030797|Pelvis|0
  C0043299|Diagnostic radiologic examination|0
  C0034571|roentgenographic|0
sixth courses
  3
  C0449922|Course (attribute)|0
  C0205440|Sixth (qualifier value)|0
  C0750729|Courses (qualifier value)|0
hematuria requiring transfusion
  3
  C0199960|Transfusion - action (qualifier value)|0
  C0018965|Hematuria|0
  C0238157|Benign hematuria|0
quality
  1
  C0332306|With quality (attribute)|0
controlled comparison
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
response categories
  2
  C0683312|categories|0
  C0871261|Responses|0
metastasis free survival
  4
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0027627|Neoplasm Metastasis|0
potential
  1
  C0237399|Potential|0
ecog
  1
  C0430797|Electrocorticogram (procedure)|0
predetermined schedule
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
insertion
  2
  C0441587|Clinical act of insertion|0
  C0021107|Implantation procedure|0
steep transvascular concentration gradient
  2
  C0086045|Concentration|0
  C0812409|GRADIENT|0
prospective randomized controlled trial
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
significantly better
  1
  C0332272|Better (qualifier value)|0
applicator flange
  1
  C0179108|Applicator (physical object)|0
major lifethreatening adverse effects
  2
  C1280500|Effect (qualifier value)|0
  C0205164|Major (qualifier value)|0
surgeons
  1
  C0582175|Surgeon (occupation)|0
one vascular lesion
  3
  C0005847|Blood Vessels|0
  C0221198|Lesion|0
  C0205447|One (qualifier value)|0
compartmental resection
  2
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
complete computerised plane
  3
  C0444660|Plane (attribute)|0
  C1049866|Planes Grapsidae|0
  C0205197|Complete (qualifier value)|0
most dependent variable
  3
  C0439828|Variable (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0851827|Dependent (qualifier value)|0
two parallel opposed fields cm
  4
  C0205448|Two (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0475210|cm (qualifier value)|0
aspiration cytology
  5
  C0010819|Cytology|0
  C0349707|Aspiration-action|0
  C0220787|Endotracheal aspiration|0
  C0004056|Aspirations (Psychology)|0
  C1305671|Cytology procedure|0
ct guided percutaneous needle aspiration
  5
  C0007431|Arterial catheterization|0
  C0302614|Guide device|0
  C0027551|Needles|0
  C0181090|Professional guide|0
  C0004056|Aspirations (Psychology)|0
antigenic heterogeneity
  1
  C0019409|Heterogeneity|0
9.0 weeks
  1
  C0439230|week (qualifier value)|0
radiotherapy significantly
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
perineal wounds
  4
  C0043250|Injury wounds|0
  C0021501|injuries|0
  C0031066|Anogenital region|0
  C0332797|Wounded|0
side effects
  1
  C0001688|adverse effects|0
multivariate methods
  2
  C0025664|Methodology|0
  C0025663|Methods|0
depth
  2
  C0449292|Depth (attribute)|0
  C0205125|Depth (qualifier value)|0
most effective doses
  3
  C0205393|Most (qualifier value)|0
  C0719635|DOS|0
  C0205414|Effective (qualifier value)|0
apparently superior results
  3
  C1274040|Result (navigational concept)|0
  C0205105|Superior (qualifier value)|0
  C0750541|APPARENTLY|0
reports
  2
  C0684224|Report (document)|0
  C0700287|Reporting|0
established distant micrometastases
  2
  C0443203|Distant (qualifier value)|0
  C0443211|Established (qualifier value)|0
accurately type
  4
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
particularly tamoxifen
  1
  C0039286|Tamoxifen|0
distant disease
  2
  C0443203|Distant (qualifier value)|0
  C0012634|Disease|0
pathological assessment
  2
  C0205469|Pathological aspects|0
  C1261322|Assessment procedure (procedure)|0
saw
  2
  C0042789|Vision|0
  C0183089|Saws|0
present
  1
  C0150312|Present|0
s3
  1
  C1179706|S3|0
only technique
  2
  C0025664|Methodology|0
  C0449851|Techniques|0
intensive postoperative course
  3
  C0449922|Course (attribute)|0
  C0032790|Postoperative Period|0
  C0750729|Courses (qualifier value)|0
similar type
  4
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
choice
  1
  C0008300|Choice Behavior|0
wrong cell type
  5
  C0007634|Cells|0
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
tumor sizes
  1
  C0475440|Tumor size (observable entity)|0
substantially more frequent mucocutaneous reactions
  3
  C0443286|Reaction (qualifier value)|0
  C0332183|Frequent (qualifier value)|0
  C0205172|More (qualifier value)|0
median
  2
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
radiation effect
  2
  C0034525|Effects of radiation|0
  C0034526|aspects of radiation effects|0
survival difference
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
israel
  1
  C0022271|Israel|0
worsening
  2
  C1279889|Deterioration of status|0
  C0332271|Worsening (qualifier value)|0
severe nausea
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0027497|Nausea|0
tumour burden
  1
  C0027651|Neoplasms|0
immune suppression
  1
  C0021079|Therapeutic immunosuppression|0
severe anorexia
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0003123|Anorexia|0
surgeon
  1
  C0582175|Surgeon (occupation)|0
toxic treatment program
  4
  C0039798|therapeutic aspects|0
  C0600688|Toxic effect|0
  C0087111|Therapeutic procedure|0
  C0376691|Programs [Publication Type]|0
dukes classification
  3
  C0008903|Taxonomic|0
  C0678229|Classification of information|0
  C0008902|Classification|0
5-fu doses
  3
  C0719635|DOS|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
equal therapeutic potency
  4
  C0039796|The science and art of healing|0
  C0439089|Equals|0
  C0302350|Therapeutic|0
  C0205163|Equal (qualifier value)|0
4.9 percent
  1
  C0439165|Percent (qualifier value)|0
murine 17-1a antibody
  5
  C0591833|Murine|0
  C0813154|Antibodies, in vitro diagnostic|0
  C0026802|Muridae|0
  C0003241|Antibodies|0
  C0450344|1A (qualifier value)|0
developed leukemia
  1
  C0023418|Leukemia|0
morbidity
  2
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
biopsy samples
  2
  C0441625|Biopsy sampling (qualifier value)|0
  C0677862|Biopsy sample (specimen)|0
international federation of gynecology and obstetrics
  4
  C0332285|Within|0
  C0700061|Obstetric Patient|0
  C0028773|Discipline of obstetrics|0
  C0018417|Gynecology|0
likelihood
  1
  C0750504|Likely|0
critical structures
  1
  C0678594|structure|0
weekly concomitant treatment
  3
  C0039798|therapeutic aspects|0
  C0332174|Weekly (qualifier value)|0
  C0087111|Therapeutic procedure|0
early termination
  1
  C0205085|Early (qualifier value)|0
highest regression rate
  3
  C0871208|Rating|0
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
same time
  4
  C0445247|Same (qualifier value)|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
suggested low serum albumin level
  5
  C0441889|Levels (qualifier value)|0
  C0229671|Serum|0
  C0234886|Lowing, function (observable entity)|0
  C0001924|Albumins|0
  C0205251|Low (qualifier value)|0
systemic relapse
  4
  C0205373|Systemic (qualifier value)|0
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
protocol adherence
  1
  C0442711|Protocols documentation|0
acute decrease
  4
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0205178|Acuteness (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
disease extension
  2
  C0231448|Extension (qualifier value)|0
  C0012634|Disease|0
major contributor
  1
  C0205164|Major (qualifier value)|0
distal edge
  2
  C0205154|Along edge (qualifier value)|0
  C0205108|Distal (qualifier value)|0
hypercoagulability
  1
  C0398623|Thrombophilia|0
decreased fraction size
  5
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0457426|Fractions of (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
  C0702146|Size (attribute)|0
second line therapy
  5
  C0039798|therapeutic aspects|0
  C0700221|Intravascular line|0
  C0205132|Linear|0
  C0457385|seconds|0
  C0087111|Therapeutic procedure|0
patient refusal
  1
  C0030705|Patients|0
cells
  2
  C0007634|Cells|0
  C1269647|Entire cell|0
delay failures
  3
  C0205421|Deferred (qualifier value)|0
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
intracavitary brachytherapy
  1
  C0021864|Radiotherapy, Intracavity|0
none
  1
  C0549184|None (qualifier value)|0
clearly defined liver edge
  4
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0205154|Along edge (qualifier value)|0
  C0023884|Liver|0
synovial sarcoma
  1
  C0039101|Sarcoma, Synovial|0
cervical carcinoma
  1
  C0302592|Carcinoma of cervix (disorder)|0
postoperative radiochemotherapy
  2
  C0032790|Postoperative Period|0
  C0436307|Radiochemotherapy NOS (procedure)|0
pyelogram
  1
  C0203108|Intravenous pyelogram|0
first group included countries
  5
  C0332257|Including (qualifier value)|0
  C0454664|Countries (geographic location)|0
  C0205435|First (qualifier value)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
treatment field
  4
  C0039798|therapeutic aspects|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0087111|Therapeutic procedure|0
serum albumin level
  2
  C0523465|Serum albumin measurement|0
  C0728877|Serum albumin level|0
cisplatin administration
  3
  C0008838|Cisplatin|0
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
first survival analysis
  5
  C0038952|Continuance of life|0
  C0002778|Analysis of substances|0
  C0205435|First (qualifier value)|0
  C0936012|Analysis|0
  C0220921|survival aspects|0
two major trials
  2
  C0205164|Major (qualifier value)|0
  C0205448|Two (qualifier value)|0
tumor regression
  3
  C0684321|Regression - mental defense mechanism|0
  C0027651|Neoplasms|0
  C0684320|Disease regression|0
routine bone scans
  5
  C0262950|Skeletal bone|0
  C0391978|Bone Tissue|0
  C0441633|Scanning|0
  C0205547|Routine (qualifier value)|0
  C1266909|Entire bony skeleton|0
bilateral pelvic wall involvement
  5
  C0030797|Pelvis|0
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0281267|bilateral breast cancer|0
  C0238767|Bilateral|0
observation time
  5
  C0040223|Time|0
  C0302523|Observation in research|0
  C0449243|Timing (attribute)|0
  C0700325|Patient observation|0
  C0392761|Timed (qualifier value)|0
min
  1
  C0439232|Minute of time|0
biopsy only
  1
  C0439796|Biopsy only (qualifier value)|0
chest radiography
  1
  C0202783|Radiographic procedure on chest (procedure)|0
dacarbazine
  1
  C0010927|Dacarbazine|0
cardiac injury
  3
  C0205041|Cardio-|0
  C0021501|injuries|0
  C0175677|Injury inflicted to the body by an external force|0
blood counts
  5
  C0392895|Bloods (ethnic group)|0
  C0005768|In Blood|0
  C0750480|COUNT|0
  C0005767|Blood|0
  C0439157|counts (qualifier value)|0
performance
  1
  C0597198|Performance|0
major symptomatic improvement
  2
  C0205164|Major (qualifier value)|0
  C0231220|Symptomatic (qualifier value)|0
abdominopelvic computerized tomography
  1
  C0040395|Tomography|0
seski’s study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
institutional state
  1
  C1301808|State (environment)|0
initial evaluation also included chest radiography
  5
  C0817096|Chest|0
  C0332257|Including (qualifier value)|0
  C0220825|Evaluation|0
  C0043299|Diagnostic radiologic examination|0
  C0034571|roentgenographic|0
extensiveness
  1
  C0439795|Extensiveness (qualifier value)|0
preestablished randomization table
  3
  C0039224|Table - furniture|0
  C1168570|Table - visual aid|0
  C0034656|Random Allocation|0
laboratory data
  1
  C0022877|Laboratories|0
obstetricians
  1
  C0334897|Obstetrician (occupation)|0
subsequent courses
  3
  C0449922|Course (attribute)|0
  C0750530|SUBSEQUENT|0
  C0750729|Courses (qualifier value)|0
laspartic acid
  1
  C0001128|Acids|0
locoregional disease
  1
  C0012634|Disease|0
positive role
  2
  C0035820|Role|0
  C0205159|Positive (qualifier value)|0
concurrent radiation
  2
  C0205420|Concurrent (qualifier value)|0
  C0851346|Radiation|0
more indolent course
  4
  C0449922|Course (attribute)|0
  C0205172|More (qualifier value)|0
  C0750729|Courses (qualifier value)|0
  C0234227|Indolent|0
fraction
  1
  C0457426|Fractions of (qualifier value)|0
question
  1
  C0876928|Questioning|0
separate criteria
  4
  C0443299|Separate (qualifier value)|0
  C0243161|criteria|0
  C0086972|Separated from cohabitee|0
  C0687118|Detached|0
leukocyte nadirs
  1
  C0023516|Leukocytes|0
only two isolated vault failures
  5
  C0205448|Two (qualifier value)|0
  C0370215|ISOLATE|0
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
  C0205409|Isolated (qualifier value)|0
less toxic analogue
  1
  C0600688|Toxic effect|0
planned treatment
  4
  C0039798|therapeutic aspects|0
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0087111|Therapeutic procedure|0
paraortic metastases
  2
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0027627|Neoplasm Metastasis|0
hysterectomy
  1
  C0020699|Hysterectomy|0
repetition
  1
  C0205341|Repeat (qualifier value)|0
primary lesion
  3
  C0221198|Lesion|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
others
  1
  C0205394|Other|0
liver scan
  1
  C0203758|Radioisotope study of liver (procedure)|0
gram-negative septicaemia
  1
  C0036685|Gram-negative septicemia NOS (disorder)|0
lateral boundaries
  1
  C0205093|Lateral (qualifier value)|0
size
  1
  C0702146|Size (attribute)|0
overall risk
  2
  C0282416|Overall [Publication Type]|0
  C0035647|Risk|0
only three patients
  2
  C0030705|Patients|0
  C0205449|Three (qualifier value)|0
lower third
  1
  C0442051|Lower third (qualifier value)|0
cooperative study group
  5
  C0557651|Room of building - Study|0
  C0679729|cooperative|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0947630|Scientific Study|0
only humoral antiidiotype response
  1
  C0871261|Responses|0
overall time savings
  5
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0282416|Overall [Publication Type]|0
  C0036245|Savings|0
  C0392761|Timed (qualifier value)|0
primary treatment modality
  5
  C0039798|therapeutic aspects|0
  C0439631|Primary operation (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0205225|Primary|0
  C0695347|MODALITY|0
magnetic resonance imaging
  1
  C0024485|Magnetic Resonance Imaging|0
coworkers
  1
  C0681088|coworker|0
pyrimidine synthesis
  3
  C0034289|Pyrimidines|0
  C0869032|Synthesis|0
  C0034284|Pyrimidine|0
liver failure
  1
  C0085605|Liver Failure|0
supportive care group
  5
  C0150499|Caring|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0728734|Caring caregiver-patient relationship|0
clear superiority
  2
  C0205305|Clear (qualifier value)|0
  C0680218|superiority|0
acute toxicity
  3
  C0040539|Toxicity aspects|0
  C0205178|Acuteness (qualifier value)|0
  C0600688|Toxic effect|0
box technique
  4
  C0179400|Boxes|0
  C0025664|Methodology|0
  C0006080|Boxing|0
  C0449851|Techniques|0
lymphangiography
  1
  C0024219|Lymphangiography|0
subgroup analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
e
  4
  C0424589|Vitality|0
  C0542479|Energy, Physics|0
  C0679138|Expectations (qualifier value)|0
  C0596544|expectancy|0
only cases
  1
  C0868928|Case (qualifier value)|0
response criteria
  2
  C0243161|criteria|0
  C0871261|Responses|0
death rate
  2
  C0205848|Death Rate|0
  C1108678|Death rate aspects|0
potent inhibitor
  1
  C0243077|inhibitors|0
portal adjuvant therapy
  4
  C0039798|therapeutic aspects|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
  C0205054|Hepatic|0
endocrine therapy
  1
  C0279025|Endocrine therapy (procedure)|0
more bladder toxicity
  5
  C1281573|Entire bladder|0
  C0040539|Toxicity aspects|0
  C0005682|Bladder|0
  C0205172|More (qualifier value)|0
  C0600688|Toxic effect|0
j m.b.
  5
  C0071272|platonin J|0
  C0019028|Hemoglobin J|0
  C0066703|monacolin J|0
  C0054870|cathepsin J|0
  C0059253|endonuclease J|0
need
  1
  C0027552|Needs|0
most severe complications
  4
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0205393|Most (qualifier value)|0
multiple drug regimens
  4
  C0684270|Drugged|0
  C0439064|Numerous (qualifier value)|0
  C0677937|regimen|0
  C0013227|Pharmaceutical Preparations|0
weekend break
  1
  C0680190|weekend|0
surveys
  1
  C0038951|Surveys|0
median survivals
  4
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
alternative explanation
  1
  C0681841|explanation|0
new agent closely
  2
  C0450442|Agent (attribute)|0
  C0205314|New (qualifier value)|0
steroids
  1
  C0038317|Steroids|0
shortness
  2
  C0453933|Shorts (physical object)|0
  C0205167|Short (qualifier value)|0
preliminary results
  2
  C1274040|Result (navigational concept)|0
  C0439611|Preliminary (qualifier value)|0
two packets
  1
  C0205448|Two (qualifier value)|0
single low-dose rate intracavitary application
  5
  C0185125|Application (procedure)|0
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0205251|Low (qualifier value)|0
prior radiation exposure
  5
  C0391838|Exposure condition|0
  C0728853|Accident due to exposure to weather conditions|0
  C0274281|EFFECTS OF EXPOSURE TO EXTERNAL CAUSES|0
  C0750516|PRIOR|0
  C0851346|Radiation|0
intravenous pyelogram
  1
  C0203108|Intravenous pyelogram|0
cycles chemotherapy alone
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0679994|alone|0
  C0013216|Pharmacotherapy|0
wilcoxon statistical test
  3
  C0039593|Testing|0
  C0220917|statistical|0
  C0392366|Tests (qualifier value)|0
myelosuppression
  1
  C0854467|Myelosuppression (finding)|0
severe illness—major contraindications
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0079164|contraindications|0
histologic confirmation
  1
  C0205462|Histologic|0
shortening
  2
  C0441636|Surgical shortening - action (qualifier value)|0
  C0392745|Shortened (qualifier value)|0
eliminating bulky disease
  1
  C0012634|Disease|0
favorable results
  1
  C1274040|Result (navigational concept)|0
monk
  1
  C0682252|monk|0
disease
  1
  C0012634|Disease|0
two treatment arms
  5
  C0039798|therapeutic aspects|0
  C0205448|Two (qualifier value)|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0087111|Therapeutic procedure|0
small decrease
  4
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0700321|Small|0
  C0547047|Decrease (qualifier value)|0
alive six patients
  2
  C0030705|Patients|0
  C0205452|Six (qualifier value)|0
allergic bleomycin reaction
  3
  C0443286|Reaction (qualifier value)|0
  C0700624|Allergic|0
  C0005740|Bleomycin|0
standardized utilization
  1
  C0042153|utilization|0
u
  1
  C0041928|Uranium|0
synchronous local relapse
  5
  C0035020|Relapse|0
  C0439580|Synchronous (qualifier value)|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
cisplatin ­ bleomycin ­ vincristine
  3
  C0008838|Cisplatin|0
  C0042679|Vincristine|0
  C0005740|Bleomycin|0
other common toxicities
  4
  C0205214|Common (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
  C0205394|Other|0
material costs
  3
  C0520510|Materials|0
  C0220812|Cost aspects|0
  C0010186|Financial cost|0
inevaluable patient
  1
  C0030705|Patients|0
selected patient characteristics
  1
  C0030705|Patients|0
serum aspartate aminotransferase level
  5
  C0441889|Levels (qualifier value)|0
  C0229671|Serum|0
  C0085845|Aspartate|0
  C0456079|Disease classification level|0
  C0002594|Transaminases|0
postradiation chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
equal fraction
  3
  C0457426|Fractions of (qualifier value)|0
  C0439089|Equals|0
  C0205163|Equal (qualifier value)|0
received radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
combined evidence
  2
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
rapid repopulation
  1
  C0439831|Rapid (qualifier value)|0
colorectal cancer
  1
  C0009402|Colorectal Cancer|0
discernable impact
  2
  C0726639|Impact|0
  C0333125|Impacted (qualifier value)|0
serial hematologic evaluations
  4
  C0220825|Evaluation|0
  C0205488|Hematologic (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
  C0031082|Periodicals|0
achieved prs
  1
  C0279766|progesterone receptor negative|0
adverse urologic effects
  2
  C1280500|Effect (qualifier value)|0
  C0205479|Urologic (qualifier value)|0
optimal dosing schedule
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
films
  1
  C0086296|Films|0
superior limit
  2
  C0439801|Limited (qualifier value)|0
  C0205105|Superior (qualifier value)|0
consecutive episodes
  2
  C0332189|Episode of|0
  C0678231|Episodes (qualifier value)|0
laboratory abnormalities
  3
  C0000769|teratologic|0
  C0000768|Congenital Abnormality|0
  C0022877|Laboratories|0
mg
  2
  C0024467|Magnesium|0
  C0439210|milligram|0
merit comment
  2
  C0282411|Published Comment|0
  C0947611|Comment|0
criteria
  1
  C0243161|criteria|0
white cell count
  5
  C0007634|Cells|0
  C0043157|Caucasians|0
  C0750480|COUNT|0
  C0220938|White color|0
  C0439157|counts (qualifier value)|0
causes
  3
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0015127|Causality|0
local dfs
  1
  C0205276|Local (qualifier value)|0
also nine patients
  2
  C0030705|Patients|0
  C0205455|Nine (qualifier value)|0
nft group
  4
  C0085400|Neurofibrillary Tangles|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
diameter
  1
  C0332517|Diameter (qualifier value)|0
regression
  2
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
random permuted blocks
  4
  C0439605|Random (qualifier value)|0
  C0233660|Mental blocking|0
  C0332206|Blocking|0
  C0028778|Obstruction|0
5-year kaplan–meier survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
present article
  1
  C0150312|Present|0
bulky tumors
  1
  C0027651|Neoplasms|0
current study
  3
  C0557651|Room of building - Study|0
  C0521116|Current (qualifier value)|0
  C0947630|Scientific Study|0
patients predominantly
  1
  C0030705|Patients|0
princess margaret hospital
  1
  C0019994|Hospitals|0
mof strept regimen
  2
  C0026766|Multiple Organ Failure|0
  C0677937|regimen|0
chemotherapy–radiotherapy group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
tolerable dose schedule
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
survival rates
  1
  C0038954|Survival Rate|0
mg total dose
  1
  C0439810|Total (qualifier value)|0
rt days
  1
  C0439228|day (qualifier value)|0
three months
  2
  C0205449|Three (qualifier value)|0
  C0439231|month (qualifier value)|0
randomized study treatment
  4
  C0557651|Room of building - Study|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0947630|Scientific Study|0
lower frequency
  4
  C0376249|With frequency|0
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
  C0439603|Frequencies (time pattern)|0
4.6 months
  1
  C0439231|month (qualifier value)|0
5-hydroxytryptamine-3 antagonists
  3
  C0243076|antagonists|0
  C0162466|Hydroxytryptamine|0
  C0231491|Antagonist muscle action|0
late toxicity
  3
  C0205087|Late (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
optimum treatment strategies
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0679199|strategy|0
original statistical design
  2
  C0220917|statistical|0
  C0205313|Original (qualifier value)|0
further exploration
  2
  C0581690|Exploration - action (qualifier value)|0
  C1280903|Exploration procedure (procedure)|0
twelve days after treatment initiation
  5
  C0231290|Status post (contextual qualifier) (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0205458|Twelve (qualifier value)|0
  C0439228|day (qualifier value)|0
  C0087111|Therapeutic procedure|0
cardiac function
  1
  C0232164|Cardiac function (observable entity)|0
early reporting
  3
  C0205085|Early (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
received treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
total length
  2
  C0439810|Total (qualifier value)|0
  C0439537|Lengths (qualifier value)|0
8.9 weeks
  1
  C0439230|week (qualifier value)|0
modification
  1
  C0205349|Altered (qualifier value)|0
second most frequent cancer
  5
  C0998265|Cancer Genus|0
  C0332183|Frequent (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0457385|seconds|0
  C0006826|Malignant Neoplasms|0
ineligible stage
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
median actual dose
  3
  C0876920|Median Statistical Measurement|0
  C0237400|Actual|0
  C0549183|Median (qualifier value)|0
new interest
  2
  C0543488|Interested (finding)|0
  C0205314|New (qualifier value)|0
sixteen daily treatments
  3
  C0039798|therapeutic aspects|0
  C0332173|Daily (qualifier value)|0
  C0087111|Therapeutic procedure|0
radiologic diagnosis
  3
  C0205483|Radiologic (qualifier value)|0
  C0348026|Diagnostic|0
  C0011900|Diagnosis|0
clinical stage
  1
  C0205563|Clinical staging (qualifier value)|0
part
  1
  C0449719|Part (attribute)|0
radiation remains
  1
  C0851346|Radiation|0
development
  2
  C0020119|Human Development|0
  C0243107|development aspects|0
primary site
  1
  C0449695|Site of primary lesion (attribute)|0
17-1a antigen
  2
  C0003320|Antigens|0
  C0450344|1A (qualifier value)|0
high incidence
  4
  C0021149|Incidence|0
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0220856|incidence of cases|0
m increments course
  2
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
combined therapy regimen
  5
  C0039798|therapeutic aspects|0
  C0336789|Combine, device (physical object)|0
  C0087111|Therapeutic procedure|0
  C0205195|Combined (qualifier value)|0
  C0677937|regimen|0
prolongation
  1
  C0439590|Prolonged (qualifier value)|0
involvement
  2
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
formation
  1
  C0439634|Formations (qualifier value)|0
toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
transperitoneal staging procedure
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0184661|Procedures|0
  C0205501|Transperitoneal approach (qualifier value)|0
  C0684248|Stage of Surgical Procedure|0
disease-free interval
  2
  C0012634|Disease|0
  C1272706|Interval (qualifier value)|0
histologic evaluation
  3
  C0220825|Evaluation|0
  C0205462|Histologic|0
  C1261322|Assessment procedure (procedure)|0
positive lymphangiography
  2
  C0205159|Positive (qualifier value)|0
  C0024219|Lymphangiography|0
significantly longer progression free survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0449258|Progression (attribute)|0
collected series
  1
  C0205549|Series (qualifier value)|0
full course radiotherapy
  5
  C0034619|radiotherapeutic|0
  C0449922|Course (attribute)|0
  C0443225|Full (qualifier value)|0
  C0034618|Radiation therapy|0
  C0750729|Courses (qualifier value)|0
capillary lymphatic space tumor involvement
  5
  C0006901|Blood capillaries|0
  C0205428|Involvements (qualifier value)|0
  C0229889|Lymphatic vessel|0
  C0392760|Not free of (attribute)|0
  C0027651|Neoplasms|0
toxicity grades
  4
  C0441800|Grade|0
  C0040539|Toxicity aspects|0
  C0796573|Cancer cells grading system|0
  C0600688|Toxic effect|0
uncertain margins
  3
  C1269830|Tumor margin status|0
  C0205424|Uncertain (qualifier value)|0
  C0205284|Marginal (qualifier value)|0
event free times
  4
  C0441471|Events (event)|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
ifosfamide 1.8 g
  2
  C0162832|APC Gene|0
  C0020823|Ifosfamide|0
doxorubicin
  1
  C0013089|Doxorubicin|0
transaminases
  2
  C0919834|Transaminase Assay|0
  C0002594|Transaminases|0
dibromodulcitol
  1
  C0026252|Mitolactol|0
few second generation trials
  4
  C0205436|Second (qualifier value)|0
  C0079411|Generations|0
  C0457385|seconds|0
  C0205388|Few (qualifier value)|0
pelvic control rate
  4
  C0702113|Controlled (qualifier value)|0
  C0030797|Pelvis|0
  C0871208|Rating|0
  C0243148|control|0
positive
  1
  C0205159|Positive (qualifier value)|0
sensitize tumor cells
  3
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0027651|Neoplasms|0
serious complications
  3
  C0205404|Serious (qualifier value)|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
one hundred twenty five patients
  3
  C0205451|Five (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
medical
  1
  C0205476|Medical (qualifier value)|0
malignant schwannoma
  2
  C0751690|Malignant Peripheral Nerve Sheath Tumors|0
  C0701838|Malignant neurilemmoma|0
four patients
  2
  C0205450|Four (qualifier value)|0
  C0030705|Patients|0
additional women
  2
  C0043210|Human adult females|0
  C0043209|Human Females|0
wk
  1
  C0439230|week (qualifier value)|0
acceptable safety profile
  1
  C0036043|Safety|0
radiotherapy actually developed chf
  3
  C0034619|radiotherapeutic|0
  C0018802|Heart Failure, Congestive|0
  C0034618|Radiation therapy|0
m mitolactol daily
  2
  C0026252|Mitolactol|0
  C0332173|Daily (qualifier value)|0
sepsis
  2
  C0243026|Systemic infection|0
  C1090821|Sepsis (Invertebrate)|0
er tumors
  2
  C0027651|Neoplasms|0
  C0279756|estrogen receptor negative|0
overall prognosis
  2
  C0033325|Forecast of outcome|0
  C0282416|Overall [Publication Type]|0
fluorouracil regimen
  2
  C0016360|Fluorouracil|0
  C0677937|regimen|0
abdominal mass cm
  4
  C0456438|Abdominal (qualifier value)|0
  C0475210|cm (qualifier value)|0
  C1306372|Mass, a measure of quantity of matter (property) (qualifier value)|0
  C0577559|Mass of body structure (finding)|0
grade nausea
  3
  C0441800|Grade|0
  C0027497|Nausea|0
  C0796573|Cancer cells grading system|0
c m
  1
  C0007886|Cesium|0
cox model analysis
  5
  C0026336|Models|0
  C0936012|Analysis|0
  C0870071|Modeling|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
study treatments
  4
  C0557651|Room of building - Study|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0947630|Scientific Study|0
declined radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
cervical tumours
  2
  C0205064|Cervical (qualifier value)|0
  C0027651|Neoplasms|0
not prior 5-fu failure
  5
  C0680095|Personal failure|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
  C0231174|Failure (biologic function)|0
  C0750516|PRIOR|0
wrong stage
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
fit
  4
  C0424576|Fit and well|0
  C0441548|Fitting - action|0
  C0036572|Seizures|0
  C1305398|Fitting procedure (procedure)|0
planned radiotherapy
  4
  C0034619|radiotherapeutic|0
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0034618|Radiation therapy|0
sutures
  4
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0502420|Suture Joint|0
  C0205368|Sutured (qualifier value)|0
irinotecan groups
  4
  C0123931|irinotecan|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
metachronous relapse
  3
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
immunomodulatory effects
  1
  C1280500|Effect (qualifier value)|0
capillary lymphatic space involvement
  5
  C1280521|Entire capillary blood vessel (organ)|0
  C0006901|Blood capillaries|0
  C0229889|Lymphatic vessel|0
  C0392760|Not free of (attribute)|0
  C0935624|Capillary, Unspecified|0
radiation effects
  2
  C0034525|Effects of radiation|0
  C0034526|aspects of radiation effects|0
time
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
repetitive dose treatments
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
mo
  1
  C0026402|Molybdenum|0
results
  1
  C1274040|Result (navigational concept)|0
mean administered doses
  3
  C0876919|Meaning|0
  C0719635|DOS|0
  C0444504|Mean (qualifier value)|0
higher frequency
  2
  C0376249|With frequency|0
  C0439603|Frequencies (time pattern)|0
30-day postoperative mortality rate
  5
  C0871208|Rating|0
  C0026565|Mortality Vital Statistics|0
  C0032790|Postoperative Period|0
  C0439228|day (qualifier value)|0
  C0026566|Aspects of mortality statistics|0
immediate postoperative intraportal infusion
  3
  C0574032|Infusion (procedure)|0
  C0205253|Immediate (qualifier value)|0
  C0032790|Postoperative Period|0
interstitial pneumonitis requiring corticosteroids
  3
  C0032285|Pneumonia|0
  C0596790|interstitial|0
  C0001617|Adrenal Cortex Hormones|0
uncontrolled infectious process
  2
  C1184743|Process|0
  C0205318|Uncontrolled (qualifier value)|0
only substantial improvement
  5
  C0683655|community improvement|0
  C0421829|Improvement grant NOS|0
  C0680092|sexual improvement|0
  C0683848|curriculum improvement|0
  C0554898|Improvement grant admin|0
humanized antibodies
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
sufficient number
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0205410|Sufficient (qualifier value)|0
three courses
  3
  C0449922|Course (attribute)|0
  C0205449|Three (qualifier value)|0
  C0750729|Courses (qualifier value)|0
m2 iv
  5
  C0591607|Humaject M2|0
  C0050935|aflatoxin M2|0
  C0588334|PULHHEEMS - M2|0
  C0257483|RSFileu m2|0
  C0638842|18O-M2|0
location
  1
  C0450429|Location (attribute)|0
biologically similar dose
  5
  C0566267|Biologically active chemical (substance)|0
  C1098477|Sik-similar protein|0
  C0574031|Biologically active substance (substance)|0
  C0158530|Anencephalus and similar anomalies NOS (disorder)|0
  C0442729|Strains similar (qualifier value)|0
poor medical condition
  5
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
  C0542537|Poor - grade value|0
  C0699761|Financially poor|0
  C0205476|Medical (qualifier value)|0
most unique toxicity
  3
  C0040539|Toxicity aspects|0
  C0205393|Most (qualifier value)|0
  C0600688|Toxic effect|0
secondary analysis
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0027627|Neoplasm Metastasis|0
general health
  1
  C0552464|GENERAL HEALTH|0
study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
suspicious radiographic findings
  3
  C0444708|Radiographic (qualifier value)|0
  C0750493|SUSPICIOUS|0
  C0243095|findings|0
cox proportional hazards model
  1
  C0010235|Cox Proportional Hazards Models|0
risk ratio
  1
  C0028873|Odds Ratio|0
figo stage iib disease
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0012634|Disease|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
histologically proven adenocarcinoma
  3
  C0700164|proven venom|0
  C0001418|Adenocarcinoma|0
  C0456369|Proven findings|0
admission
  1
  C0809949|ADMISSION|0
result
  1
  C1274040|Result (navigational concept)|0
fixed tumours
  2
  C0027651|Neoplasms|0
  C0443218|Fixed (qualifier value)|0
clinical evaluation
  3
  C0220825|Evaluation|0
  C0205210|Clinical (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
tumor diameter to
  2
  C0027651|Neoplasms|0
  C0332517|Diameter (qualifier value)|0
possible underdosing
  2
  C0332149|Possible|0
  C1112363|Underdose|0
accounts
  1
  C0000938|Accounting|0
gastrointestinal effects
  2
  C0521362|Gastrointestinal|0
  C1280500|Effect (qualifier value)|0
fluorouracil significantly
  1
  C0016360|Fluorouracil|0
tumour progression
  1
  C0178874|Neoplasm progression|0
dose limitation
  1
  C0449295|Limitation (attribute)|0
present italian co-operative study closed patient accrual
  5
  C0337810|Italians (ethnic group)|0
  C0454802|Cos (geographic location)|0
  C0022275|Italian language (qualifier value)|0
  C0150312|Present|0
  C0030705|Patients|0
third bleomycin cycle
  2
  C0205437|Third (qualifier value)|0
  C0005740|Bleomycin|0
opposed fields
  2
  C0440042|Field's stain|0
  C0331809|Fielding|0
arms
  2
  C0003792|Arm|0
  C0446516|Upper arm|0
creatinine 1.3 mg
  1
  C0010294|Creatinine|0
age
  3
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
surgery allowing
  4
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0683607|allowing|0
obstruction
  1
  C0028778|Obstruction|0
average median relative dose intensity
  4
  C0080103|Relative (related person)|0
  C0876920|Median Statistical Measurement|0
  C0205345|Relative|0
  C0549183|Median (qualifier value)|0
hydration
  1
  C0517526|hydration|0
effect
  1
  C1280500|Effect (qualifier value)|0
ultimate test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
cns toxicity
  3
  C0040539|Toxicity aspects|0
  C0927232|Neuraxis|0
  C0600688|Toxic effect|0
cls involvement
  4
  C0201952|Chloride measurement|0
  C0010575|Cycloleucine|0
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
activation
  5
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0879526|activate|0
  C0441655|Activities|0
  C0205177|Active|0
clinical characteristics
  1
  C0683325|clinical aspects|0
introduction
  1
  C1293116|Introduction (procedure)|0
striking difference
  2
  C0038452|Strikes, Employee|0
  C0275626|Struck (disorder)|0
statistical methods
  3
  C0025664|Methodology|0
  C0220917|statistical|0
  C0025663|Methods|0
peripheral hemogram
  2
  C0205100|Peripheral (qualifier value)|0
  C0200631|Complete blood count without differential (procedure)|0
negative lymph nodes
  3
  C0746922|NODE|0
  C0205160|Negative (qualifier value)|0
  C0024202|Lymph|0
first intestinal anastomosis
  5
  C0677554|Anastomosis - action|0
  C0021853|Intestines|0
  C0332853|Anastomosis|0
  C0205435|First (qualifier value)|0
  C0500470|Anatomical anastomosis|0
basic law
  3
  C0728724|Legal system|0
  C0023150|Rules of conduct|0
  C0220866|aspects of laws|0
schedule
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
third
  1
  C0205437|Third (qualifier value)|0
distal recurrences
  2
  C0034897|Recurrence|0
  C0205108|Distal (qualifier value)|0
bleomycin
  1
  C0005740|Bleomycin|0
recurrent disease
  1
  C0277556|Recurrent disease (finding)|0
folic acid
  1
  C0016410|Folic Acid|0
chemotherapy only treatment arm
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0003792|Arm|0
  C0087111|Therapeutic procedure|0
  C0013216|Pharmacotherapy|0
probable explanation
  2
  C0332148|Probable diagnosis|0
  C0681841|explanation|0
kaplan meier survival curves
  3
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
mean survival time
  1
  C0086595|Mean Survival Time|0
5-yr results
  2
  C1274040|Result (navigational concept)|0
  C0439234|year (qualifier value)|0
age group
  2
  C0596048|Age Group Unspecified|0
  C0027362|Human Age Group|0
fishers exact test
  4
  C0039593|Testing|0
  C0325045|Martes pennanti (organism)|0
  C0392366|Tests (qualifier value)|0
  C0059927|Exact|0
similar results
  1
  C1274040|Result (navigational concept)|0
meccnu treatment
  3
  C0039798|therapeutic aspects|0
  C0036637|Semustine|0
  C0087111|Therapeutic procedure|0
20% cr rate
  2
  C0871208|Rating|0
  C0008574|Chromium|0
various vesical complications
  4
  C0205058|Vesical|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0440102|Various (substance)|0
cox model analyses
  5
  C0026336|Models|0
  C0936012|Analysis|0
  C0870071|Modeling|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
similar complication
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
arm edema
  4
  C0333239|Edematous|0
  C0003792|Arm|0
  C0013604|Edema|0
  C0446516|Upper arm|0
percutaneous nephrostomies
  1
  C0027724|Nephrostomy, Percutaneous|0
apparent difference
  1
  C0750489|APPARENT|0
apparent increase
  4
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
  C0750489|APPARENT|0
mechanisms
  2
  C0457274|Mechanism (attribute)|0
  C0441712|Mechanisms (qualifier value)|0
resection type
  5
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
only patients
  1
  C0030705|Patients|0
reported p values
  3
  C0684224|Report (document)|0
  C0700287|Reporting|0
  C0042295|VALUING|0
extensive parametrial invasion
  1
  C0205231|Extensive (qualifier value)|0
complete medical history
  5
  C0019665|history|0
  C0019664|Recording of previous events|0
  C0205476|Medical (qualifier value)|0
  C0205197|Complete (qualifier value)|0
  C0262926|Medical History|0
patient selection
  1
  C0242802|Patient Selection|0
slow growing disease
  2
  C0012634|Disease|0
  C0439834|Slow (qualifier value)|0
significant advantage
  2
  C0308269|ADVANTAGE|0
  C0750502|Significant (qualifier value)|0
arm i post-operative rt
  3
  C0003792|Arm|0
  C0687676|After values (qualifier value)|0
  C0446516|Upper arm|0
pelvic area
  2
  C0205146|Area (qualifier value)|0
  C0030797|Pelvis|0
b
  5
  C0004916|Beds|0
  C0004927|Behavior|0
  C0150141|Bathing|0
  C0337527|Brothers|0
  C1040746|Bacilli|0
performance status score
  3
  C0449438|Status (attribute)|0
  C0449820|Scores (qualifier value)|0
  C0597198|Performance|0
median survival durations
  5
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
  C0449238|Duration|0
distant relapses
  4
  C0035020|Relapse|0
  C0443203|Distant (qualifier value)|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
results also
  1
  C1274040|Result (navigational concept)|0
other considerations
  2
  C0518609|CONSIDERATION|0
  C0205394|Other|0
mitolactol
  1
  C0026252|Mitolactol|0
antibody
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
strategies to
  1
  C0679199|strategy|0
poor end point
  4
  C1272693|Ended (qualifier value)|0
  C0542537|Poor - grade value|0
  C0699761|Financially poor|0
  C0444930|End (qualifier value)|0
patient safety
  1
  C1113679|patient safety|0
well recognised prognostic factor
  2
  C0220901|prognostic|0
  C0205170|Good (qualifier value)|0
additional three patients
  2
  C0030705|Patients|0
  C0205449|Three (qualifier value)|0
pelvic failure
  3
  C0030797|Pelvis|0
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
disease-free actuarial 5-year survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
cardiotoxic potencies
  5
  C0486821|GENTAMICIN.HIGH POTENCY|0
  C0487621|STREPTOMYCIN.HIGH POTENCY|0
  C0487039|KANAMYCIN.HIGH POTENCY|0
  C1096579|Potency disturbance|0
  C0678792|drug potency|0
goal
  1
  C0018017|Goals|0
three weeks
  2
  C0439230|week (qualifier value)|0
  C0205449|Three (qualifier value)|0
dose
  1
  C0178602|Dosages (qualifier value)|0
principal cause
  5
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0401925|Teaching principal|0
  C0015127|Causality|0
  C0205225|Primary|0
allowance
  1
  C0556660|Allowance (administrative concept)|0
5-fu dose to
  2
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
distinct antitumor effect
  1
  C1280500|Effect (qualifier value)|0
not only marker
  1
  C0005516|Biological Markers|0
bleomycin related pulmonary toxicity
  5
  C0163712|Relate|0
  C0024109|Lung|0
  C0600688|Toxic effect|0
  C0445223|Related (finding)|0
  C0005740|Bleomycin|0
proven high efficacy
  4
  C0700164|proven venom|0
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0456369|Proven findings|0
3.8 months
  1
  C0439231|month (qualifier value)|0
observation times
  5
  C0040223|Time|0
  C0302523|Observation in research|0
  C0449243|Timing (attribute)|0
  C0700325|Patient observation|0
  C0392761|Timed (qualifier value)|0
5-year actuarial survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
intermediate dose level
  3
  C0441889|Levels (qualifier value)|0
  C0205103|Intermediate (qualifier value)|0
  C0456079|Disease classification level|0
histology slides
  5
  C0444330|Slide (specimen)|0
  C0332246|Sliding|0
  C0205462|Histologic|0
  C0344441|Histology Procedure|0
  C0019638|Histology|0
confirmed responses
  2
  C0750484|CONFIRMED|0
  C0871261|Responses|0
year
  1
  C0439234|year (qualifier value)|0
forty nine
  1
  C0205455|Nine (qualifier value)|0
the netherlands
  1
  C0027778|Netherlands|0
survival analysis methods
  5
  C0038952|Continuance of life|0
  C0002778|Analysis of substances|0
  C0025663|Methods|0
  C0936012|Analysis|0
  C0220921|survival aspects|0
fulminant septicemia
  1
  C0036690|Septicemia|0
figo state
  1
  C1301808|State (environment)|0
one layer
  2
  C0934502|Layer|0
  C0205447|One (qualifier value)|0
statistically significant difference
  1
  C0750502|Significant (qualifier value)|0
fifth years
  2
  C0205439|Fifth (qualifier value)|0
  C0439234|year (qualifier value)|0
glimelius reported evidence
  2
  C0684224|Report (document)|0
  C0700287|Reporting|0
focus
  1
  C0344236|Finding related to focusing (finding)|0
additional pretreatment evaluations
  2
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
median follow-up duration
  5
  C0547043|Up (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0332282|Following (attribute)|0
  C0449238|Duration|0
likely consequence
  1
  C0750504|Likely|0
scarring
  2
  C0036287|Scarring|0
  C0008767|Scar|0
radiotherapy groups
  5
  C0034619|radiotherapeutic|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0034618|Radiation therapy|0
recurrence
  1
  C0034897|Recurrence|0
same postradiation regimen
  2
  C0445247|Same (qualifier value)|0
  C0677937|regimen|0
continued efforts to
  2
  C0015264|Exertion|0
  C0750536|CONTINUED|0
methodological problems
  1
  C0033213|Problem (finding)|0
clinical staging system to
  5
  C0449913|System (attribute)|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0205210|Clinical (qualifier value)|0
  C1306673|Stages (qualifier value)|0
fistula
  1
  C0016169|Fistula|0
performance status 0.2
  1
  C0935728|performance status|0
standard pretreatment evaluation
  4
  C0175675|Standards of Weights and Measures|0
  C0220825|Evaluation|0
  C0038137|standards characteristics|0
  C1261322|Assessment procedure (procedure)|0
other tests
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0205394|Other|0
decrease
  3
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
grade ? neutrophil count
  5
  C0441800|Grade|0
  C0027950|Neutrophils|0
  C0796573|Cancer cells grading system|0
  C0750480|COUNT|0
  C0439157|counts (qualifier value)|0
median follow-up time
  5
  C0547043|Up (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C1282911|Upward (qualifier value)|0
  C0549183|Median (qualifier value)|0
  C0332282|Following (attribute)|0
fourth treatment
  3
  C0039798|therapeutic aspects|0
  C0205438|Fourth (qualifier value)|0
  C0087111|Therapeutic procedure|0
locoregional radiation
  1
  C0851346|Radiation|0
also antiidlotype specific t cells
  4
  C0007634|Cells|0
  C1269647|Entire cell|0
  C1263442|SPECIFIC|0
  C0205369|Specific (qualifier value)|0
vulnerable phase
  2
  C0585064|Numerical phases (qualifier value)|0
  C0205390|Phase (qualifier value)|0
al
  1
  C0002367|Aluminum|0
predefined dose reduction scheme
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
increased cell proliferation
  5
  C0007634|Cells|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0334094|Proliferation (morphologic abnormality)|0
  C0442805|Increase (qualifier value)|0
1 2 wk to
  1
  C0439230|week (qualifier value)|0
other pelvic tissues
  3
  C0030797|Pelvis|0
  C0040300|Tissues|0
  C0205394|Other|0
high-grade spindle cell
  5
  C0007634|Cells|0
  C0205250|High|0
  C0441800|Grade|0
  C1166795|Spindle|0
  C0796573|Cancer cells grading system|0
fractions
  1
  C0457426|Fractions of (qualifier value)|0
chemotherapeutic effect
  1
  C1280500|Effect (qualifier value)|0
meta-analysis
  1
  C0920317|Meta-Analysis|0
high-risk group
  1
  C0684030|high-risk group|0
principal toxicity
  4
  C0040539|Toxicity aspects|0
  C0401925|Teaching principal|0
  C0600688|Toxic effect|0
  C0205225|Primary|0
radioactive liver scan
  4
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0441633|Scanning|0
  C0023884|Liver|0
concurrent weekly treatment
  4
  C0039798|therapeutic aspects|0
  C0332174|Weekly (qualifier value)|0
  C0205420|Concurrent (qualifier value)|0
  C0087111|Therapeutic procedure|0
prolonged exposure
  4
  C0391838|Exposure condition|0
  C0728853|Accident due to exposure to weather conditions|0
  C0274281|EFFECTS OF EXPOSURE TO EXTERNAL CAUSES|0
  C0439590|Prolonged (qualifier value)|0
1.2 years
  1
  C0439234|year (qualifier value)|0
overall incidence
  3
  C0021149|Incidence|0
  C0282416|Overall [Publication Type]|0
  C0220856|incidence of cases|0
computed tomography
  1
  C0040405|X-Ray Computed Tomography|0
previous adjuvant chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205156|Previous (qualifier value)|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
randomised patients
  1
  C0030705|Patients|0
additional risk factors
  1
  C0035647|Risk|0
study also
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
removal
  2
  C0728940|Surgical Removal - Action|0
  C0015252|Excision|0
increased frequency
  5
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0376249|With frequency|0
  C0442805|Increase (qualifier value)|0
  C0439603|Frequencies (time pattern)|0
probability values
  2
  C0033204|Probability|0
  C0042295|VALUING|0
four block stratification
  4
  C0205450|Four (qualifier value)|0
  C0233660|Mental blocking|0
  C0332206|Blocking|0
  C0028778|Obstruction|0
primary end point
  4
  C1272693|Ended (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0444930|End (qualifier value)|0
high risk factors
  3
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0035647|Risk|0
performance status less
  2
  C0449438|Status (attribute)|0
  C0597198|Performance|0
only one response
  2
  C0205447|One (qualifier value)|0
  C0871261|Responses|0
renal collecting system
  2
  C0022646|Kidney|0
  C0449913|System (attribute)|0
arizona group
  5
  C0036112|Salmonella arizonae|0
  C0003787|Arizona|0
  C0439745|Grouped (qualifier value)|0
  C1275677|Salmonella enterica subsp. arizonae|0
  C0441833|Groups (qualifier value)|0
tissue damage
  1
  C0010957|Damage (morphologic abnormality)|0
intracavitary insertions
  3
  C1298613|Intracavitary (qualifier value)|0
  C0441587|Clinical act of insertion|0
  C0021107|Implantation procedure|0
longer gold standards
  5
  C0038137|standards characteristics|0
  C1260548|Aurum metallicum, gold, Homeopathic preparation|0
  C1304897|Gold color|0
  C0947649|Gold preparation|0
  C0018026|Gold|0
nonprescribed doses
  1
  C0719635|DOS|0
not one new study
  4
  C0557651|Room of building - Study|0
  C0205447|One (qualifier value)|0
  C0205314|New (qualifier value)|0
  C0947630|Scientific Study|0
surgery induced impairment
  5
  C0231171|Physical impairment|0
  C0684336|Impaired health|0
  C0205263|Induced (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
study parameters
  4
  C0557651|Room of building - Study|0
  C0549193|Parameter (attribute)|0
  C0449381|Observation parameter (observable entity)|0
  C0947630|Scientific Study|0
responses
  1
  C0871261|Responses|0
sufficient numbers to
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0205410|Sufficient (qualifier value)|0
end result reporting
  5
  C1272693|Ended (qualifier value)|0
  C1274040|Result (navigational concept)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
  C0444930|End (qualifier value)|0
cause
  3
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0015127|Causality|0
stratification
  1
  C0205363|Stratified (qualifier value)|0
follow-up observation
  5
  C0547043|Up (qualifier value)|0
  C0302523|Observation in research|0
  C0700325|Patient observation|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
antigen s
  1
  C0003320|Antigens|0
m mitomycin
  2
  C0026254|Mitomycins|0
  C0002475|Mitomycin|0
iva disease
  2
  C1054142|Iva|0
  C0012634|Disease|0
hyperfractionated irradiation
  3
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
standard definitions
  2
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
two tail
  2
  C0205448|Two (qualifier value)|0
  C0039259|Tail|0
left ventricular function
  1
  C0080310|Ventricular Function, Left|0
obtaining written informed consent
  2
  C1301820|Obtained (attribute)|0
  C0700287|Reporting|0
other studies
  3
  C0557651|Room of building - Study|0
  C0205394|Other|0
  C0947630|Scientific Study|0
percent
  1
  C0439165|Percent (qualifier value)|0
nausea
  1
  C0027497|Nausea|0
mev
  1
  C0556642|MeV (qualifier value)|0
concomitant medications
  1
  C0013227|Pharmaceutical Preparations|0
nature
  2
  C1262865|Natures|0
  C0349590|Nature|0
alanine aminotransferase
  1
  C0001899|Alanine Transaminase|0
expected survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
perirectal fat
  2
  C0424612|Obese build|0
  C0015677|Fatty acid glycerol esters|0
locoregional control
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
less favorable results
  1
  C1274040|Result (navigational concept)|0
higher local tissue concentration
  3
  C0086045|Concentration|0
  C0205276|Local (qualifier value)|0
  C0040300|Tissues|0
survival analysis
  1
  C0038953|Survival Analysis|0
progression free survival
  1
  C0242792|Progression-Free Survival|0
deeply invasive lesions
  2
  C0221198|Lesion|0
  C0205281|Invasive (qualifier value)|0
sufficiently
  1
  C0205410|Sufficient (qualifier value)|0
bun 8.9 mmol
  1
  C0439190|mmol (qualifier value)|0
similar risk
  1
  C0035647|Risk|0
progress
  2
  C0205329|Progressive (qualifier value)|0
  C0449258|Progression (attribute)|0
dose limiting toxicity to
  3
  C0439801|Limited (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
5-year survival rate
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
residual tumor
  1
  C0543478|Residual Tumor|0
response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
standard formulas
  3
  C0489829|Mathematical formula|0
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
confirmatory arm
  3
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0750568|CONFIRMATORY|0
prior surgery
  4
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0750516|PRIOR|0
significant delay
  2
  C0205421|Deferred (qualifier value)|0
  C0750502|Significant (qualifier value)|0
actuarial 5-yr rfs
  2
  C0748398|RF|0
  C0439234|year (qualifier value)|0
beneficial effect
  1
  C1280500|Effect (qualifier value)|0
about percent
  1
  C0439165|Percent (qualifier value)|0
view
  1
  C0449911|View (attribute)|0
in vitro data
  1
  C0332285|Within|0
different regimen
  1
  C0677937|regimen|0
er
  1
  C0279756|estrogen receptor negative|0
more rigorous staging
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C0205172|More (qualifier value)|0
  C1306673|Stages (qualifier value)|0
cytologic confirmation
  1
  C0205471|Cytologic (qualifier value)|0
1.5 mg
  2
  C0024467|Magnesium|0
  C0439210|milligram|0
11.3 months v 7.5 months
  1
  C0439231|month (qualifier value)|0
planning
  2
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
one hour apart
  2
  C0205447|One (qualifier value)|0
  C0439227|Hour|0
semustine
  1
  C0036637|Semustine|0
contiguous parametrial tissue
  2
  C0205283|Contiguous (qualifier value)|0
  C0040300|Tissues|0
first event
  2
  C0441471|Events (event)|0
  C0205435|First (qualifier value)|0
significant improvements
  1
  C0750502|Significant (qualifier value)|0
escalating 5-fu arm
  4
  C0003792|Arm|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
  C0446516|Upper arm|0
scheduling
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
medical history taking
  1
  C0025084|Medical History Taking|0
objective regression rates
  4
  C0871208|Rating|0
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
  C0018017|Goals|0
years v years
  1
  C0439234|year (qualifier value)|0
radiographic test
  3
  C0039593|Testing|0
  C0444708|Radiographic (qualifier value)|0
  C0392366|Tests (qualifier value)|0
forty eight patients
  2
  C0205454|Eight (qualifier value)|0
  C0030705|Patients|0
estrogen receptor
  1
  C0034804|Estrogen Receptors|0
often first site
  3
  C0332183|Frequent (qualifier value)|0
  C0205145|Associated topography (attribute)|0
  C0205435|First (qualifier value)|0
strategy
  1
  C0679199|strategy|0
statistically significant differences
  1
  C0750502|Significant (qualifier value)|0
most likely explanation
  3
  C0750504|Likely|0
  C0205393|Most (qualifier value)|0
  C0681841|explanation|0
comparative rfs
  1
  C0748398|RF|0
study groups
  5
  C0557651|Room of building - Study|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0947630|Scientific Study|0
supine bicycle exercise
  5
  C1306338|Physical exercise (qualifier value)|0
  C0015259|Exercise|0
  C0452240|Physical therapy exercises|0
  C0005377|Bicycling|0
  C0005375|Bicycle, device (physical object)|0
comparable rfs
  1
  C0748398|RF|0
objective antitumour activity
  4
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
  C0018017|Goals|0
estimated reduction
  3
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0750572|ESTIMATED|0
radioisotopes
  1
  C0034595|Radioisotopes|0
42.resected tissue
  1
  C0040300|Tissues|0
figo stage ib
  5
  C0022104|Irritable Bowel Syndrome|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0444976|Ib (qualifier value)|0
  C1306673|Stages (qualifier value)|0
univariate cox model
  4
  C0026336|Models|0
  C0870071|Modeling|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
beneficial impact
  2
  C0726639|Impact|0
  C0333125|Impacted (qualifier value)|0
special comment
  3
  C0282411|Published Comment|0
  C0205555|Special (qualifier value)|0
  C0947611|Comment|0
good candidates
  1
  C0205170|Good (qualifier value)|0
other chemotherapeutic regiments
  1
  C0205394|Other|0
c rectal cancer
  5
  C0205052|Rectal (qualifier value)|0
  C0998265|Cancer Genus|0
  C0007886|Cesium|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
ecog performance score
  3
  C0449820|Scores (qualifier value)|0
  C0597198|Performance|0
  C0430797|Electrocorticogram (procedure)|0
foundation bergonie trials,19 used similar patient selection criteria
  5
  C0243161|criteria|0
  C0036576|Selection (Genetics)|0
  C0042153|utilization|0
  C0030705|Patients|0
  C0016617|Foundations|0
worse toxicity
  4
  C0040539|Toxicity aspects|0
  C1279889|Deterioration of status|0
  C0600688|Toxic effect|0
  C0332271|Worsening (qualifier value)|0
patient cohort
  2
  C0599755|cohort|0
  C0030705|Patients|0
7.1 months
  1
  C0439231|month (qualifier value)|0
second
  2
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
anticipated 5% loss
  5
  C0598174|chromosome loss|0
  C0542223|Speech loss|0
  C0235161|Sleep loss|0
  C0598940|neuron loss|0
  C0018840|Heat Loss|0
continuing
  1
  C0750536|CONTINUED|0
­ 25% response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
anastomosis watertight
  3
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
primary colorectal carcinoma
  4
  C0555952|Colorectal (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0007097|Carcinoma|0
  C0205225|Primary|0
loco regional recurrence
  2
  C0034897|Recurrence|0
  C0205147|Regional (qualifier value)|0
persisting more
  1
  C0205172|More (qualifier value)|0
munne monoclonal mmunoglobulin igg2a antibody
  4
  C0746619|MONOCLONAL|0
  C0020857|IgG2A|0
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
not received antibodies
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
first line treatment
  5
  C0039798|therapeutic aspects|0
  C0700221|Intravascular line|0
  C0205132|Linear|0
  C0205435|First (qualifier value)|0
  C0087111|Therapeutic procedure|0
eligible patients
  1
  C0030705|Patients|0
case
  1
  C0868928|Case (qualifier value)|0
iia disease
  1
  C0012634|Disease|0
one tail test
  4
  C0039593|Testing|0
  C0205447|One (qualifier value)|0
  C0039259|Tail|0
  C0392366|Tests (qualifier value)|0
severe diarrhoea
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0011991|Diarrhea|0
detailed gog clinical pathologic study
  4
  C0557651|Room of building - Study|0
  C0205210|Clinical (qualifier value)|0
  C0205469|Pathological aspects|0
  C0947630|Scientific Study|0
common result
  2
  C1274040|Result (navigational concept)|0
  C0205214|Common (qualifier value)|0
logistic regression model
  4
  C0026336|Models|0
  C0684321|Regression - mental defense mechanism|0
  C0870071|Modeling|0
  C0684320|Disease regression|0
median weekly dose
  3
  C0876920|Median Statistical Measurement|0
  C0332174|Weekly (qualifier value)|0
  C0549183|Median (qualifier value)|0
overall stage ib mortality
  5
  C0022104|Irritable Bowel Syndrome|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0026565|Mortality Vital Statistics|0
  C0282416|Overall [Publication Type]|0
  C0026566|Aspects of mortality statistics|0
dose level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
one meta-analysis
  4
  C0002778|Analysis of substances|0
  C0205447|One (qualifier value)|0
  C0936012|Analysis|0
  C1042496|Meta|0
kidney function
  1
  C0232804|Renal function, NOS|0
histologically proven metastatic colorectal cancer
  5
  C0700164|proven venom|0
  C0555952|Colorectal (qualifier value)|0
  C0036525|Metastatic to|0
  C0006826|Malignant Neoplasms|0
  C0456369|Proven findings|0
previous malignant disease
  4
  C0205156|Previous (qualifier value)|0
  C0012634|Disease|0
  C0006826|Malignant Neoplasms|0
  C0205282|Malignant - descriptor|0
morphologic cardiac abnormalities
  3
  C0205041|Cardio-|0
  C0000769|teratologic|0
  C0000768|Congenital Abnormality|0
altered regimen
  2
  C0205349|Altered (qualifier value)|0
  C0677937|regimen|0
permanent decrease
  4
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
  C0205355|Permanent (qualifier value)|0
yr
  1
  C0439234|year (qualifier value)|0
now sufficient evidence to
  1
  C0205410|Sufficient (qualifier value)|0
liquid diet
  1
  C0301571|Liquid diet (finding)|0
abscess
  1
  C0000833|Abscess|0
tumor characteristics
  1
  C0027651|Neoplasms|0
relatively good cardiac tolerance
  4
  C0231197|Physiologic tolerance|0
  C0205041|Cardio-|0
  C0220929|Mental tolerance|0
  C0205170|Good (qualifier value)|0
patient also
  1
  C0030705|Patients|0
drugs three weeks
  4
  C0684270|Drugged|0
  C0439230|week (qualifier value)|0
  C0205449|Three (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
platelet count less
  3
  C0005821|Blood Platelets|0
  C0750480|COUNT|0
  C0439157|counts (qualifier value)|0
treatment more
  3
  C0039798|therapeutic aspects|0
  C0205172|More (qualifier value)|0
  C0087111|Therapeutic procedure|0
three controlled trials
  3
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0205449|Three (qualifier value)|0
topoisomerase i inhibitor
  1
  C0243077|inhibitors|0
extraperitoneal staging laparotomy
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0023038|Laparotomy|0
  C0442090|Extraperitoneal (qualifier value)|0
  C1306673|Stages (qualifier value)|0
eligible patient
  1
  C0030705|Patients|0
local therapy
  1
  C0677903|local therapy|0
cervical cancer
  1
  C0007847|Malignant neoplasm of cervix uteri|0
standard
  2
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
high-dose fluorouracil
  3
  C0205250|High|0
  C0016360|Fluorouracil|0
  C0235146|Euphoric mood|0
tumor recurrence rate
  3
  C0871208|Rating|0
  C0034897|Recurrence|0
  C0027651|Neoplasms|0
excess
  2
  C0442802|Excessive (qualifier value)|0
  C0750570|EXCESSIVELY|0
start
  2
  C1272689|Started (qualifier value)|0
  C0452588|Start (substance)|0
more positive nodes
  3
  C0746922|NODE|0
  C0205159|Positive (qualifier value)|0
  C0205172|More (qualifier value)|0
20% protraction
  1
  C0491912|PROTRACTOR|0
response
  1
  C0871261|Responses|0
slightly higher doses
  2
  C0719635|DOS|0
  C0750482|SLIGHTLY|0
ribonucleotide reductase
  1
  C0035547|Ribonucleotide Reductase|0
p 0.13),a nonsignificant trend
  1
  C0040833|trends|0
observed major therapeutic response rate
  5
  C0205164|Major (qualifier value)|0
  C0039796|The science and art of healing|0
  C0871208|Rating|0
  C0302350|Therapeutic|0
  C0871261|Responses|0
variables
  1
  C0439828|Variable (qualifier value)|0
curative operations
  2
  C0038895|Surgical aspects|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
15% difference
  1
  C0443199|Differential (qualifier value)|0
merely less potent anthracycline
  2
  C0282564|Anthracyclines|0
  C0003234|Anthracycline Antibiotics|0
deaths
  1
  C0011065|Cessation of life|0
precise mucosal approximation
  1
  C0026724|Mucous Membrane|0
increased survival times
  5
  C0038952|Continuance of life|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0220921|survival aspects|0
  C0442805|Increase (qualifier value)|0
bone scan
  1
  C0203668|Radioisotope scan of bone (procedure)|0
stable lvef
  1
  C0205360|Stable (qualifier value)|0
third cycle
  1
  C0205437|Third (qualifier value)|0
lymph node metastasis
  1
  C0686619|Secondary malignant neoplasm of lymph node (disorder)|0
single agent
  4
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0450442|Agent (attribute)|0
topoisomerase i
  1
  C0012920|DNA Topoisomerase|0
alternating delivery
  4
  C0011209|Obstetric Delivery|0
  C0332270|Alternating (qualifier value)|0
  C0559563|Delivery finding (finding)|0
  C1135594|Delivery|0
required modifications
  2
  C1320750|Required property (attribute)|0
  C0376346|Required Organ Donation Request|0
four nonevaluable patients
  2
  C0205450|Four (qualifier value)|0
  C0030705|Patients|0
metastatic lesion
  2
  C0036525|Metastatic to|0
  C0221198|Lesion|0
radiation sensitization
  1
  C0851346|Radiation|0
insufficient power to
  2
  C0231180|Insufficient|0
  C0032863|Power (Psychology)|0
dosimetry calculations
  1
  C0599911|dosimetry|0
classes
  3
  C0441884|Classes (qualifier value)|0
  C0489477|LOINC class types|0
  C0456387|Class|0
supportive care included antibiotics
  4
  C0332257|Including (qualifier value)|0
  C0003232|Antibiotics|0
  C0150499|Caring|0
  C0728734|Caring caregiver-patient relationship|0
poor prognostic factors
  3
  C0542537|Poor - grade value|0
  C0220901|prognostic|0
  C0699761|Financially poor|0
calcium folinate significantly increased response rates
  5
  C0006675|Calcium|0
  C0442808|Increasing (qualifier value)|0
  C0871208|Rating|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
combination regimen
  3
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0677937|regimen|0
c
  1
  C0007886|Cesium|0
conservative surgery
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
day administration
  3
  C1262471|Administration (procedure)|0
  C0439228|day (qualifier value)|0
  C0001554|Administration|0
ten patients
  2
  C0205456|Ten (qualifier value)|0
  C0030705|Patients|0
pretreatment gynecologic examination
  2
  C0579007|Examination - action (qualifier value)|0
  C0205480|Gynecologic (qualifier value)|0
cancellation
  1
  C0205544|Cancelled (qualifier value)|0
shorter costs
  2
  C0220812|Cost aspects|0
  C0010186|Financial cost|0
nine patients
  2
  C0030705|Patients|0
  C0205455|Nine (qualifier value)|0
single distant events
  5
  C0037179|Unmarried person|0
  C0441471|Events (event)|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0443203|Distant (qualifier value)|0
radiation protocol
  2
  C0442711|Protocols documentation|0
  C0851346|Radiation|0
other reasons
  2
  C0684328|Reasoning|0
  C0205394|Other|0
stomach
  2
  C1278920|Entire stomach|0
  C0038351|Stomach|0
risk factor
  1
  C0035648|Risk Factors|0
previously described pattern
  1
  C0449774|Patterns (qualifier value)|0
endpoints
  1
  C0150100|ENDPOINT|0
patient age
  4
  C0001811|Aging|0
  C0030705|Patients|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
drugs
  2
  C0684270|Drugged|0
  C0013227|Pharmaceutical Preparations|0
diffuse peritonitis
  3
  C0205219|Diffuse (qualifier value)|0
  C0012222|Diffusion|0
  C0031154|Peritonitis|0
only isolated vaginal vault recurrences
  4
  C0370215|ISOLATE|0
  C0042232|Vagina|0
  C0034897|Recurrence|0
  C0205409|Isolated (qualifier value)|0
6% increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
median total treatment time
  5
  C0439810|Total (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0087111|Therapeutic procedure|0
failures
  2
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
colorectal carcinoma
  1
  C0009403|Colorectal Carcinoma|0
life table estimates
  1
  C0023680|Life Table Estimates|0
posterior midline attenuator
  2
  C0205095|Dorsal|0
  C0549183|Median (qualifier value)|0
optimal treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
five treatments
  3
  C0039798|therapeutic aspects|0
  C0205451|Five (qualifier value)|0
  C0087111|Therapeutic procedure|0
highest dose intensity ever
  5
  C0183477|Spot Lights, High-Intensity|0
  C0237686|Stimulus Intensity|0
  C0683109|high intensity light|0
  C0518690|Symptom intensity|0
  C0596836|light intensity|0
paraortic nodes
  1
  C0746922|NODE|0
consistent reduction
  3
  C0301630|Reduction (chemical)|0
  C0332290|Consistent with (qualifier value)|0
  C0441610|Reduction - action|0
19% reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
tumor markers
  2
  C1139415|Reagents, Tumor Markers|0
  C0041365|Tumor Markers|0
more severe nausea
  3
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0027497|Nausea|0
  C0205172|More (qualifier value)|0
ischemic continuous anastomosis
  5
  C0677554|Anastomosis - action|0
  C0475224|Ischemic|0
  C0332853|Anastomosis|0
  C0549178|Continuous (qualifier value)|0
  C0500470|Anatomical anastomosis|0
surgical stress
  3
  C0038895|Surgical aspects|0
  C0723460|Stress bismuth subsalicylate|0
  C0038435|Stress|0
concomitant administration
  2
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
significantly longer survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
treatment results
  3
  C1274040|Result (navigational concept)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
south america
  1
  C0037713|South America|0
one irinotecan
  2
  C0123931|irinotecan|0
  C0205447|One (qualifier value)|0
support
  3
  C0344211|Supportive care|0
  C0183683|Support, device|0
  C1317973|SUPPORT|0
pathologists
  1
  C0334866|Medical pathologist (occupation)|0
original hypothesis
  1
  C0205313|Original (qualifier value)|0
adriamycin
  1
  C0085752|Adriamycin|0
mean age
  5
  C0001811|Aging|0
  C0876919|Meaning|0
  C0001779|Age (qualifier value)|0
  C0444504|Mean (qualifier value)|0
  C0001792|Elderly|0
further gy
  1
  C0556636|Gy (qualifier value)|0
informed consents
  1
  C0021430|Informed Consent|0
exclusion
  1
  C0680251|exclusion|0
own findings
  1
  C0243095|findings|0
10 12 months
  1
  C0439231|month (qualifier value)|0
first uk medical research council
  3
  C0035168|Research|0
  C0205435|First (qualifier value)|0
  C0205476|Medical (qualifier value)|0
transient paraplegia
  4
  C0205374|Transitory|0
  C0687129|Encounter due to vagabond status|0
  C0030486|Paraplegia|0
  C0040704|Transient Population Group|0
25% increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
multivariate cox regression
  4
  C0684321|Regression - mental defense mechanism|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
  C0684320|Disease regression|0
extensive parametrial extension
  2
  C0231448|Extension (qualifier value)|0
  C0205231|Extensive (qualifier value)|0
anastomosis
  3
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
pelvic irradiation
  4
  C0030797|Pelvis|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
yearly clinical examinations
  3
  C0579007|Examination - action (qualifier value)|0
  C0205210|Clinical (qualifier value)|0
  C0332181|Annual (qualifier value)|0
drug administration
  1
  C0150270|Procedure related to management of drug administration (procedure)|0
retrospective study
  1
  C0035363|Retrospective Studies|0
symptoms
  1
  C0683368|symptoms|0
56.2 years
  1
  C0439234|year (qualifier value)|0
extended field radiation
  5
  C0231449|Extended (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0332258|Extending (qualifier value)|0
  C0851346|Radiation|0
patient’s health
  1
  C0018684|Health|0
stable disease
  1
  C0677946|stable disease|0
hydroureteronephrosis
  1
  C0268804|Hydroureteronephrosis (disorder)|0
patients selection
  1
  C0242802|Patient Selection|0
cox partial likelihood score statistic
  5
  C0728938|Partial (qualifier value)|0
  C0449820|Scores (qualifier value)|0
  C0038215|Science of Statistics|0
  C0442996|Cox microbiology subtype|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
4.4 group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
acceptably low morbidity
  4
  C0234886|Lowing, function (observable entity)|0
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
  C0205251|Low (qualifier value)|0
also assessed quality
  1
  C0332306|With quality (attribute)|0
apparently curative resections
  3
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
  C0750541|APPARENTLY|0
first evidence
  1
  C0205435|First (qualifier value)|0
valid statistical analyses
  3
  C0220917|statistical|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
interim testing
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
rfs
  1
  C0748398|RF|0
other randomized phase ii trials
  4
  C0585064|Numerical phases (qualifier value)|0
  C0205390|Phase (qualifier value)|0
  C0439069|Roman numeral II|0
  C0205394|Other|0
al also
  1
  C0002367|Aluminum|0
events
  1
  C0441471|Events (event)|0
custom shielding
  2
  C0183251|Shield, device (physical object)|0
  C0162343|Customs|0
c w.
  1
  C0007886|Cesium|0
pain
  1
  C0030193|Pain|0
omentum
  1
  C0028977|Omentum|0
several other comparisons
  2
  C0443302|Several (qualifier value)|0
  C0205394|Other|0
combined sometimes
  2
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
grade mucositis
  3
  C0236177|Inflammatory disease of mucous membrane (disorder)|0
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
multivanate analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
certain antineoplastic agents
  3
  C0003392|Antineoplastic Agents|0
  C0205423|Certainty (attribute)|0
  C0450442|Agent (attribute)|0
otherwise operable rectal cancer
  5
  C0205052|Rectal (qualifier value)|0
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0205188|Operable (qualifier value)|0
tumor related prognostic factors
  4
  C0220901|prognostic|0
  C0163712|Relate|0
  C0027651|Neoplasms|0
  C0445223|Related (finding)|0
s
  5
  C0175668|Secondary to|0
  C0331042|Sium (organism)|0
  C1225105|Sia|0
  C0457385|seconds|0
  C0723181|SSS|0
vagina
  2
  C0042232|Vagina|0
  C1278985|Entire vagina|0
fluorouracil mg
  1
  C0016360|Fluorouracil|0
significant prognostic factors
  2
  C0220901|prognostic|0
  C0750502|Significant (qualifier value)|0
pelvic node dissection
  5
  C0030797|Pelvis|0
  C0746922|NODE|0
  C0012737|Dissection|0
  C1293093|Dissection procedure (procedure)|0
  C1306808|Dissection - action (qualifier value)|0
intensified adjuvant chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
chest x-rays
  1
  C0202783|Radiographic procedure on chest (procedure)|0
pilot
  1
  C0473169|Pilot - aircraft (occupation)|0
high dose
  1
  C0444956|High dose (qualifier value)|0
weight loss
  1
  C0043096|Weight Loss|0
salvage surgery
  5
  C0038895|Surgical aspects|0
  C0864553|Salvage|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0442967|Salvage procedure (qualifier value)|0
two groups
  4
  C0205448|Two (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
cumulative cardiotoxicity data
  1
  C0876994|Cardiotoxicity|0
two
  1
  C0205448|Two (qualifier value)|0
prolonged administration unnecessary
  3
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
  C0439590|Prolonged (qualifier value)|0
lymph-vascular space involvement
  4
  C0005847|Blood Vessels|0
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0024202|Lymph|0
pn
  1
  C0206417|Peripheral Nervous System|0
question soon
  1
  C0876928|Questioning|0
early cholinergic syndrome
  4
  C0205085|Early (qualifier value)|0
  C0242893|Cholinergic Agents|0
  C0599668|cholinergic|0
  C0039082|Syndrome|0
second cycle
  2
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
recurrent cervical cancer
  1
  C0278579|Cervix carcinoma recurrent|0
ct rt
  1
  C0040405|X-Ray Computed Tomography|0
significant survival improvement
  3
  C0038952|Continuance of life|0
  C0750502|Significant (qualifier value)|0
  C0220921|survival aspects|0
differential effect
  2
  C1280500|Effect (qualifier value)|0
  C0443199|Differential (qualifier value)|0
substantial survival improvement
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
urological complications
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
expected 5-year survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
premenopausal women
  3
  C0043210|Human adult females|0
  C0043209|Human Females|0
  C0279752|premenopausal|0
vulnerability
  3
  C0043250|Injury wounds|0
  C0021501|injuries|0
  C0332797|Wounded|0
further analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
transient hypotension
  4
  C0205374|Transitory|0
  C0687129|Encounter due to vagabond status|0
  C0020649|Hypotension|0
  C0040704|Transient Population Group|0
prognostic factors
  1
  C0220901|prognostic|0
present study
  3
  C0557651|Room of building - Study|0
  C0150312|Present|0
  C0947630|Scientific Study|0
best response
  1
  C0871261|Responses|0
paraaortic areas
  1
  C0205146|Area (qualifier value)|0
asthenia
  1
  C0004093|Asthenia|0
delayed week
  2
  C0205421|Deferred (qualifier value)|0
  C0439230|week (qualifier value)|0
years
  1
  C0439234|year (qualifier value)|0
radiation therapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
ct rt groups
  4
  C0040405|X-Ray Computed Tomography|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
control groups
  1
  C0009932|Control Groups|0
tumor cells
  1
  C0431085|[M]Unspecified tumor cell NOS (morphologic abnormality)|0
blood supply
  3
  C0005839|Blood supply aspects|0
  C0920762|Vascular blood supply|0
  C0678861|Arterial blood supply|0
ast
  1
  C0004002|Aspartate Transaminase|0
study’s target sample size
  4
  C0870078|Sampling|0
  C0599894|targeting|0
  C0441621|Sampling - Surgical action|0
  C0702146|Size (attribute)|0
many combinations
  3
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0439064|Numerous (qualifier value)|0
broad spectrum
  1
  C0332464|Widened structure (morphologic abnormality)|0
treatment comparisons
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
sensitive enzyme linked mmunoadsorbent assay
  5
  C0014442|Enzymes|0
  C0014445|enzymology|0
  C0332324|Sensitive (qualifier value)|0
  C0208973|Link|0
  C0243073|assay|0
creatinine
  1
  C0010294|Creatinine|0
follow-up visit
  1
  C0589121|Follow-up visit (procedure)|0
pelvic control
  1
  C0561970|Ability to control pelvic posture (observable entity)|0
more level i
  3
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
  C0205172|More (qualifier value)|0
most important clinical risk factors
  3
  C0205210|Clinical (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0035647|Risk|0
nutritional status to
  2
  C0449438|Status (attribute)|0
  C0331877|Nutritionals|0
literature
  1
  C0023866|Literature|0
adjuvant trials
  1
  C0278788|adjuvant study|0
obesity
  1
  C0028754|Obesity|0
meaningful response duration
  2
  C0871261|Responses|0
  C0449238|Duration|0
progressive disease
  1
  C0677932|progressive disease|0
renal function tests
  1
  C0022662|Kidney Function Tests|0
improved progression free survival
  5
  C1272745|Improving (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
distant s
  1
  C0443203|Distant (qualifier value)|0
intraportal injection
  2
  C0021485|Injections|0
  C1272883|Injection (product)|0
randomised treatment allocation
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
survival outcome
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
late treatment-related fatalities
  5
  C0039798|therapeutic aspects|0
  C0205087|Late (qualifier value)|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
pelvic relapses
  4
  C0030797|Pelvis|0
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
daily
  1
  C0332173|Daily (qualifier value)|0
greece
  1
  C0018226|Greece|0
mean platelet count
  5
  C0005821|Blood Platelets|0
  C0876919|Meaning|0
  C0750480|COUNT|0
  C0444504|Mean (qualifier value)|0
  C0439157|counts (qualifier value)|0
chest radiogram
  2
  C0817096|Chest|0
  C1306645|Plain film (procedure)|0
investigating
  1
  C1292732|Investigates (attribute)|0
principal adverse effect
  3
  C1280500|Effect (qualifier value)|0
  C0401925|Teaching principal|0
  C0205225|Primary|0
three week epi
  2
  C0439230|week (qualifier value)|0
  C0205449|Three (qualifier value)|0
preoperative neoadjuvant chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0445204|Preoperative (qualifier value)|0
  C0013216|Pharmacotherapy|0
haemoglobin
  1
  C0019046|Hemoglobin|0
diameter cm v cm
  2
  C0475210|cm (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
follow-up
  1
  C0589120|Follow-up status (finding)|0
patient related factors
  3
  C0163712|Relate|0
  C0030705|Patients|0
  C0445223|Related (finding)|0
63,and years
  1
  C0439234|year (qualifier value)|0
major goal
  2
  C0205164|Major (qualifier value)|0
  C0018017|Goals|0
rnca abnormalities
  2
  C0000769|teratologic|0
  C0000768|Congenital Abnormality|0
guidelines
  3
  C0282423|Guideline [Publication Type]|0
  C0162791|Guidelines|0
  C0220845|guiding characteristics|0
selected patients
  1
  C0030705|Patients|0
5-fu infusion
  3
  C0574032|Infusion (procedure)|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
surgery alone group
  5
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0679994|alone|0
  C0441833|Groups (qualifier value)|0
noncompliant patients
  1
  C0030705|Patients|0
aserum creatinine concentration
  2
  C0086045|Concentration|0
  C0010294|Creatinine|0
angina pectoris
  1
  C0002962|Angina Pectoris|0
pelvic field
  3
  C0030797|Pelvis|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
weekly intravenous infusions
  3
  C0574032|Infusion (procedure)|0
  C0348016|Intravenous|0
  C0332174|Weekly (qualifier value)|0
25% planned level
  1
  C0441890|Planned level (qualifier value)|0
follow-up evaluations
  5
  C0220825|Evaluation|0
  C0547043|Up (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
recent major surgery
  5
  C0038895|Surgical aspects|0
  C0205164|Major (qualifier value)|0
  C0332185|Recent episode (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
serum creatinine levels
  1
  C0600061|Serum creatinine level|0
quality control
  1
  C0034378|Quality Control|0
escalating single agent 5-fu regimen
  5
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
6 24 days
  1
  C0439228|day (qualifier value)|0
recurrence free interval
  2
  C0034897|Recurrence|0
  C1272706|Interval (qualifier value)|0
combined treatment
  1
  C0009429|Combined Modality Therapy|0
initiation
  2
  C0678321|AOD use initiation|0
  C0589507|Cognitive function: initiation|0
quantitative data
  1
  C0392762|Quantitative (qualifier value)|0
radiosensitization
  1
  C0279024|radiosensitization|0
stage
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
surgery
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
sometimes larger numbers
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0443228|Greater (qualifier value)|0
external beam fields
  3
  C0205101|External (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
new york
  1
  C0027976|New York|0
significant differences
  1
  C0750502|Significant (qualifier value)|0
dna replication step
  4
  C0859325|Stepping|0
  C0599955|replication|0
  C1261552|Step (qualifier value)|0
  C0012854|DNA|0
liver metastases
  1
  C0494165|Secondary malignant neoplasm of liver (disorder)|0
month to
  1
  C0439231|month (qualifier value)|0
two doses
  2
  C0205448|Two (qualifier value)|0
  C0719635|DOS|0
necropsy
  1
  C0004398|Autopsy|0
relapses
  3
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
disease-free survival results
  4
  C1274040|Result (navigational concept)|0
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
urinalysis
  1
  C0042014|Urinalysis|0
chosen threshold
  1
  C0449864|Threshold (property) (qualifier value)|0
5-year survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
simulation films
  2
  C0086296|Films|0
  C0679083|simulation|0
cox proportional hazards
  4
  C0205351|Proportional (qualifier value)|0
  C0598697|hazard|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
first mention
  1
  C0205435|First (qualifier value)|0
proportional hazards procedures
  4
  C0025664|Methodology|0
  C0205351|Proportional (qualifier value)|0
  C0184661|Procedures|0
  C0598697|hazard|0
also regimen
  1
  C0677937|regimen|0
tumoricidal effects
  1
  C1280500|Effect (qualifier value)|0
little change
  3
  C0392747|Changing|0
  C0443172|Changed status|0
  C0700321|Small|0
adequate performance
  2
  C0597198|Performance|0
  C0205411|Adequate (qualifier value)|0
major response rates
  3
  C0205164|Major (qualifier value)|0
  C0871208|Rating|0
  C0871261|Responses|0
plt
  1
  C0201617|Primed lymphocyte test (procedure)|0
sd
  1
  C0332147|Suspected diagnosis (contextual qualifier) (qualifier value)|0
increased late toxicity particularly
  5
  C0205087|Late (qualifier value)|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0600688|Toxic effect|0
  C0442805|Increase (qualifier value)|0
other traditional risk factors
  3
  C0443324|Traditional (qualifier value)|0
  C0205394|Other|0
  C0035647|Risk|0
cisplatin based chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0008838|Cisplatin|0
  C0178499|Base|0
  C0013216|Pharmacotherapy|0
4 cm
  1
  C0475210|cm (qualifier value)|0
fatigue
  1
  C0015672|Fatigue|0
advantage
  1
  C0308269|ADVANTAGE|0
institutions
  1
  C1272753|Institution (social concept)|0
interrupted anastomosis
  4
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
  C0443239|Interrupted (qualifier value)|0
ninety nine patients
  2
  C0030705|Patients|0
  C0205455|Nine (qualifier value)|0
treatment induced parametrial fibrosis
  4
  C0039798|therapeutic aspects|0
  C0205263|Induced (qualifier value)|0
  C0016059|Fibrosis|0
  C0087111|Therapeutic procedure|0
hydroxyurea
  1
  C0020402|Hydroxyurea|0
not eligible previous treatment
  3
  C0039798|therapeutic aspects|0
  C0205156|Previous (qualifier value)|0
  C0087111|Therapeutic procedure|0
estimated power
  2
  C0750572|ESTIMATED|0
  C0032863|Power (Psychology)|0
stress incontinence
  1
  C0042025|Urinary Incontinence, Stress|0
most frequent cancer
  5
  C0998265|Cancer Genus|0
  C0332183|Frequent (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
disease-free survival time
  5
  C0038952|Continuance of life|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0012634|Disease|0
  C0220921|survival aspects|0
progress reports
  1
  C0242586|Progress Report|0
pneumonia days after treatment initiation
  5
  C0231290|Status post (contextual qualifier) (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0032285|Pneumonia|0
  C0439228|day (qualifier value)|0
  C0087111|Therapeutic procedure|0
crude incidence
  2
  C0021149|Incidence|0
  C0220856|incidence of cases|0
five year disease-free survival rates
  5
  C0038952|Continuance of life|0
  C0205451|Five (qualifier value)|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
positioning
  2
  C0733755|Positioning Attribute|0
  C0150305|Positioning - therapy|0
biochemical tests
  1
  C0430027|Biochemical test (procedure)|0
five function scales
  5
  C0349674|Intellectual scale|0
  C0175659|Weight measurement scales|0
  C0205451|Five (qualifier value)|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
apparent effect
  2
  C1280500|Effect (qualifier value)|0
  C0750489|APPARENT|0
major weakness
  4
  C0205164|Major (qualifier value)|0
  C0086525|Lassitude|0
  C0004093|Asthenia|0
  C0030552|Paresis|0
portal fields
  3
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0205054|Hepatic|0
fluctuating
  1
  C0231241|Fluctuating (qualifier value)|0
entire rectum
  1
  C1278926|Entire rectum|0
first application
  2
  C0185125|Application (procedure)|0
  C0205435|First (qualifier value)|0
60.0 gy
  1
  C0556636|Gy (qualifier value)|0
constant decrease
  3
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
stage wise comparison
  4
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C1306673|Stages (qualifier value)|0
significant increase
  4
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0750502|Significant (qualifier value)|0
  C0442805|Increase (qualifier value)|0
treatment crossover
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
nonlethal toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
maximum tolerated dose
  1
  C0752079|Maximum Tolerated Dose|0
patients doses
  2
  C0719635|DOS|0
  C0030705|Patients|0
lethargy
  1
  C0023380|Lethargy|0
cbc
  1
  C0009555|Blood Count, Complete|0
to better outcomes
  1
  C0332272|Better (qualifier value)|0
overall therapeutic results
  4
  C0039796|The science and art of healing|0
  C1274040|Result (navigational concept)|0
  C0302350|Therapeutic|0
  C0282416|Overall [Publication Type]|0
total cumulative dose to
  1
  C0439810|Total (qualifier value)|0
patient then
  1
  C0030705|Patients|0
cardiorespiratory arrest
  1
  C0600228|Cardiopulmonary Arrest|0
liver recurrences
  4
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0023884|Liver|0
  C0034897|Recurrence|0
empiric dose restriction
  1
  C0749647|TREATMENT EMPIRIC|0
experienceddrug induced pulmonary toxicity
  4
  C0040539|Toxicity aspects|0
  C0205263|Induced (qualifier value)|0
  C0024109|Lung|0
  C0600688|Toxic effect|0
previously untreated patients
  1
  C0030705|Patients|0
90% power to
  1
  C0032863|Power (Psychology)|0
somewhat more aggressive regimen
  5
  C1262472|Aggressive cancer|0
  C0580822|Aggressive course (qualifier value)|0
  C0205172|More (qualifier value)|0
  C0677937|regimen|0
  C0001807|Aggression|0
positive cls
  3
  C0201952|Chloride measurement|0
  C0010575|Cycloleucine|0
  C0205159|Positive (qualifier value)|0
proper histopathologic classification
  3
  C0008903|Taxonomic|0
  C0678229|Classification of information|0
  C0008902|Classification|0
39% response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
mechanism
  2
  C0457274|Mechanism (attribute)|0
  C0441712|Mechanisms (qualifier value)|0
eaceful end
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
compound competes
  2
  C0205198|Compound (qualifier value)|0
  C0719453|Compete|0
log rank
  1
  C0699794|Rank|0
two others
  2
  C0205448|Two (qualifier value)|0
  C0205394|Other|0
cancers
  3
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
interest
  1
  C0543488|Interested (finding)|0
cytotoxicity
  1
  C0596402|Cytotoxicity|0
å 0.05 level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
adria laboratories
  2
  C0331763|Adria Pharmaceuticals|0
  C0022877|Laboratories|0
premenopausal patients
  2
  C0030705|Patients|0
  C0279752|premenopausal|0
neck clinic
  4
  C0027536|Necking (finding)|0
  C0442592|Clinic (environment)|0
  C0027530|Neck|0
  C1281592|Entire neck|0
hypertension
  3
  C0235220|Hypertensive disorder, systemic arterial (disorder)|0
  C0340274|Hypertension induced by pregnancy|0
  C0020538|Hypertension|0
mitomycin mg
  2
  C0026254|Mitomycins|0
  C0002475|Mitomycin|0
drug injections
  4
  C0684270|Drugged|0
  C0021485|Injections|0
  C1272883|Injection (product)|0
  C0013227|Pharmaceutical Preparations|0
chi square
  1
  C0205120|Square (qualifier value)|0
platelets l
  1
  C0005821|Blood Platelets|0
several individual trials
  2
  C0237401|Individual (person)|0
  C0443302|Several (qualifier value)|0
known contraindications
  2
  C0205309|Known (qualifier value)|0
  C0079164|contraindications|0
abdominal perineal resections
  4
  C0456438|Abdominal (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
  C0031066|Anogenital region|0
posterior border
  2
  C0205095|Dorsal|0
  C0205284|Marginal (qualifier value)|0
distant areas
  2
  C0205146|Area (qualifier value)|0
  C0443203|Distant (qualifier value)|0
significantly higher rate
  1
  C0871208|Rating|0
survival times
  5
  C0038952|Continuance of life|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0220921|survival aspects|0
  C0392761|Timed (qualifier value)|0
throughout follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
survival outcomes
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
main differences
  1
  C0205225|Primary|0
cmf regimen
  1
  C0055982|CMF regimen|0
therapeutic index
  1
  C0678793|therapeutic index|0
temporary dose reduction only
  3
  C0301630|Reduction (chemical)|0
  C0205374|Transitory|0
  C0441610|Reduction - action|0
formula
  1
  C0489829|Mathematical formula|0
bilirubin 1.5 x n
  2
  C0005437|Bilirubin|0
  C0439225|ns (qualifier value)|0
judicious selection
  1
  C0036576|Selection (Genetics)|0
only prospective randomized clinical trials yet
  1
  C0205210|Clinical (qualifier value)|0
combined rt
  2
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
overall rfs difference
  2
  C0748398|RF|0
  C0282416|Overall [Publication Type]|0
heart rate
  1
  C0018810|Heart Rate|0
further therapy group
  5
  C0039798|therapeutic aspects|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
required evaluation
  2
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
better survival
  3
  C0038952|Continuance of life|0
  C0332272|Better (qualifier value)|0
  C0220921|survival aspects|0
­ years
  1
  C0439234|year (qualifier value)|0
concomitant malignancy
  2
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
pelvic recurrences
  2
  C0030797|Pelvis|0
  C0034897|Recurrence|0
metastatic tumor
  1
  C0027627|Neoplasm Metastasis|0
two-drug regimen
  4
  C0684270|Drugged|0
  C0205448|Two (qualifier value)|0
  C0677937|regimen|0
  C0013227|Pharmaceutical Preparations|0
drawbacks still
  4
  C0087031|Still's Disease, Juvenile-Onset|0
  C0229098|Hyaloid canal structure (body structure)|0
  C0180480|Distilling Units|0
  C0595939|Stillbirth|0
months thereafter
  1
  C0439231|month (qualifier value)|0
alive four months
  2
  C0205450|Four (qualifier value)|0
  C0439231|month (qualifier value)|0
‘‘toxicity’’ independence
  1
  C0085862|INDEPENDENCE|0
1.8 g
  1
  C0162832|APC Gene|0
other points to
  1
  C0205394|Other|0
vinblastine
  1
  C0042670|Vinblastine|0
5-year kaplan–meier disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
recent retrospective studies
  4
  C0557651|Room of building - Study|0
  C0332185|Recent episode (qualifier value)|0
  C0035363|Retrospective Studies|0
  C0947630|Scientific Study|0
adequate blood supply
  5
  C0038848|Manufactured Supplies|0
  C0699914|Economic supply|0
  C0243163|supply aspects|0
  C0205411|Adequate (qualifier value)|0
  C0005767|Blood|0
estimated duration
  2
  C0750572|ESTIMATED|0
  C0449238|Duration|0
doses less
  1
  C0719635|DOS|0
significant overall benefit
  3
  C0814225|benefits|0
  C0750502|Significant (qualifier value)|0
  C0282416|Overall [Publication Type]|0
pt
  5
  C0871051|Pay|0
  C0449719|Part (attribute)|0
  C0872386|portability|0
  C0680264|payment|0
  C0560012|pint|0
excluded patients
  2
  C0332196|Exclude (qualifier value)|0
  C0030705|Patients|0
obstruction requiring hospitalization
  2
  C0028778|Obstruction|0
  C0019993|Hospitalization|0
pelvic radiation concomitantly
  2
  C0030797|Pelvis|0
  C0851346|Radiation|0
two recent studies
  4
  C0557651|Room of building - Study|0
  C0205448|Two (qualifier value)|0
  C0332185|Recent episode (qualifier value)|0
  C0947630|Scientific Study|0
substantial protection
  5
  C0086099|Data Protection|0
  C0086461|Information Protection|0
  C0150064|Ineffective protection (finding)|0
  C0034533|Radiation Protection|0
  C0014649|Equal Protection|0
creatinine level 1.5 mg
  3
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
  C0010294|Creatinine|0
period
  2
  C0332182|Periodic (qualifier value)|0
  C0031084|Periodicity|0
possible risk
  2
  C0332149|Possible|0
  C0035647|Risk|0
category
  1
  C0683312|categories|0
approach
  1
  C0449445|Approach (attribute)|0
kaplan–meier method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
cm
  1
  C0475210|cm (qualifier value)|0
status
  1
  C0449438|Status (attribute)|0
grade 3.4 adverse events
  3
  C0441471|Events (event)|0
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
periaortic lymph node sampling
  4
  C0870078|Sampling|0
  C0746922|NODE|0
  C0441621|Sampling - Surgical action|0
  C0024202|Lymph|0
temporary interruption
  1
  C0205374|Transitory|0
different results
  1
  C1274040|Result (navigational concept)|0
first two cycles
  2
  C0205448|Two (qualifier value)|0
  C0205435|First (qualifier value)|0
numerous studies
  3
  C0557651|Room of building - Study|0
  C0439064|Numerous (qualifier value)|0
  C0947630|Scientific Study|0
chi-square test
  1
  C0008041|Chi-Square Test|0
perineal breakdown
  1
  C0031066|Anogenital region|0
similar patients
  1
  C0030705|Patients|0
overall survival rates
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
fourth cycle
  1
  C0205438|Fourth (qualifier value)|0
new prospective study
  3
  C0557651|Room of building - Study|0
  C0205314|New (qualifier value)|0
  C0947630|Scientific Study|0
postmenopausal patients
  2
  C0232970|Postmenopausal state (finding)|0
  C0030705|Patients|0
lost to follow-up
  4
  C0547043|Up (qualifier value)|0
  C0745777|LOST|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
dose adjustments
  4
  C0376209|Individual Adjustment|0
  C0001537|Clinical Adjustment|0
  C0683269|Psychological adjustment|0
  C0456081|Adjustment Action|0
drug dosages
  1
  C0870450|Drug Dosages|0
median gy
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0556636|Gy (qualifier value)|0
greater survival advantage
  4
  C0038952|Continuance of life|0
  C0308269|ADVANTAGE|0
  C0220921|survival aspects|0
  C0443228|Greater (qualifier value)|0
tumor dose
  1
  C0027651|Neoplasms|0
three underwent surgical reexploration
  3
  C0038895|Surgical aspects|0
  C1293095|Reexploration procedure (procedure)|0
  C0205449|Three (qualifier value)|0
skin hyperpigmentation
  1
  C0162834|Hyperpigmentation|0
survival months
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439231|month (qualifier value)|0
increased tumor cell kill results
  5
  C0007634|Cells|0
  C0205217|Increased (qualifier value)|0
  C0027651|Neoplasms|0
  C0162388|Killing|0
  C0442805|Increase (qualifier value)|0
post-operative radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0687676|After values (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
neoplastic recurrence
  1
  C0034897|Recurrence|0
multiple morbidity
  3
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
  C0439064|Numerous (qualifier value)|0
prior cancer
  4
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0750516|PRIOR|0
normal limits
  1
  C0442816|Normal limits (qualifier value)|0
worst morbidity
  2
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
high rate
  3
  C0205250|High|0
  C0871208|Rating|0
  C0235146|Euphoric mood|0
tumour size
  1
  C0475440|Tumor size (observable entity)|0
less significant umvariate analyses
  3
  C0002778|Analysis of substances|0
  C0750502|Significant (qualifier value)|0
  C0936012|Analysis|0
gastrointestinal function
  1
  C0516983|gastrointestinal function|0
relative risks
  1
  C0242492|Relative Risk|0
higher response rate
  2
  C0871208|Rating|0
  C0871261|Responses|0
theoretical disadvantages
  1
  C0012613|Disadvantaged|0
other serious adverse effects
  3
  C0205404|Serious (qualifier value)|0
  C1280500|Effect (qualifier value)|0
  C0205394|Other|0
several phase studies
  5
  C0557651|Room of building - Study|0
  C0585064|Numerical phases (qualifier value)|0
  C0205390|Phase (qualifier value)|0
  C0443302|Several (qualifier value)|0
  C0947630|Scientific Study|0
standard errors
  3
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
  C0743559|ERROR|0
more side-effects
  3
  C1280500|Effect (qualifier value)|0
  C0205172|More (qualifier value)|0
  C0441987|Side (qualifier value)|0
three drugs
  3
  C0684270|Drugged|0
  C0205449|Three (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
para-aortic lymph nodes
  1
  C0229789|Aortic lymph node (body structure)|0
loperamide
  1
  C0023992|Loperamide|0
response status
  2
  C0449438|Status (attribute)|0
  C0871261|Responses|0
monofilament plastic suture
  5
  C0038969|Surgical sutures|0
  C0032167|Plastics|0
  C0009068|Closure by suture|0
  C0502420|Suture Joint|0
  C0205368|Sutured (qualifier value)|0
complementary data
  5
  C0006556|DNA, Complementary|0
  C0056208|Complementary RNA|0
  C0557571|Complementary health worker (occupation)|0
  C0936077|Complementary therapies|0
  C1148474|Medicine, Complementary|0
new generation
  2
  C0079411|Generations|0
  C0205314|New (qualifier value)|0
first two infusions
  3
  C0574032|Infusion (procedure)|0
  C0205448|Two (qualifier value)|0
  C0205435|First (qualifier value)|0
survival duration
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0449238|Duration|0
theoretical explanations
  1
  C0681841|explanation|0
cohort
  1
  C0599755|cohort|0
several reports
  3
  C0443302|Several (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
moderately high dose
  2
  C0205250|High|0
  C0235146|Euphoric mood|0
effector mechanisms
  2
  C0457274|Mechanism (attribute)|0
  C0441712|Mechanisms (qualifier value)|0
phase iii multicentre randomised trial
  3
  C0585064|Numerical phases (qualifier value)|0
  C0439070|III (qualifier value)|0
  C0205390|Phase (qualifier value)|0
minimum follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
median time
  5
  C0876920|Median Statistical Measurement|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0549183|Median (qualifier value)|0
then mo
  1
  C0026402|Molybdenum|0
positive surgical margins
  4
  C0038895|Surgical aspects|0
  C1269830|Tumor margin status|0
  C0205159|Positive (qualifier value)|0
  C0205284|Marginal (qualifier value)|0
after treatment
  1
  C0001758|Aftercare|0
treatment arm
  4
  C0039798|therapeutic aspects|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0087111|Therapeutic procedure|0
common side-effects
  3
  C1280500|Effect (qualifier value)|0
  C0205214|Common (qualifier value)|0
  C0441987|Side (qualifier value)|0
non-opioids
  1
  C0242402|Opioids|0
fist successful anastomosis
  5
  C0677554|Anastomosis - action|0
  C0336667|Fist, device (physical object)|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
  C1272703|Successful (qualifier value)|0
positive nodes
  2
  C0746922|NODE|0
  C0205159|Positive (qualifier value)|0
survival curves
  3
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
prior radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0750516|PRIOR|0
  C0034618|Radiation therapy|0
potential mechanism
  3
  C0457274|Mechanism (attribute)|0
  C0237399|Potential|0
  C0441712|Mechanisms (qualifier value)|0
planned patients
  3
  C1301732|Planned (qualifier value)|0
  C0030705|Patients|0
  C0032074|Cognitive function: planning (observable entity)|0
other vesical complications
  4
  C0205058|Vesical|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0205394|Other|0
study population
  3
  C0557651|Room of building - Study|0
  C0032659|Population|0
  C0947630|Scientific Study|0
entry criteria
  1
  C0243161|criteria|0
bicycle exercise
  5
  C1306338|Physical exercise (qualifier value)|0
  C0015259|Exercise|0
  C0452240|Physical therapy exercises|0
  C0005377|Bicycling|0
  C0005375|Bicycle, device (physical object)|0
further progression
  1
  C0449258|Progression (attribute)|0
p
  5
  C0947648|Phosphorus preparation|0
  C0518611|Poise|0
  C0259980|Phosphors|0
  C0031705|Phosphorus|0
  C0031603|inorganic phosphate|0
menopausal status
  2
  C0449438|Status (attribute)|0
  C0232967|Menopausal|0
large scale clinical trials
  5
  C0349674|Intellectual scale|0
  C0175659|Weight measurement scales|0
  C0205210|Clinical (qualifier value)|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
received prior radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0750516|PRIOR|0
  C0034618|Radiation therapy|0
large tumors
  1
  C0475278|Large tumor (finding)|0
.90 probability
  1
  C0033204|Probability|0
office
  1
  C0442603|Office|0
ineligible patients
  1
  C0030705|Patients|0
results patient characteristics total
  3
  C0439810|Total (qualifier value)|0
  C1274040|Result (navigational concept)|0
  C0030705|Patients|0
considerable difference
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
life-threatening complications
  3
  C0376558|Life|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
fig b
  1
  C0349966|Figs - dietary|0
combined modality treatment arm
  5
  C0003792|Arm|0
  C0336789|Combine, device (physical object)|0
  C0087111|Therapeutic procedure|0
  C0205195|Combined (qualifier value)|0
  C0695347|MODALITY|0
compound
  1
  C0205198|Compound (qualifier value)|0
pre
  1
  C0740175|Before values (qualifier value)|0
multiagent chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
nodal involvement
  3
  C0443268|Nodal (qualifier value)|0
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
radiotherapy fractionation
  4
  C0034619|radiotherapeutic|0
  C0524811|Dose Fractionation|0
  C0016640|Fractionation|0
  C0034618|Radiation therapy|0
analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
relatively small sample size
  4
  C0870078|Sampling|0
  C0441621|Sampling - Surgical action|0
  C0700321|Small|0
  C0702146|Size (attribute)|0
minimum detectable difference
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
suspicious nodes
  2
  C0746922|NODE|0
  C0750493|SUSPICIOUS|0
protein
  2
  C0202202|Protein measurement|0
  C0033684|Proteins|0
distant metastases
  1
  C1269798|pM category (observable entity)|0
increased significance
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
poorer prognosis
  1
  C0033325|Forecast of outcome|0
follow-up program
  4
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
  C0376691|Programs [Publication Type]|0
visible disruption
  2
  C0332453|Disruption (morphologic abnormality)|0
  C0205379|Visible (qualifier value)|0
consequently adequacy
  5
  C0517937|Nutrition adequate|0
  C0518707|Hydration adequate|0
  C0517943|Supervision adequate|0
  C0205411|Adequate (qualifier value)|0
  C0747370|PELVIS ADEQUATE|0
first site
  2
  C0205145|Associated topography (attribute)|0
  C0205435|First (qualifier value)|0
untreated groups
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
o brien fleming group sequential boundary
  5
  C0262950|Skeletal bone|0
  C0331812|Fleming|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
overall reduction
  3
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0282416|Overall [Publication Type]|0
statistical analysis system
  4
  C0449913|System (attribute)|0
  C0220917|statistical|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
therapeutic effectiveness
  4
  C0039796|The science and art of healing|0
  C1280519|Effectiveness (qualifier value)|0
  C0205414|Effective (qualifier value)|0
  C0302350|Therapeutic|0
since only five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
diarrhoea score
  2
  C0449820|Scores (qualifier value)|0
  C0011991|Diarrhea|0
radical radiotherapy
  4
  C0034619|radiotherapeutic|0
  C0439807|Radical (qualifier value)|0
  C0302912|Radicals (chemistry)|0
  C0034618|Radiation therapy|0
second most frequent nonhaematological toxic effect
  5
  C0205436|Second (qualifier value)|0
  C0332183|Frequent (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0457385|seconds|0
  C0600688|Toxic effect|0
randomized controlled comparison
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
only small fraction
  2
  C0457426|Fractions of (qualifier value)|0
  C0700321|Small|0
lactation
  1
  C0022925|Lactation|0
adjuvant irradiation
  4
  C0001551|Adjuvants, Immunologic|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
increased pelvic control rates
  5
  C0702113|Controlled (qualifier value)|0
  C0030797|Pelvis|0
  C0871208|Rating|0
  C0243148|control|0
  C0442805|Increase (qualifier value)|0
assigned treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
severe symptoms
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0683368|symptoms|0
three arm
  3
  C0003792|Arm|0
  C0205449|Three (qualifier value)|0
  C0446516|Upper arm|0
abdomen
  2
  C0000726|Abdomen|0
  C1281594|Entire abdomen|0
life expectancy
  1
  C0023671|Life Expectancy|0
usually fluorouracil
  1
  C0016360|Fluorouracil|0
fifty two patients
  2
  C0205448|Two (qualifier value)|0
  C0030705|Patients|0
exploratory analyses
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
only first site
  2
  C0205145|Associated topography (attribute)|0
  C0205435|First (qualifier value)|0
two other studies
  4
  C0557651|Room of building - Study|0
  C0205448|Two (qualifier value)|0
  C0205394|Other|0
  C0947630|Scientific Study|0
rapid infusion
  2
  C0574032|Infusion (procedure)|0
  C0439831|Rapid (qualifier value)|0
abdominal ultrasound
  4
  C0456438|Abdominal (qualifier value)|0
  C0220934|Ultrasonic|0
  C0041618|Ultrasonography|0
  C0041621|Ultrasonic Shockwave|0
demographic characteristics
  1
  C0683970|demographic characteristics|0
everted anastomosis
  3
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
one ovary
  3
  C1278992|Entire ovary|0
  C0205447|One (qualifier value)|0
  C0029939|Ovary|0
combinations
  2
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
randomly allocated irinotecan
  1
  C0123931|irinotecan|0
discomforting complications
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
58.7 years
  1
  C0439234|year (qualifier value)|0
neurologic toxicity
  3
  C0040539|Toxicity aspects|0
  C0205494|Neurologic (qualifier value)|0
  C0600688|Toxic effect|0
29% response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
pain score
  1
  C0582148|Pain score (observable entity)|0
radiation therapy oncology group study
  5
  C0278627|oncology|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
  C0441833|Groups (qualifier value)|0
size recurrent tumor
  3
  C0205335|Recurrent (qualifier value)|0
  C0027651|Neoplasms|0
  C0702146|Size (attribute)|0
signs
  3
  C0220913|Manufactured sign|0
  C0311392|Physical findings|0
  C0220912|Aspects of signs|0
total dose
  1
  C0439810|Total (qualifier value)|0
more complete responses
  3
  C0871261|Responses|0
  C0205172|More (qualifier value)|0
  C0205197|Complete (qualifier value)|0
dose dependent effect
  2
  C1280500|Effect (qualifier value)|0
  C0851827|Dependent (qualifier value)|0
real difference
  1
  C0680368|real culture|0
balanced blocks
  5
  C0205415|Balanced - adjective|0
  C0028778|Obstruction|0
  C0014653|Equilibrium|0
  C0542274|Does balance|0
  C0179199|Balance, device|0
whitney cw
  1
  C0332290|Consistent with (qualifier value)|0
optimal regimen
  1
  C0677937|regimen|0
refused treatment
  3
  C0039798|therapeutic aspects|0
  C0017095|Garbage|0
  C0087111|Therapeutic procedure|0
negative v positive
  2
  C0205159|Positive (qualifier value)|0
  C0205160|Negative (qualifier value)|0
thirteen percent
  1
  C0439165|Percent (qualifier value)|0
6-cycle group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
induration
  1
  C0332534|Induration (morphologic abnormality)|0
multicentre trials
  1
  C0206012|Multicenter Trials|0
negative margins
  3
  C1269830|Tumor margin status|0
  C0205160|Negative (qualifier value)|0
  C0205284|Marginal (qualifier value)|0
m2 body surface area intravenously
  3
  C0205146|Area (qualifier value)|0
  C0242821|Human Body|0
  C0205148|Surface (qualifier value)|0
other clinical variables
  3
  C0205210|Clinical (qualifier value)|0
  C0439828|Variable (qualifier value)|0
  C0205394|Other|0
patient characteristics
  1
  C0815172|patient characteristics|0
disease-free survival
  1
  C0242793|Disease-Free Survival|0
randomisation
  1
  C0034656|Random Allocation|0
appropriate laboratory
  1
  C0022877|Laboratories|0
standard practice
  3
  C0237607|experience (practice)|0
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
recent data
  1
  C0332185|Recent episode (qualifier value)|0
antiarrhythmics
  1
  C0003195|Anti-Arrhythmia Agents|0
twice daily treatments
  3
  C0039798|therapeutic aspects|0
  C0332173|Daily (qualifier value)|0
  C0087111|Therapeutic procedure|0
other more favorable groups
  5
  C0205172|More (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0205394|Other|0
incomplete resection
  4
  C0728938|Partial (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0205257|Incomplete|0
  C0015252|Excision|0
pretreatment evaluation
  2
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
difference predominantly
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
draining
  1
  C0180499|Drain, device (physical object)|0
disposable staple gun
  5
  C1293124|Staple implantation procedure (procedure)|0
  C0018397|Guns|0
  C0725865|Disposable|0
  C0185012|Closure by staple (procedure)|0
  C0524724|Surgical Staples|0
ii breast cancer
  5
  C0998265|Cancer Genus|0
  C0006141|Breast|0
  C0006826|Malignant Neoplasms|0
  C1268990|Entire breast|0
  C0439069|Roman numeral II|0
cycle
  2
  C0439596|Cyclic (qualifier value)|0
  C0031084|Periodicity|0
anastomotic method
  3
  C0025664|Methodology|0
  C0025663|Methods|0
  C0332854|Anastomotic|0
woman
  2
  C0043210|Human adult females|0
  C0043209|Human Females|0
dukes stage
  1
  C1272820|Dukes stage (observable entity)|0
main findings
  2
  C0243095|findings|0
  C0205225|Primary|0
determining eligibility
  2
  C0013893|Eligibility Determination|0
  C0680253|inclusion, eligibility|0
grading
  2
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
radiotherapy committee
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
promising results
  1
  C1274040|Result (navigational concept)|0
normal dlco pulmonary function test
  5
  C0031843|physiological aspects|0
  C0039593|Testing|0
  C0700205|Function Axis|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
magnitude
  1
  C0439535|Magnitudes (qualifier value)|0
conversion to
  1
  C0439836|Conversions (qualifier value)|0
secondary dissemination
  4
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0036525|Metastatic to|0
  C0027627|Neoplasm Metastasis|0
m d
  1
  C0112081|D-D mixture|0
days week
  2
  C0439230|week (qualifier value)|0
  C0439228|day (qualifier value)|0
40.8 gy
  1
  C0556636|Gy (qualifier value)|0
9.9 13¡¤6 months
  1
  C0439231|month (qualifier value)|0
tumor related factors
  3
  C0163712|Relate|0
  C0027651|Neoplasms|0
  C0445223|Related (finding)|0
metastatic colorectal cancer
  1
  C0948380|Colorectal cancer metastatic|0
nodal status
  2
  C0449438|Status (attribute)|0
  C0443268|Nodal (qualifier value)|0
leucopenia
  1
  C0023530|Leukopenia|0
median months
  3
  C0876920|Median Statistical Measurement|0
  C0439231|month (qualifier value)|0
  C0549183|Median (qualifier value)|0
ps
  5
  C0947648|Phosphorus preparation|0
  C0518611|Poise|0
  C0259980|Phosphors|0
  C0031705|Phosphorus|0
  C0031603|inorganic phosphate|0
fu
  2
  C0016360|Fluorouracil|0
  C0268696|Feline urological syndrome (disorder)|0
peritonitis
  1
  C0031154|Peritonitis|0
presented 7-year follow-up data
  5
  C0547043|Up (qualifier value)|0
  C0150312|Present|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
  C0439234|year (qualifier value)|0
postcisplatin hydration
  1
  C0517526|hydration|0
measurable disease
  1
  C0677909|measurable disease|0
lower morbidity
  4
  C0026538|Morbidity - disease rate|0
  C0441994|Lower (qualifier value)|0
  C0220880|morbidity aspects|0
  C1272755|Lowered (qualifier value)|0
progression
  1
  C0449258|Progression (attribute)|0
parallel pair
  5
  C0517111|Parallel play|0
  C0445183|Paralleling technique (qualifier value)|0
  C0597171|parallel processing|0
  C0471184|Parallel Import|0
  C0599074|parallel computing|0
same two drugs
  4
  C0684270|Drugged|0
  C0205448|Two (qualifier value)|0
  C0445247|Same (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
interventions
  1
  C0886296|Interventions|0
significantly
  1
  C0750502|Significant (qualifier value)|0
excellent results
  1
  C1274040|Result (navigational concept)|0
pelvic lymphocyst
  2
  C0030797|Pelvis|0
  C0333147|Lymphocyst (morphologic abnormality)|0
most important practical aspect
  1
  C0205393|Most (qualifier value)|0
types
  4
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
sgot 2.5 x normal value
  3
  C0205307|Normal (qualifier value)|0
  C0201899|Aspartate aminotransferase assay|0
  C0042295|VALUING|0
total cumulative dose
  1
  C0439810|Total (qualifier value)|0
surgery also
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
complete history
  5
  C0019665|history|0
  C1321503|History of (contextual qualifier) (qualifier value)|0
  C0019664|Recording of previous events|0
  C0205197|Complete (qualifier value)|0
  C0262926|Medical History|0
tension
  1
  C0233494|Tension (finding)|0
leiomyosarcoma
  1
  C0023269|Leiomyosarcoma|0
competing neoplasm
  2
  C0027651|Neoplasms|0
  C0719453|Compete|0
histologic proof
  1
  C0205462|Histologic|0
tolerability
  4
  C0231197|Physiologic tolerance|0
  C0680282|implicit permission|0
  C0231198|Tolerant|0
  C0220929|Mental tolerance|0
philadelphia
  1
  C0031525|Philadelphia|0
concurrent radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0205420|Concurrent (qualifier value)|0
  C0034618|Radiation therapy|0
psychiatric illness
  1
  C0004936|Mental disorders|0
evaluations
  2
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
colon
  3
  C0009368|Colon|0
  C0684195|Cola|0
  C1281569|Entire colon|0
highly significant difference
  1
  C0750502|Significant (qualifier value)|0
specification
  2
  C1263442|SPECIFIC|0
  C0205369|Specific (qualifier value)|0
important one
  1
  C0205447|One (qualifier value)|0
normal liver function tests
  5
  C1278929|Entire liver|0
  C0700205|Function Axis|0
  C0023884|Liver|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
human
  2
  C0020114|Human|0
  C0086418|Homo sapiens|0
differences
  1
  C0443199|Differential (qualifier value)|0
estrogen receptor negative tumors
  4
  C0205160|Negative (qualifier value)|0
  C0597357|receptor|0
  C0027651|Neoplasms|0
  C0014939|Estrogens|0
cases
  1
  C0868928|Case (qualifier value)|0
laboratory cardiotoxicity data
  2
  C0876994|Cardiotoxicity|0
  C0022877|Laboratories|0
restricting therapy
  3
  C0443288|Restricted (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
grade leukopenia
  3
  C0023530|Leukopenia|0
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
life
  1
  C0376558|Life|0
fatal complications
  3
  C0009566|Complication|0
  C1302234|Fatal (qualifier value)|0
  C1171258|Complication Aspects|0
paracervical tissue involvement
  3
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
  C0040300|Tissues|0
acute treatment-related toxicity
  5
  C0163712|Relate|0
  C0205178|Acuteness (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0600688|Toxic effect|0
  C0445223|Related (finding)|0
endometrial carcinoma in situ
  3
  C0332285|Within|0
  C0007097|Carcinoma|0
  C0227843|Endometrio-|0
external beam irradiation
  4
  C0205101|External (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
two intracavitary applications
  3
  C0185125|Application (procedure)|0
  C0205448|Two (qualifier value)|0
  C1298613|Intracavitary (qualifier value)|0
screening chest x-ray
  1
  C0420046|Screening chest X-ray (procedure)|0
high dose intensities
  2
  C0205250|High|0
  C0235146|Euphoric mood|0
statistical considerations
  2
  C0220917|statistical|0
  C0518609|CONSIDERATION|0
indication
  1
  C0237000|Indications|0
bomp ct
  2
  C0040405|X-Ray Computed Tomography|0
  C0053926|BOMP protocol|0
control regimen
  3
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0677937|regimen|0
median age
  5
  C0876920|Median Statistical Measurement|0
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0549183|Median (qualifier value)|0
  C0001792|Elderly|0
higher doses
  1
  C0719635|DOS|0
polymorphous rhabdomyosarcoma
  1
  C0035412|Rhabdomyosarcoma|0
karnofsky performance status index
  4
  C0449438|Status (attribute)|0
  C0021200|Indexing|0
  C0597198|Performance|0
  C0918012|Indexes|0
behaviour
  2
  C0004927|Behavior|0
  C0677505|Behaviors and observations relating to behavior|0
cr rate
  2
  C0871208|Rating|0
  C0008574|Chromium|0
radiographs
  1
  C1306645|Plain film (procedure)|0
clinical heart failure
  5
  C0205210|Clinical (qualifier value)|0
  C0680095|Personal failure|0
  C1281570|Entire heart|0
  C0231174|Failure (biologic function)|0
  C0018787|Heart|0
intravenously days
  1
  C0439228|day (qualifier value)|0
fifty five percent
  2
  C0205451|Five (qualifier value)|0
  C0439165|Percent (qualifier value)|0
nonsquamous histology
  3
  C0205462|Histologic|0
  C0344441|Histology Procedure|0
  C0019638|Histology|0
risk factors
  1
  C0035648|Risk Factors|0
rare mortality
  3
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
  C0332184|Rare (qualifier value)|0
informed consent
  1
  C0021430|Informed Consent|0
mucocutaneous effects
  1
  C1280500|Effect (qualifier value)|0
belgium
  1
  C0004950|Belgium|0
theoretical maximum tolerated dose
  1
  C0806909|Maximum|0
dose limiting factor
  1
  C0439801|Limited (qualifier value)|0
here final status
  2
  C0449438|Status (attribute)|0
  C0205088|End-stage (qualifier value)|0
meccnu regimen
  2
  C0036637|Semustine|0
  C0677937|regimen|0
future studies
  3
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
  C0016884|Future|0
44.8 gy
  1
  C0556636|Gy (qualifier value)|0
to enroll women
  2
  C0043210|Human adult females|0
  C0043209|Human Females|0
purpose
  1
  C0449256|Purpose (attribute)|0
treatment arms
  4
  C0039798|therapeutic aspects|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0087111|Therapeutic procedure|0
continuous anastomoses
  4
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0549178|Continuous (qualifier value)|0
  C0500470|Anatomical anastomosis|0
sternum
  3
  C1085140|Sterna|0
  C1279580|Entire sternum|0
  C0038293|Sternum|0
postmastectomy chest wall
  3
  C0817096|Chest|0
  C0205380|Walled (qualifier value)|0
  C0677535|Walls of a building|0
drugs to
  2
  C0684270|Drugged|0
  C0013227|Pharmaceutical Preparations|0
ureter
  2
  C0041951|Ureter|0
  C1281572|Entire ureter|0
multiple studies
  3
  C0557651|Room of building - Study|0
  C0439064|Numerous (qualifier value)|0
  C0947630|Scientific Study|0
isodose curves
  1
  C0205134|Curved (qualifier value)|0
episodes
  2
  C0332189|Episode of|0
  C0678231|Episodes (qualifier value)|0
antitumor activity
  3
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
gynecologic oncology group
  5
  C0278627|oncology|0
  C0205480|Gynecologic (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
refused dialysis
  4
  C0011945|Physical Dialysis|0
  C1059964|Genus Dialysis|0
  C0017095|Garbage|0
  C0011946|Dialysis procedure|0
radiation enhancing potential
  2
  C0237399|Potential|0
  C0851346|Radiation|0
not essential component
  2
  C0205224|Essential (qualifier value)|0
  C0449432|Component (attribute)|0
last cycle
  2
  C0743015|DELIVERY LAST|0
  C0421234|Last fit (finding)|0
pl
  2
  C0242808|Pliability|0
  C0031676|Phospholipids|0
comparable degree
  2
  C0449286|Degree or extent|0
  C0542560|Academic degree|0
adding radiation
  1
  C0851346|Radiation|0
radical tumor resection
  5
  C0439807|Radical (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
  C0027651|Neoplasms|0
  C0302912|Radicals (chemistry)|0
aortic lymph node sampling
  5
  C0870078|Sampling|0
  C0746922|NODE|0
  C0003483|Aorta|0
  C0441621|Sampling - Surgical action|0
  C0024202|Lymph|0
severe dyspnea
  2
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0013404|Dyspnea|0
eligibility criteria
  1
  C0243161|criteria|0
significant frequency
  3
  C0376249|With frequency|0
  C0750502|Significant (qualifier value)|0
  C0439603|Frequencies (time pattern)|0
prognostic features
  1
  C0220901|prognostic|0
oxford colorectal cancer cooperative group
  5
  C0555952|Colorectal (qualifier value)|0
  C0679729|cooperative|0
  C0006826|Malignant Neoplasms|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
extent
  1
  C0439792|Extents (qualifier value)|0
prs
  1
  C0279766|progesterone receptor negative|0
techniques
  2
  C0025664|Methodology|0
  C0449851|Techniques|0
technique
  2
  C0025664|Methodology|0
  C0449851|Techniques|0
less mortality
  2
  C0026565|Mortality Vital Statistics|0
  C0026566|Aspects of mortality statistics|0
investigator
  1
  C0035173|Research Personnel|0
poor technique
  4
  C0025664|Methodology|0
  C0542537|Poor - grade value|0
  C0699761|Financially poor|0
  C0449851|Techniques|0
important method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
dox arms
  2
  C0003792|Arm|0
  C0446516|Upper arm|0
second primary tumor
  5
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
  C0027651|Neoplasms|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
relapse
  3
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
23% planned level
  1
  C0441890|Planned level (qualifier value)|0
disease-free survival probabilities
  4
  C0038952|Continuance of life|0
  C0033204|Probability|0
  C0012634|Disease|0
  C0220921|survival aspects|0
standard error
  3
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
  C0743559|ERROR|0
significantly more patients
  2
  C0030705|Patients|0
  C0205172|More (qualifier value)|0
compromising
  1
  C0518613|Compromise|0
cytotoxic agents
  1
  C0304497|Cytotoxic agent (substance)|0
antildiotype antibodies
  2
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
mg postoperatively
  5
  C0024467|Magnesium|0
  C0617935|magnesium GTPase|0
  C0619894|magnesium mesoporphyrin|0
  C0240291|Mg reduced|0
  C0065530|magnesium pyrophosphate|0
antibody treatment
  4
  C0039798|therapeutic aspects|0
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
  C0087111|Therapeutic procedure|0
lowest proportion
  3
  C0429144|Facial proportion (observable entity)|0
  C0007725|Cephalopelvic Proportion|0
  C0491073|SUBSYSTEM, PROPORTIONING|0
complete recovery
  2
  C0205197|Complete (qualifier value)|0
  C0237820|recovery from disease|0
n acetylcysteine
  1
  C0001047|Acetylcysteine|0
stage ib cervical cancers
  1
  C0278582|Cervical carcinoma stage IB|0
tumor size
  1
  C0475440|Tumor size (observable entity)|0
values
  1
  C0042295|VALUING|0
rarity
  5
  C0334679|Refractory anemia with sideroblasts (morphologic abnormality)|0
  C0871208|Rating|0
  C0034693|Rattus norvegicus|0
  C0034721|Rattus|0
  C0332184|Rare (qualifier value)|0
treatment regimens
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0677937|regimen|0
tumour related symptoms
  4
  C0683368|symptoms|0
  C0163712|Relate|0
  C0027651|Neoplasms|0
  C0445223|Related (finding)|0
withers
  1
  C0230107|Withers (body structure)|0
rectal mucosa
  1
  C0227395|Rectal mucous membrane structure (body structure)|0
sex
  2
  C0079399|Gender|0
  C0009253|Coitus|0
indicated mitolactol therapy
  3
  C0039798|therapeutic aspects|0
  C0026252|Mitolactol|0
  C0087111|Therapeutic procedure|0
chemistry panel
  1
  C1254572|Chemistry Panels|0
oral mucositis
  2
  C0236177|Inflammatory disease of mucous membrane (disorder)|0
  C0442027|Oral (qualifier value)|0
postmenopausal women
  3
  C0043210|Human adult females|0
  C0232970|Postmenopausal state (finding)|0
  C0043209|Human Females|0
superficial squamous cell carcinomas
  5
  C1182670|Squamous|0
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0205124|Superficial (qualifier value)|0
  C0007097|Carcinoma|0
ongoing randomized studies
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
progression free interval
  2
  C1272706|Interval (qualifier value)|0
  C0449258|Progression (attribute)|0
days thereafter
  1
  C0439228|day (qualifier value)|0
human 17-1a autoantibody
  5
  C0919704|Autoantibody NOS|0
  C0020114|Human|0
  C0086418|Homo sapiens|0
  C0450344|1A (qualifier value)|0
  C0004358|Autoantibodies|0
balanced distribution
  5
  C0205415|Balanced - adjective|0
  C0520511|Distributing|0
  C0014653|Equilibrium|0
  C0542274|Does balance|0
  C0037775|Spatial Distribution|0
biopsy
  2
  C0220797|biopsy characteristics|0
  C0005558|Biopsy|0
haemato biochemical parameters
  3
  C0205474|Biochemical (qualifier value)|0
  C0549193|Parameter (attribute)|0
  C0449381|Observation parameter (observable entity)|0
appreciable difference
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
hospital
  1
  C0019994|Hospitals|0
nodal radiation
  2
  C0443268|Nodal (qualifier value)|0
  C0851346|Radiation|0
anastomotic leaks
  1
  C0919691|Anastomotic leak|0
mv x-rays
  2
  C0086894|Rajiformes|0
  C0851346|Radiation|0
acute toxic reactions
  3
  C0443286|Reaction (qualifier value)|0
  C0205178|Acuteness (qualifier value)|0
  C0600688|Toxic effect|0
more well established performance status
  5
  C0449438|Status (attribute)|0
  C0597198|Performance|0
  C0205172|More (qualifier value)|0
  C0443211|Established (qualifier value)|0
  C0205170|Good (qualifier value)|0
streptozotocin
  1
  C0038432|Streptozocin|0
protocol
  1
  C0442711|Protocols documentation|0
2-weekly regimens
  2
  C0332174|Weekly (qualifier value)|0
  C0677937|regimen|0
lower risk
  3
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
  C0035647|Risk|0
not purpose
  1
  C0449256|Purpose (attribute)|0
computerized tomography
  1
  C0040405|X-Ray Computed Tomography|0
testifies
  1
  C0680706|testimony|0
metastases
  2
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0027627|Neoplasm Metastasis|0
statistical power
  1
  C0814897|statistical power|0
not realistic end point
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
staging evaluation
  5
  C0220825|Evaluation|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C1261322|Assessment procedure (procedure)|0
  C1306673|Stages (qualifier value)|0
clinical impact
  3
  C0726639|Impact|0
  C0205210|Clinical (qualifier value)|0
  C0333125|Impacted (qualifier value)|0
prior cardiac irradiation
  5
  C0205041|Cardio-|0
  C0750516|PRIOR|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
distal presentation
  2
  C0449450|Presentation (attribute)|0
  C0205108|Distal (qualifier value)|0
node status
  2
  C0449438|Status (attribute)|0
  C0746922|NODE|0
pretreatment serum albumin level 3.0 g
  5
  C0441889|Levels (qualifier value)|0
  C0229671|Serum|0
  C0162832|APC Gene|0
  C0456079|Disease classification level|0
  C0001924|Albumins|0
posteroanterior parallel ports
  3
  C0935727|port-a-cath|0
  C0475311|Harbor|0
  C0452253|Port - alcoholic beverage|0
different proportionate representation
  1
  C0205351|Proportional (qualifier value)|0
systemic activity
  4
  C0205373|Systemic (qualifier value)|0
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
atropine
  2
  C0004259|Atropine|0
  C1161352|Atropinum, atropine|0
antagonism
  1
  C0680242|antagonism|0
ecg
  2
  C0013798|Electrocardiogram|0
  C0180580|Electrocardiographic monitoring (regime/therapy)|0
cancer recurrence
  1
  C0920420|cancer recurrence|0
because radiotherapy techniques
  4
  C0025664|Methodology|0
  C0034619|radiotherapeutic|0
  C0449851|Techniques|0
  C0034618|Radiation therapy|0
antibody titers
  2
  C1287242|Finding of antibody titer (finding)|0
  C0474643|Antibody titer measurement (procedure)|0
follow-up data
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
pain-free survival
  3
  C0030193|Pain|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
extremely important clinical observation
  3
  C0205210|Clinical (qualifier value)|0
  C0302523|Observation in research|0
  C0700325|Patient observation|0
external beam x-ray treatment
  5
  C0039798|therapeutic aspects|0
  C0205101|External (qualifier value)|0
  C0086894|Rajiformes|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
patients data
  1
  C0030705|Patients|0
objectively verifiable dates
  2
  C0011008|Dates|0
  C0237553|dating|0
efficacy risk
  1
  C0035647|Risk|0
51.0 gy
  1
  C0556636|Gy (qualifier value)|0
25% reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
fewer local recurrences
  2
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
procedures
  2
  C0025664|Methodology|0
  C0184661|Procedures|0
rio de janeiro
  2
  C0445581|Rio (qualifier value)|0
  C0012203|Diethylstilbestrol|0
overall dfs
  1
  C0282416|Overall [Publication Type]|0
pleura
  2
  C0032225|Pleura|0
  C1279036|Entire pleura|0
recurrent cancer
  1
  C0549379|Recurrent cancer|0
problem
  1
  C0033213|Problem (finding)|0
improved disease-free survival
  5
  C1272745|Improving (qualifier value)|0
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0184511|Improved (qualifier value)|0
tumor diameter
  2
  C0027651|Neoplasms|0
  C0332517|Diameter (qualifier value)|0
carboplatin
  1
  C0079083|Carboplatin|0
wbc count
  1
  C0023508|White Blood Cell Count procedure|0
limited overall treatment times
  5
  C0039798|therapeutic aspects|0
  C0439801|Limited (qualifier value)|0
  C0040223|Time|0
  C0282416|Overall [Publication Type]|0
  C0087111|Therapeutic procedure|0
less circumferential clearing
  2
  C0205305|Clear (qualifier value)|0
  C0205113|Circumferential (qualifier value)|0
various combinations
  3
  C0453882|Combinations (physical object)|0
  C0440102|Various (substance)|0
  C0205195|Combined (qualifier value)|0
further chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
running 3.0 polyglycolic acid suture
  5
  C0600140|Does run (finding)|0
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0035953|Running|0
  C0001128|Acids|0
sq m
  5
  C0075046|SQ 10591|0
  C0075048|SQ 10996|0
  C0075051|SQ 15361|0
  C0075047|SQ 10631|0
  C0075049|SQ 11290|0
mild stomatitis
  2
  C0205080|Mild (qualifier value)|0
  C0038362|Stomatitis|0
limb sparing procedures
  4
  C0025664|Methodology|0
  C1280090|Entire limb|0
  C0184661|Procedures|0
  C0015385|Limb structure|0
four courses
  3
  C0205450|Four (qualifier value)|0
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
interrupted anastomoses
  4
  C0677554|Anastomosis - action|0
  C0332853|Anastomosis|0
  C0500470|Anatomical anastomosis|0
  C0443239|Interrupted (qualifier value)|0
rectal cancer
  1
  C0007113|Cancer of Rectum|0
intracellular concentration
  3
  C0086045|Concentration|0
  C0175996|Protoplasm|0
  C0178719|Intracellular|0
five needled sutures
  5
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0205451|Five (qualifier value)|0
  C0027551|Needles|0
  C0502420|Suture Joint|0
preoperative radiotherapy
  3
  C0034619|radiotherapeutic|0
  C0445204|Preoperative (qualifier value)|0
  C0034618|Radiation therapy|0
other technical problems
  2
  C0033213|Problem (finding)|0
  C0205394|Other|0
altered fractionation schedules
  5
  C0086960|Schedules|0
  C0524811|Dose Fractionation|0
  C0205349|Altered (qualifier value)|0
  C0205539|Scheduled (qualifier value)|0
  C0016640|Fractionation|0
homogeneous group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
relative risk
  1
  C0242492|Relative Risk|0
platelets less
  1
  C0005821|Blood Platelets|0
distant micrometastases
  1
  C0443203|Distant (qualifier value)|0
end to end
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
modified radical mastectomy
  2
  C0024883|Mastectomy, Modified Radical|0
  C1320277|Modified radical mastectomy (procedure)|0
27% recurrence rate
  2
  C0871208|Rating|0
  C0034897|Recurrence|0
leakage rates
  2
  C0871208|Rating|0
  C0015376|Extravasation (morphologic abnormality)|0
proctoscopy
  1
  C0033251|Proctoscopy|0
cisplatin mg
  1
  C0008838|Cisplatin|0
hlstopathologic confirmation
  2
  C0750484|CONFIRMED|0
  C0750568|CONFIRMATORY|0
chance
  1
  C0237506|Chance|0
objectives
  1
  C0018017|Goals|0
regarding patients
  1
  C0030705|Patients|0
phase i dose escalation studies
  4
  C0557651|Room of building - Study|0
  C0585064|Numerical phases (qualifier value)|0
  C0205390|Phase (qualifier value)|0
  C0947630|Scientific Study|0
full biochemical modulating effect
  4
  C0205474|Biochemical (qualifier value)|0
  C1280500|Effect (qualifier value)|0
  C0443264|Modulated (qualifier value)|0
  C0443225|Full (qualifier value)|0
comparable results
  1
  C1274040|Result (navigational concept)|0
severe proctites severe oedema
  1
  C0032954|Severe pre-eclampsia NOS (disorder)|0
ap pa
  1
  C0030125|p-Aminosalicylic Acid|0
prospective randomized trial
  2
  C0282440|Randomized Controlled Trials|0
  C0206034|Clinical Trials, Randomized|0
ileal obstruction
  2
  C0020885|ileum|0
  C0028778|Obstruction|0
laboratory investigations
  2
  C0430007|Clinical investigation|0
  C0022877|Laboratories|0
chemotherapy schedules
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
  C0013216|Pharmacotherapy|0
treatment groups
  5
  C0039798|therapeutic aspects|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
review
  1
  C0282443|Review [Publication Type]|0
additional patients
  1
  C0030705|Patients|0
packed red cell transfusions
  5
  C0007634|Cells|0
  C0441122|Pack (physical object)|0
  C0199960|Transfusion - action (qualifier value)|0
  C0184967|Insertion of pack (procedure)|0
  C1260956|Red color (qualifier value)|0
treatment outcome
  2
  C0085415|Treatment outcome|0
  C0599860|Non-human treatment outcome|0
complete physical examination
  1
  C0436120|Physical examination, complete (procedure)|0
analysis also invalidated objections
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
insufficient compensatory increase
  5
  C0231186|Compensatory|0
  C0231180|Insufficient|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
gross changes
  3
  C0392747|Changing|0
  C0443172|Changed status|0
  C0439806|Gross (qualifier value)|0
local recurrence
  2
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
bowel morbidity
  3
  C0021853|Intestines|0
  C0026538|Morbidity - disease rate|0
  C0220880|morbidity aspects|0
exact tests
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0059927|Exact|0
uneven distribution
  2
  C0520511|Distributing|0
  C0037775|Spatial Distribution|0
radiation fraction size
  3
  C0457426|Fractions of (qualifier value)|0
  C0851346|Radiation|0
  C0702146|Size (attribute)|0
pathologist
  1
  C0334866|Medical pathologist (occupation)|0
treatment related factors
  4
  C0039798|therapeutic aspects|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
diseases
  1
  C0012634|Disease|0
distant recurrences
  2
  C0443203|Distant (qualifier value)|0
  C0034897|Recurrence|0
tumour invaded bladder
  3
  C1281573|Entire bladder|0
  C0005682|Bladder|0
  C0027651|Neoplasms|0
extended field radiotherapy
  5
  C0034619|radiotherapeutic|0
  C0231449|Extended (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0034618|Radiation therapy|0
durations twenty four patients
  3
  C0205450|Four (qualifier value)|0
  C0030705|Patients|0
  C0449238|Duration|0
distant recurrence
  2
  C0443203|Distant (qualifier value)|0
  C0034897|Recurrence|0
left ventricular ejection fraction
  1
  C0428772|Left ventricular ejection fraction (observable entity)|0
grade predominantly granulocytopenia
  3
  C0441800|Grade|0
  C1261272|Granulocytopenia|0
  C0796573|Cancer cells grading system|0
two additional cycles
  1
  C0205448|Two (qualifier value)|0
severe bladder symptoms
  4
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0683368|symptoms|0
  C1281573|Entire bladder|0
  C0005682|Bladder|0
suspicious appearing lymph nodes
  3
  C0746922|NODE|0
  C0750493|SUSPICIOUS|0
  C0024202|Lymph|0
conservative radical surgery
  5
  C0038895|Surgical aspects|0
  C0439807|Radical (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
  C0302912|Radicals (chemistry)|0
sequential exposure
  3
  C0391838|Exposure condition|0
  C0728853|Accident due to exposure to weather conditions|0
  C0274281|EFFECTS OF EXPOSURE TO EXTERNAL CAUSES|0
two lateral fields
  4
  C0205093|Lateral (qualifier value)|0
  C0205448|Two (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
three different dose levels
  3
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
  C0205449|Three (qualifier value)|0
additional histopathologic features
  1
  C0919553|Histopathologic Grade|0
increased acute toxicity
  5
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0205178|Acuteness (qualifier value)|0
  C0600688|Toxic effect|0
  C0442805|Increase (qualifier value)|0
pharmacokinetic studies
  1
  C0201734|Pharmacokinetic study (procedure)|0
other ancillary treatment
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205394|Other|0
median survival times
  5
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0040223|Time|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
lateral margins
  3
  C0205093|Lateral (qualifier value)|0
  C1269830|Tumor margin status|0
  C0205284|Marginal (qualifier value)|0
non cross-resistant drugs often
  5
  C0684270|Drugged|0
  C0205203|Crossed (qualifier value)|0
  C0332183|Frequent (qualifier value)|0
  C0332325|Resistant (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
lymph nodes
  2
  C0024204|lymph nodes|0
  C1269047|Entire lymph node|0
statement
  5
  C1301808|State (environment)|0
  C0019919|Hordeolum externum|0
  C1063749|Stator|0
  C0019917|Hordeolum|0
  C0205548|Stat (qualifier value)|0
assuming first five patients
  3
  C0205451|Five (qualifier value)|0
  C0205435|First (qualifier value)|0
  C0030705|Patients|0
investigator chose one
  3
  C0812351|CHOOSING|0
  C0205447|One (qualifier value)|0
  C0035173|Research Personnel|0
schedules
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
cell type
  1
  C0449475|Type of cell (qualifier value)|0
great majority
  2
  C0680220|majority|0
  C0549177|Large|0
worse survival
  4
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C1279889|Deterioration of status|0
  C0332271|Worsening (qualifier value)|0
pelvic rt
  1
  C0030797|Pelvis|0
percent reduction
  3
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
  C0439165|Percent (qualifier value)|0
standard treatment
  4
  C0039798|therapeutic aspects|0
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
  C0087111|Therapeutic procedure|0
henschke applicators
  1
  C0179108|Applicator (physical object)|0
nonmeasurable disease
  1
  C0012634|Disease|0
noncardiac toxicity hematologic toxicity
  3
  C0040539|Toxicity aspects|0
  C0205488|Hematologic (qualifier value)|0
  C0600688|Toxic effect|0
initial accrual goal
  2
  C0205265|Initial (qualifier value)|0
  C0018017|Goals|0
adjuvant treatment
  3
  C0039798|therapeutic aspects|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
bowel perforation
  1
  C0021845|Intestinal Perforation|0
informed consent to
  1
  C0700287|Reporting|0
mucocutaneous toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
manifestation
  1
  C0205319|Manifest (qualifier value)|0
toxic reactions
  1
  C0542243|Toxic reaction (NOS)|0
breast
  2
  C0006141|Breast|0
  C1268990|Entire breast|0
crude 5-year survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
total cumulative doses
  2
  C0439810|Total (qualifier value)|0
  C0719635|DOS|0
forty seven deaths
  2
  C0011065|Cessation of life|0
  C0205453|Seven (qualifier value)|0
materials
  1
  C0520510|Materials|0
antimetabolites methotrexate
  2
  C0025677|Methotrexate|0
  C0003376|Antimetabolites|0
incomplete pretreatment testing
  4
  C0039593|Testing|0
  C0728938|Partial (qualifier value)|0
  C0205257|Incomplete|0
  C0392366|Tests (qualifier value)|0
excluding patients
  2
  C0332196|Exclude (qualifier value)|0
  C0030705|Patients|0
metastatic cancer
  2
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0346957|Widespread metastatic malignant neoplastic disease (disorder)|0
physiotherapy
  1
  C0949766|Physical Therapy Techniques|0
­ months
  1
  C0439231|month (qualifier value)|0
various doses
  2
  C0719635|DOS|0
  C0440102|Various (substance)|0
five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
diagrams
  1
  C0681494|diagram|0
late radiation morbidity scoring scheme
  5
  C0205087|Late (qualifier value)|0
  C0026538|Morbidity - disease rate|0
  C0449820|Scores (qualifier value)|0
  C0220880|morbidity aspects|0
  C0851346|Radiation|0
other imbalances
  1
  C0205394|Other|0
baseline rnca scan
  2
  C0441633|Scanning|0
  C0168634|BaseLine|0
total treatment
  3
  C0439810|Total (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
cytotoxic infusion
  1
  C0574032|Infusion (procedure)|0
probably definitive measure
  5
  C0444706|Measured (qualifier value)|0
  C0750492|Probably|0
  C0079809|Measures|0
  C0443196|Definitive (qualifier value)|0
  C0332148|Probable diagnosis|0
four months
  2
  C0205450|Four (qualifier value)|0
  C0439231|month (qualifier value)|0
therapeutic advantage
  3
  C0039796|The science and art of healing|0
  C0308269|ADVANTAGE|0
  C0302350|Therapeutic|0
locoregional disease remaining
  1
  C0012634|Disease|0
tumours
  1
  C0027651|Neoplasms|0
large proportion
  1
  C0549177|Large|0
essentially adjustment
  4
  C0376209|Individual Adjustment|0
  C0001537|Clinical Adjustment|0
  C0683269|Psychological adjustment|0
  C0456081|Adjustment Action|0
two regimens
  2
  C0205448|Two (qualifier value)|0
  C0677937|regimen|0
sample size
  1
  C0242618|Sample Size|0
aspiration pneumonia
  1
  C0032290|Pneumonia, Aspiration|0
alanine aminotransferases
  1
  C0001899|Alanine Transaminase|0
grade hematologic toxicity
  5
  C0441800|Grade|0
  C0040539|Toxicity aspects|0
  C0205488|Hematologic (qualifier value)|0
  C0796573|Cancer cells grading system|0
  C0600688|Toxic effect|0
liposomal encapsulation
  1
  C0677902|liposomal|0
long-term survival
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
95% ci
  1
  C0162854|Commonwealth of Independent States|0
other treatment variables
  4
  C0039798|therapeutic aspects|0
  C0439828|Variable (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0205394|Other|0
normally cm
  1
  C0475210|cm (qualifier value)|0
computer based procedure
  4
  C0025664|Methodology|0
  C0184661|Procedures|0
  C0178499|Base|0
  C0009622|Computers|0
previous gog study
  3
  C0557651|Room of building - Study|0
  C0205156|Previous (qualifier value)|0
  C0947630|Scientific Study|0
metastasis
  2
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0027627|Neoplasm Metastasis|0
primary radical surgery
  5
  C0439807|Radical (qualifier value)|0
  C0038894|Surgery specialty|0
  C0439631|Primary operation (qualifier value)|0
  C0302912|Radicals (chemistry)|0
  C0205225|Primary|0
final dose
  1
  C0205088|End-stage (qualifier value)|0
compared irinotecan
  1
  C0123931|irinotecan|0
not problem
  1
  C0033213|Problem (finding)|0
unfavorable local behaviour
  3
  C0004927|Behavior|0
  C0677505|Behaviors and observations relating to behavior|0
  C0205276|Local (qualifier value)|0
most frequently diagnosed malignancy
  5
  C0332183|Frequent (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0011900|Diagnosis|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
fifth year
  2
  C0205439|Fifth (qualifier value)|0
  C0439234|year (qualifier value)|0
dfs
  1
  C0011145|Deferoxamine|0
nutritional factors
  1
  C0331877|Nutritionals|0
cure rates
  1
  C0871208|Rating|0
southwest oncology group study
  5
  C0557651|Room of building - Study|0
  C0278627|oncology|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0947630|Scientific Study|0
15% increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
17-1a antibody
  3
  C0813154|Antibodies, in vitro diagnostic|0
  C0003241|Antibodies|0
  C0450344|1A (qualifier value)|0
14.1 5 months
  1
  C0439231|month (qualifier value)|0
hazards ratios
  2
  C0456603|Ratio (property) (qualifier value)|0
  C0598697|hazard|0
radical external beam
  3
  C0205101|External (qualifier value)|0
  C0439807|Radical (qualifier value)|0
  C0302912|Radicals (chemistry)|0
secondary objectives
  5
  C0175668|Secondary to|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0036525|Metastatic to|0
  C0027627|Neoplasm Metastasis|0
  C0018017|Goals|0
two treatment groups
  5
  C0205448|Two (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
randomly assigned patients irinotecan
  2
  C0123931|irinotecan|0
  C0030705|Patients|0
pelvis
  2
  C0030797|Pelvis|0
  C1279864|Entire pelvis|0
written consensus
  1
  C0376298|Consensus|0
manuscript
  1
  C0600659|Manuscripts|0
co workers
  3
  C1306056|Worker (occupation)|0
  C0454802|Cos (geographic location)|0
  C0024752|workforce|0
reduced fraction size
  3
  C0392756|Reduced (qualifier value)|0
  C0457426|Fractions of (qualifier value)|0
  C0702146|Size (attribute)|0
pelvic local failure rate
  5
  C0030797|Pelvis|0
  C0680095|Personal failure|0
  C0871208|Rating|0
  C0231174|Failure (biologic function)|0
  C0205276|Local (qualifier value)|0
pelvic sidewall lymph nodes
  3
  C0030797|Pelvis|0
  C0746922|NODE|0
  C0024202|Lymph|0
d iv bolus
  1
  C0677863|bolus|0
fractionation
  2
  C0524811|Dose Fractionation|0
  C0016640|Fractionation|0
validated qlqc30 questionnaire
  1
  C0034394|Questionnaires|0
poor survival rates
  5
  C0038952|Continuance of life|0
  C0542537|Poor - grade value|0
  C0871208|Rating|0
  C0699761|Financially poor|0
  C0220921|survival aspects|0
disease free 5-year survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
portal phlebography
  2
  C0205054|Hepatic|0
  C0031545|Phlebography|0
global quality
  2
  C0205246|Generalized (qualifier value)|0
  C0332306|With quality (attribute)|0
local relapse
  4
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
dag
  1
  C0043791|1,2-diacylglycerol|0
superficial stromal invasion
  1
  C0205124|Superficial (qualifier value)|0
x10 white blood cells
  5
  C0007634|Cells|0
  C0043157|Caucasians|0
  C1306888|White color (finding)|0
  C0220938|White color|0
  C0005767|Blood|0
diminished performance status
  3
  C0449438|Status (attribute)|0
  C0205216|Decreased (qualifier value)|0
  C0597198|Performance|0
5-year overall survival
  4
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
  C0439234|year (qualifier value)|0
primary endpoint
  3
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0150100|ENDPOINT|0
added chemotherapy
  3
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0013216|Pharmacotherapy|0
thyroid cancer
  2
  C1318516|Malignant tumor of thyroid gland (disorder)|0
  C0007115|Thyroid Cancer|0
higher percentage
  5
  C1167774|Myelocyte percentage|0
  C0587345|Percentage monocyte level|0
  C1167775|Myeloblast percentage|0
  C0587343|Percentage neutrophil level|0
  C1167975|Reticulocyte percentage|0
intraperitoneal disease
  2
  C0442120|Intraperitoneal (qualifier value)|0
  C0012634|Disease|0
fewer local relapses
  4
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
hypogastric artery
  1
  C0226364|Structure of internal iliac artery|0
ohio
  1
  C0028905|Ohio|0
beta
  2
  C0439096|Beta greek letter|0
  C0330390|Beta plant|0
used doxorubicin
  2
  C0013089|Doxorubicin|0
  C0042153|utilization|0
short duration
  1
  C0439593|Short duration (qualifier value)|0
combined irinotecan
  3
  C0123931|irinotecan|0
  C0336789|Combine, device (physical object)|0
  C0205195|Combined (qualifier value)|0
domestic animals
  1
  C0003063|Animals, Domestic|0
breast cancer
  1
  C0006142|Malignant neoplasm of breast|0
meccnu arm
  3
  C0003792|Arm|0
  C0036637|Semustine|0
  C0446516|Upper arm|0
esophagus
  2
  C0014876|Esophagus|0
  C1278919|Entire esophagus|0
23% overall local relapse
  5
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0282416|Overall [Publication Type]|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
different times
  3
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
symptomatic chf
  2
  C0018802|Heart Failure, Congestive|0
  C0231220|Symptomatic (qualifier value)|0
other histological predictors
  2
  C0205462|Histologic|0
  C0205394|Other|0
distant sites
  2
  C0443203|Distant (qualifier value)|0
  C0205145|Associated topography (attribute)|0
epi
  5
  C1317977|Epithelial metaplasia (morphologic abnormality)|0
  C0014544|Epilepsy|0
  C0221908|Epithelial|0
  C0014609|Epithelium|0
  C0334029|Epithelialization|0
medical oncologists
  1
  C0278631|Medical oncologist (occupation)|0
ileal spontaneous perforation
  3
  C0020885|ileum|0
  C0549099|Perforation (morphologic abnormality)|0
  C0205359|Spontaneous (qualifier value)|0
3/v2 months
  1
  C0439231|month (qualifier value)|0
rtog study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
similarity
  1
  C0871364|Simile|0
hemogram
  1
  C0200631|Complete blood count without differential (procedure)|0
patient
  1
  C0030705|Patients|0
questionnaire
  1
  C0034394|Questionnaires|0
palpation
  1
  C0030247|Palpation|0
alopecia
  1
  C0002170|Alopecia|0
reviews
  1
  C0282443|Review [Publication Type]|0
used radiotherapy concurrently
  3
  C0034619|radiotherapeutic|0
  C0042153|utilization|0
  C0034618|Radiation therapy|0
correct written informed consent
  3
  C0205202|Remediated (finding)|0
  C0700287|Reporting|0
  C0719517|Correct|0
log–rank test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
two drugs
  3
  C0684270|Drugged|0
  C0205448|Two (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
surgical margins
  1
  C0229985|Surgical margins (body structure)|0
12.9 months
  1
  C0439231|month (qualifier value)|0
seizures
  2
  C0036572|Seizures|0
  C0009951|Convulsions|0
poorer survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
rizzoli institute
  1
  C0021622|Institutes|0
5-year cure rate
  2
  C0871208|Rating|0
  C0439234|year (qualifier value)|0
one
  1
  C0205447|One (qualifier value)|0
objective response rates
  3
  C0871208|Rating|0
  C0871261|Responses|0
  C0018017|Goals|0
blometncal center
  2
  C0935444|Centering|0
  C0205099|Central|0
interrupted silk sutures
  5
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0074529|silk|0
  C0502420|Suture Joint|0
  C0443239|Interrupted (qualifier value)|0
received previous treatment
  3
  C0039798|therapeutic aspects|0
  C0205156|Previous (qualifier value)|0
  C0087111|Therapeutic procedure|0
38.1 months
  1
  C0439231|month (qualifier value)|0
ml
  1
  C0439242|mL (qualifier value)|0
also difference
  5
  C0178849|Species Differences|0
  C0682076|ethnic differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
radiation also improved outcome
  4
  C1272745|Improving (qualifier value)|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0851346|Radiation|0
  C0184511|Improved (qualifier value)|0
other alkylating agent
  2
  C0450442|Agent (attribute)|0
  C0205394|Other|0
other combination therapy
  5
  C0453882|Combinations (physical object)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205195|Combined (qualifier value)|0
  C0205394|Other|0
treatment administration
  4
  C0039798|therapeutic aspects|0
  C1262471|Administration (procedure)|0
  C0087111|Therapeutic procedure|0
  C0001554|Administration|0
major obstacle
  1
  C0205164|Major (qualifier value)|0
accurate continuing data
  2
  C0750536|CONTINUED|0
  C0443131|Accurate (qualifier value)|0
grade 3.4 vomiting
  5
  C0042965|Vomitus|0
  C0401156|Vomiting NOS (disorder)|0
  C0441800|Grade|0
  C0796573|Cancer cells grading system|0
  C0042963|Vomiting|0
possibly overall survival
  4
  C0332149|Possible|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
possible therapeutic role
  4
  C0039796|The science and art of healing|0
  C0332149|Possible|0
  C0035820|Role|0
  C0302350|Therapeutic|0
protocol mandated radiotherapy dose
  3
  C0034619|radiotherapeutic|0
  C0442711|Protocols documentation|0
  C0034618|Radiation therapy|0
fatal cns toxicity
  4
  C1302234|Fatal (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0927232|Neuraxis|0
  C0600688|Toxic effect|0
lymphoma
  1
  C0024299|Lymphoma|0
cox model trying to
  4
  C0026336|Models|0
  C0870071|Modeling|0
  C0033551|Prostaglandin-Endoperoxide Synthase|0
  C0442996|Cox microbiology subtype|0
patient eligibility
  1
  C0030705|Patients|0
same method
  3
  C0025664|Methodology|0
  C0445247|Same (qualifier value)|0
  C0025663|Methods|0
proliferation
  1
  C0334094|Proliferation (morphologic abnormality)|0
1.9 percent
  1
  C0439165|Percent (qualifier value)|0
received prior radiation sensitizer treatment
  4
  C0039798|therapeutic aspects|0
  C0750516|PRIOR|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
histological type
  1
  C0449574|Histological type (attribute)|0
anaesthetics
  2
  C0002930|Anesthesiology|0
  C0002932|Anesthetics|0
previous studies
  3
  C0557651|Room of building - Study|0
  C0205156|Previous (qualifier value)|0
  C0947630|Scientific Study|0
colon cancer subgroups
  5
  C0998265|Cancer Genus|0
  C0009368|Colon|0
  C0684195|Cola|0
  C0006826|Malignant Neoplasms|0
  C1281569|Entire colon|0
cervical carcinomas
  1
  C0302592|Carcinoma of cervix (disorder)|0
surgery only
  3
  C0038895|Surgical aspects|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
3.9 months
  1
  C0439231|month (qualifier value)|0
neutropenic fever
  1
  C0948631|Neutropenic fever|0
comparison group
  3
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
febrile neutropenia
  1
  C0746883|Febrile neutropenia|0
planned dose
  2
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
observations
  2
  C0302523|Observation in research|0
  C0700325|Patient observation|0
significantly greater frequency
  3
  C0376249|With frequency|0
  C0443228|Greater (qualifier value)|0
  C0439603|Frequencies (time pattern)|0
similar regimens
  1
  C0677937|regimen|0
lowest granulocyte
  1
  C0018183|Granulocytes|0
radiation therapy treatment arm
  5
  C0039798|therapeutic aspects|0
  C0003792|Arm|0
  C0446516|Upper arm|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
patient survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0030705|Patients|0
radiotherapy records
  3
  C0034619|radiotherapeutic|0
  C0034869|Records|0
  C0034618|Radiation therapy|0
estimating disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0750572|ESTIMATED|0
40-yr-old mutation theory
  5
  C0026882|Mutation|0
  C0871935|Theories|0
  C0580836|Old|0
  C0677546|Old episode|0
  C0439234|year (qualifier value)|0
third countries
  2
  C0205437|Third (qualifier value)|0
  C0454664|Countries (geographic location)|0
nodal metastases
  3
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0443268|Nodal (qualifier value)|0
  C0027627|Neoplasm Metastasis|0
same degree
  3
  C0449286|Degree or extent|0
  C0445247|Same (qualifier value)|0
  C0542560|Academic degree|0
mannitol mg
  1
  C0024730|Mannitol|0
disease stages
  2
  C0699749|disease stage|0
  C0449385|Staging of disease (attribute)|0
subsequent treatment
  3
  C0039798|therapeutic aspects|0
  C0750530|SUBSEQUENT|0
  C0087111|Therapeutic procedure|0
obvious explanation
  1
  C0681841|explanation|0
enhancement
  1
  C0086222|Enhancer|0
major drug
  3
  C0684270|Drugged|0
  C0205164|Major (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
perforation
  1
  C0549099|Perforation (morphologic abnormality)|0
n
  1
  C0439225|ns (qualifier value)|0
microscopically negative resection margins
  5
  C1269830|Tumor margin status|0
  C0205160|Negative (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0205284|Marginal (qualifier value)|0
  C0015252|Excision|0
d x days
  1
  C0439228|day (qualifier value)|0
essentially identical estimates
  2
  C0750572|ESTIMATED|0
  C0205280|Identical (qualifier value)|0
two sided p values
  3
  C0205448|Two (qualifier value)|0
  C0441987|Side (qualifier value)|0
  C0042295|VALUING|0
clinical reason to
  2
  C0205210|Clinical (qualifier value)|0
  C0684328|Reasoning|0
strategies
  1
  C0679199|strategy|0
retrospectively hama positive sera
  2
  C0229671|Serum|0
  C0205159|Positive (qualifier value)|0
controlled studies
  1
  C0681867|controlled study|0
nuclear proliferation markers
  3
  C0521447|Nuclear|0
  C0334094|Proliferation (morphologic abnormality)|0
  C0005516|Biological Markers|0
interstitial brachytherapy
  1
  C0203580|Interstitial brachytherapy (regime/therapy)|0
80% power
  1
  C0032863|Power (Psychology)|0
ii lymph nodes
  3
  C0746922|NODE|0
  C0024202|Lymph|0
  C0439069|Roman numeral II|0
iia carcinoma
  1
  C0007097|Carcinoma|0
patient related prognostic factor
  4
  C0220901|prognostic|0
  C0163712|Relate|0
  C0030705|Patients|0
  C0445223|Related (finding)|0
surgical intervention
  1
  C0549433|Surgical intervention|0
hospitals
  1
  C0019994|Hospitals|0
large randomized trial
  1
  C0549177|Large|0
one scale
  5
  C0349674|Intellectual scale|0
  C0175659|Weight measurement scales|0
  C0205447|One (qualifier value)|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
substantial improvements
  4
  C0683655|community improvement|0
  C0421829|Improvement grant NOS|0
  C0680092|sexual improvement|0
  C0683848|curriculum improvement|0
4–5 years
  1
  C0439234|year (qualifier value)|0
levels
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
twenty two patients
  2
  C0205448|Two (qualifier value)|0
  C0030705|Patients|0
hypothetical mechanisms
  2
  C0457274|Mechanism (attribute)|0
  C0441712|Mechanisms (qualifier value)|0
liver function tests
  1
  C0023901|Liver Function Tests|0
other combinations
  3
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0205394|Other|0
normal epithelial cells
  4
  C0007634|Cells|0
  C0205307|Normal (qualifier value)|0
  C1269647|Entire cell|0
  C0221908|Epithelial|0
five prs
  2
  C0205451|Five (qualifier value)|0
  C0279766|progesterone receptor negative|0
significantly different prognoses
  1
  C0033325|Forecast of outcome|0
selection
  1
  C0036576|Selection (Genetics)|0
clinical deviations
  2
  C0012727|Spatial Displacement|0
  C0205210|Clinical (qualifier value)|0
important increase
  3
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
perioperative period
  5
  C0946279|Perioperative record (physical object)|0
  C1096288|Perioperative analgesia|0
  C0150706|Perioperative Care|0
  C1301895|Perioperative death (finding)|0
  C0243166|perioperative procedures|0
bilirubin 1.2 mg
  1
  C0005437|Bilirubin|0
further patient
  1
  C0030705|Patients|0
medical illness
  2
  C0221423|Illness (finding)|0
  C0205476|Medical (qualifier value)|0
circular coiled spring
  3
  C0241232|spring|0
  C0444764|Coils (qualifier value)|0
  C1282913|Circular (qualifier value)|0
large hypoxic cell component
  5
  C0007634|Cells|0
  C0549177|Large|0
  C1269647|Entire cell|0
  C0242184|Oxygen Deficiency|0
  C0449432|Component (attribute)|0
concurrent multiagent chemoradiotherapy
  1
  C0205420|Concurrent (qualifier value)|0
high-risk features
  3
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0035647|Risk|0
only randomized trial
  2
  C0282440|Randomized Controlled Trials|0
  C0206034|Clinical Trials, Randomized|0
pelvic disease
  2
  C0030797|Pelvis|0
  C0012634|Disease|0
previous trial
  1
  C0205156|Previous (qualifier value)|0
single drug combination
  5
  C0453882|Combinations (physical object)|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0205195|Combined (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
fourth portion
  1
  C0205438|Fourth (qualifier value)|0
there skin reaction
  1
  C0221743|Skin reaction (observable entity)|0
additional dose
  5
  C0940824|Additional procedure|0
  C0449757|Additional material (attribute)|0
  C0882622|ADDITIONAL SEGMENT|0
  C0236999|Additional Codes|0
  C0345462|Additional chromosome NOS (disorder)|0
biochemical modulation approaches
  2
  C0205474|Biochemical (qualifier value)|0
  C0449445|Approach (attribute)|0
lung metastases
  1
  C0153676|Secondary malignant neoplasm of lung (disorder)|0
blood transfusions
  1
  C0005841|Blood Transfusion|0
optimal method
  2
  C0025664|Methodology|0
  C0025663|Methods|0
compensatory boost
  1
  C0231186|Compensatory|0
current practice
  2
  C0237607|experience (practice)|0
  C0521116|Current (qualifier value)|0
granulocyte colony-stimulating factor
  1
  C0079459|Granulocyte Colony-Stimulating Factor|0
stricture
  1
  C0333187|Stricture (morphologic abnormality)|0
exact time
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0059927|Exact|0
6.5 months
  1
  C0439231|month (qualifier value)|0
preoperative radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0445204|Preoperative (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
course
  2
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
chances
  1
  C0237506|Chance|0
para-aortic recurrence
  3
  C0003483|Aorta|0
  C0034897|Recurrence|0
  C0030563|PARITY|0
cervical diameters
  2
  C0205064|Cervical (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
nursing women
  5
  C0028678|nursing therapy|0
  C0028677|Discipline of Nursing|0
  C0043210|Human adult females|0
  C0043209|Human Females|0
  C0028661|Nurses|0
approximately percent
  2
  C0439165|Percent (qualifier value)|0
  C0332232|Approximate (qualifier value)|0
axis
  4
  C1321509|Entire axis vertebra|0
  C0004457|Axis vertebra|0
  C0999597|Genus Axis|0
  C0728839|Electrocardiographic axis|0
excess mortality
  1
  C0079320|Mortality, Excess|0
cystitis
  1
  C0010692|Cystitis|0
chest roentgenogram
  2
  C0817096|Chest|0
  C1306645|Plain film (procedure)|0
substantially increased incidence
  5
  C0021149|Incidence|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0442805|Increase (qualifier value)|0
  C0220856|incidence of cases|0
receiving adjuvant chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
ethical considerations
  1
  C0518609|CONSIDERATION|0
statistical analysis
  1
  C0871424|Statistical Analysis|0
univariate analyses of variance
  3
  C0332285|Within|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
calcium folinate mg
  1
  C0006675|Calcium|0
peak level
  3
  C0441889|Levels (qualifier value)|0
  C0444505|Peak (qualifier value)|0
  C0456079|Disease classification level|0
disease free survival
  1
  C0242793|Disease-Free Survival|0
significantly better quality
  2
  C0332272|Better (qualifier value)|0
  C0332306|With quality (attribute)|0
vast majority
  2
  C0680220|majority|0
  C0814230|Veterans Alcoholism Screening Test|0
high risk
  3
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0035647|Risk|0
eplthehal cell adhesion molecule
  1
  C0007578|Cell Adhesion Molecules|0
20% improvement
  3
  C1272745|Improving (qualifier value)|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
reduced motility
  2
  C0392756|Reduced (qualifier value)|0
  C0678835|Motility (finding)|0
presented results still
  2
  C1274040|Result (navigational concept)|0
  C0150312|Present|0
g csf
  1
  C0079459|Granulocyte Colony-Stimulating Factor|0
three drug regimen
  4
  C0684270|Drugged|0
  C0205449|Three (qualifier value)|0
  C0677937|regimen|0
  C0013227|Pharmaceutical Preparations|0
distant metastasis
  1
  C1269798|pM category (observable entity)|0
eighty six percent
  2
  C0439165|Percent (qualifier value)|0
  C0205452|Six (qualifier value)|0
complete staging
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0684248|Stage of Surgical Procedure|0
  C0205197|Complete (qualifier value)|0
  C1306673|Stages (qualifier value)|0
percent improvement
  1
  C0439165|Percent (qualifier value)|0
criterion
  0
so far patient
  1
  C0030705|Patients|0
following criteria
  2
  C0243161|criteria|0
  C0332282|Following (attribute)|0
fifty nine patients
  2
  C0030705|Patients|0
  C0205455|Nine (qualifier value)|0
significant treatment effects
  4
  C1280500|Effect (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0750502|Significant (qualifier value)|0
  C0087111|Therapeutic procedure|0
stage group
  5
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C1306673|Stages (qualifier value)|0
pelvic lymph node metastases
  5
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0030797|Pelvis|0
  C0746922|NODE|0
  C0024202|Lymph|0
  C0027627|Neoplasm Metastasis|0
same results
  2
  C1274040|Result (navigational concept)|0
  C0445247|Same (qualifier value)|0
measurement
  1
  C0242485|Measurement|0
conclusion
  1
  C0917903|Conclude|0
bite
  2
  C0045724|2-(4-ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole|0
  C0005658|Bites|0
histopathologic confirmation
  1
  C0919553|Histopathologic Grade|0
less hematologic toxicity
  3
  C0040539|Toxicity aspects|0
  C0205488|Hematologic (qualifier value)|0
  C0600688|Toxic effect|0
invasive procedures
  2
  C0038895|Surgical aspects|0
  C0348025|Invasive procedure (procedure)|0
only assessable patients
  1
  C0030705|Patients|0
current pessimistic view
  3
  C0521116|Current (qualifier value)|0
  C0449911|View (attribute)|0
  C0424134|Pessimistic (finding)|0
primary outcome variable
  3
  C0439828|Variable (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
postsurgical complications
  1
  C0742723|COMPLICATION POSTSURGICAL|0
or mg
  1
  C0069590|ORALIT|0
fm sequence
  5
  C1171993|alpha-methylbenzyl-2-fluoro-4-methylphenylurea|0
  C0657033|alpha-(fluoromethyl)-5-hydroxytryptophan|0
  C0060602|FM 24|0
  C0079758|Lymphoma, Mixed-Cell, Follicular|0
  C0060601|FM 100|0
5.1 months
  1
  C0439231|month (qualifier value)|0
34-kd glycoprotein
  1
  C0017968|Glycoproteins|0
specific strata
  2
  C1263442|SPECIFIC|0
  C0205369|Specific (qualifier value)|0
radiologic findings
  2
  C0205483|Radiologic (qualifier value)|0
  C0243095|findings|0
3-year survival rates
  4
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
table i
  2
  C0039224|Table - furniture|0
  C1168570|Table - visual aid|0
randomized clinical trial to
  1
  C0205210|Clinical (qualifier value)|0
more granulocytopenia
  2
  C1261272|Granulocytopenia|0
  C0205172|More (qualifier value)|0
supportive care groups
  5
  C0150499|Caring|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0728734|Caring caregiver-patient relationship|0
adequate renal function
  5
  C0022646|Kidney|0
  C0700205|Function Axis|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
  C0205411|Adequate (qualifier value)|0
several authors
  2
  C0221192|Author (occupation)|0
  C0443302|Several (qualifier value)|0
ifosfamide
  1
  C0020823|Ifosfamide|0
diameter cm
  2
  C0475210|cm (qualifier value)|0
  C0332517|Diameter (qualifier value)|0
response durations
  1
  C0237585|Response Duration|0
infectious complications
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
survival benefits
  3
  C0038952|Continuance of life|0
  C0814225|benefits|0
  C0220921|survival aspects|0
overall disease burden
  2
  C0012634|Disease|0
  C0282416|Overall [Publication Type]|0
minutes
  3
  C0439232|Minute of time|0
  C0700321|Small|0
  C1282918|Minute (qualifier value)|0
maximum
  1
  C0806909|Maximum|0
13.1 g
  1
  C0162832|APC Gene|0
median survival
  4
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
intensified treatment
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
disease stage
  2
  C0699749|disease stage|0
  C0449385|Staging of disease (attribute)|0
0.05 level
  2
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
randomized patients
  1
  C0030705|Patients|0
even cr
  2
  C0008574|Chromium|0
  C0587117|Evening (qualifier value)|0
equal lengths
  3
  C0439537|Lengths (qualifier value)|0
  C0439089|Equals|0
  C0205163|Equal (qualifier value)|0
survival
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
third years
  2
  C0205437|Third (qualifier value)|0
  C0439234|year (qualifier value)|0
paclitaxel
  1
  C0144576|Paclitaxel|0
prior hysterectomy
  2
  C0020699|Hysterectomy|0
  C0750516|PRIOR|0
69% response rate
  2
  C0878525|Cancer treatment response rate|0
  C0237629|Frequency of Responses|0
observed differences
  5
  C0178849|Species Differences|0
  C0012213|Differential Threshold|0
  C0682075|racial differences|0
  C0680440|generational differences|0
  C0428676|Arteriovenous difference (observable entity)|0
origins
  2
  C0439659|Beginning|0
  C0079946|National origin|0
years follow-up
  4
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
  C0439234|year (qualifier value)|0
indeed important advance
  2
  C0205179|Advanced phase|0
  C0725066|Advance|0
first time
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0205435|First (qualifier value)|0
  C0392761|Timed (qualifier value)|0
m orally
  1
  C0026635|Mouth Breathing|0
antigen
  1
  C0003320|Antigens|0
excellent early tumor response
  3
  C0205085|Early (qualifier value)|0
  C0027651|Neoplasms|0
  C0871261|Responses|0
more patients
  2
  C0030705|Patients|0
  C0205172|More (qualifier value)|0
treatment sequences
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
treatment-related death
  5
  C0011065|Cessation of life|0
  C0039798|therapeutic aspects|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
germany
  1
  C0017480|Germany|0
effective treatment
  3
  C0039798|therapeutic aspects|0
  C0205414|Effective (qualifier value)|0
  C0087111|Therapeutic procedure|0
5-year findings
  2
  C0243095|findings|0
  C0439234|year (qualifier value)|0
final analysis
  3
  C0205088|End-stage (qualifier value)|0
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
bleeding
  1
  C0019080|Hemorrhage|0
anemia
  2
  C0002871|Anemia|0
  C1000483|Genus Anemia|0
proportions
  1
  C0205351|Proportional (qualifier value)|0
recurrence status
  2
  C0449438|Status (attribute)|0
  C0034897|Recurrence|0
null hypothesis
  1
  C0456148|Null (qualifier value)|0
transfusion
  1
  C0199960|Transfusion - action (qualifier value)|0
larger benefit
  2
  C0814225|benefits|0
  C0443228|Greater (qualifier value)|0
metastatic disease
  1
  C0027627|Neoplasm Metastasis|0
only supportive palliative treatment
  3
  C0039798|therapeutic aspects|0
  C1285530|Palliative - procedure intent (qualifier value)|0
  C0087111|Therapeutic procedure|0
fluorouracil combination
  3
  C0453882|Combinations (physical object)|0
  C0016360|Fluorouracil|0
  C0205195|Combined (qualifier value)|0
additional concern
  3
  C0424964|Maternal concern (finding)|0
  C0850615|Concern, appearance|0
  C0030544|PARENTAL CONCERNS|0
superiority
  1
  C0680218|superiority|0
tumour
  1
  C0027651|Neoplasms|0
modulation
  2
  C1031041|Modulus|0
  C0443264|Modulated (qualifier value)|0
clinical findings
  1
  C0586173|Clinical finding (finding)|0
median 2.6 yr
  3
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
  C0439234|year (qualifier value)|0
vincristine mg
  1
  C0042679|Vincristine|0
creatinine clearance 1.17 ml
  3
  C0449297|Clearance (attribute)|0
  C0439242|mL (qualifier value)|0
  C0010294|Creatinine|0
significant factors
  1
  C0750502|Significant (qualifier value)|0
local ethics committee approval
  3
  C0015000|Ethics|0
  C1136353|Ethical Aspects|0
  C0205276|Local (qualifier value)|0
partial response rates
  3
  C0728938|Partial (qualifier value)|0
  C0871208|Rating|0
  C0871261|Responses|0
preliminary findings
  2
  C0439611|Preliminary (qualifier value)|0
  C0243095|findings|0
examined treatment group
  5
  C0039798|therapeutic aspects|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0441833|Groups (qualifier value)|0
thymidine regimen
  2
  C0040077|Thymidine|0
  C0677937|regimen|0
elimination
  2
  C0221102|Excretory function|0
  C0518891|Elimination outcomes|0
chf
  1
  C0018802|Heart Failure, Congestive|0
one observed patient
  2
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
single layer technique exclusively
  5
  C0025664|Methodology|0
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0449851|Techniques|0
stage i cervical cancer
  1
  C0278575|Cervix carcinoma stage I|0
treatment to
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
iv bicarbonate to
  1
  C0005367|Bicarbonates|0
only significant factor predicting
  1
  C0750502|Significant (qualifier value)|0
antiemetics
  1
  C0003297|Antiemetics|0
ratio
  1
  C0456603|Ratio (property) (qualifier value)|0
somewhat contrasting results
  1
  C1274040|Result (navigational concept)|0
baseline value
  2
  C0168634|BaseLine|0
  C0042295|VALUING|0
three treatment-related deaths
  5
  C0011065|Cessation of life|0
  C0163712|Relate|0
  C0205449|Three (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
negative nodes
  2
  C0746922|NODE|0
  C0205160|Negative (qualifier value)|0
girdles
  1
  C0453903|Girdle (physical object)|0
first metastasis
  3
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0205435|First (qualifier value)|0
  C0027627|Neoplasm Metastasis|0
treatment volume
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0449468|Volume (property) (qualifier value)|0
and whitney cw
  1
  C0332290|Consistent with (qualifier value)|0
liver only
  3
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0023884|Liver|0
three cycles
  1
  C0205449|Three (qualifier value)|0
cgy
  1
  C0556645|cGy (qualifier value)|0
liver involvement
  5
  C1278929|Entire liver|0
  C0023899|Liver Extract|0
  C0205428|Involvements (qualifier value)|0
  C0023884|Liver|0
  C0392760|Not free of (attribute)|0
italian prospective randomised trial
  2
  C0337810|Italians (ethnic group)|0
  C0022275|Italian language (qualifier value)|0
uterus
  2
  C1269032|Entire uterus|0
  C0042149|Uterus|0
single layer anastomosis always
  5
  C0037179|Unmarried person|0
  C0332853|Anastomosis|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0500470|Anatomical anastomosis|0
effectiveness
  2
  C1280519|Effectiveness (qualifier value)|0
  C0205414|Effective (qualifier value)|0
41.5 months
  1
  C0439231|month (qualifier value)|0
skull
  1
  C0037303|Bone structure of cranium|0
occult local metastases
  4
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0205262|Occult (qualifier value)|0
  C0027627|Neoplasm Metastasis|0
  C0205276|Local (qualifier value)|0
radiation dose
  1
  C0851346|Radiation|0
most important hematologic side effect
  4
  C1280500|Effect (qualifier value)|0
  C0205488|Hematologic (qualifier value)|0
  C0205393|Most (qualifier value)|0
  C0441987|Side (qualifier value)|0
lymph node status
  3
  C0449438|Status (attribute)|0
  C0746922|NODE|0
  C0024202|Lymph|0
anterior resection
  3
  C0205094|Anterior|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
other groups
  4
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0205394|Other|0
rectal surgical group
  5
  C0038895|Surgical aspects|0
  C0205052|Rectal (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
superior response rates
  3
  C0871208|Rating|0
  C0205105|Superior (qualifier value)|0
  C0871261|Responses|0
methyl ccnu
  1
  C0036637|Semustine|0
higher cumulative doses
  1
  C0719635|DOS|0
suspected cases
  3
  C0332147|Suspected diagnosis (contextual qualifier) (qualifier value)|0
  C0868928|Case (qualifier value)|0
  C0750491|SUSPECT|0
adequate medullary reserve
  1
  C0205411|Adequate (qualifier value)|0
current protocols
  2
  C0521116|Current (qualifier value)|0
  C0442711|Protocols documentation|0
bmdp statistical software to
  2
  C0220917|statistical|0
  C0037585|Computer software|0
long-term complications
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C0009566|Complication|0
  C1171258|Complication Aspects|0
appearance
  2
  C0233426|Personal appearance|0
  C0700364|Appearance|0
date
  2
  C0011008|Dates|0
  C0237553|dating|0
first published report
  4
  C0205435|First (qualifier value)|0
  C0034037|Publishing|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
abnormalities
  2
  C0000769|teratologic|0
  C0000768|Congenital Abnormality|0
ecog performance status
  3
  C0449438|Status (attribute)|0
  C0597198|Performance|0
  C0430797|Electrocorticogram (procedure)|0
bone x-rays
  1
  C0848406|X-ray, bones|0
m bolus
  1
  C0677863|bolus|0
rats
  2
  C0034693|Rattus norvegicus|0
  C0034721|Rattus|0
mplr stepping option
  2
  C0859325|Stepping|0
  C1261552|Step (qualifier value)|0
layers
  1
  C0934502|Layer|0
adjuvant combination chemotherapy
  5
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0453882|Combinations (physical object)|0
  C0001551|Adjuvants, Immunologic|0
  C0205195|Combined (qualifier value)|0
  C0013216|Pharmacotherapy|0
tumor response definitions
  2
  C0027651|Neoplasms|0
  C0871261|Responses|0
one patient
  2
  C0205447|One (qualifier value)|0
  C0030705|Patients|0
end point
  2
  C1272693|Ended (qualifier value)|0
  C0444930|End (qualifier value)|0
alpha
  1
  C0439095|Alpha (qualifier value)|0
life-threatening toxicities
  3
  C0376558|Life|0
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
discussion
  1
  C0557061|Discussion (procedure)|0
tumor-specific antigen
  4
  C0003320|Antigens|0
  C1263442|SPECIFIC|0
  C0027651|Neoplasms|0
  C0205369|Specific (qualifier value)|0
prolonged myelosuppression
  2
  C0854467|Myelosuppression (finding)|0
  C0439590|Prolonged (qualifier value)|0
early recurrence
  2
  C0205085|Early (qualifier value)|0
  C0034897|Recurrence|0
confidence
  1
  C0237529|Self-confidence (observable entity)|0
two intracavitary implants
  5
  C0205448|Two (qualifier value)|0
  C1298613|Intracavitary (qualifier value)|0
  C0021102|Implants|0
  C0021107|Implantation procedure|0
  C0332837|Traumatic implants|0
infusion group
  4
  C0574032|Infusion (procedure)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
different scheduling
  2
  C0086960|Schedules|0
  C0205539|Scheduled (qualifier value)|0
fewer recurrences
  1
  C0034897|Recurrence|0
postoperative course
  3
  C0449922|Course (attribute)|0
  C0032790|Postoperative Period|0
  C0750729|Courses (qualifier value)|0
late treatment-related toxicity
  5
  C0205087|Late (qualifier value)|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0600688|Toxic effect|0
  C0445223|Related (finding)|0
radiological physics
  1
  C0031837|Physics|0
initial resting lvef
  2
  C0035253|Rest|0
  C0205265|Initial (qualifier value)|0
reported two deaths
  4
  C0011065|Cessation of life|0
  C0205448|Two (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
days
  1
  C0439228|day (qualifier value)|0
pretreatment surgical evaluation
  3
  C0038895|Surgical aspects|0
  C0220825|Evaluation|0
  C1261322|Assessment procedure (procedure)|0
unknown risk
  2
  C0439673|Unknown (qualifier value)|0
  C0035647|Risk|0
yet patient
  1
  C0030705|Patients|0
one adjuvant
  2
  C0205447|One (qualifier value)|0
  C0001551|Adjuvants, Immunologic|0
therapeutic activity
  5
  C0039796|The science and art of healing|0
  C0221187|Physical activity|0
  C0600075|Endurance of activity|0
  C0302350|Therapeutic|0
  C0441655|Activities|0
convincing reason to
  1
  C0684328|Reasoning|0
several trials
  1
  C0443302|Several (qualifier value)|0
bowel
  1
  C0021853|Intestines|0
encouragement
  1
  C0870494|Encouragement|0
adenosquamous carcinoma
  1
  C0206623|Carcinoma, Adenosquamous|0
paraortic lymph nodes
  2
  C0746922|NODE|0
  C0024202|Lymph|0
same regimen
  2
  C0445247|Same (qualifier value)|0
  C0677937|regimen|0
theoretically tumor
  1
  C0027651|Neoplasms|0
weekly treatment
  3
  C0039798|therapeutic aspects|0
  C0332174|Weekly (qualifier value)|0
  C0087111|Therapeutic procedure|0
low-dose cmf
  3
  C0234886|Lowing, function (observable entity)|0
  C0950521|CMF|0
  C0205251|Low (qualifier value)|0
malignant hepatomegaly
  3
  C0019209|Hepatomegaly|0
  C0006826|Malignant Neoplasms|0
  C0205282|Malignant - descriptor|0
pregnancy
  1
  C0032961|Pregnancy|0
component
  1
  C0449432|Component (attribute)|0
chronic neurological bladder
  4
  C1281573|Entire bladder|0
  C0005682|Bladder|0
  C0205494|Neurologic (qualifier value)|0
  C0205191|Chronic (qualifier value)|0
persistent squamous cell carcinoma
  5
  C1182670|Squamous|0
  C0007634|Cells|0
  C0205322|Persistent (qualifier value)|0
  C1269647|Entire cell|0
  C0007097|Carcinoma|0
systemic treatment
  3
  C0205373|Systemic (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
postmortem study
  1
  C0683946|postmortem study|0
cost
  2
  C0220812|Cost aspects|0
  C0010186|Financial cost|0
metastatic tumor cells
  4
  C0007634|Cells|0
  C0036525|Metastatic to|0
  C1269647|Entire cell|0
  C0027651|Neoplasms|0
abdominal perineal resection
  4
  C0456438|Abdominal (qualifier value)|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
  C0031066|Anogenital region|0
median delay
  3
  C0205421|Deferred (qualifier value)|0
  C0876920|Median Statistical Measurement|0
  C0549183|Median (qualifier value)|0
thymidine
  1
  C0040077|Thymidine|0
dose reduction criteria
  3
  C0243161|criteria|0
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
bulky disease
  1
  C0012634|Disease|0
chronic organ damage
  3
  C0178784|Organ|0
  C0205191|Chronic (qualifier value)|0
  C0010957|Damage (morphologic abnormality)|0
stage ib cervical cancer risk factors
  5
  C0022104|Irritable Bowel Syndrome|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0205064|Cervical (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0035647|Risk|0
top
  2
  C0000811|Termination of pregnancy|0
  C0076833|container tops|0
kg
  1
  C0439209|kg (qualifier value)|0
radiotherapy also
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
treatment planning
  1
  C0599880|PLAN OF TREATMENT|0
eastern cooperative oncology group
  5
  C0278627|oncology|0
  C0679729|cooperative|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
substantial decrease
  3
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
treatment-related deaths
  5
  C0011065|Cessation of life|0
  C0039798|therapeutic aspects|0
  C0163712|Relate|0
  C0087111|Therapeutic procedure|0
  C0445223|Related (finding)|0
operation
  2
  C0038895|Surgical aspects|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
higher treatmentrelated toxicity
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
mastectomy
  1
  C0024881|Mastectomy|0
findings
  1
  C0243095|findings|0
two further patients
  2
  C0205448|Two (qualifier value)|0
  C0030705|Patients|0
numbers
  2
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
middle
  1
  C0549183|Median (qualifier value)|0
five minute
  4
  C0439232|Minute of time|0
  C0205451|Five (qualifier value)|0
  C0700321|Small|0
  C1282918|Minute (qualifier value)|0
ulceration present
  2
  C0041582|Ulcer|0
  C0150312|Present|0
tumor
  1
  C0027651|Neoplasms|0
blood pressure
  2
  C0428878|Arterial pressure|0
  C0005823|Blood Pressure|0
tumor cell burden
  3
  C0007634|Cells|0
  C1269647|Entire cell|0
  C0027651|Neoplasms|0
cumulative incidence function estimates
  5
  C0031843|physiological aspects|0
  C0021149|Incidence|0
  C0542341|Function|0
  C0422812|Functions (observable entity)|0
  C0220856|incidence of cases|0
second study
  4
  C0205436|Second (qualifier value)|0
  C0557651|Room of building - Study|0
  C0457385|seconds|0
  C0947630|Scientific Study|0
extension
  1
  C0231448|Extension (qualifier value)|0
undergone radical hysterectomy
  3
  C0439807|Radical (qualifier value)|0
  C0302912|Radicals (chemistry)|0
  C0020699|Hysterectomy|0
12-channel biochemical profile
  2
  C0205474|Biochemical (qualifier value)|0
  C0439799|Channel (qualifier value)|0
one advantage
  2
  C0308269|ADVANTAGE|0
  C0205447|One (qualifier value)|0
dose to
  5
  C0677884|dose-rate|0
  C0678766|Drug dose (finding)|0
  C0721282|Lac-Dose|0
  C0935905|dose-limiting|0
  C1115464|DOSE NUMBER|0
final status
  2
  C0449438|Status (attribute)|0
  C0205088|End-stage (qualifier value)|0
vaginal stenosis
  4
  C0947637|Stenosis, unspecified|0
  C0042232|Vagina|0
  C0678234|Stenosis Morphology|0
  C1261287|Constriction, Pathologic|0
possible explanatory mechanism
  4
  C0457274|Mechanism (attribute)|0
  C0332149|Possible|0
  C0681841|explanation|0
  C0441712|Mechanisms (qualifier value)|0
because radiation therapy
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
two hours
  2
  C0205448|Two (qualifier value)|0
  C0439227|Hour|0
log rank test
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0699794|Rank|0
same drugs
  3
  C0684270|Drugged|0
  C0445247|Same (qualifier value)|0
  C0013227|Pharmaceutical Preparations|0
l hypoxanthine
  2
  C0020684|Hypoxanthine|0
  C0020691|Hypoxanthines|0
limited value
  2
  C0439801|Limited (qualifier value)|0
  C0042295|VALUING|0
r0 resection
  2
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
other complications
  1
  C0009566|Complication|0
platelet counts
  2
  C1287267|Finding of platelet count (finding)|0
  C0032181|Platelet Count|0
secondary colorectal cancer
  5
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0555952|Colorectal (qualifier value)|0
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0027627|Neoplasm Metastasis|0
frequencies
  2
  C0376249|With frequency|0
  C0439603|Frequencies (time pattern)|0
evaluable populations
  1
  C0032659|Population|0
treatment centre
  3
  C0039798|therapeutic aspects|0
  C0205099|Central|0
  C0087111|Therapeutic procedure|0
leukocyte
  1
  C0023516|Leukocytes|0
two local relapse
  5
  C0205448|Two (qualifier value)|0
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
week
  1
  C0439230|week (qualifier value)|0
primarily metallic taste
  1
  C0039336|Taste|0
only few fractions
  2
  C0457426|Fractions of (qualifier value)|0
  C0205388|Few (qualifier value)|0
p values
  1
  C0879541|p-value|0
di
  1
  C0451119|Diagnostic interview schedule (assessment scale)|0
insufficient access
  2
  C0444454|Access (attribute)|0
  C0231180|Insufficient|0
degree
  2
  C0449286|Degree or extent|0
  C0542560|Academic degree|0
role
  1
  C0035820|Role|0
proportion
  1
  C0205351|Proportional (qualifier value)|0
clinical benefit
  2
  C0205210|Clinical (qualifier value)|0
  C0814225|benefits|0
failure
  2
  C0680095|Personal failure|0
  C0231174|Failure (biologic function)|0
synchronous metastases
  3
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0439580|Synchronous (qualifier value)|0
  C0027627|Neoplasm Metastasis|0
advanced carcinoma
  3
  C0205179|Advanced phase|0
  C0725066|Advance|0
  C0007097|Carcinoma|0
current results
  2
  C1274040|Result (navigational concept)|0
  C0521116|Current (qualifier value)|0
dosimetry deviations
  2
  C0599911|dosimetry|0
  C0012727|Spatial Displacement|0
hepatic ultrasonography
  5
  C0412555|Ultrasound scan - obstetric|0
  C0041618|Ultrasonography|0
  C0175676|use of ultrasonography|0
  C0996514|Hepatophyta|0
  C0205054|Hepatic|0
log rank comparison
  1
  C0699794|Rank|0
multiple transfusions
  2
  C0199960|Transfusion - action (qualifier value)|0
  C0439064|Numerous (qualifier value)|0
two sided test
  4
  C0039593|Testing|0
  C0205448|Two (qualifier value)|0
  C0441987|Side (qualifier value)|0
  C0392366|Tests (qualifier value)|0
l
  5
  C1306462|Light color|0
  C1304698|Liquid (finding)|0
  C0023700|Lighting|0
  C0475211|L (qualifier value)|0
  C0023693|Light|0
partial response rate
  3
  C0728938|Partial (qualifier value)|0
  C0871208|Rating|0
  C0871261|Responses|0
low incidence
  4
  C0021149|Incidence|0
  C0234886|Lowing, function (observable entity)|0
  C0205251|Low (qualifier value)|0
  C0220856|incidence of cases|0
research nurses
  1
  C0687693|Research nurse (occupation)|0
vaginal cuff
  2
  C0042232|Vagina|0
  C0180207|Cuffs|0
following eligibility criteria
  2
  C0243161|criteria|0
  C0332282|Following (attribute)|0
large cervical tumor
  3
  C0549177|Large|0
  C0205064|Cervical (qualifier value)|0
  C0027651|Neoplasms|0
two-thirds
  1
  C0205448|Two (qualifier value)|0
contralateral breast cancer
  1
  C1096616|Contralateral breast cancer|0
switzerland
  1
  C0039021|Switzerland|0
toxicologic effects
  2
  C1280500|Effect (qualifier value)|0
  C0205472|Toxicologic (qualifier value)|0
other two groups
  5
  C0205448|Two (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0205394|Other|0
neurological symptoms
  1
  C0235031|Neurologic Symptoms|0
suture
  4
  C0038969|Surgical sutures|0
  C0009068|Closure by suture|0
  C0502420|Suture Joint|0
  C0205368|Sutured (qualifier value)|0
efficiency
  1
  C0013682|Efficiency|0
locoregional recurrence
  1
  C0034897|Recurrence|0
platelet count depression
  5
  C0011581|Depressive disorder|0
  C0005821|Blood Platelets|0
  C0349217|Depressive episode, unspecified|0
  C0750480|COUNT|0
  C0011570|Mental Depression|0
several studies
  3
  C0557651|Room of building - Study|0
  C0443302|Several (qualifier value)|0
  C0947630|Scientific Study|0
l5-s1 junction
  2
  C1179704|S1 innervation|0
  C0205144|Junctional (qualifier value)|0
one approach
  2
  C0205447|One (qualifier value)|0
  C0449445|Approach (attribute)|0
subjective evaluation
  3
  C0220825|Evaluation|0
  C0439655|Subjective observation (qualifier value)|0
  C1261322|Assessment procedure (procedure)|0
concurrent malignant tumors
  4
  C0006826|Malignant Neoplasms|0
  C0027651|Neoplasms|0
  C0205420|Concurrent (qualifier value)|0
  C0205282|Malignant - descriptor|0
efforts to
  1
  C0015264|Exertion|0
patients also
  1
  C0030705|Patients|0
previous investigations
  2
  C0430007|Clinical investigation|0
  C0205156|Previous (qualifier value)|0
determination
  2
  C0680730|Adjudication|0
  C1148554|Determination Aspects|0
physical examinations
  1
  C0031809|Clinical examination|0
chronic bowel symptoms
  3
  C0683368|symptoms|0
  C0021853|Intestines|0
  C0205191|Chronic (qualifier value)|0
full explanation
  2
  C0443225|Full (qualifier value)|0
  C0681841|explanation|0
physical examination
  1
  C0031809|Clinical examination|0
therapeutic decision
  3
  C0039796|The science and art of healing|0
  C0302350|Therapeutic|0
  C0679006|decision|0
intestines
  1
  C0021853|Intestines|0
benefit
  1
  C0814225|benefits|0
new therapies
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0205314|New (qualifier value)|0
report
  2
  C0684224|Report (document)|0
  C0700287|Reporting|0
soft tissue sarcomas
  1
  C0677603|Sarcoma, Soft Tissue|0
major violation
  1
  C0205164|Major (qualifier value)|0
portugal
  1
  C0032729|Portugal|0
disseminated intravascular coagulation
  1
  C0012739|Disseminated Intravascular Coagulation|0
5-year disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
much lower potential
  3
  C0237399|Potential|0
  C0441994|Lower (qualifier value)|0
  C1272755|Lowered (qualifier value)|0
long-term side effects
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C1280500|Effect (qualifier value)|0
  C0441987|Side (qualifier value)|0
95% confidence
  1
  C0237529|Self-confidence (observable entity)|0
therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
patterns
  1
  C0449774|Patterns (qualifier value)|0
biologic activity
  5
  C0221187|Physical activity|0
  C0005522|Biological Products|0
  C0600075|Endurance of activity|0
  C0205460|Biologic (qualifier value)|0
  C0441655|Activities|0
retrospective evaluation
  3
  C0220825|Evaluation|0
  C0035363|Retrospective Studies|0
  C1261322|Assessment procedure (procedure)|0
heparin
  1
  C0019134|Heparin|0
contract
  2
  C1140999|Contraction (finding)|0
  C0332522|Contracts|0
secondary outcome measure
  5
  C0175668|Secondary to|0
  C0444706|Measured (qualifier value)|0
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0079809|Measures|0
  C0027627|Neoplasm Metastasis|0
muscle
  1
  C0026845|Muscle|0
only date
  2
  C0011008|Dates|0
  C0237553|dating|0
international federation of gynecology and obstetrics staging criteria
  5
  C0332285|Within|0
  C0243161|criteria|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0028773|Discipline of obstetrics|0
  C0018417|Gynecology|0
colostomy
  3
  C0448971|Colostomy stoma|0
  C0009410|Colostomy Procedure|0
  C0546255|Colostomy site|0
other variables
  2
  C0439828|Variable (qualifier value)|0
  C0205394|Other|0
univariate analysis
  1
  C0683962|univariate analysis|0
radiation energy to
  3
  C0424589|Vitality|0
  C0542479|Energy, Physics|0
  C0851346|Radiation|0
utilizing single multidrug regimen
  4
  C0037179|Unmarried person|0
  C0205171|Singular|0
  C0087136|Unmarried|0
  C0677937|regimen|0
pa
  1
  C0030125|p-Aminosalicylic Acid|0
wilcoxon rank sum test
  3
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
  C0699794|Rank|0
clusters
  1
  C0009085|Cluster Analysis|0
initial days
  2
  C0439228|day (qualifier value)|0
  C0205265|Initial (qualifier value)|0
long-term administration
  4
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
bulky cervical cancer
  4
  C0998265|Cancer Genus|0
  C0205064|Cervical (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
vessels
  1
  C0005847|Blood Vessels|0
twelve patients
  2
  C0205458|Twelve (qualifier value)|0
  C0030705|Patients|0
type
  4
  C0872404|Keyboard Typing|0
  C0441704|Typing Classification|0
  C0332307|With type (attribute)|0
  C0449470|Types (qualifier value)|0
higher pelvic radiation doses
  3
  C0030797|Pelvis|0
  C0719635|DOS|0
  C0851346|Radiation|0
clear explanation
  2
  C0205305|Clear (qualifier value)|0
  C0681841|explanation|0
treatment sequence
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
courses
  2
  C0449922|Course (attribute)|0
  C0750729|Courses (qualifier value)|0
intestinal fistula
  1
  C0021833|Intestinal Fistula|0
low purine concentrations
  5
  C0086045|Concentration|0
  C0234886|Lowing, function (observable entity)|0
  C0034140|Purines|0
  C0220903|purine|0
  C0205251|Low (qualifier value)|0
potential effectiveness
  3
  C1280519|Effectiveness (qualifier value)|0
  C0237399|Potential|0
  C0205414|Effective (qualifier value)|0
palliative irradiation only
  4
  C1285530|Palliative - procedure intent (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
cytology
  4
  C0010819|Cytology|0
  C0010820|Cellular aspects of|0
  C0849088|Test, cytology, digestive|0
  C1305671|Cytology procedure|0
abdominal computed tomography to
  2
  C0456438|Abdominal (qualifier value)|0
  C0040395|Tomography|0
same factors
  1
  C0445247|Same (qualifier value)|0
metastatic spread
  2
  C0036525|Metastatic to|0
  C0332261|Spreading (qualifier value)|0
presentation
  1
  C0449450|Presentation (attribute)|0
survival data
  2
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
regimen
  1
  C0677937|regimen|0
proliferating
  1
  C0334094|Proliferation (morphologic abnormality)|0
other distant metastases
  4
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0443203|Distant (qualifier value)|0
  C0027627|Neoplasm Metastasis|0
  C0205394|Other|0
staging method
  5
  C0025664|Methodology|0
  C0332305|With staging (attribute)|0
  C0027646|Diagnostic Neoplasm Staging|0
  C0025663|Methods|0
  C1306673|Stages (qualifier value)|0
mild symptoms
  2
  C0205080|Mild (qualifier value)|0
  C0683368|symptoms|0
further therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
different combination regimen
  3
  C0453882|Combinations (physical object)|0
  C0205195|Combined (qualifier value)|0
  C0677937|regimen|0
categorical variables
  1
  C0439828|Variable (qualifier value)|0
constant delivery
  3
  C0011209|Obstetric Delivery|0
  C0559563|Delivery finding (finding)|0
  C1135594|Delivery|0
median overall survival
  5
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
  C0549183|Median (qualifier value)|0
median survival time
  5
  C0038952|Continuance of life|0
  C0876920|Median Statistical Measurement|0
  C0040223|Time|0
  C0220921|survival aspects|0
  C0549183|Median (qualifier value)|0
developed acute leukemia
  2
  C0205178|Acuteness (qualifier value)|0
  C0023418|Leukemia|0
intraoperative boost
  1
  C0456904|Intraoperative (qualifier value)|0
sequential administration
  2
  C1262471|Administration (procedure)|0
  C0001554|Administration|0
evaluable patients to
  1
  C0030705|Patients|0
larger lumen
  4
  C1282864|Entire lumen of body system|0
  C0524461|Structure of lumen of body system|0
  C0443228|Greater (qualifier value)|0
  C1301906|Lumen (qualifier value)|0
roles
  1
  C0035820|Role|0
neoadjuvant ct
  1
  C0040405|X-Ray Computed Tomography|0
contraindications
  1
  C0079164|contraindications|0
general misinterpretation
  1
  C0205246|Generalized (qualifier value)|0
oedema
  2
  C0333239|Edematous|0
  C0013604|Edema|0
greatly.23 second
  2
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
large tumor size
  3
  C0549177|Large|0
  C0027651|Neoplasms|0
  C0702146|Size (attribute)|0
one person
  2
  C0205447|One (qualifier value)|0
  C0027361|Persons|0
diagnosis
  2
  C0348026|Diagnostic|0
  C0011900|Diagnosis|0
time deaths
  4
  C0011065|Cessation of life|0
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
suspected recurrence
  3
  C0332147|Suspected diagnosis (contextual qualifier) (qualifier value)|0
  C0034897|Recurrence|0
  C0750491|SUSPECT|0
same molecular weight
  4
  C1305866|Body Weight|0
  C0005910|Body Weight|0
  C0445247|Same (qualifier value)|0
  C0043100|Weight|0
other drugs
  3
  C0684270|Drugged|0
  C0205394|Other|0
  C0013227|Pharmaceutical Preparations|0
product limit method
  3
  C0025664|Methodology|0
  C0439801|Limited (qualifier value)|0
  C0025663|Methods|0
neutrophils
  1
  C0027950|Neutrophils|0
increase survival
  5
  C0038952|Continuance of life|0
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0220921|survival aspects|0
  C0442805|Increase (qualifier value)|0
adenocarcinoma
  1
  C0001418|Adenocarcinoma|0
in vitro document
  3
  C0332285|Within|0
  C1301725|Documented (qualifier value)|0
  C1301746|Documents (qualifier value)|0
expansile barrel shaped tumors
  3
  C0522512|With shape|0
  C0027651|Neoplasms|0
  C0332479|Shapes|0
selective procedures
  2
  C0025664|Methodology|0
  C0184661|Procedures|0
planned course
  4
  C0449922|Course (attribute)|0
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0750729|Courses (qualifier value)|0
precisely questions
  1
  C0876928|Questioning|0
disease-free survival curves
  4
  C0205134|Curved (qualifier value)|0
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
impact radiation therapy
  5
  C0726639|Impact|0
  C0039798|therapeutic aspects|0
  C0333125|Impacted (qualifier value)|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
appetite loss
  1
  C0003123|Anorexia|0
exception
  1
  C0750577|EXCEPTIONALLY|0
randomised three arm study
  5
  C0557651|Room of building - Study|0
  C0003792|Arm|0
  C0205449|Three (qualifier value)|0
  C0446516|Upper arm|0
  C0947630|Scientific Study|0
most incidence
  3
  C0021149|Incidence|0
  C0205393|Most (qualifier value)|0
  C0220856|incidence of cases|0
portals
  1
  C0205054|Hepatic|0
acute radiation morbidity scoring criteria
  5
  C0026538|Morbidity - disease rate|0
  C0449820|Scores (qualifier value)|0
  C0220880|morbidity aspects|0
  C0205178|Acuteness (qualifier value)|0
  C0851346|Radiation|0
seventy six percent
  2
  C0439165|Percent (qualifier value)|0
  C0205452|Six (qualifier value)|0
pelvic radiation therapy still
  4
  C0030797|Pelvis|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
probability distribution
  3
  C0033204|Probability|0
  C0520511|Distributing|0
  C0037775|Spatial Distribution|0
length
  1
  C0439537|Lengths (qualifier value)|0
epirubicin dose level
  3
  C0441889|Levels (qualifier value)|0
  C0456079|Disease classification level|0
  C0014582|Epirubicin|0
organ involvement
  3
  C0178784|Organ|0
  C0205428|Involvements (qualifier value)|0
  C0392760|Not free of (attribute)|0
doubt
  1
  C0870444|Doubt|0
surviving
  1
  C0310255|SURVIVE (product)|0
only danish study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
5-year actuarial disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
mitolactolor ifosfamide
  1
  C0020823|Ifosfamide|0
only 4% response rate
  2
  C0871208|Rating|0
  C0871261|Responses|0
overall local relapse rate
  5
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0282416|Overall [Publication Type]|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
neutropenia
  1
  C0027947|Neutropenia|0
not myelosuppressiveequivalent doses
  1
  C0719635|DOS|0
stepwise regression method
  4
  C0025664|Methodology|0
  C0025663|Methods|0
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
pearson’s x2 test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
medial parametria
  3
  C0205098|Medial (qualifier value)|0
  C0227822|Parametrium|0
  C1281249|Entire parametrium|0
dissection
  3
  C0012737|Dissection|0
  C1293093|Dissection procedure (procedure)|0
  C1306808|Dissection - action (qualifier value)|0
developments
  2
  C0020119|Human Development|0
  C0243107|development aspects|0
cardiac toxicity patient
  4
  C0205041|Cardio-|0
  C0040539|Toxicity aspects|0
  C0030705|Patients|0
  C0600688|Toxic effect|0
recent report
  3
  C0332185|Recent episode (qualifier value)|0
  C0684224|Report (document)|0
  C0700287|Reporting|0
mtx mg
  1
  C0025677|Methotrexate|0
5-fu dosage
  3
  C0016360|Fluorouracil|0
  C0178602|Dosages (qualifier value)|0
  C0268696|Feline urological syndrome (disorder)|0
several swedish studies
  3
  C0557651|Room of building - Study|0
  C0443302|Several (qualifier value)|0
  C0947630|Scientific Study|0
ultimately required hospitalization
  1
  C0019993|Hospitalization|0
not part
  1
  C0449719|Part (attribute)|0
nonirradiated patients
  1
  C0030705|Patients|0
bilateral mammography
  1
  C0203027|Bilateral mammography (procedure)|0
only colon cancer patients
  5
  C0009368|Colon|0
  C0684195|Cola|0
  C0006826|Malignant Neoplasms|0
  C0030705|Patients|0
  C1281569|Entire colon|0
devices
  3
  C0884854|Physical devices|0
  C0699733|Devices|0
  C0220819|device aspects|0
dexamethasone
  1
  C0011777|Dexamethasone|0
larger bites
  3
  C0045724|2-(4-ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole|0
  C0005658|Bites|0
  C0443228|Greater (qualifier value)|0
treatment plan
  1
  C0599880|PLAN OF TREATMENT|0
limited apical lung fibrosis
  5
  C0439801|Limited (qualifier value)|0
  C0016059|Fibrosis|0
  C1278908|Entire lung|0
  C0024109|Lung|0
  C0205111|Apical (qualifier value)|0
absolute improvement
  1
  C0205344|Absolute (qualifier value)|0
baseline demographic
  1
  C0168634|BaseLine|0
equal doses
  3
  C0719635|DOS|0
  C0439089|Equals|0
  C0205163|Equal (qualifier value)|0
clinical behaviour
  3
  C0205210|Clinical (qualifier value)|0
  C0004927|Behavior|0
  C0677505|Behaviors and observations relating to behavior|0
similar analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
significant benefit
  2
  C0814225|benefits|0
  C0750502|Significant (qualifier value)|0
antineoplastic activity
  4
  C0221187|Physical activity|0
  C0003392|Antineoplastic Agents|0
  C0600075|Endurance of activity|0
  C0441655|Activities|0
good estimate
  2
  C0750572|ESTIMATED|0
  C0205170|Good (qualifier value)|0
median wbc nadir
  3
  C0876920|Median Statistical Measurement|0
  C0023516|Leukocytes|0
  C0549183|Median (qualifier value)|0
important source
  1
  C0449416|Source (attribute)|0
normal renal function
  1
  C0232805|Normal renal function (finding)|0
radia to follow-up
  3
  C0547043|Up (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
pretreatment stratification
  1
  C0680382|social stratification|0
complication
  2
  C0009566|Complication|0
  C1171258|Complication Aspects|0
higher diarrhoea
  1
  C0011991|Diarrhea|0
irinotecan group subseqently received irinotecan
  4
  C0123931|irinotecan|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
multivariate regression
  2
  C0684321|Regression - mental defense mechanism|0
  C0684320|Disease regression|0
cancer recurrences
  1
  C0920420|cancer recurrence|0
initial statistical prediction
  3
  C0220917|statistical|0
  C0681842|prediction|0
  C0205265|Initial (qualifier value)|0
severe toxic effects
  3
  C1280500|Effect (qualifier value)|0
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0600688|Toxic effect|0
four randomized trials
  1
  C0205450|Four (qualifier value)|0
males
  2
  C0086582|Males|0
  C0024554|Male gender|0
low rate
  3
  C0234886|Lowing, function (observable entity)|0
  C0871208|Rating|0
  C0205251|Low (qualifier value)|0
mev photon linear accelerator
  4
  C0205132|Linear|0
  C0556642|MeV (qualifier value)|0
  C0086805|Photons|0
  C0681602|accelerator|0
not escalated therapy
  2
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
first cycle
  1
  C0205435|First (qualifier value)|0
cisplatin
  1
  C0008838|Cisplatin|0
yet epi
  5
  C1317977|Epithelial metaplasia (morphologic abnormality)|0
  C0014544|Epilepsy|0
  C0221908|Epithelial|0
  C0014609|Epithelium|0
  C0334029|Epithelialization|0
two other patients
  3
  C0205448|Two (qualifier value)|0
  C0030705|Patients|0
  C0205394|Other|0
not high cr rate
  4
  C0205250|High|0
  C0871208|Rating|0
  C0235146|Euphoric mood|0
  C0008574|Chromium|0
four additional deaths
  2
  C0011065|Cessation of life|0
  C0205450|Four (qualifier value)|0
postoperative radiation therapy
  4
  C0039798|therapeutic aspects|0
  C0032790|Postoperative Period|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
limit
  1
  C0439801|Limited (qualifier value)|0
systemic adjuvant therapy
  4
  C0205373|Systemic (qualifier value)|0
  C0039798|therapeutic aspects|0
  C0001551|Adjuvants, Immunologic|0
  C0087111|Therapeutic procedure|0
manchester study groups
  5
  C0557651|Room of building - Study|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0947630|Scientific Study|0
median monthly dose
  3
  C0876920|Median Statistical Measurement|0
  C0332177|Monthly (qualifier value)|0
  C0549183|Median (qualifier value)|0
concurrent chemoradiotherapy
  1
  C0205420|Concurrent (qualifier value)|0
inclusion criteria
  1
  C0243161|criteria|0
nine symptom scales
  5
  C0349674|Intellectual scale|0
  C0683368|symptoms|0
  C0175659|Weight measurement scales|0
  C0222045|Integumentary scale|0
  C0392757|Test scaling|0
menopausal groups
  4
  C0232967|Menopausal|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
potential efficacy
  1
  C0237399|Potential|0
monitoring
  3
  C0150369|Preventive monitoring|0
  C0181904|Biomedical Monitors|0
  C0728873|Monitor|0
dizziness
  1
  C0012833|Dizziness|0
registration forms
  3
  C0376315|Manufactured form|0
  C0205431|Formed (qualifier value)|0
  C0348078|Qualitative form|0
new prospective trials
  1
  C0205314|New (qualifier value)|0
combination therapy
  2
  C0556895|Combination electrotherapy|0
  C0009429|Combined Modality Therapy|0
local relapses simultaneously
  4
  C0035020|Relapse|0
  C0205336|Relapsing course|0
  C0580802|Relapse phase|0
  C0205276|Local (qualifier value)|0
parametrial extensions
  1
  C0231448|Extension (qualifier value)|0
published trials
  1
  C0034037|Publishing|0
patient’s preference
  1
  C0558295|Preferences (qualifier value)|0
parasitic infections
  1
  C0030499|Parasitic Diseases|0
posteroanterior opposed beams
  1
  C0578681|Difficulty opposing thumb (finding)|0
seventy five patients
  2
  C0205451|Five (qualifier value)|0
  C0030705|Patients|0
epi doses
  1
  C0719635|DOS|0
two trials
  1
  C0205448|Two (qualifier value)|0
previous experience
  2
  C0205156|Previous (qualifier value)|0
  C0596545|experience|0
sec
  1
  C0457385|seconds|0
incidence
  2
  C0021149|Incidence|0
  C0220856|incidence of cases|0
pathology slides
  5
  C0030664|Pathology|0
  C0444330|Slide (specimen)|0
  C0677042|Pathology processes|0
  C0332246|Sliding|0
  C0205469|Pathological aspects|0
biopsy proven invasive carcinoma
  5
  C0700164|proven venom|0
  C0205281|Invasive (qualifier value)|0
  C0005558|Biopsy|0
  C0456369|Proven findings|0
  C0007097|Carcinoma|0
ordered categorical data
  5
  C0425931|Cycle -menstrual - data (context-dependent category)|0
  C0010990|Data Adjustment|0
  C0425928|Menstrual data NOS (context-dependent category)|0
  C0425929|Menstrual loss data (context-dependent category)|0
  C0425930|Period - menstrual-data (context-dependent category)|0
two layer technique
  4
  C0025664|Methodology|0
  C0934502|Layer|0
  C0205448|Two (qualifier value)|0
  C0449851|Techniques|0
phase ii trial
  1
  C0278782|phase II study|0
doubts
  1
  C0870444|Doubt|0
hr
  1
  C0439227|Hour|0
exercise
  3
  C1306338|Physical exercise (qualifier value)|0
  C0015259|Exercise|0
  C0452240|Physical therapy exercises|0
significantly improved survival
  5
  C1272745|Improving (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
additive hormonal therapy
  4
  C0039798|therapeutic aspects|0
  C0458083|Hormonal (qualifier value)|0
  C0442796|Additive (qualifier value)|0
  C0087111|Therapeutic procedure|0
overall 5-year actuarial survival
  4
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
  C0439234|year (qualifier value)|0
possible interaction
  3
  C0332149|Possible|0
  C0037420|Social Interaction|0
  C0687133|Drug Interactions|0
control
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
routine use
  2
  C0042153|utilization|0
  C0205547|Routine (qualifier value)|0
forms
  3
  C0376315|Manufactured form|0
  C0205431|Formed (qualifier value)|0
  C0348078|Qualitative form|0
most active anticancer drug
  4
  C0684270|Drugged|0
  C0205393|Most (qualifier value)|0
  C0205177|Active|0
  C0013227|Pharmaceutical Preparations|0
alkylating agents
  1
  C0002073|Alkylating Agents|0
local control
  3
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
  C0205276|Local (qualifier value)|0
experience
  1
  C0596545|experience|0
meta-analysis to
  3
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C1042496|Meta|0
internal radiotherapy
  1
  C0203608|Radionuclide therapy|0
resistant neoplastic cells overgrow
  3
  C0007634|Cells|0
  C0332325|Resistant (qualifier value)|0
  C1269647|Entire cell|0
node-negative group
  5
  C0746922|NODE|0
  C0205160|Negative (qualifier value)|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
changed fractionation scheme
  4
  C0392747|Changing|0
  C0443172|Changed status|0
  C0524811|Dose Fractionation|0
  C0016640|Fractionation|0
calculated recurrence rate
  3
  C0871208|Rating|0
  C0034897|Recurrence|0
  C0444686|Calculated (qualifier value)|0
carcinoma
  1
  C0007097|Carcinoma|0
better therapeutic index
  5
  C0039796|The science and art of healing|0
  C0021200|Indexing|0
  C0332272|Better (qualifier value)|0
  C0302350|Therapeutic|0
  C0918012|Indexes|0
further dox
  5
  C0471220|Further dressings (physical object)|0
  C0578818|In further education (finding)|0
  C0250087|DOX-OXD|0
  C1134452|doxorubicin-magnetic targeted carrier complex|0
  C1135139|cBR96-doxorubicin immunoconjugate|0
most significant risk factors
  3
  C0205393|Most (qualifier value)|0
  C0750502|Significant (qualifier value)|0
  C0035647|Risk|0
historical control
  2
  C0702113|Controlled (qualifier value)|0
  C0243148|control|0
many patients
  2
  C0030705|Patients|0
  C0439064|Numerous (qualifier value)|0
iva
  1
  C1054142|Iva|0
aged years
  4
  C0001811|Aging|0
  C0001779|Age (qualifier value)|0
  C0001792|Elderly|0
  C0439234|year (qualifier value)|0
statistically significant overall effect
  3
  C1280500|Effect (qualifier value)|0
  C0750502|Significant (qualifier value)|0
  C0282416|Overall [Publication Type]|0
european organization
  4
  C0029237|Physiologic Organization|0
  C0220885|organizational|0
  C0029246|Organization administrative structures|0
  C0239307|EUROPEAN|0
cancer
  3
  C0998265|Cancer Genus|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
50% decrease
  3
  C0205216|Decreased (qualifier value)|0
  C0442797|Decreasing (qualifier value)|0
  C0547047|Decrease (qualifier value)|0
complete response
  1
  C0677874|In complete remission (qualifier value)|0
random assignment
  1
  C0814868|random assignment|0
standard criteria
  3
  C0243161|criteria|0
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
life tables
  1
  C0023683|Life Tables|0
previous chemotherapy
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0205156|Previous (qualifier value)|0
  C0013216|Pharmacotherapy|0
two tailed
  2
  C0205448|Two (qualifier value)|0
  C0039259|Tail|0
real recovery time
  4
  C0040223|Time|0
  C0449243|Timing (attribute)|0
  C0392761|Timed (qualifier value)|0
  C0237820|recovery from disease|0
distance
  1
  C0012751|Distance|0
value
  1
  C0042295|VALUING|0
other efficacy endpoints
  2
  C0150100|ENDPOINT|0
  C0205394|Other|0
addition
  1
  C0442796|Additive (qualifier value)|0
analgesics
  1
  C0002771|Analgesics|0
especially neutropenia
  1
  C0027947|Neutropenia|0
loco regional lymph nodes
  3
  C0746922|NODE|0
  C0024202|Lymph|0
  C0205147|Regional (qualifier value)|0
standard radiation
  3
  C0175675|Standards of Weights and Measures|0
  C0038137|standards characteristics|0
  C0851346|Radiation|0
probability
  1
  C0033204|Probability|0
external irradiation
  4
  C0205101|External (qualifier value)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
analysis of variance
  1
  C0002780|Analysis of Variance|0
serum electrolytes
  2
  C0587355|Serum electrolytes NOS (procedure)|0
  C1287347|Finding of serum electrolyte levels (finding)|0
planned treatment course
  5
  C0449922|Course (attribute)|0
  C1301732|Planned (qualifier value)|0
  C0032074|Cognitive function: planning (observable entity)|0
  C0087111|Therapeutic procedure|0
  C0750729|Courses (qualifier value)|0
maximum only
  1
  C0806909|Maximum|0
radiologic tests
  3
  C0205483|Radiologic (qualifier value)|0
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
not protocol treatment
  3
  C0039798|therapeutic aspects|0
  C0442711|Protocols documentation|0
  C0087111|Therapeutic procedure|0
preliminary 3-yr results
  3
  C1274040|Result (navigational concept)|0
  C0439611|Preliminary (qualifier value)|0
  C0439234|year (qualifier value)|0
dosimetry curves
  2
  C0205134|Curved (qualifier value)|0
  C0599911|dosimetry|0
not specific response
  3
  C1263442|SPECIFIC|0
  C0871261|Responses|0
  C0205369|Specific (qualifier value)|0
mucositis
  1
  C0236177|Inflammatory disease of mucous membrane (disorder)|0
preference
  1
  C0558295|Preferences (qualifier value)|0
interruption
  1
  C0443239|Interrupted (qualifier value)|0
equivalent degree
  3
  C0449286|Degree or extent|0
  C0542560|Academic degree|0
  C0439185|Eq (qualifier value)|0
questionnaires
  1
  C0034394|Questionnaires|0
first infusion
  2
  C0574032|Infusion (procedure)|0
  C0205435|First (qualifier value)|0
excluding melanoma
  2
  C0332196|Exclude (qualifier value)|0
  C0025202|Melanoma|0
prognostic information
  2
  C0220901|prognostic|0
  C0870705|Information|0
month
  1
  C0439231|month (qualifier value)|0
one year
  2
  C0205447|One (qualifier value)|0
  C0439234|year (qualifier value)|0
m local recurrence rate
  3
  C0871208|Rating|0
  C0034897|Recurrence|0
  C0205276|Local (qualifier value)|0
complication rates
  3
  C0009566|Complication|0
  C1171258|Complication Aspects|0
  C0871208|Rating|0
knowledge
  1
  C0376554|Knowledge|0
4.6 v 3.2 months
  1
  C0439231|month (qualifier value)|0
started chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C1272689|Started (qualifier value)|0
  C0452588|Start (substance)|0
  C0013216|Pharmacotherapy|0
pulmonary functions
  1
  C0231921|Pulmonary function (observable entity)|0
partial responses
  1
  C0677924|partial response|0
higher dose
  5
  C1075633|higher Epidendroideae|0
  C0996513|higher plants|0
  C1012706|Termitidae|0
  C0684068|higher animals|0
  C0424933|Higher education (finding)|0
actuarial 5-year disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
potential risk
  2
  C0237399|Potential|0
  C0035647|Risk|0
toxicities
  2
  C0040539|Toxicity aspects|0
  C0600688|Toxic effect|0
hydroxyurea therapy
  3
  C0039798|therapeutic aspects|0
  C0020402|Hydroxyurea|0
  C0087111|Therapeutic procedure|0
irinotecan
  1
  C0123931|irinotecan|0
identical postsurgery radiation therapy regimens
  5
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0677937|regimen|0
  C0851346|Radiation|0
  C0205280|Identical (qualifier value)|0
standard external beam pelvic irradiation
  5
  C0030797|Pelvis|0
  C0175675|Standards of Weights and Measures|0
  C0205101|External (qualifier value)|0
  C0038137|standards characteristics|0
  C0034618|Radiation therapy|0
two factors
  1
  C0205448|Two (qualifier value)|0
routine chemistry
  3
  C0079107|chemical aspects|0
  C0205547|Routine (qualifier value)|0
  C0007996|Science of Chemistry|0
included patients
  2
  C0332257|Including (qualifier value)|0
  C0030705|Patients|0
dose prescription
  1
  C0033080|Prescriptions|0
primary tumour site
  1
  C0475447|Site of primary tumor (attribute)|0
overall disease-free survival
  4
  C0038952|Continuance of life|0
  C0012634|Disease|0
  C0220921|survival aspects|0
  C0282416|Overall [Publication Type]|0
hair loss
  1
  C0002170|Alopecia|0
estrogen receptors
  1
  C0034804|Estrogen Receptors|0
portal adjuvant chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0001551|Adjuvants, Immunologic|0
  C0013216|Pharmacotherapy|0
  C0205054|Hepatic|0
aggressiveness
  1
  C0235099|Aggression aggravated|0
local events
  2
  C0441471|Events (event)|0
  C0205276|Local (qualifier value)|0
median platelet nadir
  3
  C0876920|Median Statistical Measurement|0
  C0005821|Blood Platelets|0
  C0549183|Median (qualifier value)|0
demonstration
  2
  C0332265|Demonstrable (qualifier value)|0
  C0335296|Demonstrator (occupation)|0
european organization for research and treatment of cancer
  5
  C0029237|Physiologic Organization|0
  C0035168|Research|0
  C0029246|Organization administrative structures|0
  C0006826|Malignant Neoplasms|0
  C0087111|Therapeutic procedure|0
group given radiotherapy
  5
  C0034619|radiotherapeutic|0
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0034618|Radiation therapy|0
5-yr total survival
  4
  C0439810|Total (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
supraclavicular node
  1
  C0229730|Structure of supraclavicular lymph node|0
hand-sewn anastomosis
  5
  C0677554|Anastomosis - action|0
  C0018563|Hand|0
  C0332853|Anastomosis|0
  C1281583|Entire hand|0
  C0500470|Anatomical anastomosis|0
cdr
  2
  C0055351|Chlordecone reductase|0
  C0011485|Deoxycytidine|0
previous surgery
  4
  C0038895|Surgical aspects|0
  C0205156|Previous (qualifier value)|0
  C0038894|Surgery specialty|0
  C0543467|GENERAL OPERATIVE PROCEDURES|0
verification
  1
  C0237944|Verification of Theories|0
tumour stabilisation
  2
  C1293130|Stabilization (procedure)|0
  C0027651|Neoplasms|0
previously received radiotherapy
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
control group
  1
  C0009932|Control Groups|0
three packets
  1
  C0205449|Three (qualifier value)|0
weekly regimen
  2
  C0332174|Weekly (qualifier value)|0
  C0677937|regimen|0
statistical evidence
  1
  C0220917|statistical|0
exploratory subset analysis
  2
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
and percent confidence intervals
  3
  C0237529|Self-confidence (observable entity)|0
  C0439165|Percent (qualifier value)|0
  C1272706|Interval (qualifier value)|0
prophylactic oral antibiotics
  4
  C0442027|Oral (qualifier value)|0
  C0009653|Condoms, Male|0
  C0445202|Prophylactic (qualifier value)|0
  C0003232|Antibiotics|0
relative cardiotoxicity
  3
  C0876994|Cardiotoxicity|0
  C0080103|Relative (related person)|0
  C0205345|Relative|0
performance status
  1
  C0935728|performance status|0
concept
  2
  C0178566|concept|0
  C0308714|CONCEPT Drug|0
lesser degrees
  3
  C0449286|Degree or extent|0
  C0542560|Academic degree|0
  C0547044|Lesser (qualifier value)|0
spain
  1
  C0037747|Spain|0
nonhaematological toxic effect
  2
  C1280500|Effect (qualifier value)|0
  C0600688|Toxic effect|0
patients rbcs
  2
  C0014792|Erythrocytes|0
  C0030705|Patients|0
disproportionately larger number
  3
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
  C0443228|Greater (qualifier value)|0
chronic adverse effects
  2
  C1280500|Effect (qualifier value)|0
  C0205191|Chronic (qualifier value)|0
most common toxicity
  4
  C0205214|Common (qualifier value)|0
  C0040539|Toxicity aspects|0
  C0205393|Most (qualifier value)|0
  C0600688|Toxic effect|0
bun mg
  5
  C0610063|TYR-BUN|0
  C0151406|BUN, mg%|0
  C0452636|Chelsea bun (substance)|0
  C0741818|BUN RISING|0
  C0741813|BUN ADMISSION|0
radical irradiation
  5
  C0439807|Radical (qualifier value)|0
  C0302912|Radicals (chemistry)|0
  C0851346|Radiation|0
  C0034618|Radiation therapy|0
  C1282930|Irradiation (physical force)|0
increased rates
  4
  C0442808|Increasing (qualifier value)|0
  C0205217|Increased (qualifier value)|0
  C0871208|Rating|0
  C0442805|Increase (qualifier value)|0
72% 5-yr survival
  3
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0439234|year (qualifier value)|0
approximately mm
  1
  C0332232|Approximate (qualifier value)|0
complete disability
  2
  C0231170|Disability NOS (finding)|0
  C0205197|Complete (qualifier value)|0
then weeks
  1
  C0439230|week (qualifier value)|0
hyperfractionated radiation
  1
  C0851346|Radiation|0
improved survival
  5
  C1272745|Improving (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
  C0332161|Attenuated by (contextual qualifier) (qualifier value)|0
  C0184511|Improved (qualifier value)|0
tumors
  1
  C0027651|Neoplasms|0
careful approximation
  3
  C0695433|Distraction, approximation|0
  C1283102|Approximation - action (qualifier value)|0
  C0518852|Skin approximation|0
radiation treatments
  3
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0851346|Radiation|0
never started chemotherapy
  5
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C1272689|Started (qualifier value)|0
  C0452588|Start (substance)|0
  C0013216|Pharmacotherapy|0
marrow reserve
  2
  C0376152|Marrow|0
  C0086590|Vegetable marrow|0
partial responders
  1
  C0728938|Partial (qualifier value)|0
serum creatinine level
  1
  C0600061|Serum creatinine level|0
prior history
  5
  C0019665|history|0
  C1321503|History of (contextual qualifier) (qualifier value)|0
  C0019664|Recording of previous events|0
  C0750516|PRIOR|0
  C0262926|Medical History|0
cervical cancer disproportionately
  4
  C0998265|Cancer Genus|0
  C0205064|Cervical (qualifier value)|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
local recurrence alone metastasis
  5
  C1290850|Secondary malignant neoplastic disease (disorder)|0
  C0034897|Recurrence|0
  C0679994|alone|0
  C0027627|Neoplasm Metastasis|0
  C0205276|Local (qualifier value)|0
small bowel follow-up
  5
  C0021853|Intestines|0
  C0547043|Up (qualifier value)|0
  C0700321|Small|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
patient pretreatment characteristics
  1
  C0030705|Patients|0
27 98 days
  1
  C0439228|day (qualifier value)|0
total survival
  3
  C0439810|Total (qualifier value)|0
  C0038952|Continuance of life|0
  C0220921|survival aspects|0
because less mesentery
  1
  C0025474|Mesentery|0
chest pain
  1
  C0008031|Chest Pain|0
primary end points
  4
  C1272693|Ended (qualifier value)|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
  C0444930|End (qualifier value)|0
ovariectomy
  1
  C0029936|Ovariectomy|0
protocol treatment
  3
  C0039798|therapeutic aspects|0
  C0442711|Protocols documentation|0
  C0087111|Therapeutic procedure|0
toxic cumulative dose
  1
  C0600688|Toxic effect|0
c1
  2
  C1305856|C1 innervation|0
  C0009499|Complement component C1|0
mucocutaneous reactions
  1
  C0443286|Reaction (qualifier value)|0
about weeks
  1
  C0439230|week (qualifier value)|0
— percent
  1
  C0439165|Percent (qualifier value)|0
fluorouracil infusion study
  4
  C0557651|Room of building - Study|0
  C0574032|Infusion (procedure)|0
  C0016360|Fluorouracil|0
  C0947630|Scientific Study|0
absence
  1
  C0424530|Absences (finding)|0
peculiar immunogenicity
  2
  C0423571|Abnormal sensation (finding)|0
  C0235293|Taste peculiar|0
deep one third stromal invasion
  3
  C0205437|Third (qualifier value)|0
  C0205447|One (qualifier value)|0
  C0205125|Depth (qualifier value)|0
reduced survival rates
  4
  C0392756|Reduced (qualifier value)|0
  C0038952|Continuance of life|0
  C0871208|Rating|0
  C0220921|survival aspects|0
continuous method
  3
  C0025664|Methodology|0
  C0025663|Methods|0
  C0549178|Continuous (qualifier value)|0
randomized phase iii trial
  3
  C0585064|Numerical phases (qualifier value)|0
  C0439070|III (qualifier value)|0
  C0205390|Phase (qualifier value)|0
power analysis
  3
  C0002778|Analysis of substances|0
  C0936012|Analysis|0
  C0032863|Power (Psychology)|0
contemporary innovation first
  1
  C0205435|First (qualifier value)|0
injection
  2
  C0021485|Injections|0
  C1272883|Injection (product)|0
tumors cm
  2
  C0475210|cm (qualifier value)|0
  C0027651|Neoplasms|0
parametrium status
  3
  C0449438|Status (attribute)|0
  C0227822|Parametrium|0
  C1281249|Entire parametrium|0
set
  2
  C0542559|contextual factors|0
  C0036849|Set (Psychology)|0
abnormal cea values
  3
  C0007082|Carcinoembryonic Antigen|0
  C0205161|Abnormal (qualifier value)|0
  C0042295|VALUING|0
main cause
  4
  C1314792|etiology|0
  C0678227|Causing (attribute)|0
  C0015127|Causality|0
  C0205225|Primary|0
apparent evidence
  1
  C0750489|APPARENT|0
previously untreated colorectal cancer patients
  5
  C0555952|Colorectal (qualifier value)|0
  C0998265|Cancer Genus|0
  C0030705|Patients|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
arbitrarily
  1
  C1264693|Arbitrary (property) (qualifier value)|0
subsequent anticancer chemotherapies
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0750530|SUBSEQUENT|0
  C0013216|Pharmacotherapy|0
intravenously wk
  1
  C0439230|week (qualifier value)|0
limb sparing procedure
  4
  C0025664|Methodology|0
  C1280090|Entire limb|0
  C0184661|Procedures|0
  C0015385|Limb structure|0
more restricted selection criteria
  4
  C0243161|criteria|0
  C0443288|Restricted (qualifier value)|0
  C0036576|Selection (Genetics)|0
  C0205172|More (qualifier value)|0
m0 primary rectal adenocarcinoma
  4
  C0205052|Rectal (qualifier value)|0
  C0001418|Adenocarcinoma|0
  C0439631|Primary operation (qualifier value)|0
  C0205225|Primary|0
similar high doses
  3
  C0205250|High|0
  C0719635|DOS|0
  C0235146|Euphoric mood|0
same procedures
  3
  C0025664|Methodology|0
  C0445247|Same (qualifier value)|0
  C0184661|Procedures|0
external beam radiation
  1
  C0796629|external radiation|0
50% dose reduction
  2
  C0301630|Reduction (chemical)|0
  C0441610|Reduction - action|0
polymorphous liposarcoma
  1
  C0023827|Liposarcoma|0
still predominant site
  1
  C0205145|Associated topography (attribute)|0
adjunctive radiotherapy significantly
  2
  C0034619|radiotherapeutic|0
  C0034618|Radiation therapy|0
bilateral pelvic lymphade center
  5
  C0030797|Pelvis|0
  C0935444|Centering|0
  C0205099|Central|0
  C0281267|bilateral breast cancer|0
  C0238767|Bilateral|0
chemotherapy program
  4
  C0013217|pharmacotherapeutic|0
  C0392920|Chemotherapy-Oncologic Procedure|0
  C0376691|Programs [Publication Type]|0
  C0013216|Pharmacotherapy|0
postoperative radiation
  2
  C0032790|Postoperative Period|0
  C0851346|Radiation|0
2 test
  2
  C0039593|Testing|0
  C0392366|Tests (qualifier value)|0
because number
  2
  C0449788|Count of entities (property) (qualifier value)|0
  C0237753|Numbers (qualifier value)|0
multivariate analysis
  1
  C0026777|Multivariate Analysis|0
radiation groups
  4
  C1300322|Group (social concept)|0
  C0439745|Grouped (qualifier value)|0
  C0441833|Groups (qualifier value)|0
  C0851346|Radiation|0
relatively low proportion
  2
  C0234886|Lowing, function (observable entity)|0
  C0205251|Low (qualifier value)|0
40% relative reduction
  4
  C0301630|Reduction (chemical)|0
  C0080103|Relative (related person)|0
  C0205345|Relative|0
  C0441610|Reduction - action|0
high creatinine concentration
  4
  C0086045|Concentration|0
  C0205250|High|0
  C0235146|Euphoric mood|0
  C0010294|Creatinine|0
congestive heart failure
  1
  C0018802|Heart Failure, Congestive|0
95% confidence interval
  1
  C0009667|Confidence Intervals|0
sq m intravenously
  1
  C0757631|myristoyl-L-methionine|0
anterior restorative resection
  3
  C0205094|Anterior|0
  C1306255|Excision - action (qualifier value)|0
  C0015252|Excision|0
american joint committee on cancer
  5
  C0392905|Articular system structure (body structure)|0
  C0022417|Joints|0
  C0006826|Malignant Neoplasms|0
  C0936282|Malignant neoplasm, primary (morphologic abnormality)|0
  C0596070|American|0
maximal tumor cytoreduction
  2
  C0205289|Maximal (qualifier value)|0
  C0027651|Neoplasms|0
protocol management
  2
  C0870834|Management|0
  C0442711|Protocols documentation|0
main aim
  1
  C0205225|Primary|0
four field techniques
  5
  C0025664|Methodology|0
  C0205450|Four (qualifier value)|0
  C0440042|Field's stain|0
  C0331809|Fielding|0
  C0449851|Techniques|0
student t tests
  1
  C0871453|Students T Test|0
severe actinic cystitis
  3
  C0205082|Severe (severity modifier) (qualifier value)|0
  C0439681|Actinic (qualifier value)|0
  C0010692|Cystitis|0
worse stomatitis
  3
  C1279889|Deterioration of status|0
  C0038362|Stomatitis|0
  C0332271|Worsening (qualifier value)|0
variations
  1
  C0205419|Variant|0
second rationale
  2
  C0205436|Second (qualifier value)|0
  C0457385|seconds|0
substantial minority recur
  3
  C0812423|recur|0
  C0205335|Recurrent (qualifier value)|0
  C0680221|minority|0
combination chemotherapy
  1
  C0013218|Drug Therapy, Combination|0
definitive statements
  1
  C0443196|Definitive (qualifier value)|0
tolerance
  2
  C0231197|Physiologic tolerance|0
  C0220929|Mental tolerance|0
study treatment
  4
  C0557651|Room of building - Study|0
  C0039798|therapeutic aspects|0
  C0087111|Therapeutic procedure|0
  C0947630|Scientific Study|0
similar rates
  1
  C0871208|Rating|0
gog study
  2
  C0557651|Room of building - Study|0
  C0947630|Scientific Study|0
ovarian cancer
  2
  C1140680|Malignant neoplasm of ovary|0
  C0029925|Ovarian Carcinoma|0
bilirubin level 2.5 mg
  3
  C0441889|Levels (qualifier value)|0
  C0005437|Bilirubin|0
  C0456079|Disease classification level|0
genitourinary toxicity
  3
  C0040539|Toxicity aspects|0
  C0447566|Urogenital structure|0
  C0600688|Toxic effect|0
only fictitious difference
  1
  C0742720|COMPLAINT FICTITIOUS|0
life-threatening conditions
  3
  C0009647|Conditioning (Psychology)|0
  C0348080|Condition (attribute)|0
  C0376558|Life|0
m cisplatin
  1
  C0008838|Cisplatin|0
long-term improvement
  2
  C0870371|Craving|0
  C0205166|Long (qualifier value)|0
higher proportion
  5
  C1075633|higher Epidendroideae|0
  C0684068|higher animals|0
  C0429144|Facial proportion (observable entity)|0
  C0007725|Cephalopelvic Proportion|0
  C0491073|SUBSYSTEM, PROPORTIONING|0
polymorphous sarcomas
  1
  C1261473|Sarcoma|0
doses
  1
  C0719635|DOS|0
other nine
  2
  C0205455|Nine (qualifier value)|0
  C0205394|Other|0
extended follow-up period
  5
  C0231449|Extended (qualifier value)|0
  C0547043|Up (qualifier value)|0
  C0332258|Extending (qualifier value)|0
  C1282911|Upward (qualifier value)|0
  C0332282|Following (attribute)|0
incorrect primary diagnosis
  4
  C0348026|Diagnostic|0
  C0439631|Primary operation (qualifier value)|0
  C0011900|Diagnosis|0
  C0205225|Primary|0
